

Cancer in Norway 2005

Cancer incidence, mortality,
survival and prevalence in Norway

Special issue:
*Predictions of cancer incidence
by Health Region 2010–2020*



Cancer in Norway 2005

Editor-in-chief: Freddie Bray PhD

Analysis: Bjørge Sæther

Layout and Design: Børge Sildnes

Special Issue by Bjørn Møller and Bjarte Aagnes

Editorial team: Bjarte Aagnes, Kjell Arne Bakke, Freddie Bray, Aage F. Johansen, Tom Børge Johannesen, Mette Kalager, Hilde Langseth, Barbara Mortensen, Bjørn Møller, Jan F. Nygård, Børge Sildnes, Bjørge Sæther, Svein Erling Tysvær, Frøydis Langmark

ISBN: 82-90343-64-7

ISSN: 0332-9631

Request for cancer information, data or possible research collaboration are welcome, and should be sent to datautlevering@kreftregisteret.no in the first instance.



Cancer in Norway 2005



Cancer incidence, mortality,
survival and prevalence in Norway

Special issue:
*Predictions of cancer incidence
by Health Region 2010–2020*

Foreword

This year's Cancer in Norway (CiN) represents a turning point in the history of the Cancer Registry of Norway. As a disease registry, we are dependent on timely reports on each patient from the clinical community to enable us to deliver incidence data within one year of the end of the diagnosis year. That we are able to deliver such data for 2005 during 2006 is a consequence of having a legal framework for cancer registration in place in Norway, and underscores the proficiency of each hospital in fulfilling their obligations to report cancers. Ultimately, the timeliness of this report is a product of the dedication of our own staff in interpreting, coding and registering new cancer cases.

We have observed slightly fewer cases in 2005 compared with 2004, possibly representing some degree of underreporting from clinicians. We believe the shortfall is sufficiently minor to warrant publication however, and, as is our remit, we present high quality and timely incidence data in this report.

Cancer in Norway 2005 represents a major transformation of the contents of the annual report. Specific developments include:

- A conversion of the incidence data from ICD-7 to ICD-10
- A more detailed exposition of the registration processes and the quality of the incidence data
- Individual sections on the main indicators: incidence, mortality, prevalence and survival
- Additional results on our website
- The incorporation of a *Special Issue* – a regular in future CiN reports integrating a research topic of national importance. The first topic providing a detailed breakdown of regional cancer incidence predictions up to 2020.

Cancer in Norway 2005 provides a more coherent link to the core research activities of the Registry, namely research on the causes of cancer, screening-based research, and clinical and registry-based research, the latter being expanded through the organ-specific special registries now being founded at the Registry. The competency within the registry, and the assured links with external milieus, provide us with considerable grounds for confidence going forward into 2007, building on the high quality cancer research activities of the Registry.

Future CiN reports will include more detailed analyses of cancer incidence and survival data that better demonstrate the geographical and temporal variations in Norway. There will also be translations into Norwegian where appropriate, available online as part of the launch of the new website in Spring 2007.

We look forward to continuing and increasing our collaborative links with the regional cancer centres and the clinical community as a whole, as well as expanding our research activities in liaison with cancer researchers, both in Norway and abroad.



Oslo, December 2006
Frøydís Langmark
Director

Table of contents

Cancer in Norway 2005:

Cancer incidence, mortality, survival and prevalence in Norway

Data Sources	7
The population of Norway	7
The Cancer Registry of Norway	8
Notifications and sources of information	8
Classification and coding	9
Data quality	10
The main database	13
Statistical methods used in this report	13
Definitions	15
Incidence	17
Mortality	51
Survival	53
Prevalence	57
References	58
Research activities at the Registry	59
Organisation and founding principles	59
Department of Etiological Research	60
Department of Screening-based Research	60
Department of Clinical- and Registry-based Research	61
List of publications 2005	63
Staff at the Cancer Registry of Norway 2006	66
 List of tables	
Table 1: Number of inhabitants in Norway 31.12.2005	7
Table 2: Stability of data over time	11
Table 3: Percentage distribution of histological verification (HV), death certificates only (DCO) 2001-2005, and M:I ratio 2000-04	12
Table 4: Number of new cases by primary site and sex - 2005	16
Table 5: Sex ratios (Male:Female) of age-standardised rates (world) in 1978-82 and 2001-2005 by primary site, sorted in descending order in last period	20
Table 6: Number of new cases by primary site and year - 1996-2005, males	22
Table 7: Number of new cases by primary site and year - 1996-2005, females	23
Table 8: Age-adjusted (world) incidence rates per 100 000 person-years by primary site and year - 1996-2005, males	24
Table 9: Age-adjusted (world) incidence rates per 100 000 person-years by primary site and year - 1996-2005, females	25
Table 10: Number of new cases by primary site and five-year age group - 2005, males	26

Table 11: Number of new cases by primary site and five-year age group - 2005, females	28
Table 12: Age-specific incidence rates per 100 000 person-years by primary site and five-year age group - 2005, males	30
Table 13: Age-specific incidence rates per 100 000 person-years by primary site and five-year age group - 2005, females	32
Table 14: Average annual number of new cases by primary site and 5-year period 1956-2005, males	34
Table 15: Average annual number of new cases by primary site and 5-year period 1956-2005, females	36
Table 16: Age-adjusted (world) incidence rates per 100 000 person-years by primary site and five-year period 1956-2005, males	38
Table 17: Age-adjusted (world) incidence rates per 100 000 person-years by primary site and five-year period 1956-2005, females	40
Table 18: Average annual number of new cases by primary site and county - 2001-2005, males	42
Table 19: Average annual number of new cases by primary site and county - 2001-2005, females	44
Table 20: Age-adjusted (world) incidence rates per 100 000 person-years by county and primary site - 2001-2005, males	46
Table 21: Age-adjusted (world) incidence rates per 100 000 person-years by county and primary site - 2001-2005, females	48
Table 22: Number of cancer deaths in Norway by primary site and sex - 2004	50
Table 23: Five-year relative survival in percent by selected primary sites, stage and period of diagnosis - 1956-2000, males	54
Table 24: Five-year relative survival in percent by selected primary sites, stage and period of diagnosis - 1956-2000, females	55
Table 25: Prevalence of cancer 31.12.1995 and 31.12.2005, both sexes	57

Special issue:

Predictions of cancer incidence by Health Region 2010–2020	S1-S76
--	--------

Data Sources and Methods

The population of Norway


The Norwegian population is principally white Caucasian, with an immigrant population (from over 200 countries) comprising around 8% of total population of 4.6 million in 2005 (Table 1). Figure 1 illustrates the changing population size and age structure of Norway, comparing population estimates in 1980 and 2005 with projections for 2030 (Statistics Norway, 2006). The population of Norway has been increasing since records began, and this growth is expected to continue in the next decades. The total number of inhabitants in Norway has increased by 12% during the last 25 years, largely as a result of rising life expectancy and more recently, increases in net immigration. By 2030, the size of the population is expected to increase a further 17% to about 5.4 million (Statistics Norway, 2004). The elderly will represent an increasingly large proportion of the population of Norway in the next quarter of a century, predominantly as a result of lengthening life expectancy. It is projected that by 2030 over one million inhabitants, or one-fifth of the population will be aged 65 or over.

Table 1: Number of inhabitants in Norway 31.12.2005


Age	Males	Females
0-4	146 674	140 709
5-9	157 023	149 085
10-14	161 087	152 233
15-19	153 434	145 741
20-24	139 588	135 420
25-29	144 790	143 021
30-34	169 674	166 205
35-39	181 573	175 082
40-44	171 271	163 999
45-49	162 013	156 895
50-54	153 370	148 775
55-59	153 055	148 111
60-64	119 651	119 271
65-69	85 663	91 638
70-74	68 928	80 858
75-79	60 397	79 109
80-84	44 401	72 249
85+	29 389	69 837
Total	2 301 981	2 338 238

Figure 1


Age structure of the Norwegian population, 1980



Age structure of the Norwegian population, 2005



Age structure of the Norwegian population, 2030*



*Forecasted, Statistics Norway

The Cancer Registry of Norway

The Cancer Registry of Norway is population-based and covers the whole of Norway. It has systematically collected notifications on cancer since its inception in 1952, and is considered complete from 1953. The reporting of cancer (and certain precancerous lesions) has been compulsory following a directive from the Ministry of Health and Social Affairs in 1951. A Health Registry Act came into force in 2002 that included statutory regulations for the Cancer Registry of Norway, strengthening the legal obligation to report new cases for cancer registration, and defining its main objectives as to:

1. Collect and, within the scope of the Regulations, process data relating to cases of cancer, and carry out studies in Norway in order to document the distribution of cancer in the country and describe changes over time;
2. Conduct, promote and provide a basis for research to develop knowledge of the causes, diagnosis, natural course, and effects of treatment of cancer in order to improve the quality of preventive measures and medical assistance to combat cancer, including the follow-up of individual patients and groups of patients;
3. Provide advice and information to public administrative bodies and the population at large on measures that may prevent the development of cancer.

The Registry is therefore focussed on three main lines of activity: i) the complete registration and follow-up of all cancer cases in Norway, ii) research on the aetiological, screening and clinical aspects of cancer in Norway, building on existing collaborations at the national and international level, and iii) the provision of cancer information to a broad range of interest groups that includes the general public, journalists and politicians, in addition to professionals within the clinical and research community.


As well as personal characteristics of the patient, the following variables are included in the registering of each tumour: diagnosis (modified ICD-7 – see *Classification and Coding*); date of diagnosis; histopathology laboratory and identification number for the tissue specimen; treatment institution: hospital, department, outpatient facility; organ of disease origin, type and metastasis; diagnostic method; treatment: surgery, chemotherapy, radiotherapy, hormonal therapy, and other treatment; date and causes of death.

Notifications and sources of information

All hospitals and oncological centres are required by the regulations to report all new cases of cancer, irrespective of whether the patient is treated, admit-

ted, or seen only as an outpatient. The Registry also receives mandatory reports from individual physicians, and from pathology and cytology laboratories. The Registry has received over 100 000 notifications in each of the last two years pertaining to diagnoses made in 2005. The Registry sends out 40 000 reminders each year to the reporting institution or physician requesting additional information or clarifications. The sources of information and the Registry process - from the initial submission of cancer information through to the storage of the patient record - are illustrated in Figure 2. If the Registry has received a notification from a pathological laboratory, but no clinical form, the hospital clinician is contacted and asked to notify the Registry about the patient. In instances of conflicting information from clinicians and pathologists, the reports are investigated further.

Figure 2: Sources of information and the registration process



Death certificate matching

The records held in the Registry are regularly matched with the Cause of Death Register run by the National Statistics Bureau, *Statistics Norway*. The automated procedure that matches registered patients to death certificates is important to maintain quality control, facilitating a high level of completeness and validity of the Registry data (see *Data Quality*). Dates of death are matched monthly, and causes of death annually, via

the national 11-digit personal identification number, which provides a reliable means of tracking patients and keeping potential duplication of registered cases down to a minimum.

Death certificates are also a complementary source of information on new cancer cases: death certificates specifying cancer inconsistent or unmatched to registry files are subject to further scrutiny within the Registry. Cancer cases first identified from death certificates are traced back to the certifying hospital or physician. The Registry then asks the doctor who completed the certificate to state whether the patient had been investigated and diagnosed when alive, or whether the diagnosis was made after death.

The regular processing of death certificates also ensures active follow-up of each and every patient with regards their vital status e.g. whether they are alive, dead or have emigrated. This information is essential in analysing the survival of cancer patients (see *Survival*).

Classification and coding

Topography and morphology

Up to and including 1992, the topographical codes of the cancer site were coded according to a slightly modified version of ICD-7 (International Classification of Diseases, 7th edition, 1957). Since 1993, the basis for coding has been ICD-O-2 (International Classification of Diseases for Oncology, 2nd edition, 1992), with the topography axis standardised with the C section of ICD-10 (International Classification of Diseases, 10th edition, 1990).

The Registry has since its first report in the late-1950s (Pedersen and Magnus, 1958) utilised ICD-7 to provide a description of the cancer-specific burden in Norway. *Cancer in Norway 2005* however, marks the first annual report for which the figures and tabulations use the ICD-10 nomenclature, following a tentative conversion of the registry data from ICD-7.

Solid tumours are tabulated according to organ of origin, stated or presumed to be primary, of specified sites (C00-C75). Non-solid tumours - stated or presumed to be primary, of the lymphoid, haematopoietic and related tissue (C81-C96) - are presented according to disease category irrespective of the organ of origin. The use of ICD-10 to code incidence data now corresponds with the system used by Statistics Norway to code deaths from cancer (see *Mortality*).

The tabulations in this report are for all new malignant neoplasms (ICD-10 C00-C96) and exclude basal cell carcinomas of the skin. The tables are classified according to three- or four-character ICD-10 codes within the following groups:

C00-C14	Lip, oral cavity and pharynx
C15-C26	Digestive organs
C30-C38	Respiratory and intrathoracic organs
C40-C41	Bone and articular cartilage
C43-C44	Skin
C45-C49	Mesothelial and soft tissue
C50	Breast
C51-C58	Female genital organs
C60-C63	Male genital organs
C64-C68	Urinary tract
C69-C72	Eye, brain and other parts of central nervous system
C73-C75	Thyroid and other endocrine glands
C76-C80	Malignant neoplasms of ill-defined, secondary and unspecified sites
C81-C96	Malignant neoplasms, stated or presumed to be primary, of lymphoid, haematopoietic and related tissue

From 1970-92, tumour morphology was coded within the Registry according to MoTNaC (Manual of Tumour Nomenclature and Coding, 1968). Since 1993, ICD-O morphology codes have been used. Carcinoma *in situ* of the uterine cervix (D06), borderline tumours of the ovary (D27) and basal cell carcinomas (ICD-O 80903-80933) are classified separately. Atypical epithelial lesions and benign papillomas of the transitional cell lined urinary tract are however included with the invasive cancers. Precancerous lesions of other sites are omitted. All neoplasms of the central nervous system, whether malignant or non-malignant, are included in the incidence tables under C72, malignant neoplasm of spinal cord, cranial nerves and other parts of central nervous system.

Staging

Most solid tumours are classified as either localised, with regional spread, with distant spread, or of unknown stage. Tumours of the uterine cervix are staged I-IV – according to the FIGO (International Federation of Gynecology and Obstetrics) staging system (Pecorelli *et al*, 1999). Breast tumour stages I-IV refer to localized tumour, lymph node metastases, direct tumour extension to the chest wall or skin, and distant metastases, respectively. Stage-specific survival by period of diagnosis and sex are examined in the *Survival* section.

Data quality

One of the central aims of the Registry – and of this report – is the provision of timely and relevant information on cancer incidence, mortality, survival and prevalence in Norway. The broad remit of the institution is however in some accordance with the expanded view of cancer registries proposed by Armstrong (1992), whereby involvement in cancer control extends beyond routine surveillance and aetiological research to a more active role in implementing, evaluating and planning specific cancer control programmes, such as screening programmes and the quality of cancer care. The value of the Registry and its ability to carry out such activities relies heavily on the quality of the data, and the quality control procedures in place (Brewster, 1995; Storm, 1996).

There are three main aspects that help to characterise the quality of the information in the Registry (Parkin *et al*, 1994). Firstly, there must be *comparability* between populations groups (registries, geographical areas etc), and within those groups over time. A basic requirement to ensure comparability is the standardisation of practices concerning the classification and coding of new cases, and consistency in basic definitions of incidence, such as rules for the coding of multiple primaries, whereby one must decide whether two or more cancers in the same individual represent a new case of cancer, or an extension, recurrence, or metastasis of the first tumour. Comparability also necessitates the data are accurate in terms of their *completeness* and *validity*. *Completeness* is the extent to which all of the incident cancers occurring in the Norwegian population are included in the Registry database. Incidence rates and survival proportions will be close to their true value if maximum completeness in case-finding procedures can be achieved. Finally, *validity* refers to the proportion of cases in the Registry with a given characteristic that truly have that attribute, and depends on the precision of source documents and the level of expertise in abstracting, coding, and recording (Parkin *et al*, 1994).

Data completeness

To date, there has been no comprehensive evaluation of the completeness of the Registry. A pilot study (as part of the 1978 annual report) indicated that overall completeness in the Registry in two counties in 1976 (accounting for 12% of the total Norwegian population) was 97.6% for solid tumours, but was less complete for leukaemia and multiple myeloma, possibly as a result of failure to diagnose some cases at the pathological laboratories (Lund, 1981).

Several ad-hoc reports by Registry workers have examined the completeness of specific cancer sites. A study of the quality of head and neck cancer registrations 1953-91 indicated that virtually all new cases were reported when compared against hospital-based registries (Mork *et al*, 1995); for prostate cancer, the deficiency in reporting was reported to be less than 1%. A report on the quality of histologically-verified ovarian cancers diagnosed 1987-96 in one region in Mid-Norway (14% of the total Norwegian population) estimated organ-specific completeness at 95.3% (Tingulstad *et al*, 2002).

On average, the Registry receives four reports per case. From 1998, it has received data files from the patient administrative systems of all Norwegian hospitals, containing information on all patients being treated for malignant and premalignant conditions. This has probably contributed to an improvement in the completeness of the registration of non-solid tumours, non-malignant brain tumours as well as some solid tumour sites.

All pathology laboratories send copies of the laboratory reports (biopsy, cytology and autopsy) to the Registry, obviating the need to fill in Registry forms, reducing potential delays in waiting for the diagnosis year to be considered complete. For haematological cancers diagnosed without pathologists however, a tendency of underreporting is observed, as noted previously (Lund, 1981).

Data validity

As with the evaluation of completeness, the accuracy of registry data in Norway has been reviewed for certain sites. Helseth *et al* examined almost 9000 cancers of the central nervous system diagnosed 1955-84, drawing a random sample of 300 cases to examine potential errors in the coding (Helseth *et al*, 1988). Over 9% of cases were reported to be erroneous, although only 0.3% of the series contained errors on restricting the analysis to the main histological groupings. A re-evaluation of a random sample of 300 cases from a corrected series of head and neck cancers diagnosed 1953-1991 indicated discrepancies between the pathologists' classification and the Registry's coding in 1.4% of all cases, and further, that the proportion without histological verification fell from 5.7% in the first decade to 2.1% during the last 9-year period (Mork *et al*, 1995).

A study examining a 1% sample of prostate cancer cases diagnosed 1957-86 indicated 6% of the patient files had an error in one of the fields in the record, irrespective of their perceived importance (Harvei *et al*, 1996). Tingulstad *et al* evaluated the accuracy of ovarian cancers diagnosed in a single region 1987-96

revealing that, of 591 cases identified with a histological diagnosis at the Registry, accuracy was about 92%. Coding errors were found in 2% of these cases, while in a further 6% it was not possible to reproduce the original diagnosis of ovarian cancer at re-evaluation (Tingulstad *et al*, 2002).

Selected data quality indicators 2001-2005

Three routinely derivable indicators of data quality are displayed in Table 3 according to tumour site, and serve to confirm the general quality of the Registry. The proportion of cases histologically verified (%HV) is mainly a measure of the validity of Registry data, although percentages very close to 100% may serve to indicate an over-reliance on pathological laboratories, and a possible under-reporting of registered cases (Parkin *et al*, 1994).

A high proportion of cancers for which no other information than a death certificate mentioning cancer can be obtained - death certificate only registration or DCOs - tend to be indicative of inadequate case-finding procedures. Its value as a measure of completeness has been questioned however, given it is strongly dependent on both the case fatality rate and the misclassification rates of cancer deaths among unregistered patients (Brenner, 1995).

Finally, the mortality/incidence ratio (M:I ratio) - with the mortality data obtained from an independent source - is another estimator of the completeness of registration. The M:I ratio will equal 1-survival probability for a steady state of constant incidence and survival (Parkin *et al*, 1994). Thus changes in the M:I

ratio should be consistent with known changes in survival rates, and values close to unity are reasonable for cancers associated with very poor survival. In general, M:I ratios should be less than one unless incidence is declining rapidly relative to mortality (Brewster, 1995).

Timeliness of registry data

Figure 3 shows the timeline from the end of the year of diagnosis until publication of *Cancer in Norway* less than one year later. It illustrates the time-consuming procedures required to make the Registry both practically complete and of sufficient quality to permit publication. The registry has become more timely of recent, with the median time from date of diagnosis to registration of a new case shortened from around 527 days in 2005 to 262 days in 2006.

As a result of some delays in notification from hospitals and other sources however, there will be some increases in the number of registered cases for 2005 some years after publication of this report (Table 2).

The shortfall in incidence in 2005 is, at the time of going to press (early December 2006), estimated to be around 300 cases. The Deaths Registry has not yet accounted for all deaths in Norway in 2005, having processed 93% of the total number of death certificates. The Registry will therefore likely accrue most of the missing incident cases during 2007, and this will be met by a reduction in the DCO proportion - currently estimated to be 2.9% - to a figure close to the present 2004 DCO estimate of 0.8%. The discrepancy thus represents a trade-off between timeliness of publication

Table 2: Stability of data over time

	Incidence year														
Publ.year	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005
1991	18 541														
1992	18 612	19 059													
1993	18 586	19 158	18 950												
1994	18 565	19 169	19 341	19 284											
1995	18 594	19 219	19 459	19 568	19 863										
1996	18 630	19 299	19 560	19 777	20 185	20 780									
1997	18 510	19 199	19 432	19 642	19 986	20 655	20 981								
1998	18 546	19 257	19 445	19 673	20 034	20 539	21 280	21199							
1999	18 593	19 312	19 516	19 750	20 136	20 671	21 427	21449	21 200						
2000	18 611	19 330	19 535	19 770	20 187	20 716	21 438	21466	21 414	22 185					
2001	18 633	19 353	19 561	19 781	20 230	20 749	21 425	21530	21 533	22 402	22 468				
2002	18 648	19 375	19 591	19 815	20 231	20 738	21 374	21502	21 544	22 304	22 481	22 694			
2003	18 650	19 384	19 595	19 823	20 236	20 739	21 376	21504	21 541	22 307	22 495	22 779	23 307		
2004	18 651	19 389	19 598	19 827	20 246	20 760	21 391	21528	21 582	22 337	22 520	22 815	23 613	24 434	
2005	18 696	19 439	19 643	19 866	20 287	20 829	21 433	21577	21 639	22 400	22 585	22 900	23 873	24 822	24 229
Max	18 696	19 439	19 643	19 866	20 287	20 829	21 438	21577	21 639	22 402	22 585	22 900	23 873	24 822	
Min	18 510	19 059	18 950	19 284	19 863	20 539	20 981	21199	21 200	22 185	22 468	22 694	23 307	24 434	
Average	18 604	19 282	19 479	19 715	20 147	20 718	21 347	21469	21 493	22 323	22 510	22 797	23 598	24 628	
Max - min	186	380	693	582	424	290	457	378	439	217	117	206	566	388	
Max variation, %	1,0%	2,0%	3,7%	3,0%	2,1%	1,4%	2,2%	1,8%	2,1%	1,0%	0,5%	0,9%	2,4%	1,6%	


The table shows the total number of registrations annually (italicised diagonals) and the updated numbers for each year following publication.

Table 3: Percentage distribution of histological verification (HV), death certificates only (DCO) 2001-2005, and M:I ratio 2000-04

ICD10	Site	Cases	HV %	DCO %	M:I ratio
C00-96	All sites	118406	88.0	1.3	0.44
C00-14	Mouth, pharynx	1940	96.8	0.2	0.38
C00	Lip	360	99.7	0.0	0.08
C01-02	Tongue	390	97.7	0.0	0.39
C03-06	Mouth, other	405	99.5	0.2	0.51
C07-08	Salivary glands	196	87.8	0.0	0.33
C09-14	Pharynx	589	95.4	0.5	0.49
C15-26	Digestive organs	26095	88.3	1.7	0.60
C15	Oesophagus	936	94.1	1.6	0.85
C16	Stomach	2819	95.0	0.9	0.81
C17	Small intestine	508	95.1	0.2	0.44
C18	Colon	10933	94.7	1.0	0.50
C19-21	Rectum, rectosigmoid, anus	6031	97.1	0.5	0.43
C22	Liver	623	73.7	4.7	0.88
C23-24	Gallbladder, bile ducts	673	67.9	2.4	0.73
C25	Pancreas	3116	53.7	4.9	0.98
C26	Other digestive organs	456	45.2	15.4	0.44
C30-34, C38	Respiratory organs	12044	78.0	2.1	0.81
C30-31	Nose, sinuses	199	98.5	0.5	0.39
C32	Larynx, epiglottis	606	97.5	0.3	0.36
C33-34	Lung, trachea	11160	76.8	2.2	0.84
C38	Mediastinum, pleura	104	60.6	7.7	0.89
C40-41	Bone	215	96.3	0.9	0.49
C43	Melanoma of the skin	5239	99.0	0.2	0.22
C44	Skin, non-melanoma	6069	99.0	0.1	0.03
C45	Mesothelioma	356	89.3	0.3	0.66
C46	Kaposi's sarcoma	45	93.3	0.0	0.02
C47	Autonomic nervous system	48	93.8	0.0	0.23
C48-49	Soft tissues	624	94.7	0.5	0.56
C50	Breast	13686	97.0	0.3	0.27
C51-58	Female genital organs	7628	95.8	0.8	0.40
C53	Cervix uteri	1463	99.5	0.1	0.33
C54	Corpus uteri	3158	98.7	0.3	0.19
C55	Uterus, other	56	73.2	10.7	1.96
C56	Ovary	2270	90.4	1.2	0.68
C51-52, C57	Other female genital	661	95.0	2.0	0.42
C58	Placenta	20	45.0	0.0	0.05
C60-63	Male genital organs	17997	93.3	1.2	0.30
C61	Prostate	16508	92.8	1.3	0.32
C62	Testis	1272	99.1	0.2	0.05
C60, C63	Other male genital	217	97.7	0.9	0.16
C64-68	Urinary organs	9330	90.4	1.0	0.35
C64-65	Kidney	3078	82.4	1.6	0.43
C66-68	Bladder, ureter, urethra	6252	94.3	0.7	0.31
C69	Eye	305	50.2	0.3	0.23
C70-72	Central nervous system	4348	64.0	1.4	0.33
C73	Thyroid gland	995	92.8	0.2	0.17
C37, C74-75	Other endocrine glands	115	81.7	1.7	0.73
C39, C76, C80	Other or unspecified	2636	53.0	7.2	1.10
C81-96	Lymphoid and haematopoietic tissue	8666	73.2	1.5	0.51
C81	Hodgkin lymphoma	560	98.4	0.0	0.14
C82-85, C96	Non-Hodgkin lymphoma	3659	96.8	0.4	0.45
C88	Malignant immunoproliferative diseases	210	52.4	4.8	0.37
C90	Multiple myeloma	1640	45.3	2.2	0.69
C91-95	Leukaemia	2597	53.8	2.6	0.59

and completeness of data. For the Registry, rapid dissemination of accurate and close-to-complete data outweigh concerns regarding the accrual of additional cases over several years, given they represent a minor proportion of the total annual incidence.

Figure 3: Quality checks undertaken by the Registry before a registration is made



Future work on data quality

The validation and consistency checks within the Registry, the basic indicators in Table 3, and the conclusions of several research papers indicate the data are of high quality, and that the statistics generated in this report are reasonably undistorted by variations in the efficacy of registration procedures. It is however imperative that a comprehensive internal evaluation and documentation of the quality of the registry data is undertaken to confirm such high standards are met in general, thereby justifying the use of specific datasets in epidemiological and clinical studies.

The next annual report, *Cancer in Norway 2006*, will include as a special issue a detailed evaluation of the comparability, completeness and validity of the Registry data for each of the cancer sites listed in Table 3. This will include an examination of the Registry's adherence to international standards as well as an assessment of the accuracy of each of the collected variables, and the variability by tumour site. Given the lack of reliability of the DCO index as a measure of completeness, the report will also use analytic methods to quantify the level of completeness of the Registry data by tumour site and by health region (Bullard *et al*, 2000).

A recent U.S. study estimated longer times to availability – the time between diagnosis and registration – for both prostate cancers and melanoma (Smith-Gagen *et al*, 2005). An analysis of reporting and processing in Norway will aim to ascertain and describe factors related to delays in the availability of cancer cases to the Registry.

The main database

The main cancer database contains the basic data items collected from clinicians and pathologists, as well as from administrative patient discharge and mortality sources. As of December 2006, the Registry database contained information from 1953 on 1 053 326 cancer cases and premalignant conditions in 1 284 743 persons. A total of 3 056 291 notifications have been received since then. For all cases registered since 1953, 86.4% are histologically verified and 1.3% of the diagnoses are based on death certificates alone. The database is updated continuously with information on both new cases, as well as cases diagnosed in previous years.

Statistical methods used in this report

Four measures are used in this report to describe the burden and risk of disease: incidence, mortality, survival and prevalence.

Incidence and mortality refer to the number of new cases and deaths occurring, respectively. The latter is the product of incidence and the fatality of a given cancer, the proportion of cancer patients that die. Both measures can be expressed as the absolute number of cases (or deaths), or as the incidence (or mortality) rate, taking into account the size of the population at risk. Rates are essential in the comparisons between groups, and within groups over time. The denominator is the underlying person-time at risk in which the cases or deaths in the numerator arose. Prevalence and survival (see below) are proportions rather than rates as there is no time dimension, although the term is frequently attached to both measures.

Cancer incidence and mortality in Norway are presented in this report as both numbers and rates. Several types of rate are used in this report.

Age-specific rates

There are compelling grounds for adjusting for the effects of age when comparing cancer risk in populations. Age is a very strong determinant of cancer risk, with rates of epithelial cancers increasing approximately as a fifth power of age (Armitage and Doll, 1954). The *crude rate*, a rate based on the frequency of cancer in the entire population, is calculated ignoring

possible stratifications by age. Although the measure can be useful as an indicator of the extent of burden, its utility in comparing cancer risk is severely limited where there are differing age structures across groups, or where demographic changes have impacted on the size and age structure of a population over time. To obtain a more accurate picture of the true risk of cancer, rates are calculated for each age strata, usually grouped in five-year intervals. The age-specific rate for age class i , denoted as r_i is obtained by dividing the number of events in each age class d_i by the corresponding person-years of observation Y_i and multiplying by 100 000:

$$r_i = d_i / Y_i \times 100\,000$$

Rates are given separately for males and females, because of the often very different cancer patterns by sex. Age and sex-specific incidence and mortality rates are the foundation of epidemiological analysis of cancer frequency data.


Age-standardised rates

To facilitate comparisons however, a summary rate is required that absorbs the schedule of age-specific rates in each comparison group. The summary measure that appears in this report is the age-standardised rate (ASR), a statistic that is independent of the effects of age, thus allowing comparisons of cancer risk between different groups. The calculation of the ASR is an example of direct standardisation, whereby the observed age-specific rates are applied to a standard population. The populations in each age class of the Standard Population are known as the *weights* to be used in the standardisation process. Many possible sets of weights, w_i , can be used. The *world* standard population, a commonly-used reference, is utilised in this report (Segi, 1960; Doll *et al.*, 1966). Although the weights of the world standard fail to resemble those of the Norwegian population in 2005 (Figure 4), this observation is of relatively little importance, since it is the *ratio* of ASRs, an estimate of the age-adjusted relative risk between populations or within a population over time, that is the focus of interest. This characteristic has been shown to be rather insensitive to the choice of standard (Bray *et al.* 2002).

For weights w_i in the i th age class of the world standard and for A age classes with $i = 1, 2, \dots, A$, r_i , as before, is the age-specific rate in the i th age class. The ASR is calculated as:

$$ASR = \frac{\sum_i r_i w_i}{\sum_i w_i} \times 100\,000$$

Figure 4: Comparison of population weights



Survival

The study of cancer survival using registry data allows a population-based perspective, important for monitoring and evaluating the effectiveness of cancer care in Norway. The survival time of a cancer patient is defined as the time that elapsed between diagnosis and death. Computation of survival depends upon follow-up of diagnosed cancer patients, and the calculation of the numbers surviving after different intervals of time. In order to estimate *cause-specific* (or *corrected*) survival, we require accurate data on cause of death. Such information is generally based on the coding of death certificates, a source that is generally not considered to be sufficiently reliable.

A common alternative to corrected survival – and as used in this report – is to compute *relative survival* and compare the observed mortality (or *hazard*) rate in patients with the expected rate in the population from which they arise (Ederer *et al.*, 1961). Relative survival is defined as the observed survival among cancer patients divided by the expected survival for a comparable group from the general population with respect to the main factors affecting survival, commonly sex, age, and calendar year.

To calculate observed survival the *actuarial* method was used, the period of observation was thus partitioned into a series of time intervals and the conditional (interval-specific) survival proportions for five consecutive 1-year intervals estimated. Cumulative survival $S(t)$ up to time t was estimated as the product of the interval-specific survival proportions for all intervals up to and including the specified interval. The cor-

responding expected survival probabilities were calculated using the *Ederer II* method (Estève *et al*, 1994), from the published annual probabilities of death in Norway. The appropriate probability was obtained on stratification by sex, the age of the patient, and the year of registration, obtained from population life tables.

The cohort-based approach to survival analysis was used here, whereby patients diagnosed from the beginning of 1996 to the end of 2000 were followed up with regards their vital status for at least five years. Trends in cancer survival for cancer patients diagnosed in five-year periods from the late-1950s up to the late-1990s are also provided in this report. DCO registrations were excluded from the analyses.

Prevalence

Prevalence is the proportion of a population that has the disease at a given point in time. It is a rather complex measure of cancer incidence, fatality, and other influences operating in affected individuals prior to death or *cure*. Although prevalence usefully describes the number of individuals requiring care for disease like hypertension and diabetes, many persons diagnosed with cancer in the past may now be considered cured, in that they no longer have an excess risk of death. Some residual disability may be present however, subsequent to a specific treatment intervention, for example.

Lifetime cancer prevalence can be defined as all persons living and ever diagnosed with cancer, and such a measure can easily be derived at the Cancer Registry of Norway given the very long-term registration of cases, and complete follow up of vital status over many years. Although such statistics are provided in this report, *partial* prevalence estimates are perhaps of more utility in quantifying resource requirements: the numbers of persons alive as of 31 December 2005, whom were diagnosed with cancer within one year, one to four years, five to nine years, and 10 or more years, are therefore also incorporated into this report.

Definitions*

Incidence

The number of new cases of cancer in a defined population within a specific period of time.

Incidence rate

The number of new cases that arise in a population (incidence) divided by the number of people who are at risk of getting cancer in the same period. The rate is expressed per 100 000 person-years**.

Crude rate

As above, with rates estimated for the entire population ignoring possible stratifications, such as by age group.

Age-specific rate

A rate calculated on stratifying by age, often based on a five-year interval.

Age-standardised incidence rate

Age-standardised (or age-adjusted) incidence rates are summary rates which would have been observed, given the schedule of age-specific rates, in a population with the age composition of a given standard population. The World standard population (Doll *et al*, 1966) is used in this report.

Relative survival

The ratio of the observed survival to the expected survival for a group of patients. The expected survival is based on the mortality in a comparable group of people in the total population. This group has the same age and sex distribution as the patient group in the same time period.

Prevalence

Prevalence is the proportion of a population that has the disease at a given point in time.

* Last's "A Dictionary of Epidemiology 4th Ed" was consulted.

** *Person-years* is a measurement that combines persons and time (in years) as the denominator in rates.

Table 4 Number of new cases by primary site and sex - 2005

ICD10	Site	Males	Females	Total
C00-96	All sites	12706	11522	24228
C00-14	Mouth, pharynx	235	180	415
C00	Lip	41	36	77
C01-02	Tongue	45	32	77
C03-06	Mouth, other	39	42	81
C07-08	Salivary glands	23	25	48
C09-14	Pharynx	87	45	132
C15-26	Digestive organs	2674	2529	5203
C15	Oesophagus	137	61	198
C16	Stomach	287	228	515
C17	Small intestine	48	41	89
C18	Colon	1052	1168	2220
C19-21	Rectum, rectosigmoid, anus	675	553	1228
C22	Liver	72	59	131
C23-24	Gallbladder, bile ducts	72	68	140
C25	Pancreas	289	286	575
C26	Other digestive organs	42	65	107
C30-34, C38	Respiratory organs	1474	947	2421
C30-31	Nose, sinuses	21	17	38
C32	Larynx, epiglottis	93	16	109
C33-34	Lung, trachea	1347	905	2252
C38	Mediastinum, pleura	13	9	22
C40-41	Bone	28	15	43
C43	Melanoma of the skin	572	564	1136
C44	Skin, non-melanoma	662	680	1342
C45	Mesothelioma	67	7	74
C46	Kaposi's sarcoma	8	2	10
C47	Autonomic nervous system	5	4	9
C48-49	Soft tissues	50	74	124
C50	Breast	18	2780	2798
C51-58	Female genital organs		1547	1547
C53	Cervix uteri		292	292
C54	Corpus uteri		666	666
C55	Uterus, other		11	11
C56	Ovary		420	420
C51-52, C57	Other female genital		152	152
C58	Placenta		6	6
C60-63	Male genital organs	3928		3928
C61	Prostate	3631		3631
C62	Testis	249		249
C60, C63	Other male genital	48		48
C64-68	Urinary organs	1301	578	1879
C64-65	Kidney	373	243	616
C66-68	Bladder, ureter, urethra	928	335	1263
C69	Eye	24	23	47
C70-72	Central nervous system	380	425	805
C73	Thyroid gland	65	161	226
C37, C74-75	Other endocrine glands	5	14	19
C39, C76, C80	Other or unspecified	232	272	504
C81-96	Lymphoid and haematopoietic tissue	978	720	1698
C81	Hodgkin lymphoma	63	50	113
C82-85, C96	Non-Hodgkin lymphoma	435	342	777
C88	Malignant immunoproliferative diseases	19	13	32
C90	Multiple myeloma	196	134	330
C91-95	Leukaemia	265	181	446

Incidence

There were 24 228 incident cases of cancer in Norway in 2005, 12 706 among men and 11 522 among women (Table 4). Registrations of the four most common forms of cancer – prostate, female breast, colon and lung – account for over half of the total cancer burden (12 111 new cases). Prostate cancer is the most frequent cancer in men (3631), followed by colorectal (1727) and lung cancer (1347). Breast cancer dominates in women: there were 2780 new cases in 2005, with colorectal and lung cancer ranking second and third, with 1721 and 905 incident cases, respectively.

While cancer affects all ages, its frequency increases rapidly with age, with the vast majority in Norway – about four-fifths – occurring in men and women aged over 55 (Figure 5). Separating these into broad age classes, the highest proportion of cancers occur in persons aged 55-74: almost half of all cancers diagnosed in men, and 40% of those diagnosed in women occur in this age class. An additional one-third of cancer affects men and women aged 75 or over, while one in five female cancers are diagnosed in women aged 30 to 54, a higher proportion than seen in men.

The relative contribution of different types of cancer varies considerably according to the age group under study. Figure 6 identifies the main cancers that contribute to the disease burden in children (aged 0-14), adolescents and young adults (15-29), the middle-aged

and the elderly (30-54, 55-74 and age 75 or over).

Table 5 compares the ratios of age-standardised rates of selected cancer types common to both sexes in 1978-1982 and 2001-2005. An excess incidence of most cancer types in men is clearly evident in both time periods. The primary exceptions are thyroid cancer and melanoma of the skin. The male:female (M:F) ratios are highest for several cancers affecting the head and neck, although a number of very common cancers – lung, bladder, stomach and rectum – are consistently more frequent among men. That the M:F ratios have been declining for certain neoplasms in the last 25 years is indicative of either decreasing trends among men, increasing trends among women, or a combination of both. For lung cancer, the halving of the M:F ratios during the last 25 years points to more rapidly increasing trends in female rates relative to those in men.

The time trends of selected cancers in Figure 7 provide more detail regarding the changing evolution of cancer risk in Norwegian men and women. Of note are: 1) the unprecedented rise in prostate cancer incidence since 1990, largely as a result of the rapidly increasing use of the Prostate Specific Antigen (PSA) test since it became commercially available in 1989; 2) the continued increases in both breast cancer and lung cancer among women, and colorectal cancer in both sexes; 3) the continuing declines in stomach cancer in both sexes; and 4) the rapid increases in a number of cancers for which the underlying causes (and pro-

Figure 5: Percentage distribution of cancer incidence by age, 2001-2005






Figure 6: The most frequent incident cancers by age and sex, 2001–2005


MALES all ages (61 559 cases)




FEMALES all ages (56 850 cases)




MALES 0–14 years (390 cases)



FEMALES 0–14 years (325 cases)



MALES 15–29 years (961 cases)



FEMALES 15–29 years (790 cases)






Figure 6 cont.


MALES 30–54 years (7120 cases)




FEMALES 30–54 years (11 621 cases)




MALES 55–74 years (29 732 cases)




FEMALES 55–74 years (23 421 cases)



MALES 75+ years (23 356 cases)



FEMALES 75+ years (20 693 cases)



spects for primary prevention) remain enigmatic: testicular cancer in men and non-Hodgkin lymphoma in both sexes.

The burden of cancer in Norway - the total number of new cases - has been increasing in the last decade (Table 6 and 7) and as far back as the Registry began reporting in 1953. This observation in part reflects real increases in the risk of several common cancers including colorectal and lung, but it also pertains to an increasing ability to diagnose the disease over time (remarkably so for prostate cancer). The increases are partially compensated by decreasing incidence trends of several cancer types, notably stomach cancer (in both sexes) and, in the near future, lung cancer in men.

A larger proportion of the increasing burden can be attributed to the global phenomenon of population growth and ageing, as was described for Norway in Figure 1. The special issue in the back of this report provides a detailed assessment of the predicted cancer burden and rates – partitioned into changes due to demographic effects and changing risk – for 49 cancer types in the five regions of Norway up to the year 2020.

Tables 8-21 provide further information on the distribution of cancer incidence in Norway. The number

of incident cases and rates are tabulated according to year of diagnosis, age group and county of residence.

Incidence on www.cancerregistry.no

In keeping with previous Cancer in Norway reports, further graphical descriptions for 23 cancer sites are available on our website. Graphical descriptions of age-specific incidence rates for the year 2005, time trends of age-adjusted incidence rates 1956-2005, and maps depicting the geographical variation by region 2001-2005 can be downloaded from our website by following the link:

www.cancerregistry.no/cin

Future work on incidence

While valuable information can be gleaned about temporal risk patterns from such an analysis of age-standardised rates, summary rates may hide important interactions between age and calendar time, indicative, for example, of the presence of strong birth cohort effects. Graphical descriptions of age-specific patterns according to both calendar period and birth cohort are an integral part of temporal analyses, and will be incorporated into future reports.

Table 5 Sex ratios (Male:Female) of age-standardised rates (world) in 1978-82 and 2001-2005 by primary site, sorted in descending order in last period

ICD10	Site	1978-82			2001-05		
		M	F	M:F ratio	M	F	M:F ratio
C32	Larynx, epiglottis	3.1	0.3	10.3	2.9	0.4	6.5
C66-68	Bladder, ureter, urethra	18.6	5.7	3.3	22.4	6.6	3.4
C15	Oesophagus	2.7	0.7	3.8	3.6	1.1	3.3
C09-14	Pharynx	1.7	0.5	3.3	2.6	0.9	3.0
C01-02	Tongue	1.0	0.4	2.6	1.6	0.6	2.4
C00	Lip	3.4	0.4	7.9	1.2	0.5	2.2
C22	Liver	1.8	1.0	1.8	2.1	1.0	2.0
C64-65	Kidney	8.3	4.4	1.9	10.6	5.3	2.0
C16	Stomach	18.0	9.2	2.0	8.2	4.3	1.9
C33-34	Lung, trachea	30.9	7.3	4.3	35.9	21.3	1.7
C91-95	Leukaemia	8.1	5.4	1.5	9.2	5.9	1.6
C81	Hodgkin lymphoma	2.6	1.6	1.6	2.7	1.8	1.6
C19-21	Rectum, rectosigmoid, anus	14.7	10.1	1.5	17.6	11.5	1.5
C90	Multiple myeloma	4.6	3.0	1.5	4.5	3.1	1.5
C82-85, C96	Non-Hodgkin lymphoma	6.2	4.5	1.4	11.2	8.3	1.4
C25	Pancreas	8.4	5.3	1.6	7.6	6.1	1.3
C23-24	Gallbladder, bile ducts	1.1	1.6	0.7	1.7	1.4	1.2
C18	Colon	17.1	17.4	1.0	25.4	22.9	1.1
C43	Melanoma of the skin	8.9	10.4	0.9	14.8	15.8	0.9
C73	Thyroid gland	1.6	5.1	0.3	1.7	4.6	0.4

Figure 7: Time trends in age-standardised incidence rates (world) in Norway for selected cancers (semi-log scale)

MALES

FEMALES

- Stomach
- Prostate
- Lung, trachea
- Colon
- Rectum, rectosigmoid, anus
- Pancreas
- Non-Hodgkin lymphoma
- Lip
- Oesophagus
- Testis
- Melanoma of the skin

- Breast
- Stomach
- Cervix uteri
- Colon
- Rectum, rectosigmoid, anus
- Pancreas
- Lung, trachea
- Melanoma of the skin
- Non-Hodgkin lymphoma





Table 6 Number of new cases by primary site and year - 1996-2005

MALES

ICD10	Site	Year									
		1996	97	98	99	00	01	02	03	04	2005
C00-96	All sites	10774	11124	11336	11357	11547	11656	11586	12493	13116	12706
C00-14	Mouth, pharynx	274	268	256	252	275	240	254	245	254	235
C00	Lip	76	72	52	58	62	51	59	38	35	41
C01-02	Tongue	39	53	49	51	41	51	50	52	54	45
C03-06	Mouth, other	67	44	42	50	57	36	46	52	50	39
C07-08	Salivary glands	15	22	22	22	28	21	22	17	16	23
C09-14	Pharynx	77	77	91	71	87	81	77	86	99	87
C15-26	Digestive organs	2430	2560	2539	2507	2554	2665	2630	2692	2787	2674
C15	Oesophagus	107	121	126	134	102	121	123	136	148	137
C16	Stomach	464	404	387	370	366	369	332	345	348	287
C17	Small intestine	29	42	44	39	45	65	47	57	44	48
C18	Colon	847	914	940	901	987	1001	968	992	1068	1052
C19-21	Rectum, rectosigmoid, anus	535	641	604	595	621	633	687	679	689	675
C22	Liver	69	46	69	86	71	79	83	75	82	72
C23-24	Gallbladder, bile ducts	51	62	59	61	54	69	53	56	69	72
C25	Pancreas	282	274	272	276	271	289	305	311	294	289
C26	Other digestive organs	46	56	38	45	37	39	32	41	45	42
C30-34, C38	Respiratory organs	1447	1427	1368	1428	1449	1494	1503	1562	1511	1474
C30-31	Nose, sinuses	19	21	25	24	27	23	28	17	25	21
C32	Larynx, epiglottis	119	99	88	112	111	120	115	93	98	93
C33-34	Lung, trachea	1293	1286	1241	1274	1296	1335	1348	1434	1378	1347
C38	Mediastinum, pleura	16	21	14	18	15	16	12	18	10	13
C40-41	Bone	23	24	18	21	20	22	28	21	26	28
C43	Melanoma of the skin	402	480	450	466	467	487	472	480	482	572
C44	Skin, non-melanoma	505	582	546	535	580	589	655	646	692	662
C45	Mesothelioma	52	37	52	56	51	61	52	64	69	67
C46	Kaposi's sarcoma	8	9	6	3	3	5	6	7	9	8
C47	Autonomic nervous system	8	3	7	6	7	4	5	7	2	5
C48-49	Soft tissues	42	48	51	44	51	50	56	50	54	50
C50	Breast	13	11	21	14	17	13	14	20	14	18
C60-63	Male genital organs	2809	2974	3252	3308	3345	3194	3034	3704	4137	3928
C61	Prostate	2534	2712	2984	3033	3069	2897	2757	3396	3827	3631
C62	Testis	237	220	234	248	248	266	237	255	265	249
C60, C63	Other male genital	38	42	34	27	28	31	40	53	45	48
C64-68	Urinary organs	1169	1176	1212	1158	1157	1191	1265	1265	1438	1301
C64-65	Kidney	325	327	339	321	313	358	366	364	440	373
C66-68	Bladder, ureter, urethra	844	849	873	837	844	833	899	901	998	928
C69	Eye	38	24	26	27	35	23	31	39	31	24
C70-72	Central nervous system	324	300	322	347	339	379	369	410	358	380
C73	Thyroid gland	41	50	45	45	52	52	53	52	49	65
C37, C74-75	Other endocrine glands	12	11	8	15	19	10	12	18	11	5
C39, C76, C80	Other or unspecified	323	300	285	276	262	237	231	251	217	232
C81-96	Lymphoid and haematopoietic tissue	854	840	872	849	864	940	916	960	975	978
C81	Hodgkin lymphoma	56	59	52	61	63	55	54	87	75	63
C82-85, C96	Non-Hodgkin lymphoma	360	332	371	330	386	356	343	386	418	435
C88	Malignant immunoproliferative diseases	19	25	17	20	13	27	29	31	22	19
C90	Multiple myeloma	159	176	168	155	148	181	165	163	168	196
C91-95	Leukaemia	260	248	264	283	254	321	325	293	292	265

Table 7 Number of new cases by primary site and year - 1996-2005

FEMALES

ICD10	Site	Year									
		1996	97	98	99	00	01	02	03	04	2005
C00-96	All sites	10055	10309	10241	10282	10852	10929	11313	11379	11706	11522
C00-14	Mouth, pharynx	148	113	136	133	128	138	135	126	133	180
C00	Lip	30	30	28	19	23	29	28	21	22	36
C01-02	Tongue	28	19	24	34	29	27	27	25	27	32
C03-06	Mouth, other	39	41	35	25	29	35	34	29	42	42
C07-08	Salivary glands	25	11	20	22	23	24	18	19	11	25
C09-14	Pharynx	26	12	29	33	24	23	28	32	31	45
C15-26	Digestive organs	2362	2432	2485	2410	2564	2469	2542	2549	2558	2529
C15	Oesophagus	32	48	50	45	56	51	48	56	55	61
C16	Stomach	276	259	262	233	240	210	256	223	221	228
C17	Small intestine	28	29	51	40	48	47	60	49	50	41
C18	Colon	1042	1089	1109	1079	1157	1136	1136	1230	1182	1168
C19-21	Rectum, rectosigmoid, anus	480	503	506	508	533	516	521	505	573	553
C22	Liver	36	33	41	62	52	48	43	42	40	59
C23-24	Gallbladder, bile ducts	77	82	82	83	89	62	80	82	62	68
C25	Pancreas	312	323	329	294	333	344	351	318	329	286
C26	Other digestive organs	79	66	55	66	56	55	47	44	46	65
C30-34, C38	Respiratory organs	722	701	673	790	830	840	853	925	960	947
C30-31	Nose, sinuses	16	13	19	17	13	15	15	10	28	17
C32	Larynx, epiglottis	23	19	21	19	19	22	18	18	13	16
C33-34	Lung, trachea	676	663	628	742	789	795	816	895	907	905
C38	Mediastinum, pleura	7	6	5	12	9	8	4	2	12	9
C40-41	Bone	24	17	9	28	22	21	20	19	15	15
C43	Melanoma of the skin	479	565	443	481	532	529	554	546	553	564
C44	Skin, non-melanoma	439	456	457	454	506	484	519	571	571	680
C45	Mesothelioma	7	4	10	10	10	5	8	11	12	7
C46	Kaposi's sarcoma	4	7	2	3	8	0	3	2	3	2
C47	Autonomic nervous system	10	10	8	2	3	5	4	3	9	4
C48-49	Soft tissues	47	42	50	63	75	68	64	71	87	74
C50	Breast	2352	2403	2416	2409	2527	2622	2696	2723	2786	2780
C51-58	Female genital organs	1421	1398	1487	1372	1426	1497	1528	1491	1565	1547
C53	Cervix uteri	333	332	345	284	285	301	306	296	268	292
C54	Corpus uteri	485	465	521	489	565	593	589	627	683	666
C55	Uterus, other	6	8	11	8	15	6	11	15	13	11
C56	Ovary	469	461	475	459	455	452	514	423	461	420
C51-52, C57	Other female genital	125	128	132	126	105	142	105	126	136	152
C58	Placenta	3	4	3	6	1	3	3	4	4	6
C64-68	Urinary organs	521	576	512	526	533	535	602	574	581	578
C64-65	Kidney	233	230	209	213	199	215	245	239	235	243
C66-68	Bladder, ureter, urethra	288	346	303	313	334	320	357	335	346	335
C69	Eye	28	29	30	29	20	28	34	34	38	23
C70-72	Central nervous system	358	369	384	405	411	464	514	511	538	425
C73	Thyroid gland	122	101	113	120	146	129	139	131	164	161
C37, C74-75	Other endocrine glands	5	9	16	11	15	9	14	11	11	14
C39, C76, C80	Other or unspecified	326	315	298	296	326	286	313	306	291	272
C81-96	Lymphoid and haematopoietic tissue	680	762	712	740	770	800	771	775	831	720
C81	Hodgkin lymphoma	39	31	43	40	64	33	43	54	46	50
C82-85, C96	Non-Hodgkin lymphoma	270	331	303	332	331	335	342	335	367	342
C88	Malignant immunoproliferative diseases	5	12	13	8	9	16	19	13	21	13
C90	Multiple myeloma	139	155	139	157	122	173	162	150	148	134
C91-95	Leukaemia	227	233	214	203	244	243	205	223	249	181

Table 8 Age-adjusted (world) incidence rates per 100 000 person-years by primary site and year - 1996-2005

MALES

ICD10	Site	Year									
		1996	97	98	99	00	01	02	03	04	2005
C00-96	All sites	307.2	317.7	317.5	319.2	321.8	320.2	315.4	335.6	345.8	329.2
C00-14	Mouth, pharynx	9.0	8.2	8.0	7.8	8.3	7.2	7.7	7.4	7.5	6.6
C00	Lip	2.3	1.9	1.5	1.6	1.7	1.4	1.7	1.0	0.9	1.1
C01-02	Tongue	1.2	1.7	1.6	1.6	1.2	1.6	1.6	1.7	1.6	1.3
C03-06	Mouth, other	2.2	1.4	1.3	1.6	1.7	1.1	1.3	1.5	1.5	1.1
C07-08	Salivary glands	0.5	0.7	0.7	0.7	0.8	0.6	0.6	0.5	0.5	0.6
C09-14	Pharynx	2.8	2.5	2.9	2.4	2.9	2.5	2.4	2.6	3.0	2.5
C15-26	Digestive organs	66.2	70.0	66.9	67.4	67.1	69.5	68.3	68.9	69.9	66.1
C15	Oesophagus	3.2	3.6	3.5	3.7	2.8	3.2	3.5	3.7	3.9	3.5
C16	Stomach	12.2	10.7	9.6	9.4	9.3	9.0	8.5	8.5	8.2	6.7
C17	Small intestine	0.8	1.2	1.3	1.1	1.3	1.9	1.3	1.7	1.2	1.2
C18	Colon	22.6	25.1	24.2	24.1	25.8	25.5	24.7	24.7	26.3	25.9
C19-21	Rectum, rectosigmoid, anus	15.4	17.7	16.6	16.6	16.6	17.4	18.1	17.9	17.7	16.9
C22	Liver	1.9	1.5	1.9	2.4	1.9	2.0	2.3	2.1	1.9	2.0
C23-24	Gallbladder, bile ducts	1.4	1.6	1.5	1.5	1.4	1.9	1.4	1.4	1.7	2.0
C25	Pancreas	7.7	7.1	7.4	7.3	7.0	7.6	7.8	8.0	7.7	7.0
C26	Other digestive organs	1.1	1.3	0.9	1.2	1.0	0.9	0.7	1.0	1.2	0.9
C30-34, C38	Respiratory organs	42.6	41.6	39.2	40.6	39.7	40.4	40.8	41.4	39.0	37.0
C30-31	Nose, sinuses	0.6	0.6	0.8	0.8	0.8	0.6	0.9	0.5	0.7	0.6
C32	Larynx, epiglottis	3.8	3.2	2.5	3.2	3.3	3.1	3.3	2.8	2.7	2.5
C33-34	Lung, trachea	37.8	37.0	35.5	36.1	35.2	36.2	36.3	37.8	35.3	33.7
C38	Mediastinum, pleura	0.4	0.7	0.4	0.5	0.4	0.5	0.3	0.4	0.2	0.3
C40-41	Bone	1.1	1.2	0.9	0.8	0.9	0.9	1.2	0.8	1.0	1.0
C43	Melanoma of the skin	13.2	16.1	14.6	14.5	14.2	14.9	14.2	14.4	14.3	16.1
C44	Skin, non-melanoma	12.5	14.5	13.4	13.2	14.4	14.1	15.3	14.7	15.0	14.4
C45	Mesothelioma	1.5	1.2	1.3	1.7	1.3	1.6	1.4	1.7	1.8	1.6
C46	Kaposi's sarcoma	0.3	0.3	0.1	0.1	0.1	0.1	0.1	0.2	0.3	0.2
C47	Autonomic nervous system	0.4	0.2	0.3	0.3	0.3	0.2	0.3	0.4	0.1	0.3
C48-49	Soft tissues	1.5	1.4	1.7	1.5	1.7	1.6	1.8	1.5	1.7	1.5
C50	Breast	0.4	0.4	0.5	0.3	0.5	0.4	0.3	0.5	0.3	0.5
C60-63	Male genital organs	75.2	81.2	88.5	90.8	93.6	88.0	82.0	98.6	110.1	103.5
C61	Prostate	64.1	70.5	77.5	79.9	82.3	76.2	71.0	86.7	98.2	91.7
C62	Testis	10.0	9.5	10.1	10.3	10.5	10.9	9.9	10.3	10.9	10.5
C60, C63	Other male genital	1.1	1.2	0.9	0.7	0.8	0.9	1.2	1.5	1.0	1.3
C64-68	Urinary organs	32.3	32.7	33.3	31.0	30.7	31.2	33.1	32.7	35.9	32.0
C64-65	Kidney	9.7	9.9	10.2	9.2	9.1	10.3	10.5	10.1	12.1	10.1
C66-68	Bladder, ureter, urethra	22.6	22.8	23.1	21.8	21.7	20.9	22.6	22.6	23.8	21.9
C69	Eye	1.3	0.8	1.0	1.1	1.0	0.7	1.0	1.1	1.1	0.7
C70-72	Central nervous system	11.8	11.2	11.5	12.4	11.7	13.0	13.2	14.6	11.8	12.5
C73	Thyroid gland	1.2	1.8	1.6	1.5	1.8	1.8	1.7	1.6	1.5	2.0
C37, C74-75	Other endocrine glands	0.5	0.5	0.3	0.5	0.8	0.4	0.4	0.7	0.5	0.2
C39, C76, C80	Other or unspecified	8.4	7.8	7.2	6.7	6.6	5.5	5.6	5.8	5.0	5.3
C81-96	Lymphoid and haematopoietic tissue	27.6	26.7	27.3	26.9	27.2	28.8	27.0	28.7	29.2	27.6
C81	Hodgkin lymphoma	2.4	2.5	2.2	2.6	2.6	2.2	2.2	3.5	3.1	2.7
C82-85, C96	Non-Hodgkin lymphoma	11.7	10.2	11.6	10.3	12.0	10.7	9.9	11.3	12.1	11.9
C88	Malignant immunoproliferative diseases	0.5	0.7	0.4	0.5	0.4	0.8	0.8	0.7	0.5	0.4
C90	Multiple myeloma	4.4	4.8	4.4	4.0	3.9	5.0	4.3	4.2	4.3	4.8
C91-95	Leukaemia	8.6	8.5	8.7	9.4	8.3	10.1	9.8	9.0	9.2	7.8

Table 9 Age-adjusted (world) incidence rates per 100 000 person-years by primary site and year - 1996-2005

FEMALES

ICD10	Site	Year									
		1996	97	98	99	00	01	02	03	04	2005
C00-96	All sites	262.3	269.1	259.1	261.4	270.7	274.0	280.2	277.2	283.9	274.8
C00-14	Mouth, pharynx	3.6	2.8	3.6	3.6	3.1	3.0	3.4	3.2	3.1	4.1
C00	Lip	0.6	0.5	0.7	0.5	0.5	0.5	0.6	0.4	0.5	0.7
C01-02	Tongue	0.7	0.5	0.7	0.9	0.7	0.5	0.7	0.6	0.7	0.7
C03-06	Mouth, other	1.0	1.0	0.9	0.6	0.7	0.6	0.9	0.7	0.9	0.9
C07-08	Salivary glands	0.6	0.3	0.5	0.7	0.6	0.7	0.5	0.5	0.2	0.6
C09-14	Pharynx	0.7	0.4	0.9	1.0	0.7	0.6	0.8	0.9	0.8	1.2
C15-26	Digestive organs	47.7	49.8	50.1	49.3	50.7	50.0	50.5	49.9	51.2	48.9
C15	Oesophagus	0.7	0.9	1.2	0.9	1.0	1.1	0.9	1.1	1.1	1.2
C16	Stomach	5.1	4.9	4.7	4.6	4.7	3.9	4.7	4.0	4.5	4.2
C17	Small intestine	0.6	0.7	1.2	1.1	1.3	1.1	1.4	1.1	1.2	0.9
C18	Colon	22.0	22.1	22.4	22.2	22.8	22.8	22.5	23.8	23.2	22.1
C19-21	Rectum, rectosigmoid, anus	10.0	11.7	11.4	11.1	11.5	11.4	11.5	10.9	12.0	11.6
C22	Liver	0.7	0.8	1.0	1.3	1.1	1.1	0.9	0.9	0.9	1.4
C23-24	Gallbladder, bile ducts	1.5	1.7	1.4	1.7	1.7	1.4	1.4	1.4	1.1	1.3
C25	Pancreas	6.0	6.0	6.1	5.5	5.9	6.4	6.4	6.3	6.3	5.2
C26	Other digestive organs	1.1	0.8	0.8	1.0	0.7	0.8	0.7	0.6	0.8	1.1
C30-34, C38	Respiratory organs	19.9	19.0	17.5	21.0	21.8	21.5	21.4	22.9	23.1	22.2
C30-31	Nose, sinuses	0.4	0.3	0.5	0.4	0.3	0.4	0.5	0.2	0.5	0.4
C32	Larynx, epiglottis	0.7	0.6	0.5	0.5	0.4	0.6	0.5	0.5	0.3	0.5
C33-34	Lung, trachea	18.6	18.0	16.4	19.8	20.9	20.4	20.4	22.1	22.1	21.3
C38	Mediastinum, pleura	0.2	0.1	0.1	0.3	0.2	0.2	0.0	0.0	0.2	0.1
C40-41	Bone	1.2	0.6	0.4	1.1	0.9	0.9	0.9	0.8	0.6	0.6
C43	Melanoma of the skin	15.2	18.6	13.3	14.8	15.6	15.6	16.2	15.7	15.6	15.7
C44	Skin, non-melanoma	7.8	8.3	7.8	7.8	8.3	8.6	8.5	9.2	9.4	10.3
C45	Mesothelioma	0.2	0.1	0.3	0.2	0.2	0.1	0.2	0.2	0.2	0.1
C46	Kaposi's sarcoma	0.1	0.1	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0
C47	Autonomic nervous system	0.4	0.4	0.3	0.1	0.2	0.2	0.3	0.1	0.5	0.2
C48-49	Soft tissues	1.5	1.2	1.3	1.6	2.0	2.1	1.6	2.0	2.4	2.3
C50	Breast	69.1	71.7	69.9	68.6	72.9	75.4	76.8	76.7	77.2	75.7
C51-58	Female genital organs	42.0	41.0	42.2	39.1	39.1	40.7	41.3	39.7	41.0	40.0
C53	Cervix uteri	11.6	11.3	11.7	9.7	9.3	9.8	10.1	9.5	8.6	9.4
C54	Corpus uteri	14.0	13.8	13.5	13.3	14.8	14.9	15.1	16.1	17.0	16.2
C55	Uterus, other	0.2	0.2	0.2	0.1	0.3	0.1	0.2	0.2	0.3	0.2
C56	Ovary	13.4	12.7	13.7	12.9	12.3	12.6	13.6	11.0	12.2	10.7
C51-52, C57	Other female genital	2.7	2.8	3.0	2.8	2.3	3.1	2.3	2.8	2.7	3.3
C58	Placenta	0.1	0.2	0.1	0.3	0.0	0.1	0.1	0.1	0.2	0.3
C64-68	Urinary organs	11.7	12.5	10.8	12.2	11.3	11.6	12.6	11.8	11.4	12.2
C64-65	Kidney	5.7	5.6	4.7	5.3	4.7	4.9	5.3	5.6	5.2	5.5
C66-68	Bladder, ureter, urethra	6.0	6.9	6.1	6.9	6.6	6.7	7.2	6.1	6.2	6.7
C69	Eye	0.9	0.8	0.9	0.8	0.4	0.7	1.0	0.8	1.0	0.8
C70-72	Central nervous system	12.1	12.2	12.1	12.7	12.8	14.2	16.7	15.6	15.8	13.5
C73	Thyroid gland	4.1	3.2	3.7	3.8	5.0	4.3	4.5	4.2	5.2	5.0
C37, C74-75	Other endocrine glands	0.2	0.3	0.7	0.3	0.5	0.4	0.4	0.3	0.3	0.7
C39, C76, C80	Other or unspecified	6.1	6.4	5.4	5.3	5.6	4.6	5.2	4.7	5.0	4.8
C81-96	Lymphoid and haematopoietic tissue	18.3	20.1	18.7	19.1	20.0	20.0	18.8	19.4	20.9	17.6
C81	Hodgkin lymphoma	1.7	1.3	2.0	1.6	2.7	1.4	1.6	2.1	1.7	2.0
C82-85, C96	Non-Hodgkin lymphoma	7.2	8.8	7.5	8.3	8.2	8.4	8.2	7.9	8.9	8.0
C88	Malignant immunoproliferative diseases	0.1	0.2	0.2	0.2	0.2	0.3	0.4	0.3	0.4	0.2
C90	Multiple myeloma	2.7	3.3	2.8	3.2	2.4	3.5	3.3	2.8	3.1	2.9
C91-95	Leukaemia	6.6	6.5	6.2	5.8	6.5	6.4	5.3	6.4	6.7	4.5

Table 10 Number of new cases by primary site and five-year age group - 2005

MALES

ICD10	Site	Age																	
		0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+
C00-96	All sites	31	18	18	33	61	100	131	131	207	341	556	1150	1497	1710	1901	1976	1675	1170
C00-14	Mouth, pharynx	0	0	0	0	1	0	0	3	11	11	20	37	31	39	27	26	13	16
C00	Lip	0	0	0	0	0	0	0	0	2	2	2	3	6	4	6	6	2	8
C01-02	Tongue	0	0	0	0	0	0	0	1	2	5	3	5	6	9	5	4	3	2
C03-06	Mouth, other	0	0	0	0	0	0	0	1	2	0	5	12	3	5	3	5	2	1
C07-08	Salivary glands	0	0	0	0	1	0	0	0	1	2	0	3	1	4	3	4	1	3
C09-14	Pharynx	0	0	0	0	0	0	0	1	4	2	10	14	15	17	10	7	5	2
C15-26	Digestive organs	0	3	0	1	2	1	13	19	44	66	114	233	315	346	400	442	387	288
C15	Oesophagus	0	0	0	0	0	0	0	0	2	9	8	23	14	19	16	20	16	10
C16	Stomach	0	0	0	0	0	0	1	2	5	7	9	21	27	27	47	48	45	48
C17	Small intestine	0	0	0	0	0	0	1	3	2	3	4	3	4	1	9	7	7	4
C18	Colon	0	0	0	0	2	0	7	5	19	20	42	82	129	130	171	182	155	108
C19-21	Rectum, rectosigmoid, anus	0	0	0	0	0	1	0	5	12	19	32	60	85	93	95	111	89	73
C22	Liver	0	3	0	1	0	0	1	1	2	2	3	10	10	9	6	10	6	8
C23-24	Gallbladder, bile ducts	0	0	0	0	0	0	1	1	1	2	5	4	9	17	10	8	8	6
C25	Pancreas	0	0	0	0	0	0	2	2	1	4	10	26	34	47	40	50	53	20
C26	Other digestive organs	0	0	0	0	0	0	0	0	0	0	1	4	3	3	6	6	8	11
C30-34, C38	Respiratory organs	0	0	1	0	0	1	1	2	10	38	56	141	207	204	241	276	192	104
C30-31	Nose, sinuses	0	0	1	0	0	0	0	0	1	1	2	3	2	2	3	0	2	4
C32	Larynx, epiglottis	0	0	0	0	0	0	0	0	1	0	5	16	16	16	12	14	9	4
C33-34	Lung, trachea	0	0	0	0	0	1	1	2	8	37	47	121	188	184	225	258	180	95
C38	Mediastinum, pleura	0	0	0	0	0	0	0	0	0	0	2	1	1	2	1	4	1	1
C40-41	Bone	0	1	0	3	4	0	0	2	2	1	2	5	1	1	1	3	1	1
C43	Melanoma of the skin	0	0	0	2	0	11	14	18	18	40	47	67	65	68	69	67	49	37
C44	Skin, non-melanoma	0	0	0	0	1	3	4	2	4	9	18	41	37	63	89	131	130	130
C45	Mesothelioma	0	0	0	0	0	0	0	0	0	0	4	0	8	6	21	11	9	8
C46	Kaposi's sarcoma	0	0	0	0	0	0	0	0	0	0	1	0	0	4	0	0	2	1
C47	Autonomic nervous system	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0
C48-49	Soft tissues	0	1	0	1	1	0	1	2	1	7	5	5	3	3	10	2	6	2
C50	Breast	0	0	1	0	0	0	0	0	0	0	3	3	2	2	2	0	1	4
C60-63	Male genital organs	1	0	2	7	31	52	56	34	32	47	112	331	502	675	655	583	495	313
C61	Prostate	0	0	0	0	0	0	0	0	3	30	94	319	496	669	645	578	489	308
C62	Testis	1	0	2	6	31	50	55	33	28	15	16	5	2	1	2	0	1	1
C60, C63	Other male genital	0	0	0	1	0	2	1	1	1	2	2	7	4	5	8	5	5	4
C64-68	Urinary organs	2	3	0	0	2	1	5	9	19	39	62	121	158	126	199	230	186	139
C64-65	Kidney	1	3	0	0	1	1	4	4	6	17	31	43	65	32	52	49	43	21
C66-68	Bladder, ureter, urethra	1	0	0	0	1	0	1	5	13	22	31	78	93	94	147	181	143	118
C69	Eye	0	0	0	0	0	1	0	0	1	2	4	5	2	2	3	0	1	3
C70-72	Central nervous system	11	5	7	4	10	11	14	17	30	26	27	44	33	39	27	28	33	14
C73	Thyroid gland	0	0	0	1	0	2	5	1	5	8	10	12	4	5	5	4	3	0
C37, C74-75	Other endocrine glands	0	0	0	0	0	0	0	0	0	2	1	0	1	1	0	0	0	0
C39, C76, C80	Other or unspecified	0	0	0	0	0	0	0	0	2	9	8	18	18	28	27	37	45	40
C81-96	Lymphoid and haematopoietic tissue	14	5	7	14	9	17	18	22	28	36	62	87	110	98	125	135	121	70
C81	Hodgkin lymphoma	0	2	5	7	5	7	9	6	3	1	3	3	3	5	1	2	1	0
C82-85, C96	Non-Hodgkin lymphoma	1	1	0	2	2	6	4	11	12	26	32	47	56	43	56	55	53	28
C88	Malignant immunoproliferative diseases	0	0	0	0	0	0	0	0	0	0	2	0	4	2	1	2	6	2
C90	Multiple myeloma	0	0	0	0	0	0	2	2	4	5	9	18	21	28	24	35	31	17
C91-95	Leukaemia	13	2	2	5	2	4	3	3	9	4	16	19	26	20	43	41	30	23

Table 11 - Number of new cases by primary site and five-year age group - 2005

FEMALES

ICD10	Site	Age																	
		0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+
C00-96	All sites	36	20	9	24	53	76	165	283	398	650	850	1163	1239	1154	1162	1428	1391	1421
C00-14	Mouth, pharynx	0	0	1	1	0	0	1	1	5	7	14	22	21	19	17	26	21	24
C00	Lip	0	0	0	0	0	0	1	0	0	0	4	3	1	3	2	12	6	4
C01-02	Tongue	0	0	0	0	0	0	0	0	0	1	2	4	3	5	3	5	3	6
C03-06	Mouth, other	0	0	0	0	0	0	0	0	2	2	1	8	7	2	3	3	7	7
C07-08	Salivary glands	0	0	1	1	0	0	0	1	1	0	1	2	3	3	3	3	2	4
C09-14	Pharynx	0	0	0	0	0	0	0	0	2	4	6	5	7	6	6	3	3	3
C15-26	Digestive organs	0	0	0	1	3	3	10	25	50	64	103	166	221	256	312	406	458	451
C15	Oesophagus	0	0	0	0	0	0	0	1	0	1	3	3	7	7	7	10	9	13
C16	Stomach	0	0	0	0	0	0	2	4	4	6	10	13	20	16	32	25	51	45
C17	Small intestine	0	0	0	0	0	0	0	2	1	1	2	2	6	3	7	10	0	7
C18	Colon	0	0	0	1	2	2	4	8	23	27	40	66	90	119	156	208	219	203
C19-21	Rectum, rectosigmoid, anus	0	0	0	0	0	1	3	8	10	20	34	54	52	59	65	71	87	89
C22	Liver	0	0	0	0	1	0	0	0	4	1	2	5	10	6	6	10	7	7
C23-24	Gallbladder, bile ducts	0	0	0	0	0	0	0	0	1	1	3	3	7	10	6	14	17	6
C25	Pancreas	0	0	0	0	0	0	1	2	4	5	9	17	25	30	28	51	53	61
C26	Other digestive organs	0	0	0	0	0	0	0	0	3	2	0	3	4	6	5	7	15	20
C30-34, C38	Respiratory organs	0	0	0	0	1	1	2	2	14	27	69	104	125	129	148	167	97	61
C30-31	Nose, sinuses	0	0	0	0	0	0	0	0	0	0	3	3	3	2	1	1	1	3
C32	Larynx, epiglottis	0	0	0	0	0	0	0	0	1	1	1	1	4	4	1	1	2	0
C33-34	Lung, trachea	0	0	0	0	1	1	2	2	13	25	65	100	118	123	146	163	91	55
C38	Mediastinum, pleura	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	2	3	3
C40-41	Bone	0	0	2	0	2	2	0	2	0	3	0	1	1	0	0	1	1	0
C43	Melanoma of the skin	0	0	1	2	8	9	24	29	46	55	34	58	64	43	58	48	41	44
C44	Skin, non-melanoma	0	0	0	2	2	1	1	4	11	9	18	27	29	43	62	92	130	249
C45	Mesothelioma	0	0	0	0	0	0	0	0	0	0	1	1	0	1	1	0	3	0
C46	Kaposi's sarcoma	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0
C47	Autonomic nervous system	1	0	0	0	0	1	0	0	1	1	0	0	0	0	0	0	0	0
C48-49	Soft tissues	1	1	0	3	3	2	2	0	3	3	9	11	7	4	12	4	2	7
C50	Breast	0	0	0	0	1	9	34	96	157	281	337	400	364	305	172	200	234	190
C51-58	Female genital organs	0	1	0	2	13	19	50	70	52	87	140	181	184	154	149	164	154	127
C53	Cervix uteri	0	0	0	0	6	14	41	48	24	20	27	22	21	16	16	19	14	4
C54	Corpus uteri	0	0	0	0	0	1	2	9	8	36	62	83	89	82	87	85	60	62
C55	Uterus, other	0	0	0	0	0	1	0	0	0	0	1	0	2	0	0	1	5	1
C56	Ovary	0	1	0	2	4	3	5	9	15	24	37	62	60	37	35	39	52	35
C51-52, C57	Other female genital	0	0	0	0	0	0	1	3	5	6	13	14	12	19	11	20	23	25
C58	Placenta	0	0	0	0	3	0	1	1	0	1	0	0	0	0	0	0	0	0
C64-68	Urinary organs	3	1	0	0	0	2	2	4	6	16	17	56	59	61	91	104	84	72
C64-65	Kidney	3	1	0	0	0	2	2	2	4	9	7	24	22	29	36	54	30	18
C66-68	Bladder, ureter, urethra	0	0	0	0	0	0	0	2	2	7	10	32	37	32	55	50	54	54
C69	Eye	4	0	0	0	0	1	0	1	1	1	0	1	3	1	4	5	1	0
C70-72	Central nervous system	13	8	4	8	7	5	15	14	26	35	35	43	56	42	30	42	20	22
C73	Thyroid gland	0	2	0	2	4	9	14	15	8	16	10	19	14	11	6	11	8	12
C37, C74-75	Other endocrine glands	3	1	0	0	0	1	0	0	2	0	1	1	3	1	1	0	0	0
C39, C76, C80	Other or unspecified	0	0	0	0	1	0	3	1	3	7	10	18	23	20	19	51	43	73
C81-96	Lymphoid and haematopoietic tissue	11	6	1	3	8	11	7	19	13	38	52	54	65	64	80	106	93	89
C81	Hodgkin lymphoma	1	1	1	2	6	6	2	7	5	5	1	3	0	3	3	4	0	0
C82-85, C96	Non-Hodgkin lymphoma	0	1	0	0	1	3	2	6	7	23	35	32	30	34	34	57	42	35
C88	Malignant immunoproliferative diseases	0	0	0	0	0	0	0	0	0	0	0	1	0	4	0	2	3	3
C90	Multiple myeloma	0	0	0	0	0	0	0	0	0	3	9	10	20	10	29	17	18	18
C91-95	Leukaemia	10	4	0	1	1	2	3	6	1	7	7	8	15	13	14	26	30	33

Table 12 - Age-specific incidence rates per 100 000 person-years by primary site and five-year age group - 2005

MALES

ICD10	Site	Age																	
		0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+
C00-96	All sites	21.1	11.5	11.2	21.5	43.7	69.1	77.2	72.1	120.9	210.5	362.5	751.4	1251.1	1996.2	2758.0	3271.7	3772.4	3981.1
C00-14	Mouth, pharynx	0.0	0.0	0.0	0.0	0.7	0.0	0.0	1.7	6.4	6.8	13.0	24.2	25.9	45.5	39.2	43.0	29.3	54.4
C00	Lip	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.2	1.2	1.3	2.0	5.0	4.7	8.7	9.9	4.5	27.2
C01-02	Tongue	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	1.2	3.1	2.0	3.3	5.0	10.5	7.3	6.6	6.8	6.8
C03-06	Mouth, other	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	1.2	0.0	3.3	7.8	2.5	5.8	4.4	8.3	4.5	3.4
C07-08	Salivary glands	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.6	1.2	0.0	2.0	0.8	4.7	4.4	6.6	2.3	10.2
C09-14	Pharynx	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	2.3	1.2	6.5	9.1	12.5	19.8	14.5	11.6	11.3	6.8
C15-26	Digestive organs	0.0	1.9	0.0	0.7	1.4	0.7	7.7	10.5	25.7	40.7	74.3	152.2	263.3	403.9	580.3	731.8	871.6	980.0
C15	Oesophagus	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.2	5.6	5.2	15.0	11.7	22.2	23.2	33.1	36.0	34.0
C16	Stomach	0.0	0.0	0.0	0.0	0.0	0.0	0.6	1.1	2.9	4.3	5.9	13.7	22.6	31.5	68.2	79.5	101.3	163.3
C17	Small intestine	0.0	0.0	0.0	0.0	0.0	0.0	0.6	1.7	1.2	1.9	2.6	2.0	3.3	1.2	13.1	11.6	15.8	13.6
C18	Colon	0.0	0.0	0.0	0.0	1.4	0.0	4.1	2.8	11.1	12.3	27.4	53.6	107.8	151.8	248.1	301.3	349.1	367.5
C19-21	Rectum, rectosigmoid, anus	0.0	0.0	0.0	0.0	0.0	0.7	0.0	2.8	7.0	11.7	20.9	39.2	71.0	108.6	137.8	183.8	200.4	248.4
C22	Liver	0.0	1.9	0.0	0.7	0.0	0.0	0.6	0.6	1.2	1.2	2.0	6.5	8.4	10.5	8.7	16.6	13.5	27.2
C23-24	Gallbladder, bile ducts	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.6	0.6	1.2	3.3	2.6	7.5	19.8	14.5	13.2	18.0	20.4
C25	Pancreas	0.0	0.0	0.0	0.0	0.0	0.0	1.2	1.1	0.6	2.5	6.5	17.0	28.4	54.9	58.0	82.8	119.4	68.1
C26	Other digestive organs	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	2.6	2.5	3.5	8.7	9.9	18.0	37.4
C30-34, C38	Respiratory organs	0.0	0.0	0.6	0.0	0.0	0.7	0.6	1.1	5.8	23.5	36.5	92.1	173.0	238.1	349.6	457.0	432.4	353.9
C30-31	Nose, sinuses	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.6	0.6	1.3	2.0	1.7	2.3	4.4	0.0	4.5	13.6
C32	Larynx, epiglottis	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	3.3	10.5	13.4	18.7	17.4	23.2	20.3	13.6
C33-34	Lung, trachea	0.0	0.0	0.0	0.0	0.0	0.7	0.6	1.1	4.7	22.8	30.6	79.1	157.1	214.8	326.4	427.2	405.4	323.3
C38	Mediastinum, pleura	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.3	0.7	0.8	2.3	1.5	6.6	2.3	3.4
C40-41	Bone	0.0	0.6	0.0	2.0	2.9	0.0	0.0	1.1	1.2	0.6	1.3	3.3	0.8	1.2	1.5	5.0	2.3	3.4
C43	Melanoma of the skin	0.0	0.0	0.0	1.3	0.0	7.6	8.3	9.9	10.5	24.7	30.6	43.8	54.3	79.4	100.1	110.9	110.4	125.9
C44	Skin, non-melanoma	0.0	0.0	0.0	0.0	0.7	2.1	2.4	1.1	2.3	5.6	11.7	26.8	30.9	73.5	129.1	216.9	292.8	442.3
C45	Mesothelioma	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.6	0.0	6.7	7.0	30.5	18.2	20.3	27.2
C46	Kaposi's sarcoma	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	4.7	0.0	0.0	4.5	3.4
C47	Autonomic nervous system	2.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.7	2.3	0.0
C48-49	Soft tissues	0.0	0.6	0.0	0.7	0.7	0.0	0.6	1.1	0.6	4.3	3.3	3.3	2.5	3.5	14.5	3.3	13.5	6.8
C50	Breast	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.0	2.0	1.7	2.3	2.9	0.0	2.3	13.6
C60-63	Male genital organs	0.7	0.0	1.2	4.6	22.2	35.9	33.0	18.7	18.7	29.0	73.0	216.3	419.6	788.0	950.3	965.3	1114.8	1065.0
C61	Prostate	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.8	18.5	61.3	208.4	414.5	781.0	935.8	957.0	1101.3	1048.0
C62	Testis	0.7	0.0	1.2	3.9	22.2	34.5	32.4	18.2	16.3	9.3	10.4	3.3	1.7	1.2	2.9	0.0	2.3	3.4
C60, C63	Other male genital	0.0	0.0	0.0	0.7	0.0	1.4	0.6	0.6	0.6	1.2	1.3	4.6	3.3	5.8	11.6	8.3	11.3	13.6
C64-68	Urinary organs	1.4	1.9	0.0	0.0	1.4	0.7	2.9	5.0	11.1	24.1	40.4	79.1	132.1	147.1	288.7	380.8	418.9	473.0
C64-65	Kidney	0.7	1.9	0.0	0.0	0.7	0.7	2.4	2.2	3.5	10.5	20.2	28.1	54.3	37.4	75.4	81.1	96.8	71.5
C66-68	Bladder, ureter, urethra	0.7	0.0	0.0	0.0	0.7	0.0	0.6	2.8	7.6	13.6	20.2	51.0	77.7	109.7	213.3	299.7	322.1	401.5
C69	Eye	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.6	1.2	2.6	3.3	1.7	2.3	4.4	0.0	2.3	10.2
C70-72	Central nervous system	7.5	3.2	4.3	2.6	7.2	7.6	8.3	9.4	17.5	16.0	17.6	28.7	27.6	45.5	39.2	46.4	74.3	47.6
C73	Thyroid gland	0.0	0.0	0.0	0.7	0.0	1.4	2.9	0.6	2.9	4.9	6.5	7.8	3.3	5.8	7.3	6.6	6.8	0.0
C37, C74-75	Other endocrine glands	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.2	0.7	0.0	0.8	1.2	0.0	0.0	0.0	0.0
C39, C76, C80	Other or unspecified	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.2	5.6	5.2	11.8	15.0	32.7	39.2	61.3	101.3	136.1
C81-96	Lymphoid and haematopoietic tissue	9.5	3.2	4.3	9.1	6.4	11.7	10.6	12.1	16.3	22.2	40.4	56.8	91.9	114.4	181.3	223.5	272.5	238.2
C81	Hodgkin lymphoma	0.0	1.3	3.1	4.6	3.6	4.8	5.3	3.3	1.8	0.6	2.0	2.0	2.5	5.8	1.5	3.3	2.3	0.0
C82-85, C96	Non-Hodgkin lymphoma	0.7	0.6	0.0	1.3	1.4	4.1	2.4	6.1	7.0	16.0	20.9	30.7	46.8	50.2	81.2	91.1	119.4	95.3
C88	Malignant immunoproliferative diseases	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.3	0.0	3.3	2.3	1.5	3.3	13.5	6.8
C90	Multiple myeloma	0.0	0.0	0.0	0.0	0.0	0.0	1.2	1.1	2.3	3.1	5.9	11.8	17.6	32.7	34.8	57.9	69.8	57.8
C91-95	Leukaemia	8.9	1.3	1.2	3.3	1.4	2.8	1.8	1.7	5.3	2.5	10.4	12.4	21.7	23.3	62.4	67.9	67.6	78.3

Table 13 Age-specific incidence rates per 100 000 person-years by primary site and five-year age group - 2005

FEMALES

ICD10	Site	Age																	
		0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+
C00-96	All sites	25.6	13.4	5.9	16.5	39.1	53.1	99.3	161.6	242.7	414.3	571.3	785.2	1038.8	1259.3	1437.1	1805.1	1925.3	2034.7
C00-14	Mouth, pharynx	0.0	0.0	0.7	0.7	0.0	0.0	0.6	0.6	3.0	4.5	9.4	14.9	17.6	20.7	21.0	32.9	29.1	34.4
C00	Lip	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	2.7	2.0	0.8	3.3	2.5	15.2	8.3	5.7
C01-02	Tongue	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	1.3	2.7	2.5	5.5	3.7	6.3	4.2	8.6
C03-06	Mouth, other	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.2	1.3	0.7	5.4	5.9	2.2	3.7	3.8	9.7	10.0
C07-08	Salivary glands	0.0	0.0	0.7	0.7	0.0	0.0	0.0	0.6	0.6	0.0	0.7	1.4	2.5	3.3	3.7	3.8	2.8	5.7
C09-14	Pharynx	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.2	2.5	4.0	3.4	5.9	6.5	7.4	3.8	4.2	4.3
C15-26	Digestive organs	0.0	0.0	0.0	0.7	2.2	2.1	6.0	14.3	30.5	40.8	69.2	112.1	185.3	279.4	385.9	513.2	633.9	645.8
C15	Oesophagus	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.6	2.0	2.0	5.9	7.6	8.7	12.6	12.5	18.6
C16	Stomach	0.0	0.0	0.0	0.0	0.0	0.0	1.2	2.3	2.4	3.8	6.7	8.8	16.8	17.5	39.6	31.6	70.6	64.4
C17	Small intestine	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.1	0.6	0.6	1.3	1.4	5.0	3.3	8.7	12.6	0.0	10.0
C18	Colon	0.0	0.0	0.0	0.7	1.5	1.4	2.4	4.6	14.0	17.2	26.9	44.6	75.5	129.9	192.9	262.9	303.1	290.7
C19-21	Rectum, rectosigmoid, anus	0.0	0.0	0.0	0.0	0.0	0.7	1.8	4.6	6.1	12.7	22.9	36.5	43.6	64.4	80.4	89.7	120.4	127.4
C22	Liver	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.0	2.4	0.6	1.3	3.4	8.4	6.5	7.4	12.6	9.7	10.0
C23-24	Gallbladder, bile ducts	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.6	2.0	2.0	5.9	10.9	7.4	17.7	23.5	8.6
C25	Pancreas	0.0	0.0	0.0	0.0	0.0	0.0	0.6	1.1	2.4	3.2	6.0	11.5	21.0	32.7	34.6	64.5	73.4	87.3
C26	Other digestive organs	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.8	1.3	0.0	2.0	3.4	6.5	6.2	8.8	20.8	28.6
C30-34, C38	Respiratory organs	0.0	0.0	0.0	0.0	0.7	0.7	1.2	1.1	8.5	17.2	46.4	70.2	104.8	140.8	183.0	211.1	134.3	87.3
C30-31	Nose, sinuses	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.0	2.0	2.5	2.2	1.2	1.3	1.4	4.3
C32	Larynx, epiglottis	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.6	0.7	0.7	3.4	4.4	1.2	1.3	2.8	0.0
C33-34	Lung, trachea	0.0	0.0	0.0	0.0	0.7	0.7	1.2	1.1	7.9	15.9	43.7	67.5	98.9	134.2	180.6	206.0	126.0	78.8
C38	Mediastinum, pleura	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	2.5	4.2	4.3
C40-41	Bone	0.0	0.0	1.3	0.0	1.5	1.4	0.0	1.1	0.0	1.9	0.0	0.7	0.8	0.0	0.0	1.3	1.4	0.0
C43	Melanoma of the skin	0.0	0.0	0.7	1.4	5.9	6.3	14.4	16.6	28.0	35.1	22.9	39.2	53.7	46.9	71.7	60.7	56.7	63.0
C44	Skin, non-melanoma	0.0	0.0	0.0	1.4	1.5	0.7	0.6	2.3	6.7	5.7	12.1	18.2	24.3	46.9	76.7	116.3	179.9	356.5
C45	Mesothelioma	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.7	0.0	1.1	1.2	0.0	4.2	0.0
C46	Kaposi's sarcoma	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.3	1.4	0.0
C47	Autonomic nervous system	0.7	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.6	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C48-49	Soft tissues	0.7	0.7	0.0	2.1	2.2	1.4	1.2	0.0	1.8	1.9	6.0	7.4	5.9	4.4	14.8	5.1	2.8	10.0
C50	Breast	0.0	0.0	0.0	0.0	0.7	6.3	20.5	54.8	95.7	179.1	226.5	270.1	305.2	332.8	212.7	252.8	323.9	272.1
C51-58	Female genital organs	0.0	0.7	0.0	1.4	9.6	13.3	30.1	40.0	31.7	55.5	94.1	122.2	154.3	168.1	184.3	207.3	213.2	181.9
C53	Cervix uteri	0.0	0.0	0.0	0.0	4.4	9.8	24.7	27.4	14.6	12.7	18.1	14.9	17.6	17.5	19.8	24.0	19.4	5.7
C54	Corpus uteri	0.0	0.0	0.0	0.0	0.0	0.7	1.2	5.1	4.9	22.9	41.7	56.0	74.6	89.5	107.6	107.4	83.0	88.8
C55	Uterus, other	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.7	0.0	1.7	0.0	0.0	1.3	6.9	1.4
C56	Ovary	0.0	0.7	0.0	1.4	3.0	2.1	3.0	5.1	9.1	15.3	24.9	41.9	50.3	40.4	43.3	49.3	72.0	50.1
C51-52, C57	Other female genital	0.0	0.0	0.0	0.0	0.0	0.0	0.6	1.7	3.0	3.8	8.7	9.5	10.1	20.7	13.6	25.3	31.8	35.8
C58	Placenta	0.0	0.0	0.0	0.0	2.2	0.0	0.6	0.6	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C64-68	Urinary organs	2.1	0.7	0.0	0.0	0.0	1.4	1.2	2.3	3.7	10.2	11.4	37.8	49.5	66.6	112.5	131.5	116.3	103.1
C64-65	Kidney	2.1	0.7	0.0	0.0	0.0	1.4	1.2	1.1	2.4	5.7	4.7	16.2	18.4	31.6	44.5	68.3	41.5	25.8
C66-68	Bladder, ureter, urethra	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.1	1.2	4.5	6.7	21.6	31.0	34.9	68.0	63.2	74.7	77.3
C69	Eye	2.8	0.0	0.0	0.0	0.0	0.7	0.0	0.6	0.6	0.6	0.0	0.7	2.5	1.1	4.9	6.3	1.4	0.0
C70-72	Central nervous system	9.2	5.4	2.6	5.5	5.2	3.5	9.0	8.0	15.9	22.3	23.5	29.0	47.0	45.8	37.1	53.1	27.7	31.5
C73	Thyroid gland	0.0	1.3	0.0	1.4	3.0	6.3	8.4	8.6	4.9	10.2	6.7	12.8	11.7	12.0	7.4	13.9	11.1	17.2
C37, C74-75	Other endocrine glands	2.1	0.7	0.0	0.0	0.0	0.7	0.0	0.0	1.2	0.0	0.7	0.7	2.5	1.1	1.2	0.0	0.0	0.0
C39, C76, C80	Other or unspecified	0.0	0.0	0.0	0.0	0.7	0.0	1.8	0.6	1.8	4.5	6.7	12.2	19.3	21.8	23.5	64.5	59.5	104.5
C81-96	Lymphoid and haematopoietic tissue	7.8	4.0	0.7	2.1	5.9	7.7	4.2	10.9	7.9	24.2	35.0	36.5	54.5	69.8	98.9	134.0	128.7	127.4
C81	Hodgkin lymphoma	0.7	0.7	0.7	1.4	4.4	4.2	1.2	4.0	3.0	3.2	0.7	2.0	0.0	3.3	3.7	5.1	0.0	0.0
C82-85, C96	Non-Hodgkin lymphoma	0.0	0.7	0.0	0.0	0.7	2.1	1.2	3.4	4.3	14.7	23.5	21.6	25.2	37.1	42.0	72.1	58.1	50.1
C88	Malignant immunoproliferative diseases	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	4.4	0.0	2.5	4.2	4.3
C90	Multiple myeloma	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.9	6.0	6.8	16.8	10.9	35.9	21.5	24.9	25.8
C91-95	Leukaemia	7.1	2.7	0.0	0.7	0.7	1.4	1.8	3.4	0.6	4.5	4.7	5.4	12.6	14.2	17.3	32.9	41.5	47.3

Table 14 Average annual number of new cases by primary site and 5-year period 1956-2005

MALES

ICD10	Site	Period									
		1956-60	1961-65	1966-70	1971-75	1976-80	1981-85	1986-90	1991-95	1996-00	2001-05
C00-96	All sites	3976	4613	5421	6304	7427	8470	9190	10264	11228	12311
C00-14	Mouth, pharynx	189	187	203	245	239	248	256	256	265	246
C00	Lip	101	93	103	121	116	98	94	75	64	45
C01-02	Tongue	18	21	21	25	29	36	36	41	47	50
C03-06	Mouth, other	22	22	32	29	34	46	46	55	52	45
C07-08	Salivary glands	12	13	14	14	14	14	15	21	22	20
C09-14	Pharynx	35	39	32	56	45	54	64	64	81	86
C15-26	Digestive organs	1642	1725	1864	1952	2151	2363	2371	2466	2518	2690
C15	Oesophagus	74	80	77	84	87	87	98	107	118	133
C16	Stomach	851	794	769	662	603	588	529	459	398	336
C17	Small intestine	10	11	18	15	19	31	25	32	40	52
C18	Colon	236	291	357	402	521	648	740	840	918	1016
C19-21	Rectum, rectosigmoid, anus	155	189	257	317	438	522	538	585	599	673
C22	Liver	19	23	36	55	50	66	59	61	68	78
C23-24	Gallbladder, bile ducts	17	22	27	28	39	43	49	54	57	64
C25	Pancreas	143	176	218	250	264	299	292	281	275	298
C26	Other digestive organs	137	140	106	140	131	78	42	47	44	40
C30-34, C38	Respiratory organs	327	451	633	788	1009	1192	1293	1364	1424	1509
C30-31	Nose, sinuses	20	22	21	22	24	22	24	20	23	23
C32	Larynx, epiglottis	32	46	67	70	90	104	106	102	106	104
C33-34	Lung, trachea	263	373	532	679	876	1052	1156	1223	1278	1368
C38	Mediastinum, pleura	12	11	13	17	20	15	7	19	17	14
C40-41	Bone	13	16	18	22	20	24	21	22	21	25
C43	Melanoma of the skin	51	76	103	157	206	254	351	434	453	499
C44	Skin, non-melanoma	84	73	90	171	222	270	354	465	550	649
C45	Mesothelioma	0	3	3	8	19	25	39	34	50	63
C46	Kaposi's sarcoma	2	4	4	6	6	8	12	15	6	7
C47	Autonomic nervous system	20	14	16	11	9	8	8	7	6	5
C48-49	Soft tissues	21	24	34	43	52	45	43	46	47	52
C50	Breast	7	8	9	9	10	13	13	13	15	16
C60-63	Male genital organs	728	932	1109	1336	1611	1868	2049	2574	3138	3599
C61	Prostate	654	840	1012	1227	1477	1694	1859	2343	2866	3302
C62	Testis	55	68	75	85	107	142	164	197	237	254
C60, C63	Other male genital	18	24	22	24	27	31	26	33	34	43
C64-68	Urinary organs	310	415	531	666	808	975	1054	1154	1174	1292
C64-65	Kidney	103	132	168	198	226	282	290	313	325	380
C66-68	Bladder, ureter, urethra	207	283	362	468	581	693	764	842	849	912
C69	Eye	20	18	23	18	26	25	24	26	30	30
C70-72	Central nervous system	120	136	145	161	188	219	245	254	326	379
C73	Thyroid gland	20	23	35	35	43	45	50	45	47	54
C37, C74-75	Other endocrine glands	4	7	5	8	9	12	13	15	13	11
C39, C76, C80	Other or unspecified	54	85	125	146	182	222	270	290	289	234
C81-96	Lymphoid and haematopoietic tissue	362	416	472	523	615	654	726	784	856	954
C81	Hodgkin lymphoma	44	52	60	63	67	56	50	50	58	67
C82-85, C96	Non-Hodgkin lymphoma	97	107	138	136	166	210	277	311	356	388
C88	Malignant immunoproliferative diseases	0	0	2	6	7	10	8	16	19	26
C90	Multiple myeloma	72	83	90	117	149	152	162	160	161	175
C91-95	Leukaemia	150	175	184	201	225	227	228	247	262	299

Table 15 Average annual number of new cases by primary site and 5-year period 1956-2005

FEMALES

ICD10	Site	Period									
		1956-60	1961-65	1966-70	1971-75	1976-80	1981-85	1986-90	1991-95	1996-00	2001-05
C00-96	All sites	4139	4576	5308	6010	6991	7721	8432	9322	10348	11370
C00-14	Mouth, pharynx	60	67	74	78	88	101	112	122	132	142
C00	Lip	8	9	10	10	16	19	27	29	26	27
C01-02	Tongue	10	13	17	16	18	23	24	23	27	28
C03-06	Mouth, other	11	13	17	17	20	24	28	35	34	36
C07-08	Salivary glands	8	14	14	12	13	14	13	17	20	19
C09-14	Pharynx	23	19	17	22	21	20	20	19	25	32
C15-26	Digestive organs	1384	1436	1579	1691	1987	2143	2206	2339	2451	2529
C15	Oesophagus	23	29	30	30	31	35	37	42	46	54
C16	Stomach	595	538	501	423	411	390	352	305	254	228
C17	Small intestine	10	11	13	19	19	27	28	31	39	49
C18	Colon	273	337	427	495	656	771	872	984	1095	1170
C19-21	Rectum, rectosigmoid, anus	127	138	214	266	360	419	441	499	506	534
C22	Liver	11	14	19	30	34	44	41	44	45	46
C23-24	Gallbladder, bile ducts	47	52	61	49	70	83	78	71	83	71
C25	Pancreas	97	119	156	183	218	265	287	303	318	326
C26	Other digestive organs	202	198	158	195	188	109	70	58	64	51
C30-34, C38	Respiratory organs	89	108	156	195	241	331	454	587	743	905
C30-31	Nose, sinuses	13	13	12	14	13	12	16	16	16	17
C32	Larynx, epiglottis	2	4	6	7	10	11	11	18	20	17
C33-34	Lung, trachea	70	84	131	165	212	303	423	546	700	864
C38	Mediastinum, pleura	4	7	6	8	6	5	4	6	8	7
C40-41	Bone	9	11	12	13	13	14	15	17	20	18
C43	Melanoma of the skin	55	88	120	178	259	336	431	484	500	549
C44	Skin, non-melanoma	53	47	49	106	146	206	274	381	462	565
C45	Mesothelioma	0	1	1	2	3	4	6	9	8	9
C46	Kaposi's sarcoma	0	1	2	4	3	5	6	6	5	2
C47	Autonomic nervous system	17	11	14	10	7	5	9	7	7	5
C48-49	Soft tissues	17	26	27	35	42	45	45	47	55	73
C50	Breast	917	1039	1191	1363	1536	1676	1812	2008	2421	2721
C51-58	Female genital organs	865	952	1101	1219	1295	1284	1301	1384	1421	1526
C53	Cervix uteri	341	358	396	436	410	365	336	353	316	293
C54	Corpus uteri	174	216	260	310	370	383	408	455	505	632
C55	Uterus, other	23	21	14	9	7	6	6	8	10	11
C56	Ovary	259	286	358	338	375	414	439	454	464	454
C51-52, C57	Other female genital	66	69	69	122	131	113	108	111	123	132
C58	Placenta	3	2	4	3	3	4	5	5	3	4
C64-68	Urinary organs	198	224	272	325	379	417	466	497	534	574
C64-65	Kidney	80	93	120	132	153	167	203	211	217	235
C66-68	Bladder, ureter, urethra	118	131	152	193	226	250	264	286	317	339
C69	Eye	15	18	17	18	23	21	23	30	27	31
C70-72	Central nervous system	106	120	130	139	184	212	252	284	385	490
C73	Thyroid gland	53	58	85	107	129	142	135	139	120	145
C37, C74-75	Other endocrine glands	6	5	4	3	8	12	15	14	11	12
C39, C76, C80	Other or unspecified	47	70	97	103	163	221	270	312	312	294
C81-96	Lymphoid and haematopoietic tissue	248	297	376	420	488	545	599	656	733	779
C81	Hodgkin lymphoma	31	37	45	41	45	37	37	31	43	45
C82-85, C96	Non-Hodgkin lymphoma	63	76	117	110	144	195	238	281	313	344
C88	Malignant immunoproliferative diseases	0	0	0	4	3	6	7	12	9	16
C90	Multiple myeloma	37	58	77	106	125	128	137	138	142	153
C91-95	Leukaemia	116	126	136	158	171	179	181	194	224	220

Table 16 Age-adjusted (world) incidence rates per 100 000 person-years by primary site and five-year period 1956-2005

MALES

ICD10	Site	Period									
		1956-60	1961-65	1966-70	1971-75	1976-80	1981-85	1986-90	1991-95	1996-00	2001-05
C00-96	All sites	171.3	181.8	197.9	215.5	239.2	259.3	272.0	294.4	316.7	329.3
C00-14	Mouth, pharynx	8.0	7.4	7.4	8.6	8.0	8.1	8.4	8.3	8.3	7.3
C00	Lip	4.2	3.7	3.7	4.2	3.8	3.0	2.8	2.2	1.8	1.2
C01-02	Tongue	0.8	0.9	0.8	0.9	1.0	1.2	1.3	1.4	1.5	1.6
C03-06	Mouth, other	0.9	0.8	1.2	1.0	1.2	1.5	1.5	1.8	1.7	1.3
C07-08	Salivary glands	0.5	0.5	0.6	0.5	0.5	0.5	0.5	0.6	0.7	0.6
C09-14	Pharynx	1.5	1.6	1.2	2.0	1.5	1.9	2.2	2.3	2.7	2.6
C15-26	Digestive organs	69.1	65.9	65.5	64.3	66.7	69.3	67.6	68.4	67.5	68.5
C15	Oesophagus	3.1	3.1	2.6	2.7	2.7	2.7	3.0	3.2	3.4	3.6
C16	Stomach	35.6	30.1	26.9	21.7	18.6	16.9	14.6	12.3	10.2	8.2
C17	Small intestine	0.5	0.4	0.7	0.5	0.7	1.0	0.8	1.0	1.1	1.5
C18	Colon	9.9	11.2	12.6	13.2	16.2	19.0	21.3	23.0	24.4	25.4
C19-21	Rectum, rectosigmoid, anus	6.5	7.2	9.1	10.5	13.8	15.6	15.6	16.7	16.6	17.6
C22	Liver	0.8	0.9	1.3	1.9	1.6	2.1	1.8	1.8	1.9	2.1
C23-24	Gallbladder, bile ducts	0.7	0.9	0.9	0.9	1.1	1.3	1.3	1.5	1.5	1.7
C25	Pancreas	6.2	6.8	7.6	8.2	8.2	8.7	8.2	7.7	7.3	7.6
C26	Other digestive organs	5.7	5.3	3.7	4.6	3.9	2.0	1.1	1.2	1.1	0.9
C30-34, C38	Respiratory organs	14.5	18.2	23.6	27.6	33.3	37.7	39.5	40.8	40.7	39.7
C30-31	Nose, sinuses	0.8	0.8	0.8	0.8	0.8	0.7	0.7	0.6	0.7	0.7
C32	Larynx, epiglottis	1.4	1.8	2.6	2.5	3.1	3.5	3.4	3.3	3.2	2.9
C33-34	Lung, trachea	11.7	15.1	19.7	23.7	28.8	33.0	35.2	36.3	36.3	35.9
C38	Mediastinum, pleura	0.6	0.4	0.5	0.7	0.7	0.5	0.2	0.6	0.5	0.3
C40-41	Bone	0.8	0.8	0.8	1.0	0.9	1.1	0.9	0.9	1.0	1.0
C43	Melanoma of the skin	2.4	3.5	4.6	6.6	8.4	9.9	13.0	15.0	14.5	14.8
C44	Skin, non-melanoma	3.5	2.7	3.1	5.4	6.5	7.5	9.6	11.7	13.6	14.7
C45	Mesothelioma	0.0	0.1	0.1	0.3	0.6	0.8	1.2	1.0	1.4	1.6
C46	Kaposi's sarcoma	0.1	0.1	0.1	0.2	0.2	0.2	0.3	0.4	0.2	0.2
C47	Autonomic nervous system	1.0	0.7	0.7	0.5	0.5	0.5	0.4	0.3	0.3	0.2
C48-49	Soft tissues	1.0	1.0	1.4	1.7	2.0	1.7	1.5	1.6	1.6	1.6
C50	Breast	0.3	0.3	0.3	0.3	0.3	0.4	0.4	0.4	0.4	0.4
C60-63	Male genital organs	29.5	34.5	37.7	42.0	47.1	51.4	53.9	67.0	85.9	96.4
C61	Prostate	25.7	29.9	32.9	36.9	40.9	43.9	45.9	57.7	74.9	84.8
C62	Testis	3.0	3.7	4.0	4.3	5.3	6.5	7.1	8.3	10.1	10.5
C60, C63	Other male genital	0.7	0.9	0.8	0.8	0.9	1.0	0.8	0.9	0.9	1.2
C64-68	Urinary organs	13.5	16.3	19.2	22.8	25.9	29.9	30.6	32.7	32.0	33.0
C64-65	Kidney	4.6	5.4	6.3	7.1	7.7	9.4	9.0	9.4	9.6	10.6
C66-68	Bladder, ureter, urethra	8.9	10.9	12.9	15.7	18.2	20.5	21.6	23.3	22.4	22.4
C69	Eye	0.9	0.8	1.0	0.7	1.0	1.0	0.9	0.9	1.0	0.9
C70-72	Central nervous system	6.1	6.6	6.8	7.1	8.1	9.0	9.7	9.7	11.7	13.0
C73	Thyroid gland	0.9	1.0	1.4	1.4	1.6	1.6	1.8	1.6	1.6	1.7
C37, C74-75	Other endocrine glands	0.2	0.4	0.3	0.4	0.5	0.6	0.6	0.7	0.5	0.4
C39, C76, C80	Other or unspecified	2.4	3.4	4.5	4.9	5.8	6.6	7.5	7.8	7.3	5.4
C81-96	Lymphoid and haematopoietic tissue	17.2	18.1	19.2	19.6	21.7	22.2	24.2	25.1	27.1	28.2
C81	Hodgkin lymphoma	2.2	2.6	2.7	2.7	2.7	2.3	2.0	2.1	2.5	2.7
C82-85, C96	Non-Hodgkin lymphoma	4.5	4.5	5.6	5.0	5.8	7.2	9.2	10.2	11.2	11.2
C88	Malignant immunoproliferative diseases	0.0	0.0	0.1	0.2	0.2	0.3	0.2	0.5	0.5	0.6
C90	Multiple myeloma	3.1	3.2	3.2	3.8	4.7	4.5	4.7	4.4	4.3	4.5
C91-95	Leukaemia	7.3	7.8	7.7	7.9	8.3	7.9	8.0	8.0	8.7	9.2

Table 17 Age-adjusted (world) incidence rates per 100 000 person-years by primary site and five-year period 1956-2005

FEMALES

ICD10	Site	Period									
		1956-60	1961-65	1966-70	1971-75	1976-80	1981-85	1986-90	1991-95	1996-00	2001-05
C00-96	All sites	163.5	168.1	180.9	194.4	211.4	219.1	228.1	245.8	264.5	278.0
C00-14	Mouth, pharynx	2.3	2.3	2.3	2.3	2.3	2.7	2.9	3.2	3.4	3.4
C00	Lip	0.3	0.3	0.3	0.3	0.4	0.5	0.6	0.7	0.6	0.5
C01-02	Tongue	0.4	0.4	0.4	0.4	0.5	0.6	0.6	0.6	0.7	0.6
C03-06	Mouth, other	0.4	0.4	0.5	0.5	0.5	0.6	0.7	0.8	0.8	0.8
C07-08	Salivary glands	0.3	0.5	0.5	0.4	0.4	0.4	0.4	0.5	0.5	0.5
C09-14	Pharynx	0.9	0.7	0.6	0.7	0.5	0.6	0.6	0.5	0.7	0.9
C15-26	Digestive organs	48.8	45.8	45.4	45.2	48.4	48.6	47.3	49.5	49.5	50.1
C15	Oesophagus	0.8	0.9	0.8	0.7	0.7	0.7	0.8	0.8	0.9	1.1
C16	Stomach	20.7	16.8	14.1	11.0	9.6	8.5	7.1	5.9	4.8	4.3
C17	Small intestine	0.4	0.4	0.4	0.6	0.5	0.7	0.7	0.8	1.0	1.1
C18	Colon	9.8	10.9	12.5	13.7	16.4	18.0	19.0	20.9	22.3	22.9
C19-21	Rectum, rectosigmoid, anus	4.6	4.6	6.5	7.4	9.4	10.2	10.1	11.6	11.1	11.5
C22	Liver	0.4	0.6	0.6	0.9	0.9	1.1	1.0	1.0	1.0	1.0
C23-24	Gallbladder, bile ducts	1.6	1.7	1.7	1.2	1.6	1.8	1.6	1.5	1.6	1.4
C25	Pancreas	3.5	3.9	4.5	4.8	5.2	5.7	5.9	6.0	5.9	6.1
C26	Other digestive organs	6.9	6.1	4.3	4.8	4.1	1.9	1.1	1.0	0.9	0.8
C30-34, C38	Respiratory organs	3.4	3.8	5.0	6.0	7.1	9.4	12.6	16.1	19.8	22.2
C30-31	Nose, sinuses	0.5	0.4	0.4	0.5	0.3	0.3	0.4	0.4	0.4	0.4
C32	Larynx, epiglottis	0.1	0.2	0.2	0.2	0.3	0.3	0.3	0.5	0.5	0.4
C33-34	Lung, trachea	2.7	2.9	4.2	5.1	6.3	8.7	11.7	15.0	18.7	21.3
C38	Mediastinum, pleura	0.2	0.3	0.2	0.3	0.2	0.1	0.1	0.2	0.2	0.1
C40-41	Bone	0.5	0.5	0.6	0.6	0.6	0.6	0.6	0.7	0.8	0.7
C43	Melanoma of the skin	2.4	4.0	5.1	7.5	10.1	12.4	15.4	16.2	15.5	15.8
C44	Skin, non-melanoma	1.9	1.5	1.4	2.7	3.4	4.3	5.1	7.1	8.0	9.2
C45	Mesothelioma	0.0	0.0	0.0	0.1	0.1	0.1	0.2	0.2	0.2	0.2
C46	Kaposi's sarcoma	0.0	0.0	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.0
C47	Autonomic nervous system	0.8	0.5	0.7	0.4	0.3	0.3	0.4	0.3	0.3	0.3
C48-49	Soft tissues	0.7	1.1	1.1	1.3	1.5	1.5	1.4	1.5	1.5	2.1
C50	Breast	37.4	39.7	42.7	46.7	50.0	51.3	53.0	58.2	70.4	76.3
C51-58	Female genital organs	37.1	38.2	42.3	45.1	45.7	42.8	40.8	41.9	40.7	40.5
C53	Cervix uteri	15.3	15.6	17.1	18.6	16.7	13.9	12.1	12.3	10.7	9.5
C54	Corpus uteri	7.2	8.2	9.1	10.5	12.1	12.2	12.4	13.3	13.9	15.8
C55	Uterus, other	0.8	0.7	0.4	0.2	0.2	0.1	0.1	0.1	0.2	0.2
C56	Ovary	11.1	11.2	13.3	12.2	13.1	13.5	13.4	13.5	13.0	12.0
C51-52, C57	Other female genital	2.5	2.3	2.1	3.3	3.4	2.8	2.6	2.5	2.7	2.8
C58	Placenta	0.2	0.2	0.2	0.1	0.1	0.2	0.2	0.2	0.2	0.2
C64-68	Urinary organs	7.5	7.6	8.3	9.2	9.9	10.1	10.9	11.2	11.7	11.9
C64-65	Kidney	3.2	3.4	3.9	4.0	4.4	4.4	5.1	5.0	5.2	5.3
C66-68	Bladder, ureter, urethra	4.3	4.2	4.4	5.2	5.5	5.7	5.8	6.1	6.5	6.6
C69	Eye	0.7	0.8	0.7	0.7	0.7	0.9	0.8	1.0	0.8	0.9
C70-72	Central nervous system	5.1	5.4	5.7	5.9	7.4	8.0	9.2	9.8	12.4	15.2
C73	Thyroid gland	2.2	2.4	3.3	4.2	5.0	5.1	4.8	4.8	4.0	4.6
C37, C74-75	Other endocrine glands	0.3	0.2	0.2	0.2	0.4	0.6	0.7	0.6	0.4	0.4
C39, C76, C80	Other or unspecified	1.8	2.5	3.0	2.8	4.1	4.8	5.6	6.2	5.8	4.8
C81-96	Lymphoid and haematopoietic tissue	10.7	11.9	13.2	13.5	14.7	15.6	16.4	17.3	19.2	19.3
C81	Hodgkin lymphoma	1.5	1.7	1.9	1.6	1.8	1.4	1.4	1.3	1.9	1.8
C82-85, C96	Non-Hodgkin lymphoma	2.6	2.8	4.1	3.5	4.4	5.4	6.7	7.4	8.0	8.3
C88	Malignant immunoproliferative diseases	0.0	0.0	0.0	0.1	0.1	0.2	0.1	0.3	0.2	0.3
C90	Multiple myeloma	1.4	2.0	2.2	2.9	3.1	3.0	2.9	2.8	2.9	3.1
C91-95	Leukaemia	5.2	5.3	5.0	5.4	5.3	5.7	5.3	5.5	6.3	5.9

Table 18 Average annual number of new cases by primary site and county - 2001-2005

MALES

ICD10	Site	Norway	Østfold	Akershus	Oslo	Hedmark	Oppland	Buskerud	Vestfold	Telemark	Aust-Agder	Vest-Agder	Rogaland	Hordaland	Sogn og Fjordane	Møre og Romsdal	Sør-Trøn- delag	Nord-Trøn- delag	Nordland	Troms	Finmark
C00-96	All sites	12311	729	1132	1209	632	555	663	679	482	315	451	1012	1153	330	705	691	366	659	382	167
C00-14	Mouth, pharynx	246	19	24	31	9	11	14	12	9	7	8	19	17	7	12	12	7	14	9	3
C00	Lip	45	4	4	2	2	2	3	3	1	2	2	4	2	2	2	4	2	1	1	0
C01-02	Tongue	50	4	5	7	2	3	3	2	2	2	1	3	5	1	2	1	1	4	2	1
C03-06	Mouth, other	45	4	4	5	2	2	3	3	2	1	1	4	3	2	2	2	1	3	1	0
C07-08	Salivary glands	20	1	3	2	1	1	0	1	0	0	1	2	1	1	2	1	1	1	1	0
C09-14	Pharynx	86	6	9	16	2	3	5	4	3	2	3	6	6	1	4	4	3	6	3	1
C15-26	Digestive organs	2690	170	237	252	135	117	144	136	98	56	89	220	267	74	159	170	80	156	88	41
C15	Oesophagus	133	7	12	15	7	8	9	8	5	3	5	10	12	3	6	6	2	7	4	2
C16	Stomach	336	25	24	24	17	15	14	15	11	5	9	28	35	11	21	24	12	24	15	9
C17	Small intestine	52	3	6	4	4	2	2	1	2	1	1	5	5	1	3	5	1	3	1	0
C18	Colon	1016	65	96	92	53	41	58	54	35	18	35	81	98	28	63	63	31	62	31	13
C19-21	Rectum, rectosigmoid, anus	673	40	61	61	30	28	38	34	25	14	23	61	72	20	39	44	19	36	18	10
C22	Liver	78	4	6	14	3	4	4	2	3	3	3	6	7	1	3	5	2	4	3	1
C23-24	Gallbladder, bile ducts	64	4	4	6	3	2	2	6	3	2	3	5	7	2	3	4	2	3	1	1
C25	Pancreas	298	20	26	32	15	15	16	15	12	8	9	22	29	6	16	17	10	15	11	4
C26	Other digestive organs	40	2	3	4	3	2	2	1	2	2	1	3	3	1	7	1	1	1	2	1
C30-34, C38	Respiratory organs	1509	102	137	141	68	57	75	89	60	45	61	119	138	33	78	86	44	90	56	31
C30-31	Nose, sinuses	23	2	2	3	1	1	1	1	1	1	1	2	2	1	1	1	0	1	1	1
C32	Larynx, epiglottis	104	8	11	10	3	5	6	6	3	4	3	7	8	2	7	4	3	6	5	2
C33-34	Lung, trachea	1368	91	123	127	64	50	67	82	55	39	56	109	126	30	70	81	39	81	49	28
C38	Mediastinum, pleura	14	1	1	2	0	1	1	0	0	0	0	1	1	0	0	1	1	2	0	0
C40-41	Bone	25	1	3	2	2	1	1	1	1	0	1	2	3	0	1	1	1	1	0	0
C43	Melanoma of the skin	499	35	58	55	23	19	28	34	20	13	20	49	40	8	22	33	16	12	9	2
C44	Skin, non-melanoma	649	42	58	67	36	26	49	40	31	21	37	64	58	13	26	31	14	22	10	4
C45	Mesothelioma	63	4	8	7	3	3	6	6	3	1	3	3	6	1	3	3	1	1	1	0
C46	Kaposi's sarcoma	7	1	0	2	0	0	0	0	0	0	0	0	2	0	0	0	0	0	0	0
C47	Autonomic nervous system	5	0	1	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0
C48-49	Soft tissues	52	3	5	5	3	3	3	3	2	1	3	2	5	2	1	4	1	4	1	1
C50	Breast	16	1	1	2	1	0	1	0	1	1	0	0	1	0	1	2	0	0	1	0
C60-63	Male genital organs	3599	171	313	347	200	190	185	199	138	101	133	304	352	118	221	180	113	188	108	40
C61	Prostate	3302	154	280	314	187	174	174	186	127	96	122	278	322	114	199	162	102	177	99	36
C62	Testis	254	15	29	28	10	13	9	10	10	5	10	23	25	4	19	16	9	9	8	4
C60, C63	Other male genital	43	3	5	6	3	2	2	3	2	0	1	3	4	0	2	2	2	2	1	1
C64-68	Urinary organs	1292	85	115	122	70	56	61	66	51	28	44	103	119	30	84	80	36	78	46	18
C64-65	Kidney	380	28	36	38	20	17	18	19	13	8	13	31	31	6	22	26	11	25	12	5
C66-68	Bladder, ureter, urethra	912	57	79	84	50	39	44	47	37	20	30	72	88	24	62	54	25	53	33	13
C69	Eye	30	1	2	4	1	3	2	2	0	0	1	1	2	1	2	1	0	2	2	0
C70-72	Central nervous system	379	21	43	40	17	15	21	19	15	8	13	30	39	10	20	21	12	17	14	4
C73	Thyroid gland	54	3	6	5	2	2	2	2	2	1	1	3	6	3	5	3	2	4	2	2
C37, C74-75	Other endocrine glands	11	1	1	1	1	0	0	0	0	0	0	1	1	1	1	1	0	2	1	0
C39, C76, C80	Other or unspecified	234	16	21	26	10	10	15	13	11	6	6	16	24	6	9	9	7	17	7	4
C81-96	Lymphoid and haematopoietic tissue	954	53	100	99	50	42	53	55	41	24	30	76	73	22	59	53	31	50	28	14
C81	Hodgkin lymphoma	67	6	8	7	4	3	4	3	2	1	1	5	5	2	6	3	2	3	1	0
C82-85, C96	Non-Hodgkin lymphoma	388	20	39	43	22	16	19	21	16	10	14	32	29	10	24	22	12	21	12	7
C88	Malignant immunoproliferative diseases	26	1	4	2	1	2	1	1	1	1	0	2	3	1	1	1	1	1	1	1
C90	Multiple myeloma	175	7	18	15	8	10	9	9	11	5	5	12	15	3	11	10	8	12	3	3
C91-95	Leukaemia	299	19	31	32	16	10	21	21	12	7	10	24	20	6	17	17	9	12	10	4

Table 19 Average annual number of new cases by primary site and county - 2001-2005

FEMALES

ICD10	Site	Norway	Østfold	Akershus	Oslo	Hedmark	Oppland	Buskerud	Vestfold	Telemark	Aust-Agder	Vest-Agder	Rogaland	Hordaland	Sogn og Fjordane	Møre og Romsdal	Sør-Trøn- delag	Nord-Trøn- delag	Nordland	Troms	Finmark
C00-96	All sites	11370	686	1118	1338	532	485	656	587	445	261	417	893	1044	249	598	648	304	637	334	139
C00-14	Mouth, pharynx	142	9	13	17	6	6	8	8	4	2	7	10	11	3	9	7	3	12	6	1
C00	Lip	27	2	3	1	0	1	1	1	1	1	2	3	1	1	3	2	0	1	2	0
C01-02	Tongue	28	1	3	3	2	2	1	2	1	0	0	1	3	1	2	1	1	2	1	1
C03-06	Mouth, other	36	2	3	5	2	2	2	2	1	0	1	3	4	0	2	2	1	4	2	0
C07-08	Salivary glands	19	1	2	2	1	1	2	1	1	1	1	1	1	0	1	0	0	2	1	0
C09-14	Pharynx	32	2	2	6	1	1	1	2	1	0	2	2	2	0	1	2	1	3	1	0
C15-26	Digestive organs	2529	155	221	290	112	111	131	122	91	54	87	199	274	62	148	151	72	142	77	29
C15	Oesophagus	54	3	7	8	2	3	5	3	2	1	2	4	4	1	2	2	1	3	2	1
C16	Stomach	228	12	16	26	9	11	10	10	10	4	6	20	27	6	13	12	7	14	11	4
C17	Small intestine	49	3	5	6	4	1	3	1	2	1	3	2	4	1	4	5	1	2	1	0
C18	Colon	1170	71	94	131	49	49	62	59	43	24	43	92	133	31	76	68	36	65	33	12
C19-21	Rectum, rectosigmoid, anus	534	34	51	59	25	25	31	24	18	13	13	47	61	11	26	29	15	30	15	5
C22	Liver	46	3	5	5	3	2	2	1	2	1	2	4	4	1	2	4	1	3	3	1
C23-24	Gallbladder, bile ducts	71	4	7	8	4	5	3	2	3	2	4	5	7	2	3	5	1	4	1	1
C25	Pancreas	326	21	30	42	15	15	13	18	11	8	11	22	30	8	16	22	9	19	10	5
C26	Other digestive organs	51	3	6	5	2	1	3	3	2	1	3	3	4	1	4	4	2	2	1	1
C30-34, C38	Respiratory organs	905	55	93	115	37	34	46	55	36	25	41	65	68	16	40	55	25	55	29	14
C30-31	Nose, sinuses	17	2	2	3	0	1	1	1	0	1	1	1	2	1	1	1	1	1	1	0
C32	Larynx, epiglottis	17	1	2	2	1	1	1	2	0	1	1	0	1	0	1	1	0	2	1	0
C33-34	Lung, trachea	864	51	89	110	36	33	44	52	35	24	40	63	65	15	38	53	24	52	28	13
C38	Mediastinum, pleura	7	1	0	1	0	0	1	0	0	0	0	0	0	0	1	0	0	0	0	0
C40-41	Bone	18	1	1	2	0	0	1	1	1	1	0	2	2	1	0	2	1	1	1	0
C43	Melanoma of the skin	549	44	60	64	22	18	37	36	22	10	20	57	46	10	29	31	15	17	10	1
C44	Skin, non-melanoma	565	45	48	63	27	18	45	35	31	15	33	61	42	8	22	30	14	15	9	3
C45	Mesothelioma	9	0	2	2	0	0	0	1	1	0	0	1	0	0	1	0	0	0	0	0
C46	Kaposi's sarcoma	2	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0
C47	Autonomic nervous system	5	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	0	1	0	0
C48-49	Soft tissues	73	3	10	8	3	2	4	4	2	2	2	6	4	2	5	7	3	3	2	1
C50	Breast	2721	156	300	339	124	114	179	136	107	54	93	201	246	54	147	149	70	142	79	32
C51-58	Female genital organs	1526	85	149	164	85	81	81	74	63	38	52	121	149	34	67	80	35	97	48	22
C53	Cervix uteri	293	16	31	35	15	13	17	15	11	7	12	23	24	5	11	13	6	21	11	6
C54	Corpus uteri	632	34	60	70	35	38	32	30	25	14	20	46	65	15	31	32	16	41	19	7
C55	Uterus, other	11	1	0	1	0	0	1	1	1	0	0	2	1	1	0	0	0	0	0	0
C56	Ovary	454	27	46	41	28	25	23	22	20	13	15	37	47	9	21	24	10	27	14	6
C51-52, C57	Other female genital	132	7	12	16	7	5	7	6	6	5	5	11	11	4	5	10	4	7	4	2
C58	Placenta	4	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0
C64-68	Urinary organs	574	32	49	66	31	23	31	29	19	16	20	41	47	15	34	36	18	42	16	10
C64-65	Kidney	235	13	20	24	13	10	11	12	8	5	8	16	18	7	14	16	9	19	7	5
C66-68	Bladder, ureter, urethra	339	19	29	42	18	13	19	17	11	10	12	25	30	8	20	20	9	23	9	4
C69	Eye	31	1	3	2	1	1	2	2	1	2	1	3	2	1	3	2	1	2	1	0
C70-72	Central nervous system	490	27	50	50	22	23	22	27	22	14	20	38	41	13	24	33	12	31	14	7
C73	Thyroid gland	145	7	14	18	9	4	7	7	6	2	3	7	17	4	10	9	3	12	6	3
C37, C74-75	Other endocrine glands	12	0	1	1	1	0	1	1	0	0	0	1	1	0	0	0	0	1	1	0
C39, C76, C80	Other or unspecified	294	17	26	39	16	14	18	12	12	7	9	22	27	8	13	16	7	18	8	4
C81-96	Lymphoid and haematopoietic tissue	779	50	78	98	35	36	41	38	26	19	27	57	63	19	45	39	25	46	26	10
C81	Hodgkin lymphoma	45	2	5	7	2	2	3	2	1	1	1	3	4	1	1	2	2	3	1	1
C82-85, C96	Non-Hodgkin lymphoma	344	22	32	40	13	17	17	16	11	8	14	26	31	9	19	20	13	19	12	6
C88	Malignant immunoproliferative diseases	16	0	3	2	1	1	1	1	0	0	0	1	1	1	1	1	0	1	1	0
C90	Multiple myeloma	153	10	13	20	7	8	7	7	5	4	6	11	11	4	12	7	3	12	5	1
C91-95	Leukaemia	220	15	25	29	11	9	14	12	8	6	6	16	16	4	11	10	7	11	8	3

Table 20 Age-adjusted (world) incidence rates per 100 000 person-years by county and primary site - 2001-2005

MALES

ICD10	Site	Norway	Østfold	Akershus	Oslo	Hedmark	Oppland	Buskerud	Vestfold	Telemark	Aust-Agder	Vest-Agder	Rogaland	Hordaland	Sogn og Fjordane	Møre og Romsdal	Sør-Trøn- delag	Nord-Trøn- delag	Nordland	Troms	Finmark
C00-96	All sites	329.3	329.2	311.3	328.3	335.1	316.5	315.3	366.9	316.7	371.7	364.8	363.3	326.3	340.5	329.8	319.9	310.9	313.2	317.7	290.6
C00-14	Mouth, pharynx	7.3	9.6	6.7	9.4	6.2	6.9	7.3	7.4	6.5	9.7	6.9	7.5	5.7	7.2	6.5	5.7	6.9	7.7	7.9	6.8
C00	Lip	1.2	2.0	1.0	0.6	1.2	1.0	1.6	1.3	0.8	2.6	1.5	1.7	0.5	1.9	1.1	1.7	1.2	0.6	1.1	0.8
C01-02	Tongue	1.6	2.1	1.3	2.2	1.8	2.1	1.4	1.4	2.0	2.4	0.9	1.4	1.7	1.1	1.0	0.5	0.8	2.1	1.9	2.2
C03-06	Mouth, other	1.3	1.9	1.3	1.4	1.1	1.1	1.4	1.6	1.3	1.5	1.3	1.2	1.2	2.6	1.1	1.0	1.2	1.4	1.0	0.6
C07-08	Salivary glands	0.6	0.6	0.7	0.4	0.9	0.6	0.2	0.8	0.3	0.2	0.8	0.8	0.4	0.5	1.0	0.5	0.6	0.5	0.8	1.1
C09-14	Pharynx	2.6	3.0	2.4	4.9	1.2	2.1	2.8	2.3	2.1	3.0	2.4	2.5	1.9	1.0	2.3	2.1	3.1	3.1	3.2	2.1
C15-26	Digestive organs	68.5	73.4	62.4	66.5	67.4	63.2	66.2	69.5	59.7	62.4	67.8	76.9	72.4	72.2	68.4	72.8	65.0	70.5	70.5	70.6
C15	Oesophagus	3.6	3.4	3.3	4.2	3.4	4.5	4.0	4.3	3.6	4.2	4.1	3.6	3.7	3.3	2.6	2.7	1.8	3.7	3.6	4.2
C16	Stomach	8.2	10.2	6.3	6.3	7.3	7.5	6.5	7.4	6.3	4.8	6.5	9.2	8.5	9.7	8.3	10.3	9.1	10.3	12.4	14.2
C17	Small intestine	1.5	1.4	1.5	1.1	2.5	1.3	1.2	0.9	1.8	1.5	1.0	1.8	1.6	1.0	1.4	2.4	1.2	1.4	1.3	0.6
C18	Colon	25.4	27.9	24.9	24.1	26.1	21.9	26.2	26.1	20.3	19.4	25.7	28.1	25.9	27.1	26.7	26.1	24.5	27.7	24.3	22.7
C19-21	Rectum, rectosigmoid, anus	17.6	17.4	16.2	16.4	16.1	16.0	17.6	18.3	15.2	15.6	17.7	21.8	20.2	20.3	16.8	19.6	16.6	16.4	15.3	17.5
C22	Liver	2.1	1.8	1.6	3.9	1.2	1.9	1.9	1.1	1.8	3.7	2.3	2.1	2.2	1.1	1.1	2.3	1.8	1.7	2.9	1.2
C23-24	Gallbladder, bile ducts	1.7	2.1	1.1	1.4	1.5	0.9	0.8	3.4	2.1	2.3	2.7	2.0	1.8	2.4	1.1	1.7	1.1	1.4	1.1	1.8
C25	Pancreas	7.6	8.5	6.8	8.2	8.2	8.2	7.3	7.6	7.9	9.4	6.9	7.6	7.8	6.5	7.0	7.1	8.2	7.2	8.7	6.5
C26	Other digestive organs	0.9	0.8	0.6	1.0	1.1	1.0	0.8	0.4	0.8	1.6	0.9	0.8	0.8	0.9	3.4	0.5	0.6	0.7	1.0	1.9
C30-34, C38	Respiratory organs	39.7	44.8	36.1	38.4	35.6	31.4	35.4	47.8	39.3	52.3	49.4	42.6	39.2	35.3	35.9	38.2	35.9	41.3	44.2	53.2
C30-31	Nose, sinuses	0.7	0.8	0.4	0.8	0.4	0.9	0.5	0.5	1.1	0.7	0.6	0.9	0.7	0.7	0.7	0.6	0.5	0.6	0.7	0.8
C32	Larynx, epiglottis	2.9	3.5	2.9	2.8	1.5	2.8	2.7	3.5	2.2	5.0	3.1	2.5	2.6	2.6	3.5	1.5	2.7	3.0	4.7	3.5
C33-34	Lung, trachea	35.9	39.8	32.4	34.5	33.4	27.4	31.9	43.6	35.7	46.2	45.2	39.1	35.6	31.7	31.6	35.7	31.9	37.1	38.6	48.2
C38	Mediastinum, pleura	0.3	0.6	0.4	0.3	0.2	0.3	0.3	0.2	0.3	0.4	0.5	0.2	0.2	0.3	0.2	0.3	0.8	0.6	0.2	0.7
C40-41	Bone	1.0	0.7	1.1	1.0	1.6	1.9	1.2	1.1	0.5	0.7	0.7	1.0	1.3	0.3	0.9	0.8	0.7	1.1	0.4	1.5
C43	Melanoma of the skin	14.8	18.3	16.8	14.8	14.0	12.9	15.9	20.6	14.7	17.1	17.7	18.5	12.8	9.3	12.6	17.3	16.8	6.9	8.7	4.2
C44	Skin, non-melanoma	14.7	16.3	14.1	14.1	15.7	11.7	20.0	20.5	17.0	21.2	26.9	20.2	13.6	11.0	9.3	11.6	9.6	9.0	7.2	7.0
C45	Mesothelioma	1.6	1.9	2.1	1.7	1.8	1.5	2.7	2.8	1.8	1.0	2.4	1.2	1.8	0.5	1.2	1.2	0.9	0.5	1.2	0.2
C46	Kaposi's sarcoma	0.2	0.3	0.0	0.7	0.2	0.2	0.2	0.0	0.0	0.3	0.0	0.0	0.3	0.0	0.1	0.1	0.0	0.2	0.3	0.0
C47	Autonomic nervous system	0.2	0.0	0.3	0.1	0.2	0.0	0.4	0.2	0.0	0.7	0.0	0.1	0.5	0.7	0.1	0.3	0.0	0.1	0.5	0.9
C48-49	Soft tissues	1.6	1.6	1.5	1.5	2.1	2.4	1.7	2.2	1.7	1.0	2.2	0.8	1.6	1.6	0.9	1.6	0.9	2.3	1.9	1.5
C50	Breast	0.4	0.6	0.3	0.6	0.3	0.2	0.5	0.2	0.2	1.2	0.4	0.1	0.4	0.2	0.8	0.8	0.3	0.2	0.6	0.3
C60-63	Male genital organs	96.4	76.2	88.3	96.7	103.5	107.9	86.6	107.0	89.9	118.2	110.3	108.0	99.9	119.8	104.6	87.2	95.1	87.2	89.6	67.8
C61	Prostate	84.8	63.6	75.6	86.8	90.7	91.9	78.3	96.7	77.6	109.2	98.2	96.1	88.2	111.2	88.5	74.8	80.1	78.7	78.9	56.2
C62	Testis	10.5	11.1	11.5	8.2	11.1	14.8	7.2	9.0	11.2	8.6	11.5	10.9	10.5	8.1	15.2	11.4	13.7	7.2	9.9	10.6
C60, C63	Other male genital	1.2	1.5	1.3	1.7	1.7	1.2	1.1	1.4	1.0	0.4	0.6	0.9	1.2	0.5	0.8	1.1	1.3	1.3	0.7	1.0
C64-68	Urinary organs	33.0	37.1	29.7	31.3	35.2	30.7	27.5	33.3	33.9	31.0	33.7	35.5	31.8	30.4	38.0	36.5	28.4	36.1	36.0	30.5
C64-65	Kidney	10.6	13.2	9.9	10.4	11.1	10.5	8.5	11.0	10.2	11.0	11.9	11.4	9.2	6.3	10.9	13.1	9.2	12.9	10.5	9.1
C66-68	Bladder, ureter, urethra	22.4	23.9	19.8	20.9	24.1	20.3	18.9	22.3	23.8	20.0	21.8	24.1	22.6	24.1	27.2	23.4	19.1	23.2	25.5	21.5
C69	Eye	0.9	0.7	0.5	1.2	0.7	1.7	1.0	1.3	0.4	1.0	0.6	0.5	0.8	1.7	0.9	0.9	0.5	2.0	1.9	0.7
C70-72	Central nervous system	13.0	11.6	14.2	13.7	12.1	11.5	11.5	13.1	13.6	14.1	12.7	13.4	14.2	14.6	12.1	13.5	13.9	11.0	13.6	9.3
C73	Thyroid gland	1.7	1.5	1.8	1.6	1.5	1.6	1.6	0.9	1.6	2.1	1.0	1.3	1.9	3.3	2.7	1.6	1.9	1.9	1.9	2.6
C37, C74-75	Other endocrine glands	0.4	0.6	0.5	0.3	0.5	0.2	0.1	0.4	0.0	0.5	0.4	0.4	0.3	0.5	0.7	0.2	0.5	1.3	0.5	0.0
C39, C76, C80	Other or unspecified	5.4	6.4	5.3	6.0	5.0	4.5	6.1	6.2	5.9	5.7	4.2	5.3	5.8	5.5	3.4	3.2	4.7	6.9	5.9	6.8
C81-96	Lymphoid and haematopoietic tissue	28.2	27.8	29.8	28.8	31.6	26.1	29.4	32.4	29.9	31.2	27.5	29.8	22.2	26.4	30.6	26.6	28.7	26.9	25.0	26.7
C81	Hodgkin lymphoma	2.7	4.0	3.2	2.3	4.3	3.0	3.0	2.8	2.5	2.0	1.6	2.7	2.1	3.0	4.2	2.0	2.5	2.6	2.0	1.2
C82-85, C96	Non-Hodgkin lymphoma	11.2	9.8	11.5	12.2	13.0	10.1	9.7	11.7	11.1	14.2	12.5	12.6	8.3	11.1	11.6	10.6	10.2	11.3	10.8	13.1
C88	Malignant immunoproliferative diseases	0.6	0.4	1.0	0.4	0.3	1.1	0.4	0.8	0.5	1.0	0.2	0.6	0.8	1.5	0.6	0.5	0.9	0.4	0.4	0.9
C90	Multiple myeloma	4.5	3.4	4.9	4.0	4.1	5.5	3.8	4.6	7.1	5.9	4.1	4.3	4.3	3.2	4.7	4.5	6.2	5.5	2.8	4.3
C91-95	Leukaemia	9.2	10.2	9.3	9.9	9.8	6.5	12.5	12.6	8.7	8.1	9.0	9.7	6.7	7.6	9.4	8.9	8.9	7.1	9.0	7.2

Table 21 Age-adjusted (world) incidence rates per 100 000 person-years by county and primary site - 2001-2005

FEMALES

ICD10	Site	Norway	Østfold	Akershus	Oslo	Hedmark	Oppland	Buskerud	Vestfold	Telemark	Aust-Agder	Vest-Agder	Rogaland	Hordaland	Sogn og Fjordane	Møre og Romsdal	Sør-Trøn- delag	Nord-Trøn- delag	Nordland	Troms	Finmark
C00-96	All sites	278.0	285.8	278.9	288.0	283.0	268.4	292.2	286.8	279.8	278.7	292.1	286.6	267.7	252.4	262.4	273.8	251.5	294.1	266.2	238.9
C00-14	Mouth, pharynx	3.4	3.5	3.2	4.0	3.0	2.6	3.7	3.6	3.1	2.5	5.0	3.0	2.9	2.9	3.3	3.1	2.4	5.3	4.2	2.1
C00	Lip	0.5	0.6	0.6	0.3	0.1	0.3	0.3	0.3	0.7	0.6	1.4	0.8	0.4	0.9	0.9	0.6	0.1	0.4	1.2	0.7
C01-02	Tongue	0.6	0.5	0.7	0.7	1.0	0.7	0.5	0.6	0.6	0.4	0.2	0.4	0.6	0.8	0.9	0.7	0.5	1.0	0.9	0.9
C03-06	Mouth, other	0.8	0.8	0.7	0.8	0.8	1.0	1.0	0.9	0.7	0.0	0.5	0.6	1.1	0.5	0.9	0.8	0.7	1.5	0.8	0.0
C07-08	Salivary glands	0.5	0.4	0.5	0.6	0.4	0.2	1.4	0.8	0.5	1.2	1.1	0.4	0.2	0.7	0.3	0.2	0.2	0.8	0.4	0.0
C09-14	Pharynx	0.9	1.2	0.7	1.6	0.8	0.4	0.5	1.0	0.6	0.3	1.9	0.8	0.6	0.0	0.3	0.9	0.8	1.5	1.0	0.4
C15-26	Digestive organs	50.1	50.5	47.3	49.7	47.8	49.0	49.5	47.8	46.2	46.4	51.6	51.5	56.9	49.6	51.4	50.7	47.9	52.2	50.7	42.6
C15	Oesophagus	1.1	0.9	1.7	1.5	0.9	1.2	1.7	1.1	0.6	0.5	1.3	1.0	0.6	1.3	0.6	0.6	1.1	0.9	1.2	1.7
C16	Stomach	4.3	3.4	3.4	4.5	3.7	4.3	3.1	3.1	5.3	3.3	3.3	5.1	5.6	4.7	3.9	3.5	4.1	4.6	7.2	6.2
C17	Small intestine	1.1	1.2	1.2	1.0	1.9	0.5	1.4	0.5	0.9	0.9	2.6	0.7	1.1	1.1	1.5	2.0	0.6	0.8	0.8	0.7
C18	Colon	22.9	23.2	19.6	21.9	19.6	21.4	24.0	22.7	22.5	20.9	23.9	23.9	27.1	23.7	25.9	23.6	23.2	23.2	21.3	16.5
C19-21	Rectum, rectosigmoid, anus	11.5	12.2	11.7	10.8	11.9	11.4	12.3	10.6	9.3	11.4	9.5	12.8	13.8	10.0	10.7	10.4	11.5	12.2	10.7	8.9
C22	Liver	1.0	0.7	1.1	0.9	2.1	1.0	0.8	0.7	0.7	0.8	1.1	1.1	0.9	1.7	0.7	1.1	0.3	1.5	1.7	0.8
C23-24	Gallbladder, bile ducts	1.4	1.6	1.5	1.6	1.1	2.2	0.8	0.8	1.4	2.1	2.4	1.2	1.4	1.2	1.0	1.4	0.2	1.3	1.2	0.6
C25	Pancreas	6.1	6.3	6.2	6.7	6.2	6.5	4.9	7.1	5.0	6.0	6.2	4.9	6.1	5.3	5.3	7.1	5.7	7.0	6.0	6.0
C26	Other digestive organs	0.8	0.8	1.0	0.8	0.6	0.5	0.6	1.1	0.5	0.5	1.2	0.7	0.4	0.5	1.9	1.0	1.2	0.7	0.6	1.3
C30-34, C38	Respiratory organs	22.2	22.3	22.8	24.6	19.3	18.6	19.4	26.4	22.3	28.1	29.5	21.9	18.5	16.6	17.7	24.4	21.8	25.1	22.2	24.7
C30-31	Nose, sinuses	0.4	0.6	0.5	0.5	0.0	0.5	0.4	0.6	0.3	0.6	0.4	0.3	0.3	0.4	0.3	0.2	0.5	0.4	0.5	0.4
C32	Larynx, epiglottis	0.4	0.4	0.6	0.4	0.5	0.4	0.3	0.7	0.2	0.6	0.8	0.2	0.5	0.4	0.3	0.5	0.1	0.5	0.8	0.7
C33-34	Lung, trachea	21.3	21.0	21.6	23.6	18.8	17.5	18.6	25.0	21.7	26.9	28.2	21.4	17.6	15.8	17.1	23.5	20.9	24.1	20.8	23.6
C38	Mediastinum, pleura	0.1	0.2	0.1	0.2	0.0	0.1	0.2	0.2	0.0	0.0	0.0	0.1	0.1	0.1	0.1	0.1	0.4	0.1	0.1	0.0
C40-41	Bone	0.7	1.0	0.3	0.7	0.0	0.0	0.9	1.2	1.5	2.1	0.3	0.7	1.0	1.6	0.1	1.0	0.9	0.7	0.9	0.6
C43	Melanoma of the skin	15.8	20.4	16.9	14.8	13.4	11.6	19.2	21.1	17.0	14.2	17.6	21.7	13.1	10.7	15.7	16.5	16.4	10.2	9.5	2.4
C44	Skin, non-melanoma	9.2	13.0	9.1	8.7	8.2	5.7	12.7	10.6	11.5	9.0	15.3	13.8	7.5	5.1	6.5	8.6	8.6	5.1	6.0	5.4
C45	Mesothelioma	0.2	0.2	0.3	0.3	0.0	0.0	0.2	0.2	0.5	0.6	0.0	0.2	0.1	0.0	0.2	0.0	0.0	0.2	0.2	0.0
C46	Kaposi's sarcoma	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.0	0.1	0.1	0.0
C47	Autonomic nervous system	0.3	0.4	0.2	0.1	0.0	0.0	0.0	0.0	0.4	0.0	0.2	0.3	0.5	0.1	0.9	0.2	0.1	0.9	0.0	0.0
C48-49	Soft tissues	2.1	1.9	2.6	2.2	1.8	1.9	2.0	2.2	2.1	2.1	1.8	2.2	1.4	1.4	2.3	3.0	3.1	1.9	2.3	1.1
C50	Breast	76.3	76.0	81.8	85.0	76.7	73.6	89.8	76.2	76.7	64.0	74.5	73.7	72.4	64.2	75.9	73.8	68.5	74.8	69.6	61.4
C51-58	Female genital organs	40.5	38.8	38.7	38.7	49.8	48.3	38.8	38.7	42.8	45.7	39.4	41.9	43.0	40.5	32.2	36.8	30.0	48.9	41.5	40.1
C53	Cervix uteri	9.5	9.5	9.0	9.5	11.8	10.8	10.4	9.7	10.1	10.4	12.0	9.2	8.7	6.9	7.3	7.2	6.3	13.5	11.0	10.4
C54	Corpus uteri	15.8	14.9	15.1	15.9	19.1	20.9	14.9	14.4	14.8	13.9	13.9	15.0	18.3	16.1	13.4	14.4	11.9	19.3	15.6	14.7
C55	Uterus, other	0.2	0.1	0.1	0.1	0.1	0.1	0.3	0.3	0.3	0.1	0.2	0.5	0.2	0.9	0.2	0.1	0.0	0.3	0.2	0.1
C56	Ovary	12.0	12.1	11.7	10.0	15.2	14.1	10.6	11.4	14.5	17.2	10.6	13.5	13.1	12.2	9.8	11.5	9.4	12.4	11.2	11.2
C51-52, C57	Other female genital	2.8	2.2	2.6	3.0	3.7	2.4	2.5	2.5	3.0	4.1	2.7	3.2	2.7	3.8	1.5	3.6	2.4	3.0	2.9	3.7
C58	Placenta	0.2	0.0	0.2	0.1	0.0	0.0	0.1	0.4	0.0	0.0	0.0	0.7	0.0	0.6	0.0	0.0	0.0	0.4	0.6	0.0
C64-68	Urinary organs	11.9	13.5	10.4	11.9	14.8	10.9	12.2	11.0	10.2	12.3	11.4	11.4	10.1	11.1	12.8	12.7	11.8	16.2	10.9	14.3
C64-65	Kidney	5.3	6.5	5.0	4.7	7.1	4.4	4.7	5.1	4.4	4.7	5.1	4.8	4.4	4.9	5.0	6.3	6.2	7.9	4.8	8.3
C66-68	Bladder, ureter, urethra	6.6	7.0	5.4	7.2	7.7	6.6	7.5	5.9	5.8	7.7	6.2	6.6	5.7	6.2	7.7	6.4	5.6	8.3	6.1	6.0
C69	Eye	0.9	0.5	1.0	0.7	1.1	0.5	1.2	0.9	0.5	1.8	1.2	0.8	0.7	1.0	1.6	0.8	0.8	0.5	0.5	0.6
C70-72	Central nervous system	15.2	14.2	15.0	14.6	15.6	15.0	12.7	17.9	19.1	19.2	18.4	15.6	12.6	18.8	13.0	16.7	11.9	17.0	15.9	14.2
C73	Thyroid gland	4.6	2.9	4.0	5.1	6.6	3.3	4.3	4.7	4.9	2.4	3.5	2.5	5.6	5.8	6.5	4.9	3.0	7.2	5.4	5.2
C37, C74-75	Other endocrine glands	0.4	0.2	0.1	0.4	0.5	0.3	0.7	0.9	0.7	0.7	0.0	0.5	0.5	0.7	0.3	0.2	0.2	0.7	0.5	0.5
C39, C76, C80	Other or unspecified	4.8	4.8	4.9	5.6	5.9	5.2	5.8	4.4	4.4	5.4	3.3	5.2	4.4	4.8	3.5	4.3	4.0	5.7	3.9	5.2
C81-96	Lymphoid and haematopoietic tissue	19.3	21.8	20.1	21.0	18.4	21.8	19.1	18.9	16.0	22.2	19.2	19.6	16.4	17.5	18.4	16.1	20.1	21.5	22.1	18.6
C81	Hodgkin lymphoma	1.8	2.1	1.9	2.3	2.1	2.6	1.6	1.3	1.2	3.5	1.1	1.5	1.5	1.3	1.0	1.1	2.6	2.1	1.8	1.2
C82-85, C96	Non-Hodgkin lymphoma	8.3	9.1	7.9	8.5	6.6	9.3	7.6	7.2	7.7	7.3	9.0	8.6	7.8	8.9	7.6	8.3	9.8	8.5	9.6	12.1
C88	Malignant immunoproliferative diseases	0.3	0.1	0.6	0.5	0.7	0.3	0.2	0.5	0.0	0.5	0.0	0.3	0.2	0.2	0.3	0.2	0.2	0.2	0.5	0.4
C90	Multiple myeloma	3.1	3.5	2.9	3.9	3.1	3.5	2.7	2.9	2.0	3.2	4.2	3.3	2.1	3.3	3.8	2.4	1.5	5.0	2.9	1.1
C91-95	Leukaemia	5.9	6.9	6.8	5.8	5.9	6.0	6.9	7.1	5.1	7.8	4.8	5.8	4.8	3.7	5.7	4.2	5.9	5.7	7.4	3.8

Table 22 Number of cancer deaths in Norway by primary site and sex - 2004

ICD10	Site	Males	Females	Total
C00-96	All sites	5589	4900	10489
C00-14	Mouth, pharynx	88	50	138
C00	Lip	1	1	2
C01-02	Tongue	21	11	32
C03-06	Mouth, other	21	19	40
C07-08	Salivary glands	7	3	10
C09-14	Pharynx	38	16	54
C15-26	Digestive organs	1606	1467	3073
C15	Oesophagus	137	59	196
C16	Stomach	244	164	408
C17	Small intestine	20	24	44
C18	Colon	562	608	1170
C19-21	Rectum, rectosigmoid, anus	244	172	416
C22	Liver	65	70	135
C23-24	Gallbladder, bile ducts	23	31	54
C25	Pancreas	297	325	622
C26	Other digestive organs	14	14	28
C30-34, C38	Respiratory organs	1227	758	1985
C30-31	Nose, sinuses	11	4	15
C32	Larynx, epiglottis	37	9	46
C33-34	Lung, trachea	1174	740	1914
C38	Mediastinum, pleura	5	5	10
C40-41	Bone	13	12	25
C43	Melanoma of the skin	143	123	266
C44	Skin, non-melanoma	12	15	27
C45	Mesothelioma	40	10	50
C46	Kaposi's sarcoma			
C47	Autonomic nervous system	1		1
C48-49	Soft tissues	24	39	63
C50	Breast	3	694	697
C51-58	Female genital organs		599	599
C53	Cervix uteri		81	81
C54	Corpus uteri		81	81
C55	Uterus, other		50	50
C56	Ovary		330	330
C51-52, C57	Other female genital		57	57
C58	Placenta			
C60-63	Male genital organs	1091		1091
C61	Prostate	1074		1074
C62	Testis	13		13
C60, C63	Other male genital	4		4
C64-68	Urinary organs	434	235	669
C64-65	Kidney	153	107	260
C66-68	Bladder, ureter, urethra	281	128	409
C69	Eye	2	3	5
C70-72	Central nervous system	177	134	311
C73	Thyroid gland	11	18	29
C37, C74-75	Other endocrine glands	6	10	16
C39, C76, C80	Other or unspecified	220	309	529
C81-96	Lymphoid and haematopoietic tissue	491	424	915
C81	Hodgkin lymphoma	9	8	17
C82-85, C96	Non-Hodgkin lymphoma	170	141	311
C88	Malignant immunoproliferative diseases	9	8	17
C90	Multiple myeloma	129	123	252
C91-95	Leukaemia	174	144	318

Mortality

There were 10 489 cancer deaths in Norway 2004, of which 5589 were in men and 4900 in women (Table 22). Taken together, lung, colorectal, prostate and female breast cancer are responsible for almost 5300 deaths, about of half of the total mortality burden. In terms of numbers of cancer deaths, lung cancer ranks first in men, responsible for 1174 deaths in 2004, but closely followed by prostate cancer (1074). Colorectal cancer ranks third, with 806 deaths in 2005. In women, colorectal cancer (780 deaths), lung cancer (740) and breast cancer (694) are the most frequent causes of cancer death. Figure 8 shows the distribution of age-standardised mortality rates by cancer site sorted in descending order: rates of lung cancer are highest in both men and women, with breast cancer mortality rates in women almost equal to those lung cancer in women.


Figure 9 shows the temporal evolution of the sex-specific mortality rates for selected cancers in Norway. In

men, there have been steady increases in the mortality rates of the three most frequent causes of cancer death - lung, prostate and colorectal cancer - since the 1970s. There is some evidence however that recent mortality trends are more favorable for these three cancers, with trends having either reached a plateau, or beginning to decline. In women, lung cancer has been rising rapidly in the last decades relative to other cancer mortality rates, while colorectal and breast cancer mortality have been increasing slowly. During the 1990s however, breast cancer mortality rates have been observed to be decreasing.

As observed for incidence, there is a steady long-term decline in stomach cancer mortality in Norway. There have also been some notable declines in the mortality rates of several tumours beginning in the 1970s, particularly among younger populations, including testicular cancer in men and leukaemia. Advances in cancer care, including the development of new treatment regimens as well as a multidisciplinary approach to cancer care, have likely contributed to the observed time trends.

Figure 8: Age-standardised (world) mortality rates in Norway 2004 for selected cancers
(Source: Statistics Norway)

MALES



FEMALES






Figure 9: Time trends in age-standardised (world) mortality rates in Norway for selected cancers (semi-log scale)
(Source: WHO)

MALES

FEMALES



Survival

The estimated five-year survival probabilities in Norway illustrate the considerable variability in prognosis following the diagnosis of specific cancer types (Figure 10). Testicular cancer, for example, the most frequent cancer among young men, has an excellent overall prognosis, with five-year survival estimated at over 95% for patients diagnosed 1996-2000. Survival is generally higher where early diagnosis and treatment can materially influence prognosis, as is the case for certain common cancers including cancers of the breast and colorectum.

Survival of cancer patients in Norway has increased steadily from the 1950s for a number of specific primary sites, predominantly as a result of advances in therapy and cancer care during this time (Figure 10). In the period of diagnosis 1996-2000, five-year survival following a cancer diagnosis was estimated at 56% and 62% for men and women respectively, a differential partly reflecting a higher incidence of cancers associated with better prognosis among women, relative to men. Survival probabilities in men have doubled from 29% for those diagnosed with cancer in 1955-59, and by 50% in women from 41% in the late-1950s.

Patients diagnosed with cancers of liver, lung and pancreas have among the poorest chances of surviving their illness. Five-year relative survival for pancreatic cancer is only 2-3%, and as with several other poor-prognosis cancers, survival has not altered appreciably in the last few decades (Figure 11).

Table 23-24 shows five-year relative survival probabilities according to five-year period of diagnosis by primary site, sex and stage. Caution should be applied to the interpretation of stage-specific survival, particularly where the proportions of patient with stage unknown is high. Survival estimates based on fewer than 50 diagnoses in the latest period are not shown.

Survival on www.cancerregistry.no

In keeping with previous Cancer in Norway reports, more detailed results for 24 cancer types are available on our website. Graphical descriptions of relative survival trends for cases diagnosed 1955-2000 and five-year survival probabilities by stage can be downloaded from our website following the link:

www.cancerregistry.no/cin

Future work on survival

Future publications from the Registry will provide more detailed and insightful analyses of the survival of Norwegian cancer patients than afforded in this report. An analysis of long-term survival of cancer patients in Norway using the period analysis approach will be introduced to derive more up-to-date estimates (Brenner *et al*, 2004). Systematic analyses of time trends in cancer survival will account for differences in the age distribution of patients over time via age-standardisation (Brenner and Hakulinen, 2005). To monitor trends in survival of curable disease, the cure fraction - the proportion of patients statistically cured of disease - will be estimated for each primary site, where applicable (Lambert *et al*, 2006).

Figure 10: Five-year relative survival probabilities in Norway for selected cancers, diagnoses 1996-2000




Table 23 Five-year relative survival in percent by selected primary sites, stage and period of diagnosis - 1956-2000

MALES

				Relative survival (%)										
ICD10	Site	Stage	n 1996-2000	1956-1960	1961-1965	1966-1970	1971-1975	1976-1980	1981-1985	1986-1990	1991-1995	1996-2000		
C00-96	All sites	Total	54498	28.9	27.8	31.2	35.6	39.9	42.6	45.0	50.0	55.6		
C00	Lip	Total	320	89.2	89.6	92.1	96.3	90.6	90.8	90.5	89.5	90.4		
		Localized	239	93.2	90.7	93.9	99.3	93.5	92.9	93.8	93.9	95.2		
		Unknown	59	76.9	61.4	95.9	61.4	91.6	76.6	73.1	86.7	82.1		
C15	Oesophagus	Total	579	2.4	2.1	3.7	4.0	2.5	4.6	4.8	5.4	7.3		
		Localized	143	3.3	3.1	5.4	5.1	2.7	6.2	7.6	9.5	17.8		
		Regional	125	2.7	0.0	0.0	2.9	4.2	7.5	5.0	5.7	7.6		
		Distant	159	0.0	1.4	0.0	0.0	1.2	0.0	0.8	0.0	0.0		
		Unknown	152	0.0	0.0	11.1	20.6	0.0	0.0	13.1	0.0	5.6		
C16	Stomach	Total	1963	12.1	11.3	12.7	14.0	18.6	18.0	20.1	18.5	19.3		
		Localized	390	30.0	28.1	35.5	40.0	44.9	38.9	41.1	39.5	53.6		
		Regional	580	12.3	12.0	13.0	13.7	21.4	19.9	21.5	18.7	20.2		
		Distant	672	1.2	2.1	1.4	1.8	1.3	1.7	0.8	0.5	2.0		
		Unknown	321	4.8	0.9	6.7	7.5	3.9	3.8	4.6	6.9	14.2		
C18	Colon	Total	4505	33.8	31.1	37.0	39.9	43.6	49.2	48.8	50.5	56.3		
		Localized	874	55.7	52.3	63.1	72.5	72.7	77.8	79.9	80.4	91.5		
		Regional	2200	34.2	35.6	41.1	42.8	51.4	57.6	58.3	61.4	69.8		
		Distant	1166	4.9	3.8	5.3	6.0	7.1	4.6	4.2	4.4	6.6		
		Unknown	265	11.0	3.3	18.6	14.3	17.7	16.6	11.8	15.2	51.2		
C19-21	Rectum, rectosigmoid, anus	Total	2984	27.7	28.3	31.1	35.5	41.1	44.8	48.0	51.7	58.2		
		Localized	969	48.1	49.0	52.5	58.9	61.5	66.6	68.9	74.8	82.2		
		Regional	1161	14.2	13.7	21.2	24.4	36.7	39.3	47.1	50.2	65.2		
		Distant	568	1.9	3.2	2.4	4.1	4.4	2.8	2.8	4.0	9.8		
		Unknown	286	11.4	5.4	18.5	8.5	29.4	21.9	42.8	25.2	47.5		
C22	Liver	Total	311	0.0	0.0	0.0	3.6	5.1	2.2	2.5	7.0	6.7		
		Localized	113	0.0	0.0	0.0	8.0	7.4	3.4	4.2	9.8	16.6		
		Distant	69	0.0	0.0	0.0	0.0	4.4	0.0	0.0	2.5	0.0		
		Unknown	107	0.0	0.0	0.0	0.0	0.0	4.0	0.0	3.5	1.3		
C25	Pancreas	Total	1310	3.1	1.8	2.0	1.6	1.6	1.5	1.9	2.5	3.4		
		Localized	101	4.4	2.0	6.0	3.4	3.5	2.7	3.7	3.9	9.5		
		Regional	168	2.0	1.3	2.8	1.6	2.3	3.2	4.4	6.6	7.3		
		Distant	647	0.5	1.7	0.2	1.1	0.5	0.3	1.0	1.2	1.8		
		Unknown	394	15.3	3.3	0.0	1.4	4.4	3.7	0.0	2.2	2.7		
		C33-34	Lung, trachea	Total	6201	7.0	8.1	8.2	7.9	8.4	8.5	8.6	8.9	9.4
				Localized	1173	17.7	16.0	18.4	18.6	17.8	19.3	17.2	18.5	30.6
				Regional	1577	5.4	10.0	9.7	7.9	9.9	9.3	12.0	10.6	9.7
Distant	2646			0.0	0.5	0.7	0.9	1.1	0.9	0.8	0.6	0.7		
Unknown	805			3.5	3.7	2.1	1.9	5.8	1.8	3.0	8.9	7.2		
C43	Melanoma of the skin	Total	2254	47.9	49.2	49.9	62.9	70.2	72.4	75.4	79.6	78.3		
		Localized	1517	60.5	65.5	62.5	73.0	79.3	82.0	83.5	87.1	86.7		
		Regional	69	36.8	18.0	29.4	36.1	30.2	27.4	37.8	31.1	36.8		
		Distant	129	10.1	17.5	6.3	12.1	11.3	0.0	9.4	10.6	8.3		
		Unknown	539	40.4	64.4	60.2	55.2	44.8	63.6	41.6	55.8	76.1		
C61	Prostate	Total	13983	43.2	44.7	48.0	52.1	56.2	57.7	58.1	65.9	78.1		
		Localized	5350	55.4	55.8	59.4	65.7	70.8	73.5	71.5	76.9	93.4		
		Regional	543	27.8	31.0	37.2	37.4	39.9	38.8	57.7	70.6	78.1		
		Distant	1998	19.8	18.6	19.1	17.5	19.9	20.5	25.6	23.4	24.7		
		Unknown	6092	38.3	44.9	47.7	42.1	39.1	45.1	49.0	57.5	80.5		
		C62	Testis	Total	1183	60.2	62.1	67.7	66.9	82.0	93.0	94.6	95.8	96.0
				Localized	676	76.2	81.8	83.2	87.9	94.7	98.1	98.4	99.3	98.6
				Regional	177	72.9	64.0	77.4	74.2	84.4	95.9	96.2	96.2	98.3
Distant	160			9.4	15.8	21.0	22.4	43.9	75.2	75.5	75.9	81.0		
Unknown	170			90.2	60.7	72.4	38.6	91.3	53.3	86.2	87.1	97.2		
C66-68	Bladder, ureter, urethra	Total	4067	53.3	52.2	57.0	61.8	65.7	69.1	70.5	73.7	73.3		
		Localized	2416	62.7	58.8	65.4	71.8	74.3	77.0	76.9	78.8	83.1		
		Regional	197	9.8	10.2	13.6	19.2	27.3	23.7	26.8	26.0	23.7		
		Distant	158	4.8	4.1	0.0	7.7	1.0	3.1	9.3	5.9	4.3		
		Unknown	1296	31.0	34.8	46.7	43.6	33.7	38.5	58.0	58.6	70.7		
		C81	Hodgkin lymphoma	Total	288	23.4	23.1	42.1	56.5	54.4	67.7	76.2	84.2	90.1
		C82-85, C96	Non-Hodgkin lymphoma	Total	1747	25.2	24.3	29.9	33.6	41.5	44.3	48.7	50.1	55.4
		C91-95	Leukaemia	Total	1248	9.0	10.1	12.1	20.5	25.2	28.5	36.7	43.6	49.8

Table 24 Five-year relative survival in percent by selected primary sites, stage and period of diagnosis - 1956-2000



FEMALES

ICD10	Site	Stage	n 1996-2000	Relative survival (%)								
				1956-1960	1961-1965	1966-1970	1971-1975	1976-1980	1981-1985	1986-1990	1991-1995	1996-2000
C00-96	All sites	Total	50446	40.9	41.0	43.9	48.4	51.4	53.0	55.2	58.3	62.2
C16	Stomach	Total	1241	11.2	10.9	10.6	12.7	16.8	21.0	23.2	22.0	25.2
		Localized	280	26.6	27.2	31.3	32.8	40.4	48.6	41.4	42.9	62.4
		Regional	314	13.3	10.7	14.0	16.5	18.8	17.2	26.0	24.9	32.0
		Distant	394	1.7	1.8	1.0	2.9	1.5	1.0	1.0	1.5	3.2
		Unknown	253	5.3	4.6	4.0	5.1	6.8	9.2	13.5	18.3	11.9
C18	Colon	Total	5385	33.0	32.7	36.7	41.5	44.6	49.1	52.4	54.4	58.5
		Localized	1069	53.2	54.9	62.5	72.1	72.6	79.5	82.0	85.0	88.9
		Regional	2673	37.6	34.6	40.1	44.7	55.5	56.3	62.2	62.2	71.0
		Distant	1230	2.4	4.1	4.7	5.8	4.3	4.3	4.4	6.0	9.0
		Unknown	413	7.4	7.6	20.8	25.4	25.0	12.1	22.7	25.0	45.5
C19-21	Rectum, rectosigmoid, anus	Total	2509	31.9	31.8	34.2	39.7	46.4	49.0	52.5	58.2	60.3
		Localized	841	47.3	53.7	57.9	65.6	69.5	72.0	74.6	75.9	88.5
		Regional	935	28.9	17.8	21.3	25.2	39.8	42.4	50.8	59.7	62.8
		Distant	456	2.1	0.9	5.0	4.1	7.2	4.7	4.7	5.4	7.6
		Unknown	277	27.1	17.2	28.0	14.2	25.5	22.4	24.9	36.4	51.1
C22	Liver	Total	198	0.0	3.6	5.6	7.0	1.6	5.6	6.7	10.9	9.0
		Localized	58	0.0	4.2	9.9	14.2	3.3	9.1	10.2	14.6	22.6
		Unknown	75	0.0	28.9	0.0	0.0	0.0	6.1	0.0	7.0	3.7
C25	Pancreas	Total	1502	2.8	1.5	2.2	1.4	1.9	1.9	2.3	3.2	3.2
		Localized	123	4.6	2.1	5.7	4.6	3.7	3.1	5.3	7.4	12.0
		Regional	182	5.8	4.1	1.6	1.0	5.3	5.9	4.9	5.5	4.1
		Distant	692	1.5	0.8	0.9	0.5	0.8	0.7	0.4	1.0	0.9
		Unknown	505	0.0	0.0	0.0	0.0	0.0	0.8	1.7	1.9	4.2
C33-34	Lung, trachea	Total	3360	5.3	8.0	12.9	10.4	12.6	8.1	10.0	12.1	13.5
		Localized	554	16.5	23.1	27.9	26.7	30.3	22.4	22.8	27.1	45.9
		Regional	776	9.5	4.3	14.6	10.3	15.6	6.7	11.5	13.9	12.8
		Distant	1488	0.0	0.6	2.8	1.2	1.2	0.3	1.2	1.5	1.7
		Unknown	542	0.0	5.1	11.2	5.8	11.5	8.7	5.7	5.3	13.7
C43	Melanoma of the skin	Total	2496	61.5	75.1	73.5	81.2	83.9	85.1	89.5	89.6	90.4
		Localized	1734	72.2	82.4	84.2	88.0	89.0	90.6	93.1	93.4	96.3
		Regional	56	29.8	45.2	32.7	41.0	38.9	43.5	45.8	48.3	60.3
		Distant	108	18.1	18.8	22.7	21.1	18.6	5.8	15.6	17.6	17.7
		Unknown	598	56.5	58.4	78.4	49.1	67.0	63.8	70.1	71.5	88.0
C50	Breast	Total	12047	63.1	63.9	64.9	67.4	71.8	74.2	75.6	77.7	85.3
		I	6547	83.7	84.1	85.1	85.2	87.2	87.2	89.3	89.9	94.1
		II	4418	55.0	55.3	55.1	57.6	61.3	66.2	74.0	75.4	83.6
		III	416	30.1	40.1	37.5	48.8	50.6	50.7	53.8	60.2	60.9
		IV	603	10.5	14.7	12.1	13.1	14.8	14.3	18.3	19.1	16.9
		Unknown	63	68.8	55.7	72.9	75.1	77.0	88.7	53.5	60.4	100.4
C53	Cervix uteri	Total	1573	59.3	64.2	67.9	71.8	69.4	69.3	66.5	71.9	73.4
		I	922	75.1	85.0	86.9	89.4	87.6	87.1	85.6	85.7	91.8
		II	336	58.9	63.0	59.0	67.7	61.9	60.6	56.4	61.5	59.6
		III	166	34.7	29.9	30.7	32.5	30.9	34.0	22.7	34.4	38.3
		IV	123	12.1	6.7	9.2	11.1	7.1	5.2	20.5	22.0	8.5
C54	Corpus uteri	Total	2513	67.8	69.6	69.0	78.4	78.1	76.3	76.3	79.6	81.9
		Localized	1679	77.5	77.8	80.0	85.9	87.2	86.7	86.2	88.7	92.6
		Regional	290	23.1	28.6	28.7	55.2	61.0	58.1	64.9	69.5	74.9
		Distant	334	15.9	20.1	21.4	22.7	20.2	25.6	26.6	34.5	36.7
		Unknown	210	51.4	46.5	69.6	52.4	40.2	37.5	33.7	41.6	76.0
C56	Ovary	Total	2286	29.1	31.7	34.6	37.9	40.5	38.0	36.8	39.9	44.1
		Localized	454	59.9	66.4	74.6	67.9	81.4	80.3	82.8	84.2	91.4
		Regional	65	30.1	28.9	48.2	35.1	45.2	49.7	49.2	47.8	63.8
		Distant	1528	9.7	11.3	13.5	13.9	21.2	17.3	16.9	20.9	26.6
		Unknown	239	20.0	31.7	23.4	16.0	53.0	38.2	17.0	26.8	58.3
C66-68	Bladder, ureter, urethra	Total	1475	35.1	39.3	46.7	50.6	54.7	58.5	64.2	63.5	65.6
		Localized	773	50.7	54.9	59.7	66.2	69.9	70.2	72.3	71.2	82.8
		Regional	85	2.6	11.4	12.0	15.9	10.9	13.5	17.1	22.5	30.0
		Distant	101	3.1	4.2	8.8	4.7	4.9	5.5	5.8	7.1	3.7
		Unknown	516	8.9	23.1	46.6	30.7	19.1	19.3	53.7	28.4	57.6
C81	Hodgkin lymphoma	Total	215	34.0	40.2	48.2	48.2	63.4	63.1	77.4	80.1	90.0
C82-85, C96	Non-Hodgkin lymphoma	Total	1537	32.0	29.1	31.0	39.6	44.5	49.5	55.6	54.4	58.8
C91-95	Leukaemia	Total	1060	10.2	11.2	15.6	19.8	24.9	30.6	32.2	46.9	50.8

Figure 11: Time trends in five-year relative survival in Norway for selected cancers, diagnoses 1956-2000

MALES

FEMALES



Prevalence

By the end of December 2005, almost 168 000 persons were alive after having had a prior cancer diagnosis in Norway. The more useful prevalence measures in Table 24 are those that approximate the number of patients still requiring some form of cancer care i.e. persons alive with cancer a given number of years after diagnosis (<1, 4-9, 5-9 and ≥10 years). A comparison of such prevalence measures with incidence is a good pointer to long-term prognosis of specific cancers, given they depend on both incidence and subsequent survival.

Common neoplasms associated with reasonable prognosis – breast, colorectal and prostate cancer - have the highest 10-year prevalence in Norway, a measure that serves as a weak surrogate for the number of patients that may be considered “cured” of cancer. The number of persons alive and diagnosed with melanoma of the skin 10 or more years after diagnosis ranks second only to breast cancer, and is seven times higher than that of lung cancer. Differences in prognosis - considerably poorer survival associated with lung cancer - rather than incidence explains much of the differential: the annual number of new cases of lung cancer is twice that of melanoma in Norway.

Table 24 Prevalence of cancer 31.12.1995 and 31.12.2005, both sexes

ICD10	Site	Total no. of persons alive		Years after diagnosis			
		31.12.95	31.12.05	<1	1-4	5-9	10+
C00-96	All sites	112338	167861	18474	51112	39169	59106
C00-14	Mouth, pharynx	2900	3264	359	895	742	1268
C00	Lip	1384	1147	76	212	240	619
C01-02	Tongue	360	531	67	185	130	149
C03-06	Mouth, other	509	581	70	181	134	196
C07-08	Salivary glands	352	443	44	107	89	203
C09-14	Pharynx	352	595	106	219	156	114
C15-26	Digestive organs	19855	26702	3630	8616	6218	8238
C15	Oesophagus	171	273	112	88	39	34
C16	Stomach	2359	1961	286	511	392	772
C17	Small intestine	305	536	66	227	109	134
C18	Colon	10534	14692	1811	4745	3607	4529
C19-21	Rectum, rectosigmoid, anus	6470	8883	1073	2915	2091	2804
C22	Liver	98	173	51	48	25	49
C23-24	Gallbladder, bile ducts	205	284	77	91	53	63
C25	Pancreas	340	448	198	134	57	59
C26	Other digestive organs	79	127	30	56	19	22
C30-36, C38	Respiratory organs	3884	5207	1324	1755	1010	1118
C30-31	Nose, sinuses	219	267	31	81	71	84
C32	Larynx, epiglottis	968	1037	98	321	275	343
C33-34	Lung, trachea	2668	3882	1189	1358	662	673
C38	Mediastinum, pleura	56	44	9	9	5	21
C40-41	Bone	407	566	39	116	113	298
C43	Melanoma of the skin	10586	15172	1080	3289	3195	7608
C44	Skin, non-melanoma	6327	9916	1278	3543	2548	2547
C45	Mesothelioma	52	90	42	36	3	9
C46	Kaposi's sarcoma	106	89	10	20	22	37
C47	Autonomic nervous system	217	232	8	27	34	163
C48-49	Soft tissues	819	1074	106	263	192	513
C50	Breast	21646	31548	2703	9259	8048	11538
C51-58	Female genital organs	16637	19314	1354	4111	3565	10284
C53	Cervix uteri	6642	6722	276	897	997	4552
C54	Corpus uteri	5955	7755	621	1985	1627	3522
C55	Uterus, other	42	50	6	17	10	17
C56	Ovary	3074	3763	341	974	734	1714
C51-52, C57	Other female genital	1120	1218	129	297	248	544
C58	Placenta	113	141	6	12	16	107
C60-63	Male genital organs	14918	26940	3678	10669	7361	5232
C61	Prostate	11557	21588	3391	9580	6191	2426
C62	Testis	3188	5060	244	975	1094	2747
C60, C63	Other male genital	272	365	45	119	90	111
C64-68	Urinary organs	10843	13950	1521	4400	3272	4757
C64-65	Kidney	2983	4125	487	1364	898	1376
C66-68	Bladder, ureter, urethra	8098	10078	1064	3115	2437	3462
C69	Eye	692	842	46	205	161	430
C70-72	Central nervous system	4044	7394	657	2258	1664	2815
C73	Thyroid gland	3055	3806	206	634	599	2367
C37, C74-75	Other endocrine glands	202	249	13	52	54	130
C39, C76, C80	Other or unspecified	443	543	161	167	85	130
C81-96	Lymphoid and haematopoietic tissue	7837	11871	1348	3884	2767	3872
C81	Hodgkin lymphoma	1279	1862	108	376	414	964
C82-85, C96	Non-Hodgkin lymphoma	3469	5375	652	1750	1284	1689
C88	Malignant immunoproliferative diseases	183	253	25	122	50	56
C90	Multiple myeloma	1001	1228	250	590	259	129
C91-95	Leukaemia	1948	3216	321	1068	773	1054

References



- Armitage P, Doll R. The age distribution of cancer and a multi-stage theory of carcinogenesis. *Br J Cancer* 1954;8:1–12.
- Armstrong BK. The role of the cancer registry in cancer control. *Cancer Causes Control*. 1992 Nov;3(6):569–79.
- Brenner H. Limitations of the death certificate only index as a measure of incompleteness of cancer registration. *Br J Cancer* 1995;72(2):506–10.
- Brenner H, Hakulinen T. Age adjustment of cancer survival rates: methods, point estimates and standard errors. *Br J Cancer* 2005;93(3):372–5.
- Brenner H, Gefeller O, Hakulinen T. Period analysis for ‘up-to-date’ cancer survival data: theory, empirical evaluation, computational realisation and applications. *Eur J Cancer*. 2004 Feb;40(3):326–35.
- Brewster D. Improving the quality of cancer registration data. *J R Soc Med* 1995;88(5):268–71.
- Bullard J, Coleman MP, Robinson D, Lutz JM, Bell J, Peto J. Completeness of cancer Registration: a new method for routine use. *Br J Cancer* 2000;82(5):1111–6.
- Doll, R., Payne, P. & Waterhouse, J. (eds) (1966) *Cancer Incidence in Five Continents: A Technical Report*, Berlin, Springer-Verlag (for UICC).
- Ederer F, Axtell LM, Cutler SJ. The relative survival rate: a statistical methodology. *Natl Cancer Inst Monogr*. 1961;6:101–21.
- Estève J, Benhamou E, Raymond L. *Statistical Methods in Cancer Research, Vol IV. Descriptive Epidemiology*. Lyon: IARC Scientific Publications No. 128, 1994.
- Helseth A, Langmark F, Mork SJ. Neoplasms of the central nervous system in Norway. I. Quality control of the registration in the Norwegian Cancer Registry. *APMIS*. 1988 Nov;96(11):1002–8.
- Harvei S, Tretli S, Langmark F. Quality of prostate cancer data in the cancer registry of Norway. *Eur J Cancer*. 1996 Jan;32A(1):104–10.
- Lambert PC, Thompson JR, Weston CL, Dickman PW. Estimating and modelling the cure fraction in population-based cancer survival analysis. *Biostatistics*, in press.
- Last JM. *A Dictionary of Epidemiology* 4th ed. Oxford: Oxford University Press, 2001.
- Lund E. Pilot study for the evaluation of completeness of reporting of the cancer registry. In: *Statistics in Norway 1978, The Cancer Registry of Norway*, 1981.
- Mork J, Thoresen S, Faye-Lund H, Langmark F, Glatte E. Head and neck cancer in Norway. A study of the quality of the Cancer Registry of Norway’s data on head and neck cancer for the period 1953–1991. *APMIS* 1995;103(5):375–82.
- Parkin DM, Chen V, Ferlay J, Galceran J, Storm HH, Whelan SL. *Comparability and Quality Control in Cancer Registration (IARC Technical Reports No. 19)*. Lyon: International Agency for Research on Cancer; 1994.
- Pecorelli S, Benedet JL, Creasman WT, Shepherd JH. FIGO staging of gynecologic cancer. 1994–1997 FIGO Committee on Gynecologic Oncology. International Federation of Gynecology and Obstetrics. *Int J Gynaecol Obstet* 1999;64(1):5–10.
- Statistics Norway. *Statistical Yearbook of Norway 2005*. Oslo: Statistics Norway, 2006.
- Statistics Norway. *Population Projections 2002–2050. National and Regional Figures*. Oslo: Statistics Norway, 2004.
- Segi, M. *Cancer Mortality for Selected Sites in 24 Countries (1950–57)*, Sendai, Tohoku University School of Public Health, 1960.
- Storm HH. Cancer registries in epidemiologic research. *Cancer Causes Control*. 1996;7:299–301.
- Perdersen E, Magnus K. *Cancer Registration in Norway. The Incidence of Cancer in Norway 1953–1954*. The Norwegian Cancer Society, Oslo, 1959.
- Smith-Gagen J, Cress RD, Drake CM, Felter MC, Beaumont JJ. Factors associated with time to availability for cases reported to population-based cancer registries. *Cancer Causes Control*. 2005 May;16(4):449–54.
- Tingulstad S, Halvorsen T, Norstein J, Hagen B, Skjeldestad FE. Completeness and accuracy of registration of ovarian cancer in the cancer registry of Norway. *Int J Cancer*. 2002;98(6):907–11.
- World Health Organization. *International Statistical Classification of Diseases, Injuries, and Causes of Death, 7th Revision (1955)*. Geneva: WHO, 1957.
- World Health Organization. *International Classification of Diseases for Oncology, Second Edition*, eds. Percy, C, Van Holten, V, Muir, C. Geneva: WHO, 1990.
- World Health Organization. *International Statistical Classification of Diseases and Related Health Problems, 10th Revision (1990)*. Geneva: WHO, 1992.

Research activities at the Registry

Organisation and founding principles

The Cancer Registry of Norway is a national, population-based cancer research institute, which was founded and financed by the Cancer Society 1951-1979. Since then the institution has been governmental, with a board (except for the period 1994-2002) and a chapter in the National Budget plan. Since 2002 it has been allied to the Norwegian Radium Hospital and from 2005 to the merged Rikshospitalet-Radium-hospitalet Health Trust (RR HF). This organisational platform signals the importance attached to close links with cancer research milieus and cancer clinics. It also increases the possibilities for Norway as a nation to move towards the Comprehensive Cancer Centre organisational model. As early as 1951, reporting of cancer and some precancers has been mandatory from all milieus that diagnose and treat cancer. From 2002 however, new regulations have strongly enforced the legal premises, substantially improving the Cancer Registry's capacity to perform clinical population-based research and evaluate the quality control of health care. Comparative advantages are compulsory reporting without patients' consent and the uniquely identifying personal number. As a result of these advantages, organ-specific treatment quality registries are increasingly part of the Cancer Registry's duties, in close collaboration with the clinical milieus.

Structure of the Cancer Registry of Norway



Department of Etiological Research

Head: Prof Steinar Tretli PhD

Department objectives

The principal goal of the Department of Etiological Research is to provide new insights into the causes of cancer. The focal points for research in recent years have been cancer risk and its relation to occupational and environmental factors, and to hormonal status and diet. In future studies, an increased emphasis will be put on testable biologically-founded hypotheses, using biological markers of exposures, and collaboration with researchers in the relevant fields. Specifically this will include utilisation of the JANUS serum bank. The tradition of collaboration with the other Nordic countries, as well as international collaboration will be continued and expanded. The high quality population-based registries in the Nordic countries make such partnerships especially valuable.

Current research priorities

Life course research

A focus on the total life course implies research on long-term effects of lifestyle factors and other exposures during early life in utero, childhood, youth and adult life. The department will give priority to research that increases the understanding of what early life conditions means in relation to exposure and later risk of cancer. Several studies have focused on the importance of early life on adult cancer risk, specifically for hormone-related cancers such as breast, prostate, and testicular cancer.

Occupational and environmental cancer studies

Research on cancers associated with occupational and environmental exposures has long traditions in the department, and the identification and quantification of such risks will still be in focus. Studies on working populations may often be the only method to obtain knowledge of possible population effects of low-dose exposures. Occupation is also an important classification variable concerning the knowledge on differences in cancer risk by social class.

Modelling and simulation studies

The understanding of the carcinogenic process has traditionally been based on three sources of information: experimental, clinical, and epidemiological research. Through modelling and simulation we will assess the importance of different mechanisms in the disease process. Ongoing projects are studying the growth rates of tumours and the variation of these rates in breast cancer patients. This research is rooted in the mammography-screening database.

Recent important results

In 2005, the research activity at the department led to over 50 scientific publications in international and national journals. The publications focused on factors like organochlorine, nickel, *Helicobacter pylori*, vitamin D, alcohol, physical activity, pregnancy, inheritance, and life conditions after cancer. Some of the results are from international collaboration studies. In addition, four doctoral dissertations were published in 2005.

Theses published in 2005

Svensson KE. Epidemiological studies of colorectal cancer – early life conditions and later risk. University of Oslo 2005.

Roessink J. 50-Hz magnetic fields, light at night and risk of breast cancer. University of Oslo 2005.

Hernes E. Advanced prostate cancer: selected aspects of human pathology, clinical oncology and epidemiology. University of Oslo 2005.

Aschim EL. Factors contributing to testicular dysgenesis. University of Oslo 2005.

Department of Screening-based Research

Head: Prof Steinar Ø. Thoresen MD PhD

Acting Head: Dr Rita Steen MD PhD

Department objectives

The Screening Department administers two programmes for early detection of cancer and premalignant disease, the Breast Cancer Screening Programme and the Cervical Cancer Screening Programme. Since 1995, the Cervical Cancer Screening Programme has recommended women aged 25-69 years undergo a PAP smear every third year, whereas all women aged 50-69 years are offered mammography screening every two years. The Cervical Cancer Screening Programme mails a personal letter to women whom have had no PAP test in the last three years, with a recommendation to get tested. Invitation to mammography screening is mailed to eligible women, together with a pre-specified date of examination.

The Screening Department monitors the programmes' effectiveness and efficacy by examining early quality indicators (e.g. coverage/attendance, detection rate, and tumour stage), as well as changes in rates of incidence and mortality. The main objective of the Norwegian Breast Cancer Screening Programme is to reduce mortality by 30% among women invited to mammography screening. For the Cervical Cancer

Screening Programme, the main objective is to achieve a reduction of 50% in the incidence and mortality rates of cervical cancer compared to the rates prior to the programme launch. The most important factor determining the success of these screening programmes is high coverage. In 2005, coverage was 79% in the Cervical Cancer Screening Programme, and the attendance rate was 76% in the Breast Cancer Screening Programme, raising expectations that the programmes will accomplish these objectives.

Current Research Priorities

The current research priorities of the Cervical Cancer Screening Programme are:

- 1) Evaluation of the CIN (cervical intraepithelial neoplasia) register, a follow-up register with data on treatment, established in 1997.
- 2) Study of the impact of HPV-testing in triage after PAP smear screening on CIN 2+.
- 3) Long-term follow-up after HPV vaccination of participating women. Study of HPV prevalence among women 18-45 years, both in the general population and in those with cervical cancer.
- 4) Study of the impact of changing the screening interval and screening age range.
- 5) Studies of the efficacy and effectiveness of screening in women aged 25-69 years.
- 6) Study of the screening history of women diagnosed with cervical cancer before reaching the age of 25, including a re-examination of their PAP tests, pathological tissue and samples.
- 7) Study of the screening history of women aged over 70 years diagnosed with cervical cancer.
- 8) Investigate the need for a more individual-orientated approach to Cervical Cancer Screening Programme, dependent on vaccination status.

The current research priorities of the Breast Cancer Screening Programme are:

- 1) Further investigation of early (process) indicators, as well as studies on radiological performance.
- 2) Study of the effectiveness of the programme in relation to breast cancer survival and mortality.
- 3) Study of overdiagnosis associated with the Breast Cancer Screening Programme.
- 4) Descriptive analyses aimed at profiling non-attenders.
- 5) Investigate in a pilot project whether expansion of the programme to cover age groups outside of 50-69 years is feasible and warranted. This project is in co-operation with the Norwegian Cancer Society.

For the Breast Cancer Screening Programme, two recent doctoral theses have been published in 2005. A

study of early indicators in mammography screening concluded that there were promising signs of a future mortality reduction (Hofvind, 2005). One full-time PhD student is currently investigating effects of mammography screening on breast cancer survival and mortality. As for the Cervical Cancer Screening Programme, two doctoral theses have been published, the latest in 2005, concluding that the screening programme increased coverage, and consequently reduced the cervical cancer incidence by 23% in 2000-2002. Further, the mailing of a personal letter to women provided a cost-effective solution in an environment where opportunistic screening is substantial (Nygård, 2005).

Theses published in 2005

Hofvind SSH. The Norwegian Breast Cancer Screening Programme: Selected process indicators and their utilization in epidemiological research. University of Oslo, 2005.

Nygård J. Effectiveness of cervical cancer screening. An epidemiological study based on register data from a population based, co-ordinated cervical screening program. University of Oslo, 2005.

Department of Clinical- and Registry-based Research

Head: Dr Bjørn Møller PhD

Department objectives

The Clinical Research department has a broad remit. One of its fundamental responsibilities is the continued collection, storage and quality control of data on all incident cases of cancer in Norway, as defined by the Statutory Regulations. This information - from clinicians, pathologists, administrative patient discharge files, and the cause of death registry - is held in the main database. Two important aims of the Department are i) to provide a comprehensive evaluation of the quality of the main database; ii) to seek optimum utilisation of the data via collaborations with the clinical and research community. The Department provides routine information on cancer patterns and changes in cancer over time in Norway, via various dissemination routes including scientific publications and reports such as the *Cancer In Norway* series. The Department has put an emphasis on activating and collaborating in good research projects at the national and international level, initiated in-house, or via external requests or invitations.

Both the Registry and the Department have expanded recently: three sections have been created identifying three key areas of ongoing activity: 1) management of the Registry, with an emphasis on the documentation of quality control and the revision of in-house coding procedures; 2) research using the main database, focussing on areas of particular public health importance alongside the application of appropriate methodologies; 3) building on strong ties with the clinical milieu in Norway, the continued technical development of the Registry infrastructure, and the launch of several clinical registries linked to the main database. These Registries offer novel opportunities for population-based research into cancer care (see below).

Special registries

The Statutory Regulations for the Cancer Registry of Norway include the registration of treatment and follow-up of Norwegian cancer patients. By establishing special registries – comprehensive registration schemes dedicated to specific cancers – the Registry supplements the cancer registry record with detailed information on diagnostic measures, therapy, and follow-up.

By fostering strong collaborative links with the clinical community, the aims are to provide an empirical base for:

- scientific studies regarding prognostic factors and treatment outcomes
- evaluation of quality of cancer care

The ongoing and expanding activities of these clinical registries is a major focus for the Registry, and several clinical registries are now established. Each clinical register is underpinned by a Reference Group, a panel of multi-disciplinary experts drawn from the clinical and research milieu in Norway, whose remit is to advise on the operations of the registry, and its strategic direction. The table below indicates the status of the special registries as of December 2006. All newly-established clinical registries will be integrated with the Registry's main database.

Theses published in 2005

Bray FI. Temporal studies of cancer occurrence and applications of the age-period-cohort method to trends in Europe. London School of Hygiene and Tropical Medicine, University of London, 2005.

Status of the special registries, December 2006.

Registry	Name	Date of launch or anticipated date
Integrated Clinical Registries	Norwegian Prostate Cancer Registry	01.01.2004
	Colorectal Cancer Registry	01.01.2007
	Norwegian Breast Cancer Registry	01.01.2008
	Norwegian Malignant Melanoma Registry	01.01.2008
	Norwegian Lymphoma Registry	01.01.2009
"Standalone" Clinical Registries	Lung Cancer Registry	1993-2002
	Ovarian Cancer Registry	01.01.2002
	Rectal Cancer Registry*	01.01.1993-31.12.2006
Other	Nordic Solid Tumours in children (NOPHO)	01.01.1982
	Polyposis Families Registry	1974 / 1994**
Screening Registries***	Mammography Screening Registry	01.01.1996
	Cervical Screening Registry	01.01.1992
	Colorectal Screening Registry (NORCCAP)	1999-2001

* From 01.01.2007 Registry will be expanded to include colon cancer, and integrated with the main database.

** Housed in the Clinical Research Department since 1994.

*** Housed in the Screening Department.

List of publications 2005

Registry staff and affiliated researchers collaborated on 81 research papers in 2005, 71 of which were published in international journals.

Albrektsen G, Heuch I, **Hansen S**, Kvale G. Breast cancer risk by age at birth, time since birth and time intervals between births: exploring interaction effects. *Br J Cancer* 2005; 92(1):167-175.

Alvik A, **Haldorsen T**, Lindemann R. Consistency of reported alcohol use by pregnant women: anonymous versus confidential questionnaires with item nonresponse differences. *Alcohol Clin Exp Res* 2005; 29(8):1444-1449.

Anttila T, Tenkanen L, Lumme S, Leinonen M, **Gislefoss RE**, Hallmans G, **Thoresen S**, Hakulinen T, Luostarinen T, Stattin P, Saikku P, Dillner J, Lehtinen M, Hakama M. Chlamydial antibodies and risk of prostate cancer. *Cancer Epidemiol Biomarkers Prev* 2005; 14(2):385-389.

Aschim EL, **Grotmol T**, **Tretli S**, Haugen TB. Is there an association between maternal weight and the risk of testicular cancer? An epidemiologic study of Norwegian data with emphasis on World War II. *Int J Cancer* 2005; 116(2):327-330.

Aschim EL, Giwercman A, Stahl O, Eberhard J, Cwikiel M, Nordenskjold A, Haugen TB, **Grotmol T**, Giwercman YL. The Rsa1 polymorphism in the ER{beta} gene is associated with male infertility. *J Clin Endocrinol Metab* 2005; 90(9):5343-5348.

Baksaas ST, Geiran OR, **Rostad HA**, Svennevig JL. [Tracheal resections]. *Trakealreseksjoner*. *Tidsskr Nor Laegeforen* 2005; 125(1):36-37.

Bjorge T, **Tretli S**, Engeland A. Height and body mass index in relation to cancer of the small intestine in two million Norwegian men and women. *Br J Cancer* 2005; 93(7):807-810.

Boffetta P, **Aagnes B**, **Weiderpass E**, **Andersen A**. Smokeless tobacco use and risk of cancer of the pancreas and other organs. *Int J Cancer* 2005; 114(6):992-995.

Braaten T, **Weiderpass E**, Kumle M, Lund E. Explaining the socioeconomic variation in cancer risk in the Norwegian Women and Cancer Study. *Cancer Epidemiol Biomarkers Prev* 2005; 14(11 Pt 1):2591-2597.

Bray F, Dos Santos Silva I, Moller H, **Weiderpass E**. Endometrial cancer incidence trends in Europe: underlying determinants and prospects for prevention. *Cancer Epidemiol Biomarkers Prev* 2005; 14(5):1132-1142.

Bray F, Loos AH, Oostindier M, **Weiderpass E**. Geographic and temporal variations in cancer of the corpus uteri: Incidence and mortality in pre- and postmenopausal women in Europe. *Int J Cancer* 2005.

Bray F, Carstensen B, Moller H, Zappa M, Zakelj MP, Lawrence G, Hakama M, **Weiderpass E**. Incidence trends of adenocarcinoma of the cervix in 13 European countries. *Cancer Epidemiol Biomarkers Prev* 2005; 14(9):2191-2199.

Bray F, Loos AH, McCarron P, **Weiderpass E**, Arbyn M, Moller H, Hakama M, Parkin DM. Trends in cervical squamous cell carcinoma incidence in 13 European countries: changing risk and the effects of screening. *Cancer Epidemiol Biomarkers Prev* 2005; 14(3):677-686.

Brennan P, Scelo G, Hemminki K, Møller J, Tracey E, **Andersen A**, Brewster DH, Pukkala E, McBride ML, Kliever EV, Tonita JM, Seow

A, Pompe-Kirn V, Martos C, Jonasson JG, Colin D, Boffetta P. Second primary cancers among 109 000 cases of non-Hodgkin's lymphoma. *Br J Cancer* 2005; 93(1):159-166.

Bretthauer M, **Hoff G**. [Quality improvement in Norwegian hospitals]. *Kvalitetsforbedring i norske sykehus*. *Tidsskr Nor Laegeforen* 2005; 125(9):1150.

Collett K, Stefansson IM, Eide J, Braaten A, Wang H, Eide GE, **Thoresen SO**, Foulkes WD, Akslen LA. A Basal epithelial phenotype is more frequent in interval breast cancers compared with screen detected tumors. *Cancer Epidemiol Biomarkers Prev* 2005; 14(5):1108-1112.

Devesa SS, **Bray F**, Vizcaino AP, Parkin DM. International lung cancer trends by histologic type: male:female differences diminishing and adenocarcinoma rates rising. *Int J Cancer* 2005; 117(2):294-299.

Einarsdottir K, Rylander-Rudqvist T, Humphreys K, Ahlberg S, Jonasdottir G, **Weiderpass E**, Chia KS, Ingelman-Sundberg M, Persson I, Liu J, Hall P, Wedren S. CYP17 gene polymorphism in relation to breast cancer risk: a case-control study. *Breast Cancer Res* 2005; 7(6):R890-R896.

Endreseth BH, Myrvold HE, Romundstad P, **Hestvik UE**, Bjerkeset T, Wibe A. Transanal Excision vs. Major Surgery for T1 Rectal Cancer. *Dis Colon Rectum* 2005; 48(7):1380-1388.

Engeland A, **Tretli S**, Austad G, Bjorge T. Height and body mass index in relation to colorectal and gallbladder cancer in two million Norwegian men and women. *Cancer Causes Control* 2005; 16(8):987-996.

Eriksen MT, Wibe A, **Norstein J**, Haffner J, Wiig JN. Anastomotic leakage following routine mesorectal excision for rectal cancer in a national cohort of patients. *Colorectal Dis* 2005; 7(1):51-57.

Fossa SD, Holte H, Holmen MM, Bjoro T, **Langmark F**, Hess SL, Kvaloy S. [Long-term effects after mantle field radiotherapy for Hodgkin's lymphoma] Langtidseffekter etter kappfeltsbehandling for Hodgkins lymfom. *Tidsskr Nor Laegeforen* 2005; 125(1):41-44.

Fossa SD, Magelssen H, Melve K, Jacobsen AB, **Langmark F**, Skjaerven R. Parenthood in Survivors After Adulthood Cancer and Perinatal Health in Their Offspring: A Preliminary Report. *J Natl Cancer Inst Monogr* 2005; 2005(34):77-82.

Franceschi S, Rajkumar R, Snijders PJ, Arslan A, Mahe C, Plummer M, Sankaranarayanan R, Cherian J, Meijer CJ, **Weiderpass E**. Papillomavirus infection in rural women in southern India. *Br J Cancer* 2005; 92(3):601-606.

Franco-Lie I, Iversen T, **Tretli S**, Kringlen E, Berg K, Abdelnoor M. Malignant melanoma of the skin: risk, tumour characteristics and mortality in adult twins born in Norway between 1905 and 1. *Melanoma Res* 2005; 15(5):461-466.

Gondal G, **Grotmol T**, Hofstad B, **Bretthauer M**, Eide TJ, **Hoff G**. Biopsy of colorectal polyps is not adequate for grading of neoplasia. *Endoscopy* 2005; 37(12):1193-1197.

Gondal G, **Grotmol T**, Hofstad B, **Bretthauer M**, Eide TJ, **Hoff G**. Lifestyle-related risk factors and chemoprevention for colorectal neoplasia: experience from the large-scale NORCCAP screening trial. *Eur J Cancer Prev* 2005; 14(4):373-379.

Gram IT, Braaten T, Terry PD, Sasco AJ, Adami HO, Lund E, **Weiderpass E**. Breast cancer risk among women who start smoking as teenagers.

Cancer Epidemiol Biomarkers Prev 2005; 14(1):61-66.

Grimsrud TK, Berge SR, **Haldorsen T**. Can Lung Cancer Risk Among Nickel Refinery Workers Be Explained by Occupational Exposures Other Than Nickel? Epidemiology 2005; 16(2):146-154.

Groholt B, Ekeberg O, Wichstrom L, **Haldorsen T**. Suicidal and nonsuicidal adolescents: different factors contribute to self-esteem. Suicide Life Threat Behav 2005; 35(5):525-535.

Guren MG, **Eriksen MT**, Wiig JN, Carlsen E, Nesbakken A, Sigurdsson HK, Wibe A, Tveit KM. Quality of life and functional outcome following anterior or abdominoperineal resection for rectal cancer. Eur J Surg Oncol 2005; 31(7):735-742.

Hakama M, **Hoff G**, Kronborg O, Pahlman L. Screening for colorectal cancer. Acta Oncol 2005; 44(5):425-439.

Haldorsen T, **Tynes T**. Cancer in the Sami population of North Norway, 1970-1997. Eur J Cancer Prev 2005; 14(1):63-68.

Hem E, **Haldorsen T**, Aasland OG, Tyssen R, Vaglum P, Ekeberg O. Suicide among physicians. Am J Psychiatry 2005; 162(11):2199-2200.

Hem E, **Haldorsen T**, Aasland OG, Tyssen R, Vaglum P, Ekeberg O. Suicide rates according to education with a particular focus on physicians in Norway 1960-2000. Psychol Med 2005; 35(6):873-880.

Hemminki K, Scelo G, Boffetta P, Møller J, Tracey E, **Andersen A**, Brewster DH, Pukkala E, McBride M, Kiewer EV, Chia KS, Pompe-Kirn V, Martos C, Jonasson JG, Li X, Brennan P. Second primary malignancies in patients with male breast cancer. Br J Cancer 2005; 92(7):1288-1292.

Hernes E, Harvei S, **Glatte E**, Gjertsen F, Fossa SD. High prostate cancer mortality in Norway: influence of Cancer Registry information? APMIS 2005; 113(7-8):542-549.

Hjartaker A, Adami HO, Lund E, **Weiderpass E**. Body mass index and mortality in a prospectively studied cohort of Scandinavian women: the women's lifestyle and health cohort study. Eur J Epidemiol 2005; 20(9):747-754.

Hofvind S, Skaane P, Vitak B, Wang H, **Thoresen S**, Eriksen L, Bjørndal H, Braaten A, Bjørstam N. Influence of review design on percentages of missed interval breast cancers: retrospective study of interval cancers in a population-based screening program. Radiology 2005; 237(2):437-443.

Kjaerheim K, Ulvestad B, **Martinsen JI**, **Andersen A**. Cancer of the gastrointestinal tract and exposure to asbestos in drinking water among lighthouse keepers (Norway). Cancer Causes Control 2005; 16(5):593-598.

Klaeboe L, Lonn S, Scheie D, Auvinen A, Christensen HC, Feychting M, Johansen C, Salminen T, **Tynes T**. Incidence of intracranial meningiomas in Denmark, Finland, Norway and Sweden, 1968-1997. Int J Cancer 2005; 117(6):996-1001.

Klaeboe L, Blaasaas KG, Haldorsen T, **Tynes T**. Residential and occupational exposure to 50-Hz magnetic fields and brain tumours in Norway: A population-based study. Int J Cancer 2005; 115(1):137-141.

Korodi Z, Dillner J, Jellum E, Lumme S, Hallmans G, **Thoresen S**, Hakulinen T, Stattin P, Luostarinen T, Lehtinen M, Hakama M. Human papillomavirus 16, 18, and 33 infections and risk of prostate cancer: a Nordic nested case-control study. Cancer Epidemiol Biomarkers Prev 2005; 14(12):2952-2955.

Kvam BM, Romundstad PR, Boffetta P, **Andersen A**. Cancer in the Norwegian printing industry. Scand J Work Environ Health 2005; 31(1):36-43.

Levin TR, Farraye FA, Schoen RE, **Hoff G**, Atkin W, Bond JH, Winawer S, Burt RW, Johnson DA, Kirk LM, Litin SC, Rex DK. Quality in the technical performance of screening flexible sigmoidoscopy: recommendations of an international multi-society task group. Gut 2005; 54(6):807-813.

Lie AK, Risberg B, Borge B, Sandstad B, Delabie J, Rimala R, Onsrud M, **Thoresen S**. DNA- versus RNA-based methods for human papillomavirus detection in cervical neoplasia. Gynecol Oncol 2005; 97(3):908-915.

Lyngstadaas A, Ekanger R, Hagen B, Himmelmann A, Iversen OE, Iversen T, Nordal R, Norheim OF, Onsrud M, **Tretli S**, Trope C. [Treatment of primary ovarian cancer: a systematic review.] Primærbehandling av ovarialcancer. Tidsskr Nor Lægeforen 2005; 125(3):278-281.

Margolis KL, Mucci L, Braaten T, Kumle M, Trolle LY, Adami HO, Lund E, **Weiderpass E**. Physical activity in different periods of life and the risk of breast cancer: the Norwegian-Swedish Women's Lifestyle and Health cohort study. Cancer Epidemiol Biomarkers Prev 2005; 14(1):27-32.

Moan J, Porojnicu AC, **Robsaam TE**, Dahlback A, Juzeniene A, **Tretli S**, Grant W. Solar radiation, vitamin D and survival rate of colon cancer in Norway. J Photochem Photobiol B 2005; 78(3):189-193.

Molano M, Meijer CJ, **Weiderpass E**, Arslan A, Posso H, Franceschi S, Ronderos M, Munoz N, van den Brule AJ. The natural course of Chlamydia trachomatis infection in asymptomatic Colombian women: a 5-year follow-up study. J Infect Dis 2005; 191(6):907-916.

Molden T, Kraus I, Karlsen F, Skomedal H, **Nygard JF**, Hagmar B. Comparison of Human Papillomavirus Messenger RNA and DNA Detection: A Cross-sectional Study of 4,136 Women >30 Years of Age with a 2-Year Follow-up of High-Grade Squamous Intraepithelial Lesion. Cancer Epidemiol Biomarkers Prev 2005; 14(2):367-372.

Molden T, **Nygard JF**, Kraus I, Karlsen F, **Nygard M**, **Skare GB**, Skomedal H, **Thoresen SO**, Hagmar B. Predicting CIN2+ when detecting HPV mRNA and DNA by PreTect HPV-proofer and consensus PCR: A 2-year follow-up of women with ASCUS or LSIL pap smear. Int J Cancer 2005; 114(6):973-976.

Moller B, **Weedon-Fekjaer H**, **Haldorsen T**. Empirical evaluation of prediction intervals for cancer incidence. BMC Med Res Methodol 2005; 5(1):21.

Moller B, **Weedon-Fekjaer H**, Hakulinen T, Tryggvadottir L, Storm HH, Talback M, **Haldorsen T**. The influence of mammographic screening on national trends in breast cancer incidence. Eur J Cancer Prev 2005; 14(2):117-128.

Nordby KC, **Andersen A**, Irgens LM, Kristensen P. Indicators of mancozeb exposure in relation to thyroid cancer and neural tube defects in farmers' families. Scand J Work Environ Health 2005; 31(2):89-96.

Nygard JF, **Nygard M**, **Skare GB**, **Thoresen SO**. Screening histories of women with CIN 2/3 compared with women diagnosed with invasive cervical cancer: a retrospective analysis of the Norwegian Coordinated Cervical Cancer Screening Program. Cancer Causes Control 2005; 16(4):463-474.

- Olsen JH, Hahneemann JM, Borresen-Dale AL, **Tretli S**, Kleinerman R, Sankila R, Hammarstrom L, **Robsaahm TE**, Kaariainen H, Bregard A, Brondum-Nielsen K, Yuen J, Tucker M. Breast and other cancers in 1445 blood relatives of 75 Nordic patients with ataxia telangiectasia. *Br J Cancer* 2005; 93(2):215-223.
- Patnick J, Ransohoff D, Atkin W, Ma BJ, Elwood M, **Hoff G**, Nadel M, Russo A, Simon J, **Weiderpass-Vaino E**, Zappa M, Smith R. Workgroup III: facilitating screening for colorectal cancer: quality assurance and evaluation. UICC International Workshop on Facilitating Screening for Colorectal Cancer, Oslo, Norway (29 and 30 June 2002). *Ann Oncol* 2005; 16(1):34-37.
- Paulsen T, Kaern J, **Kjaerheim K**, Trope C, **Tretli S**. Symptoms and referral of women with epithelial ovarian tumors. *Int J Gynaecol Obstet* 2005; 88(1):31-37.
- Porojnicu AC, **Robsaahm TE**, Ree AH, Moan J. Season of diagnosis is a prognostic factor in Hodgkin's lymphoma: a possible role of sun-induced vitamin D. *Br J Cancer* 2005; 93(5):571-574.
- Robsaahm TE, Tretli S**. Weak associations between sociodemographic factors and breast cancer: possible effects of early detection. *Eur J Cancer Prev* 2005; 14(1):7-12.
- Rostad H, Naalsund A, Strand TE, Jacobsen R, Talleraas O, Norstein J**. Results of pulmonary resection for lung cancer in Norway, patients older than 70 years. *Eur J Cardiothorac Surg* 2005; 27(2):325-328.
- Schoemaker MJ, Swerdlow AJ, Ahlbom A, Auvinen A, Blaasaas KG, Cardis E, Christensen HC, Feychting M, Hepworth SJ, Johansen C, **Klaeboe L**, Lonn S, McKinney PA, Muir K, Raitanen J, Salminen T, Thomsen J, **Tynes T**. Mobile phone use and risk of acoustic neuroma: results of the Interphone case-control study in five North European countries. *Br J Cancer* 2005; 93(7):842-848.
- Skaane P, Skjennald A, Young K, Egge E, Jepsen I, Sager EM, Scheel B, Sovik E, **Ertzaas AK, Hofvind S**, Abdelnoor M. Follow-up and final results of the Oslo I Study comparing screen-film mammography and full-field digital mammography with soft-copy reading. *Acta Radiol* 2005; 46(7):679-689.
- Skogstad M, **Haldorsen T**, Arnesen AR, Kjuus H. Hearing thresholds among young professional divers: a 6-year longitudinal study. *Aviat Space Environ Med* 2005; 76(4):366-369.
- Skovlund E, **Bretthauer M, Grotmol T, Larsen IK, Hoff G**. Sensitivity of Pain Rating Scales in an Endoscopy Trial. *Clin J Pain* 2005; 21(4):292-296.
- Soldin OP, Guo T, **Weiderpass E**, Tractenberg RE, Hilakivi-Clarke L, Soldin SJ. Steroid hormone levels in pregnancy and 1 year postpartum using isotope dilution tandem mass spectrometry. *Fertil Steril* 2005; 84(3):701-710.
- Strand TE**, Malayeri C, Eskonsipo PK, **Grimsrud TK, Norstein J, Grotmol T**. [Teenage smoking and lung cancer incidence in early adult age, 1954-1998] Tenåringsrøyking og lungekreft i tidlig voksen alder, 1954-98. *Tidsskr Nor Laegeforen* 2005; 125(9):1174-1176.
- Sudmann A**, Skarre E, **Talleraas O, Norstein J**. [Breast-conserving surgery and sentinel node procedure in Norway, 1993-2001]. Brystbevarende kirurgi og vaktpostlymfeknuteprosedyre ved brystkreft i Norge 1993-2001. *Tidsskr Nor Laegeforen* 2005; 125(5):556-559.
- Svensson E, Moller B, Tretli S**, Barlow L, Engholm G, Pukkala E, Rahu M, Tryggvadottir L, **Langmark F, Grotmol T**. Early life events and later risk of colorectal cancer: age-period-cohort modelling in the Nordic countries and Estonia. *Cancer Causes Control* 2005; 16(3):215-223.
- Travis LB, Fossa SD, Schonfeld SJ, McMaster ML, Lynch CF, Storm H, Hall P, Holowaty E, **Andersen A**, Pukkala E, Andersson M, Kaijser M, Gospodarowicz M, Joensuu T, Cohen RJ, Boice JD, Jr., Dores GM, Gilbert ES. Second cancers among 40,576 testicular cancer patients: focus on long-term survivors. *J Natl Cancer Inst* 2005; 97(18):1354-1365.
- Tretli S, Weiderpass-Vaino E, Grotmol T**. Conditions in utero and cancer risk. *Nor J Epidemiol* 2005; 15(1):55-63.
- Svensson E, Moller B, Tretli S**, Barlow L, Engholm G, Pukkala E, Rahu M, Tryggvadottir L, **Langmark F, Grotmol T**. Early life events and later risk of colorectal cancer: age-period-cohort modelling in the Nordic countries and Estonia. *Cancer Causes Control* 2005; 16(3):215-223.
- Tretli S**. Forekomst av kreft. In: Kåresen R, Wist E, editors. *Kreftsykdommer : en basisbok for helsepersonell*. Oslo: Gyldendal akademisk, 2005: 18-26.
- Tretli S**. Risikofaktorer og forebygging. In: Kåresen R, Wist E, editors. *Kreftsykdommer: en basisbok for helsepersonell*. Oslo: Gyldendal akademisk, 2005: 27-34.
- Trolle-Lagerros Y, Mucci LA, Kumle M, Braaten T, **Weiderpass E**, Hsieh CC, Sandin S, Lagiou P, Trichopoulos D, Lund E, Adami HO. Physical activity as a determinant of mortality in women. *Epidemiology* 2005; 16(6):780-785.
- Vainio H, **Weiderpass E**. From hazard identification to weighing the benefits and drawbacks of prevention. *Toxicol Appl Pharmacol* 2005; 207(2 Suppl.):28-33.2005/50
- Vatten LJ, Lund Nilsen TI, **Tretli S**, Trichopoulos D, Romundstad PR. Kroppsstørrelse ved fødsel og brystkreftisiko i voksen alder: En prospektiv undersøkelse. *Nor J Epidemiol* 2005; 15(1):15-19.
- Vatten LJ, Nilsen TI, **Tretli S**, Trichopoulos D, **Romundstad PR**. Size at birth and risk of breast cancer: Prospective population-based study. *Int J Cancer* 2005; 113(6):1002-1004.
- Weedon-Fekjaer H**, Vatten LJ, Aalen OO, Lindquist B, **Tretli S**. Estimating mean sojourn time and screening test sensitivity in breast cancer mammography screening: new results. *J Med Screen* 2005; 12(4):172-178.
- Wibe A, **Eriksen MT, Syse A, Tretli S**, Myrvold HE, Soreide O. Effect of hospital caseload on long-term outcome after standardization of rectal cancer surgery at a national level. *Br J Surg* 2005; 92(2):217-224.

Staff at the Cancer Registry of Norway 2006

Name	Position	E.mail
Langmark, Frøydis	Director	froydis.langmark@kreftregisteret.no
Department of Administration		
Engen, Egil	Head of Administration	egil.engen@kreftregisteret.no
Alhaug, Grete	Senior Adviser (law)	grete.alhaug@kreftregisteret.no
Breie, Grethe	Executive Secretary	grethe.breie@kreftregisteret.no
Heradstveit, Gunvor	Senior Adviser (economy)	gunvor.heradstveit@kreftregisteret.no
Vik, Christian	Consultant (economy)	christian.vik@kreftregisteret.no
Larøningen, Siri	Research Assistant (data delivery)	siri.laroenningen@kreftregisteret.no
Talleraas, Olau	Senior Consultant (data delivery)	olaug.talleraas@kreftregisteret.no
Information- and Documentation Section		
Bakke, Kjell Arne	Head of Information/Head of Section	kjell.arne.bakke@kreftregisteret.no
Mortensen, Barbara	Adviser (information)	barbara.mortensen@kreftregisteret.no
Sildnes, Børge	Adviser (information)	borge.sildnes@kreftregisteret.no
Semcesen, Sonja	Senior Librarian	sonja.semcesen@kreftregisteret.no
Wendel, Anne-Kari	Head of Archives	anne-kari.wendel@kreftregisteret.no
Larsen, Nann	Consultant (archives and administration)	nann.larsen@kreftregisteret.no
Bliksrud, Ulf	Switchboard operator	ulf.bliksrud@kreftregisteret.no
Gruszczynska, Mariola Anna	Receptionist	mariola.anna.gruszczynska@kreftregisteret.no
Mørk, Jorunn	Receptionist	jorunn.mork@kreftregisteret.no
IT Section		
Johansen, Aage F	Head of IT/Head of Section	aage.johansen@kreftregisteret.no
Hansen, Steinar	Adviser (IT)	steinar.hansen@kreftregisteret.no
Rønning, Frank	Senior Adviser (IT)	frank.ronning@kreftregisteret.no
Bergersen, Bård	Adviser (IT)	bard.bergersen@kreftregisteret.no
Eriksen, Tormod	Adviser (IT)	tormod.eriksen@kreftregisteret.no
Finstad, Leif Magne	Adviser (IT)	leif.magne.finstad@kreftregisteret.no
Hüber, Therese	Adviser (IT)	therese.huber@kreftregisteret.no
Kleive, Victoria	Adviser (IT)	victoria.kleive@kreftregisteret.no
Lingjærde, Jan Ottar	Adviser (IT)	jan.ottar.lingjaerde@kreftregisteret.no
Martinsen, Jan Ivar	Adviser (IT)	jan.ivar.martinsen@kreftregisteret.no
Sæther, Børge	Adviser (IT)	bjoerge.saether@kreftregisteret.no
Tysvær, Svein Erling	Adviser (IT)	svein.erling.tysvaer@kreftregisteret.no
Aagnes, Bjarte	Adviser (IT)	bjarte.aagnes@kreftregisteret.no
Department of Etiological Research		
Tretli, Steinar	Head of Department/Head for Etiological Research/ Head of The Cancer Registry's Strategic Council for Research	steinar.tretli@kreftregisteret.no
Kjærheim, Kristina	Assistant Head of Department/Researcher	kristina.kjaerheim@kreftregisteret.no
Grotmol, Tom	Researcher/Assistant Head of the The Cancer Registry's Strategic Council for Research	tom.grotmol@kreftregisteret.no
Weiderpass Vainio, Elisabete	Researcher	elisabete.weiderpass@kreftregisteret.no
Hestvik, Unn Elisabet	Senior Consultant	unn.elisabet.hestvik@kreftregisteret.no
Robsaahm, Trude Eid	Researcher	trude.eid.robahm@kreftregisteret.no
Hjartåker, Anette	Researcher	anette.hjartaker@kreftregisteret.no
Strand, Leif Åge	Researcher/PhD student	leif.aage.strand@kreftregisteret.no
Grimsrud, Tom Kristian	Researcher (Janus)	tom.grimsrud@kreftregisteret.no
Dahl, Nina Janecke Opaas	Senior Consultant (Janus)	nina.janecke.opaas.dahl@kreftregisteret.no
Lauritzen, Marianne	Research Assistant (Janus)	marianne.lauritzen@kreftregisteret.no
Stornes, Adele	Research Assistant (Janus)	adele.stornes@kreftregisteret.no
Kaurin, Margareth H	Research Assistant	margareth.kaurin@kreftregisteret.no
Meo, Margrethe Sitek	Research Assistant	margrethe.meo@kreftregisteret.no
Råberg, Marte K	Research Assistant	
Aalen, Odd O	Researcher	
Kravdal, Øystein	Researcher	
Klæbo, Lars	Researcher	lars.klaeboe@kreftregisteret.no
Tynes, Tore	Researcher	
Adami, Hans-Olov	Researcher	hans-olov.adami@kreftregisteret.no
Glattre, Eystein	Researcher	eystein.glattre@kreftregisteret.no
Romundstad, Pål	Researcher	paal.romundstad@kreftregisteret.no
Gislefoss, Randi Elin	PhD student	randi.elin.gislefoss@kreftregisteret.no
Hansen, Svein	PhD student	svein.hansen@kreftregisteret.no
Langseth, Hilde	PhD student	hilde.langseth@kreftregisteret.no
Lie, Jenny-Anne Sigstad	PhD student	jenny-anne.sigstad.lie@kreftregisteret.no
Syse, Astri	PhD student	astri.syse@kreftregisteret.no
Weedon-Fekjær, Harald	PhD student	harald.fekjaer@kreftregisteret.no
Department of Screening-based Research		
Thoresen, Steinar Ø.	Head of Department/Head of Screening-based Research	rita.steen@kreftregisteret.no
Steen, Rita	Acting Head of Department/Acting Head of Screening-based Research	rita.steen@kreftregisteret.no
Haldorsen, Tor	Assistant Head of Department/Researcher	tor.haldorsen@kreftregisteret.no
Hofvind, Solveig S-H	Researcher	solveig.hofvind@kreftregisteret.no
Nygård, Mari	Researcher (HPV)	mari.nygard@kreftregisteret.no

Berger, Inger Sophie	Research Assistant (HPV)	sophie.berger@kreftregisteret.no
Hagerup-Jenssen, Maria	Research Assistant (HPV)	maria.hagerup-jenssen@kreftregisteret.no
Sjøen, Monica Lund	Research Assistant (HPV)	monica.lund.sjoen@kreftregisteret.no
Hoff, Geir	Researcher (The Norwegian Colorectal Cancer Prevention)	geir.hoff@kreftregisteret.no
Lie, Agnes Kathrine	Head of the The Norwegian Cervical Cancer Screening Programme	kathrine.lie@kreftregisteret.no
Skare, Gry Baadstrand	Adviser (The Norwegian Cervical Cancer Screening Programme)	gry.baadstrand.skare@kreftregisteret.no
Waage, Randi	Senior Consultant (The Norwegian Cervical Cancer Screening Programme)	randi.waage@kreftregisteret.no
Bilet, Ellinor Festo	Research Assistant	ellinor.festoe.bilet@kreftregisteret.no
Molund, Ingrid Mørk	Research Assistant	ingrid.mork.molund@kreftregisteret.no
Ertzaas, Anne K O	Adviser (The Norwegian Breast Cancer Screening Programme)	anne.kathrin.olsen.ertzaas@kreftregisteret.no
Husebye, Jan	Adviser (The Norwegian Breast Cancer Screening Programme)	jan.husebye@kreftregisteret.no
Mangerud, Gunhild	Senior Consultant (The Norwegian Breast Cancer Screening Programme)	gunhild.mangerud@kreftregisteret.no
Dahli, Eva Lisa Piiksi	Research Assistant	eva.lisa.piiksi.dahli@kreftregisteret.no
Melby, Wenche	Research Assistant	wenche.melby@kreftregisteret.no
Hestmann, Cecilie L.	Research Assistant	cecilie.lobak.hestmann@kreftregisteret.no
Langbråten, Stine	Research Assistant	stine.langbraaten@kreftregisteret.no
Lie, Solveig	Research Assistant	solveig.lie@kreftregisteret.no
Sorum, Ragnhild	Research Assistant	ragnhild.sorum@kreftregisteret.no
Aas, Gjoril Bergva	Research Assistant	gjoril.bergva.aas@kreftregisteret.no
Bretthauer, Michael	Researcher	
Klungsoyr, Ole	Researcher	
Kalager, Mette	PhD student	mette.kalager@kreftregisteret.no
Molden, Tor	PhD student	tor.molden@kreftregisteret.no

Department of Clinical and Registry-based Research

Møller, Bjørn	Head of Department/Head of Clinical and Registry-based Research	bjorn.moller@kreftregisteret.no
Registration Section		
Johannesen, Tom Børge	Assistant Head of Department/Head of Section	tom.borge.johannesen@kreftregisteret.no
Dahl, Tove	Senior Adviser (coding)	tove.dahl@kreftregisteret.no
Kjøberg, Grete	Senior Executive Consultant	grete.kjoelberg@kreftregisteret.no
Aune, Ingunn	Research Assistant	ingunn.aune@kreftregisteret.no
Hatle, Inga	Research Assistant	inga.hatle@kreftregisteret.no
Hem, Ling Yuan	Research Assistant	ling.yuan.hem@kreftregisteret.no
Herredsvela, Ingunn	Research Assistant	ingunn.herredsvela@kreftregisteret.no
Hovet, Linda Tyvand	Research Assistant	linda.tyvand.hovet@kreftregisteret.no
Korsen, Yvonne Elisabeth	Research Assistant	yvonne.elisabeth.korsen@kreftregisteret.no
Nymoen, Solfrid	Research Assistant	solfrid.nymoen@kreftregisteret.no
Olsen, Anne Marie	Research Assistant	anne.marie.olsen@kreftregisteret.no
Pècseli, Henriette	Research Assistant	henriette.pecseli@kreftregisteret.no
Pedersen, Torhild Karen	Research Assistant	torhild.pedersen@kreftregisteret.no
Ringlund, Berit Gunvor	Research Assistant	berit.ringlund@kreftregisteret.no
Schoultz, Marianne	Research Assistant	marianne.schoultz@kreftregisteret.no
Thyssell, Liv Karin	Research Assistant	liv.thyssell@kreftregisteret.no
Research Section		
Bray, Freddie Ian	Head of Section	freddie.bray@kreftregisteret.no
Hernes, Eivor	Researcher	eivor.hernes@kreftregisteret.no
van Dijk, Tini	Senior Consultant	tini.van.dijk@kreftregisteret.no
Frostad, Anne	PhD student	anne.frostad@kreftregisteret.no
Larsen, Inger Kristin	PhD student (The Norwegian Colorectal Cancer Prevention)	inger.kristin.larsen@kreftregisteret.no
Stensheim, Hanne	PhD student	hanne.stensheim@kreftregisteret.no
Innovation Section		
Nygård, Jan F	Head of Section	jan.nygard@kreftregisteret.no
Serkland, Camilla Walle	Research Assistant (Norwegian Malignant Melanoma Registry)	camilla.walle.serkland@kreftregisteret.no
Bergmann, Mette	Research Assistant (Ovarian Cancer Registry)	mette.bergmann@kreftregisteret.no
Wesenberg, Finn	Researcher (Nordic Society of Paediatric Haematology and Oncology – NOPHO)	finn.wesenberg@kreftregisteret.no
Froland, Siv Elisabeth	Research Assistant (Nordic Society of Paediatric Haematology and Oncology – NOPHO)	siv.elisabeth.froland@kreftregisteret.no
Gaard, Maria	Researcher (Colorectal Cancer Registry)	maria.gaard@kreftregisteret.no
Dorum, Liv Marit Rønning	Research Assistant (Colorectal Cancer Registry)	liv.marit.dorum@kreftregisteret.no
Kyrdalen, Anne Edvardsen	Research Assistant (Norwegian Prostate Cancer Registry)	anne.edvardsen.kyrdalen@kreftregisteret.no
Rostad, Hans Anton	Researcher (Lung Cancer Registry)	hans.rostad@kreftregisteret.no
Myhren, Kristine Tamburstuen	Research Assistant (Lung Cancer Registry)	kristine.tamburstuen.myhren@kreftregisteret.no
Kvåle, Rune	PhD student (Norwegian Prostate Cancer Registry)	rune.kvale@kreftregisteret.no
Strand, Trond-Eirik	PhD student (Lung Cancer Registry)	trond-eirik.strand@kreftregisteret.no
Paulsen, Torbjørn	PhD student (Ovarian Cancer Registry)	torbjorn.paulsen@kreftregisteret.no
Lie, Hilde Koch	Research Assistant	hilde.koch.lie@kreftregisteret.no
Seglem, Ann Helen	Research Assistant	ann.helen.seglem@kreftregisteret.no
Idsoe, Cathrine	Research Assistant	cathrine.idsoe@kreftregisteret.no
Johansen, Monica	Research Assistant (Norwegian Breast Cancer Registry)	monica.johansen@kreftregisteret.no
Sudmann, Åshild A	Research Assistant (Norwegian Breast Cancer Registry)	aashild.sudmann@kreftregisteret.no
Heimdal, Ketil	Researcher (Polyposis Families Registry)	ketil.heimdal@kreftregisteret.no
Cederkvist, Jannicke Bærheim	Research Assistant (Polyposis Families Registry)	jannicke.cederkvist@kreftregisteret.no
Dahl, Linn Anita	Research Assistant	linn.anita.dahl@kreftregisteret.no

Predictions of cancer incidence by health region 2010–2020

Bjørn Møller & Bjarte Aagnes

Special issue of Cancer in Norway 2005

Contents

Introduction, Material and Methods	S3	Trachea, bronchus, lung	S46
Results and Discussion	S4	Pleura	S47
References	S5	Mediastinum, thymus, heart	S48
Norwegian Health Regions	S6	Bone	S49
Drift parameters for trendbased models	S6	Melanoma of skin	S50
Population figures	S6	Other skin	S51
Cancer sites by ICD-7 and ICD-10	S7	Connective tissue	S52
Eastern Norway Health Region, 2010–2020	S9	Breast	S53
Southern Norway Health Region, 2010–2020	S12	Uterine cervix	S54
Western Norway Health Region, 2010–2020	S15	Uterine corpus	S55
Central Norway Health Region, 2010–2020	S18	Placenta	S56
Northern Norway Health Region, 2010–2020	S21	Uterus unspecified	S57
Norway , all Health Regions, 2010–2020	S24	Ovary, etc	S58
Lip	S27	Other female genitals	S59
Tongue	S28	Prostate	S60
Floor of mouth	S29	Testis	S61
Other parts of mouth	S30	Other male genitals	S62
Salivary glands	S31	Kidney	S63
Mesopharynx	S32	Renal pelvis, ureter	S64
Nasopharynx	S33	Bladder and other urinary organs	S65
Hypopharynx	S34	Eye	S66
Oesophagus	S35	Brain, central nervous system	S67
Stomach	S36	Thyroid gland	S68
Small intestine	S37	Other endocrine organs	S69
Colon	S38	Other and unspecified sites	S70
Rectum	S39	Hodgkin lymphoma	S71
Liver	S40	Non-Hodgkin lymphoma	S72
Gallbladder	S41	Multiple myeloma	S73
Pancreas	S42	Leukaemia, acute	S74
Other digestive organs	S43	Leukaemia, non-acute	S75
Nose, sinuses	S44	All sites	S76
Larynx	S45		

Copyright©2006 by Cancer Registry of Norway.

Published by Cancer Registry of Norway
Institute of Population-based Cancer Research.
All rights reserved.

<http://www.kreftregisteret.no>

Predictions of cancer incidence by health region 2010–2020 is included as a special issue of **Cancer in Norway 2005**.

Predictions of cancer incidence by health region 2010–2020

Bjørn Møller & Bjarte Aagnes

Special issue of Cancer in Norway 2005

Introduction

The prediction of cancer incidence is of great interest to both health authorities and the scientific community. As observations in the past do not necessarily hold in the future, predicting future cancer occurrence is fraught with uncertainty (Bray and Møller, 2006). Nevertheless, estimates of the future cancer burden can be useful to indicate the appropriate amounts of resources that will be needed for diagnosis, treatment and rehabilitation.

The aim of this report is to provide predictions of cancer incidence in Norway by cancer site and region, so as to facilitate regional, as well as national planning.

Material

The basis for the predictions consists of data on new cancer cases diagnosed in the five health regions in Norway (Table S1) in 1985–2004, regional population figures for 1985–2004 and the forecasts of population size and structure in 2010, 2015 and 2020 produced by *Statistics Norway* (SSB, 2005). The number of cases corresponds to the numbers published in *Cancer in Norway 2004*. In that report, the ICD-7 classification system was used, whereas a conversion to ICD-10 has been adapted in the first part of the current issue of *Cancer in Norway*. ICD-10 labels for the ICD-7 codes are listed in Table S4 to facilitate comparisons between the two coding systems.

The new cancer cases were grouped according to five-year calendar periods (1985–1989, 1990–1994, 1995–1999, 2000–2004), five-year age groups (0–4, 5–9, ..., 80–84, 85+ years) and 49 cancer types. The types of cancer are listed in Table S4. For all types of cancer combined, predictions were made for each sex separately as the sum of the site-specific predictions.

Methods for predictions

The predicted numbers of new cancer cases in the years 2010, 2015 and 2020 were calculated by first predicting the incidence rates based on observed rates up to 2004, then multiplying these rates by the population forecasts for the future periods. For the most common types of cancer (cancers of the stomach, colon, rectum, pancreas, lung, skin, breast, cervix, ovary, testis, kidney, bladder, melanoma of the skin

and Non-Hodgkin lymphoma), except prostate cancer, the rates were predicted based on the trends in the last 20 years. For the less common types of cancer, this approach is associated with larger uncertainties, and the rates were simply assumed to remain constant into the future. The constant rate approach was also used for prostate cancer, given the lack of stability in the current trends.

The predicted percentage change in the annual number of cases was divided into two parts, one due to changing risk of being diagnosed with cancer, and another due to changes in the population size and age distribution (Møller *et al.* 2002).

In all the tables, the numbers were rounded separately, so the totals in the table may differ from the sums of each component.

Trend-based predictions of cancer incidence

For all the cancer sites listed in Table S2, incidence rates were modelled as a function of age, calendar period and birth cohort. Synthetic birth cohorts were calculated as mid-year of five-year age groups subtracted from mid-year of five-year calendar periods.

The approach used in Nordic predictions of cancer incidence rates was adapted (Møller *et al.* 2002). It is based on a standard age-period-cohort model (Osmond C, 1985), with some modifications which have been shown empirically to improve the predictions (Møller *et al.* 2003). The multiplicative relationship between the rate and the covariates in the standard model produces predictions in which the rates may grow exponentially with time. The first modification was to use a power link instead of the log link to level off this growth. The model can be written $R_{ap} = (A_a + D \cdot p + P_p + C_c)^5$, where R_{ap} is the incidence rate in age group a in calendar period p , A_a is the age component for age group a , D is the common drift parameter (Clayton and Schiffers, 1987), P_p is the non-linear period component of period p , and C_c is the non-linear cohort component of cohort c . The linear component D and the non-linear cohort-effects were projected. This means that if the rates on average increase 3% per five-year period, we assumed that the incidence rate would continue to increase by this amount in the next five-year period (2005–2009). To allow for an attenuation of the impact of current

trends in the future time periods, a gradual reduction in the drift parameter in the subsequent five-year periods of 25% (2010–2014), 50% (2015–2019) and 75% (2020–2024) was used. To accommodate predictions for the single years 2010, 2015 and 2020, linear interpolations between the two five-year periods closest to the specific years were calculated. For instance, predicted rates for the year 2010 were calculated as $\frac{2}{3}$ times the predicted rate for the period 2005–2009 plus $\frac{1}{3}$ times the predicted rate for the period 2010–2014.

Drift is the average linear increase in the observation period. One problem with projecting the drift is that it is influenced by less recent, perhaps less relevant trends. If the rates displayed significant curvature in the prediction base, the trend in the last ten years was used as the drift component to be projected. If we have p periods, then the most recent slope is $D - P_p = D_{last}$, where D is the common drift and P_p is the last deviation from this. Technically, the choice between using an older secant (D) or a recent tangent (D_{last}) is based on the model $R_{ap} = (A_a + D \cdot p + S \cdot p^2 + C_c)^5$. If there was significant curvature in the trend over time, *i.e.* if the estimate of S (the parameter for p^2) was significant, D_{last} was used, otherwise we used D . Whether average (D) or recent (D_{last}) trend was used is shown in Table S2.

For each site, the rates in the specific regions were calculated by following either the regional or the national trend. If the regional trend deviated from the average trend in the whole country, trends were based only on data from that region. For regions that did not deviate significantly from the whole country, the national trend was used (*i.e.* using data from the whole country), but the level was adjusted. This means that if the region had, for example, 10% lower rates than the national average in the last observed period, the trend-based predictions based on the whole country were adjusted down by 10% for that region.

A lower age limit to be included in the model was chosen so that the number of cases exceeds 10 in all observation periods for a specific region. For age groups below this limit, future rates were estimated using the average rates in the last two five-year periods.

Predictions based on constant rates

For the combination of cancer site and sex not listed in Table S2, the age-specific rates for the whole country in 2000–2004 were used to estimate the future rates, but the level was adjusted for each region. This was done by calculating the relative difference in the

age-standardised rates (standardised according to the national population distribution in 2000–2004) between a region and the whole country. For example, if the region was 10% below the national rates, each of the future age-specific rates were reduced by 10% for that region. In age groups with less than 10 cases in the whole country in 2000–2004, the rates for the last 10 years (1995–2004) were used as the basis for the constant rate calculations.

Results

For males, the number of new cases for Norway, *i.e.* all regions combined, is expected to increase by 11%, from an average annual number of around 12 000 in 2000–2004 to more than 13 200 in 2010 (Table S20). The percentage increase up to the years 2015 and 2020 are 21% and 33%, respectively (Tables S21 and S22). For all cancer sites combined, the risk of cancer is not predicted to increase, and the increase in number of new cases is due to the expected change in the age distribution and population size in the coming years. The population changes have the largest impact on the Western Health Region (38% increase by 2020, Table S13), while the annual numbers in regions Central and North are expected to increase by 31% up to the year 2020 (Tables S16 and S19). The latter two regions also have the smallest expected increase in population size in the same period (Table S3).

For females, the number of cases is expected to increase by 12%, from an annual number of around 11 200 in 2000–2004 to more than 12 500 in 2010 (Table S20). The percentage increase up to the years 2015 and 2020 are 21% and 31%, respectively (Tables S21 and S22). In 2010, about half the increase is attributed to a predicted increase in risk, while the other half is due to changes in the population size and structure. By 2020, two thirds of the expected increase will be the result of population changes. Regional differences for females resemble those of the males.

Tables S72a and S72b show the predicted number of cases for all cancer sites combined by age group, and it is expected that a large proportion of the predicted increase will materialise in the age group 55–74 years. Similar patterns can be seen for most of the specific cancer sites (Tables S23a–S73b).

The risk component of the change in number of cases up to the years 2010, 2015 and 2020 was based on predictions of the cancer rates in each of the cancer sites, and is displayed in Figures S1a–S50b.

Discussion

The number of new cases, for all sites, for all regions combined is predicted to increase by about 10%, 20% and 30% up to the years 2010, 2015 and 2020, respectively. For males, the increase is mainly due to ageing of the population, while for females, an expected increase in the risk of cancer also contributes. The main purpose of this publication is to provide regions with tailored predictions for the different types of cancers regularly published in *Cancer in Norway*. The remaining paragraphs comment on the methodological approaches used in making these predictions.

For cancer sites where we have used a constant rate model, the percentage change in the number of cases due to change of risk might deviate somewhat from the expected value of zero. The reason for this is that the rates in the future periods for less frequent types of cancers are based on the average in the last 10 years of observation, 1995–2004. This approach achieved a broader prediction base, but when compared to the observed rates in 2000–2004, it may produce large deviances, especially for sites that have changed markedly during the last 10 years.

PSA testing has made it very difficult to provide

sensible trend-based predictions for prostate cancer. The number of annual cases in the period 2000–2004 varied greatly. From 3060 cases in the year 2000, the numbers fell to 2889 and 2745 in 2001 and 2002, respectively, followed by a large increase in 2003 (3346 cases) and 2004 (3823 cases). The decrease in 2001 and 2002 was probably due to the release of official recommendations against PSA testing in symptom-free men. The increase in the last two years indicates a transient effect of these recommendations. It is not possible to foresee the extent of PSA testing in the coming years, and therefore we have chosen to base the predictions on average rates in the last five years.

For cancer sites with relatively few cases, the report describes how the population changes are likely to affect the number of cases in the future, assuming the rates remain unchanged. For the more common sites, namely cancers of the stomach, colon, rectum, pancreas, lung, skin, breast, cervix, ovary, testis, kidney, bladder, melanoma of the skin and Non-Hodgkin lymphoma, the rates were assumed to follow the projections of the observed trends. In both situations, the predictions should be interpreted with caution, and seen as a guide to the future cancer pattern in Norway.

References

- Bray, F. Møller, B., Predicting the future burden of cancer, *Nat.Rev.Cancer*, 2006, vol. 6, no. 1, pp. 63-74.
- Cancer in Norway 2004*, Cancer Registry of Norway.
- Clayton, D. Schifflers, E., Models for temporal variation in cancer rates. II: Age-period-cohort models, *Statistics in Medicine*, 1987, vol. 6, no. 4, pp. 469-481.
- Møller, B., Fekjær, H., Hakulinen, T., Tryggvadóttir, L., Storm, H. H., Talbäck, M., Haldorsen, T., Prediction of cancer incidence in the Nordic countries up to the year 2020, *Eur J Cancer Prev Suppl*, 2002, vol.11, no.1, p.S1-S96.
- Møller, B., Fekjær, H., Hakulinen, T., Sigvaldason, H., Storm, H. H., Talbäck, M., Haldorsen, T., Prediction of cancer incidence in the Nordic countries: empirical comparison of different approaches, *Stat.Med.*, 2003, vol. 22, no. 17, pp. 2751-2766.
- Osmond, C., Using age, period and cohort models to estimate future mortality rates, *Int. J of Epidemiology*, 1985, vol. 14, no. 1, pp. 124-129.
- SSB. Statistics Norway, <http://statbank.ssb.no/statistikkbanken/>, (Variant MMMM - medium national growth, accessed 19.09.2005).

Addendum

The R statistical computing language and L^AT_EX was used to make this report.

Table S1: Norwegian Health Regions and the counties that constitute each region.

Norwegian Health Regions			Counties
Eastern	(E)	Helse Øst	Østfold, Akershus, Oslo, Hedmark, Oppland
Southern	(S)	Helse Sør	Buskerud, Vestfold, Telemark, Aust-Agder, Vest-Agder
Western	(W)	Helse Vest	Rogaland, Hordaland, Sogn og Fjordane
Central	(C)	Helse Midt-Norge	Møre og Romsdal, Sør-Trøndelag, Nord-Trøndelag
Northern	(N)	Helse Nord	Nordland, Troms, Finnmark

Table S2: The choices of drift parameters¹ for trend-based models, by sex and region.

	Men					Women				
	E	S	W	C	N	E	S	W	C	N
Stomach		n				$\bar{r}$				
Colon										
Rectum	$\bar{r}$									
Pancreas			n							
Lung	$\bar{r}$		$\bar{r}$	$\bar{r}$		$\bar{r}$				
Testis		n	$\bar{r}$			.	.	.	.	.
Breast	.	.	.	.	.		n	n		$\bar{r}$
Uterine cervix	.	.	.	.	.	n			r	r
Ovary	.	.	.	.	.					
Kidney										
Bladder	n									
Melanoma of skin	n			$\bar{r}$	n		$\bar{r}$			n
Skin, other	n		r			n		r	n	
Non-Hodgkin lymphoma			n			.	.	.	.	.

¹The letters r and n indicates whether regional or national trends were applied, respectively. A bar indicates that the average trend over the whole observation period was used, whereas no bar means that the most recent trend was used. The most common combination; average trend over the whole observation period using national trends ($\bar{n}$) is not shown. (The notation “.” indicates that trend-based predictions were not performed).

Table S3: Population size (pop) in thousands, percentage 60 years or older (60+) in 2000-2004 and 2020, and the percentage increase in population size (Δpop) from 2000-2004 to 2020, by sex and region.

	Men					Women				
	2000–2004		2020			2000–2004		2020		
	pop	60+	pop	60+	Δpop	pop	60+	pop	60+	Δpop
Eastern	800	16.9	895	22.0	11.8	827	21.6	916	25.2	10.8
Southern	438	17.7	486	23.6	11.1	449	22.4	491	27.1	9.3
Western	466	15.8	516	21.6	10.6	468	20.3	516	24.7	10.3
Central	319	17.7	339	24.2	6.2	321	22.2	338	27.2	5.2
Northern	233	17.3	240	23.9	3.2	230	21.7	238	27.0	3.1
Norway	2256	17.0	2476	22.7	9.8	2293	21.6	2499	25.9	9.0

Table S4: Cancer sites according to modified ICD-7 with ICD-10 labelling.

modified ICD-7 ¹	ICD-10 labelling	
140 Lip	C00	Lip
141 Tongue	C01, C02	Tongue
143 Floor of mouth	C04	Floor of mouth
144 Other parts of mouth	C03, C05, C06	Mouth, palate and unspecified parts of mouth
142 Salivary glands	C07, C08	Salivary glands
145 Mesopharynx	C10	Oropharynx
146 Nasopharynx	C11	Nasopharynx
147 Hypopharynx	C12, C13	Hypopharynx
150 Oesophagus	C15	Oesophagus
151 Stomach	C16	Stomach
152 Small intestine	C17	Small intestine
153 Colon	C18, C19	Colon
154 Rectum	C20, C21	Rectum
155 Liver	C22	Liver
156 Gallbladder, etc.	C23, C24	Gallbladder
157 Pancreas	C25	Pancreas
159 Other digestive organs	C26	Other digestive organs
160 Nose, sinuses, etc.	C30, C31	Nose, sinuses
161 Larynx	C32	Larynx, epiglottis
162 Trachea, bronchus and lung	C33, C34	Lung, trachea
163 Pleura	C38.4, C45	Pleura
164 Mediastinum, thymus and heart	C37, C38 (excl C38.4)	Mediastinum, thymus and heart
196 Bone	C40–41	Bone
190 Melanoma of skin	C43	Melanoma of skin
191 Other skin	C44	Other skin
197 Connective tissue	C49	Connective and soft tissue
170 Breast	C50	Breast
171 Uterine cervix	C53	Cervix uteri
172 Uterine corpus	C54	Corpus uteri
173 Placenta	C58	Placenta
174 Uterus unspecified	C55	Uterus other
175 Ovary, etc.	C56	Ovary
176 Other female genital organs	C51, C52, C57	Other and unspecified female genital organs
177 Prostate	C61	Prostate
178 Testis	C62	Testis
179 Other male genital organs	C60, C63	Other and unspecified male genital organs
180 Kidney excluding renal pelvis	C64	Kidney except renal pelvis
180 Renal pelvis and ureter	C65, C66	Renal pelvis and ureter
181 Bladder and other urinary organs	C67, C68	Bladder and other and unspecified urinary organs
192 Eye	C69	Eye
193 Brain, central nervous system	C70–C72, D32, D33	Brain, CNS
194 Thyroid gland	C73	Thyroid gland
195 Other endocrine organs	C74, C75	Adrenal and other endocrine glands and related structures
199 Other and unspecified sites	C76–C80	Secondary, ill-defined and unspecified sites
201 Hodgkin lymphoma	C81	Hodgkin lymphoma
200+202 Non-Hodgkin lymphoma	C82–C85, C96	Non-Hodgkin lymphoma
203 Multiple myeloma	C90	Multiple myeloma
204 Leukaemia, acute	C91–C95 acute	Leukaemia, acute
204 Leukaemia, non-acute	C91–C95 non-acute	Leukaemia, non-acute
All sites	All sites	All sites

¹ See Cancer in Norway 2004 page 20 for specification of organs included.

Table S5: EASTERN NORWAY HEALTH REGION. Observed (2000–2004) and predicted (2010) incidence, percent changes from last observed period (ΔT), hereof changes due to risk (ΔR) or population (ΔP), by gender and cancer site.

Cancer sites ¹	Men					Women				
	incidence		changes (%)			incidence		changes (%)		
	2004 ²	2010	ΔT	ΔR	ΔP	2004 ²	2010	ΔT	ΔR	ΔP
Lip	10	13	27	17	10	4	5	14	6	8
Tongue	21	23	10	-4	14	10	11	6	-3	8
Floor of mouth	9	11	29	16	13	6	7	21	13	7
Mouth, other	12	15	23	9	14	9	10	8	-3	12
Salivary glands	8	9	7	0	7	8	8	7	-4	11
Mesopharynx	18	20	13	-2	15	6	7	11	0	11
Nasopharynx	3	3	16	10	6	2	1	-13	-24	11
Hypopharynx	9	11	25	17	8	3	3	0	-6	6
Oesophagus	49	55	12	1	11	21	21	1	-6	7
Stomach	110	96	-13	-22	9	73	57	-22	-26	4
Small intestine	20	20	0	-10	10	18	16	-9	-14	6
Colon	368	421	15	5	9	408	452	11	7	4
Rectum	197	211	7	-3	10	177	197	11	6	5
Liver	31	33	8	-1	9	17	18	5	1	4
Gallbladder	17	17	3	-8	11	30	31	6	1	5
Pancreas	102	108	6	-4	10	122	127	5	0	5
Other digestive organs	6	6	-3	-13	9	14	11	-19	-23	5
Nose, sinuses, etc.	8	9	5	-3	8	8	9	7	1	5
Larynx	37	42	12	1	10	6	7	14	10	5
Trachea, bronchus and lung	452	459	2	-8	9	311	388	25	18	7
Pleura	24	26	9	-1	10	3	4	15	10	5
Mediastinum, thymus and heart	4	4	16	8	8	4	3	-13	-22	8
Bone	10	11	12	-1	12	4	5	4	-2	6
Melanoma of skin	181	184	2	-7	9	204	219	8	2	5
Other skin	210	257	22	14	8	182	224	23	19	4
Connective tissue	29	33	14	8	7	25	27	5	-3	8
Breast	5	6	8	-1	10	995	1228	23	14	9
Uterine cervix	.	.	.	.	.	113	98	-13	-18	5
Uterine corpus	.	.	.	.	.	229	246	7	0	7
Placenta	.	.	.	.	.	0	0	9	11	-2
Uterus unspecified	.	.	.	.	.	4	4	-12	-16	4
Ovary, etc.	.	.	.	.	.	180	183	2	-5	7
Other female genital organs	.	.	.	.	.	35	38	9	6	4
Prostate	1084	1204	11	0	11	.	.	.	.	.
Testis	91	104	14	15	0	.	.	.	.	.
Other male genital organs	15	16	7	-9	15	.	.	.	.	.
Kidney excluding renal pelvis	112	137	22	14	8	63	68	7	1	6
Renal pelvis and ureter	26	29	14	8	6	18	18	-1	-8	7
Bladder and other urinary organs	291	309	6	-2	8	111	120	8	3	4
Eye	11	12	4	-5	8	9	10	4	-1	5
Brain, nervous system	131	141	8	0	8	165	175	6	0	6
Thyroid gland	15	16	6	-3	9	47	49	4	-1	5
Other endocrine organs	3	3	-13	-18	6	3	3	0	-5	5
Other and unspecified sites	105	115	10	1	9	136	143	5	1	4
Hodgkin lymphoma	24	26	8	0	8	18	16	-9	-13	4
Non-Hodgkin lymphoma	137	164	20	11	9	123	130	6	0	6
Multiple myeloma	53	58	11	2	9	54	56	3	-3	6
Leukemia, acute	44	47	6	0	7	40	41	3	1	2
Leukemia, non-acute	67	73	9	-1	10	57	59	2	-3	5
All sites	4159	4559	10	0	9	4075	4553	12	5	6

¹ Modified ICD-7 (ICD-10 conversion table; Table S4 on page S7).² Average annual number of new cases 2000–2004.

Table S6: EASTERN NORWAY HEALTH REGION. Observed (2000–2004) and predicted (2015) incidence, percent changes from last observed period (ΔT), hereof changes due to risk (ΔR) or population (ΔP), by gender and cancer site.

Cancer sites ¹	Men					Women				
	incidence		changes (%)			incidence		changes (%)		
	2004 ²	2015	ΔT	ΔR	ΔP	2004 ²	2015	ΔT	ΔR	ΔP
Lip	10	14	39	21	19	4	5	19	4	15
Tongue	21	25	20	-4	24	10	12	11	-4	15
Floor of mouth	9	12	42	15	26	6	8	29	16	13
Mouth, other	12	17	35	11	24	9	10	14	-5	19
Salivary glands	8	9	18	0	18	8	9	12	-2	14
Mesopharynx	18	21	21	-3	24	6	7	17	2	15
Nasopharynx	3	4	26	5	22	2	1	-7	-19	12
Hypopharynx	9	12	38	15	24	3	3	6	-11	17
Oesophagus	49	61	25	2	23	21	22	7	-6	12
Stomach	110	96	-13	-32	20	73	53	-28	-36	9
Small intestine	20	22	10	-13	23	18	18	-1	-16	14
Colon	368	462	26	5	21	408	483	19	8	10
Rectum	197	228	15	-6	21	177	215	21	11	11
Liver	31	36	17	-1	19	17	19	12	1	11
Gallbladder	17	19	12	-8	20	30	33	11	0	11
Pancreas	102	118	15	-5	20	122	133	10	0	10
Other digestive organs	6	6	5	-13	18	14	12	-12	-25	14
Nose, sinuses, etc.	8	9	15	-4	19	8	9	12	0	12
Larynx	37	46	24	0	24	6	8	24	13	11
Trachea, bronchus and lung	452	482	7	-16	22	311	439	41	25	17
Pleura	24	29	20	1	19	3	4	24	11	14
Mediastinum, thymus and heart	4	5	25	8	17	4	3	-9	-25	16
Bone	10	11	16	-3	19	4	5	6	-2	8
Melanoma of skin	181	187	3	-14	18	204	227	11	1	11
Other skin	210	288	37	21	16	182	245	35	27	8
Connective tissue	29	36	22	9	14	25	28	9	-3	12
Breast	5	6	15	-6	21	995	1385	39	23	16
Uterine cervix	.	.	.	.	.	113	93	-17	-26	9
Uterine corpus	.	.	.	.	.	229	264	15	-1	16
Placenta	.	.	.	.	.	0	0	11	16	-5
Uterus unspecified	.	.	.	.	.	4	4	-9	-14	5
Ovary, etc.	.	.	.	.	.	180	189	5	-9	14
Other female genital organs	.	.	.	.	.	35	40	14	8	6
Prostate	1084	1340	24	0	24	.	.	.	.	.
Testis	91	111	21	19	2	.	.	.	.	.
Other male genital organs	15	18	17	-11	29	.	.	.	.	.
Kidney excluding renal pelvis	112	158	41	23	18	63	72	14	2	12
Renal pelvis and ureter	26	33	27	9	18	18	19	6	-10	16
Bladder and other urinary organs	291	332	14	-4	18	111	126	14	2	11
Eye	11	13	11	-6	17	9	10	10	0	10
Brain, nervous system	131	150	14	0	15	165	185	12	1	11
Thyroid gland	15	17	13	-1	14	47	51	8	0	9
Other endocrine organs	3	3	-9	-21	12	3	3	5	-4	8
Other and unspecified sites	105	125	19	0	19	136	149	9	1	8
Hodgkin lymphoma	24	28	13	1	12	18	17	-6	-14	7
Non-Hodgkin lymphoma	137	186	36	18	18	123	139	13	0	12
Multiple myeloma	53	65	22	3	19	54	59	10	-4	13
Leukemia, acute	44	50	14	0	14	40	43	7	1	6
Leukemia, non-acute	67	79	19	-1	20	57	62	7	-3	11
All sites	4159	4968	19	-1	20	4075	4921	21	8	13

¹ Modified ICD-7 (ICD-10 conversion table; Table S4 on page S7).² Average annual number of new cases 2000–2004.

Table S7: EASTERN NORWAY HEALTH REGION. Observed (2000–2004) and predicted (2020) incidence, percent changes from last observed period (ΔT), hereof changes due to risk (ΔR) or population (ΔP), by gender and cancer site.

Cancer sites ¹	Men					Women				
	incidence		changes (%)			incidence		changes (%)		
	2004 ²	2020	ΔT	ΔR	ΔP	2004 ²	2020	ΔT	ΔR	ΔP
Lip	10	16	53	22	32	4	6	29	5	24
Tongue	21	27	28	-3	31	10	12	19	-5	24
Floor of mouth	9	13	52	19	33	6	8	39	18	21
Mouth, other	12	18	47	9	38	9	11	22	-5	27
Salivary glands	8	10	29	-4	32	8	9	19	-1	20
Mesopharynx	18	23	30	-3	33	6	8	26	3	23
Nasopharynx	3	4	35	2	33	2	2	-2	-17	15
Hypopharynx	9	14	51	15	36	3	3	13	-16	29
Oesophagus	49	68	38	1	37	21	24	15	-7	22
Stomach	110	101	-8	-41	34	73	53	-27	-44	17
Small intestine	20	24	21	-13	34	18	19	7	-17	24
Colon	368	510	39	3	35	408	522	28	8	20
Rectum	197	249	26	-8	35	177	238	34	14	20
Liver	31	40	30	-1	31	17	21	22	-1	23
Gallbladder	17	21	25	-7	32	30	36	20	0	20
Pancreas	102	131	29	-5	34	122	144	18	-1	19
Other digestive organs	6	7	15	-16	31	14	13	-3	-27	25
Nose, sinuses, etc.	8	10	26	-4	30	8	10	22	2	20
Larynx	37	51	37	0	36	6	9	33	13	20
Trachea, bronchus and lung	452	508	12	-25	37	311	484	56	28	28
Pleura	24	33	36	0	36	3	4	39	13	26
Mediastinum, thymus and heart	4	5	36	7	30	4	4	-1	-22	21
Bone	10	12	20	-1	21	4	5	10	-2	11
Melanoma of skin	181	188	4	-24	29	204	233	14	-3	17
Other skin	210	322	53	23	30	182	267	47	31	16
Connective tissue	29	38	32	8	24	25	29	15	-2	17
Breast	5	7	27	-6	33	995	1534	54	32	22
Uterine cervix	.	.	.	.	.	113	91	-19	-33	14
Uterine corpus	.	.	.	.	.	229	285	24	-1	25
Placenta	.	.	.	.	.	0	0	17	18	-1
Uterus unspecified	.	.	.	.	.	4	4	-4	-12	8
Ovary, etc.	.	.	.	.	.	180	195	9	-14	23
Other female genital organs	.	.	.	.	.	35	42	22	8	14
Prostate	1084	1499	38	0	39	.	.	.	.	.
Testis	91	116	27	22	5	.	.	.	.	.
Other male genital organs	15	20	30	-11	41	.	.	.	.	.
Kidney excluding renal pelvis	112	182	62	32	31	63	79	24	3	21
Renal pelvis and ureter	26	37	45	8	37	18	21	16	-8	24
Bladder and other urinary organs	291	365	26	-8	33	111	134	21	0	21
Eye	11	14	22	-7	29	9	11	19	-1	20
Brain, nervous system	131	161	23	0	23	165	196	19	1	19
Thyroid gland	15	19	21	1	20	47	54	14	0	14
Other endocrine organs	3	3	-5	-21	17	3	3	10	-5	15
Other and unspecified sites	105	139	33	0	34	136	160	18	1	17
Hodgkin lymphoma	24	29	17	2	16	18	17	-2	-14	12
Non-Hodgkin lymphoma	137	208	52	23	29	123	150	22	1	21
Multiple myeloma	53	72	36	3	33	54	65	20	-4	24
Leukemia, acute	44	55	24	0	24	40	46	14	1	13
Leukemia, non-acute	67	88	32	0	32	57	67	16	-3	20
All sites	4159	5457	31	-2	34	4075	5330	31	10	21

¹ Modified ICD-7 (ICD-10 conversion table; Table S4 on page S7).² Average annual number of new cases 2000–2004.

Table S8: SOUTHERN NORWAY HEALTH REGION. Observed (2000–2004) and predicted (2010) incidence, percent changes from last observed period (ΔT), hereof changes due to risk (ΔR) or population (ΔP), by gender and cancer site.

Cancer sites ¹	Men					Women				
	incidence		changes (%)			incidence		changes (%)		
	2004 ²	2010	ΔT	ΔR	ΔP	2004 ²	2010	ΔT	ΔR	ΔP
Lip	11	15	32	25	7	4	4	13	11	3
Tongue	8	9	10	-5	16	4	4	6	-2	8
Floor of mouth	6	8	30	18	12	2	3	22	14	8
Mouth, other	5	6	22	12	10	5	6	8	-2	10
Salivary glands	4	4	7	-2	9	6	6	7	1	6
Mesopharynx	11	11	5	-8	14	2	2	10	6	4
Nasopharynx	2	3	15	2	13	1	1	-14	-29	15
Hypopharynx	4	5	26	8	18	2	2	0	-17	17
Oesophagus	28	31	11	2	9	11	11	-3	-7	4
Stomach	57	49	-15	-24	8	40	33	-16	-21	5
Small intestine	10	10	-1	-15	14	10	10	-7	-17	10
Colon	205	235	14	6	8	235	263	12	6	5
Rectum	117	130	12	2	9	93	104	12	4	8
Liver	13	14	2	-6	8	6	6	4	-2	5
Gallbladder	16	17	8	-3	11	13	15	9	5	4
Pancreas	57	61	6	-5	11	63	66	5	-1	6
Other digestive organs	4	4	-4	-14	9	7	5	-19	-27	9
Nose, sinuses, etc.	5	5	5	-9	14	3	3	8	10	-2
Larynx	24	27	12	1	11	4	5	15	10	5
Trachea, bronchus and lung	292	308	6	-4	10	190	250	31	24	7
Pleura	18	20	12	4	7	3	3	15	14	1
Mediastinum, thymus and heart	1	2	15	1	14	1	1	-14	-22	7
Bone	3	3	10	4	5	6	6	4	-5	9
Melanoma of skin	109	121	11	2	9	119	122	3	-5	8
Other skin	168	210	25	16	9	145	188	29	25	4
Connective tissue	14	16	12	2	10	10	10	6	1	5
Breast	3	3	8	-4	12	567	689	21	13	9
Uterine cervix	.	.	.	.	.	61	59	-4	-8	4
Uterine corpus	.	.	.	.	.	116	126	8	-1	9
Placenta	.	.	.	.	.	0	0	2	15	-14
Uterus unspecified	.	.	.	.	.	4	4	-12	-15	3
Ovary, etc.	.	.	.	.	.	98	100	2	-5	7
Other female genital organs	.	.	.	.	.	23	25	9	4	5
Prostate	658	731	11	0	11	.	.	.	.	.
Testis	44	50	14	12	1	.	.	.	.	.
Other male genital organs	8	8	6	-4	9	.	.	.	.	.
Kidney excluding renal pelvis	62	76	22	11	11	40	42	6	3	4
Renal pelvis and ureter	14	15	7	2	6	6	6	-1	0	-1
Bladder and other urinary organs	169	182	8	0	8	59	64	9	3	5
Eye	6	6	3	-3	6	8	8	4	-2	6
Brain, nervous system	71	75	5	-3	8	98	103	6	-1	7
Thyroid gland	8	8	7	0	7	24	24	-2	-5	4
Other endocrine organs	1	1	-12	-11	-1	2	2	2	-7	9
Other and unspecified sites	63	70	10	1	9	76	80	6	1	5
Hodgkin lymphoma	11	11	0	-7	7	8	7	-10	-13	3
Non-Hodgkin lymphoma	78	94	21	10	10	63	67	7	1	6
Multiple myeloma	35	39	10	1	9	29	30	5	2	4
Leukemia, acute	28	29	2	-6	8	22	23	5	2	3
Leukemia, non-acute	42	46	10	0	9	25	25	1	-4	5
All sites	2494	2765	11	1	10	2315	2616	13	6	7

¹ Modified ICD-7 (ICD-10 conversion table; Table S4 on page S7).² Average annual number of new cases 2000–2004.

Table S9: SOUTHERN NORWAY HEALTH REGION. Observed (2000–2004) and predicted (2015) incidence, percent changes from last observed period (ΔT), hereof changes due to risk (ΔR) or population (ΔP), by gender and cancer site.

Cancer sites ¹	Men					Women				
	incidence		changes (%)			incidence		changes (%)		
	2004 ²	2015	ΔT	ΔR	ΔP	2004 ²	2015	ΔT	ΔR	ΔP
Lip	11	16	45	24	21	4	5	19	13	6
Tongue	8	10	20	-6	26	4	4	11	-2	13
Floor of mouth	6	9	42	18	24	2	3	31	14	17
Mouth, other	5	7	35	14	21	5	6	14	0	14
Salivary glands	4	4	18	-9	27	6	6	13	0	12
Mesopharynx	11	12	13	-6	19	2	3	17	7	10
Nasopharynx	2	3	26	11	15	1	1	-8	-27	20
Hypopharynx	4	6	40	13	26	2	2	7	-21	28
Oesophagus	28	34	25	4	21	11	12	3	-7	10
Stomach	57	48	-16	-35	19	40	32	-19	-31	12
Small intestine	10	11	9	-21	30	10	10	0	-19	19
Colon	205	259	26	8	18	235	282	20	7	13
Rectum	117	144	24	5	19	93	114	22	8	15
Liver	13	15	11	-5	16	6	7	11	-6	17
Gallbladder	16	19	19	-1	20	13	15	15	7	8
Pancreas	57	66	16	-6	21	63	70	10	-1	11
Other digestive organs	4	4	5	-18	22	7	6	-12	-26	14
Nose, sinuses, etc.	5	5	16	-7	24	3	3	13	6	6
Larynx	24	30	25	1	24	4	5	25	8	17
Trachea, bronchus and lung	292	329	13	-10	23	190	288	51	34	17
Pleura	18	22	23	3	20	3	3	26	18	8
Mediastinum, thymus and heart	1	2	25	-4	29	1	1	-9	-26	17
Bone	3	3	14	6	8	6	6	6	-6	12
Melanoma of skin	109	128	17	-1	18	119	123	4	-11	14
Other skin	168	239	43	24	19	145	211	45	38	7
Connective tissue	14	17	20	-1	21	10	11	10	-1	11
Breast	3	4	16	2	14	567	774	36	21	16
Uterine cervix	.	.	.	.	.	61	59	-4	-11	6
Uterine corpus	.	.	.	.	.	116	135	16	-1	17
Placenta	.	.	.	.	.	0	0	4	23	-19
Uterus unspecified	.	.	.	.	.	4	4	-10	-16	6
Ovary, etc.	.	.	.	.	.	98	103	5	-8	13
Other female genital organs	.	.	.	.	.	23	26	14	2	13
Prostate	658	818	24	0	25	.	.	.	.	.
Testis	44	53	19	16	3	.	.	.	.	.
Other male genital organs	8	9	17	1	16	.	.	.	.	.
Kidney excluding renal pelvis	62	88	41	19	22	40	45	14	4	10
Renal pelvis and ureter	14	16	20	3	17	6	7	7	2	5
Bladder and other urinary organs	169	197	17	-1	18	59	68	15	3	11
Eye	6	7	12	-2	14	8	9	10	-2	12
Brain, nervous system	71	80	12	-2	14	98	109	12	-2	14
Thyroid gland	8	9	14	-2	16	24	25	2	-7	9
Other endocrine organs	1	1	-8	-8	0	2	2	7	-9	16
Other and unspecified sites	63	76	20	2	17	76	83	10	1	9
Hodgkin lymphoma	11	12	4	-8	12	8	7	-7	-14	6
Non-Hodgkin lymphoma	78	107	37	17	20	63	72	14	1	13
Multiple myeloma	35	43	22	0	22	29	32	13	1	11
Leukemia, acute	28	31	9	-7	16	22	24	9	2	7
Leukemia, non-acute	42	50	20	0	20	25	26	7	-5	11
All sites	2494	3042	22	1	21	2315	2838	23	9	13

¹ Modified ICD-7 (ICD-10 conversion table; Table S4 on page S7).² Average annual number of new cases 2000–2004.

Table S10: SOUTHERN NORWAY HEALTH REGION. Observed (2000–2004) and predicted (2020) incidence, percent changes from last observed period (ΔT), hereof changes due to risk (ΔR) or population (ΔP), by gender and cancer site.

Cancer sites ¹	Men					Women				
	incidence		changes (%)			incidence		changes (%)		
	2004 ²	2020	ΔT	ΔR	ΔP	2004 ²	2020	ΔT	ΔR	ΔP
Lip	11	18	60	26	34	4	5	29	14	15
Tongue	8	10	29	-6	35	4	4	19	-4	23
Floor of mouth	6	9	52	17	35	2	3	41	9	32
Mouth, other	5	7	47	16	32	5	7	22	-1	23
Salivary glands	4	5	29	-10	39	6	7	19	1	18
Mesopharynx	11	13	21	-8	29	2	3	25	4	21
Nasopharynx	2	3	35	11	24	1	1	-3	-31	29
Hypopharynx	4	6	53	16	37	2	2	14	-19	33
Oesophagus	28	38	38	3	35	11	13	11	-8	19
Stomach	57	51	-12	-46	35	40	33	-15	-38	22
Small intestine	10	12	21	-22	43	10	11	9	-18	27
Colon	205	287	40	6	34	235	305	30	6	23
Rectum	117	161	38	6	32	93	126	35	11	24
Liver	13	17	24	-3	27	6	7	20	-10	30
Gallbladder	16	21	33	0	33	13	17	25	7	19
Pancreas	57	74	30	-5	35	63	75	20	-1	21
Other digestive organs	4	4	15	-26	41	7	6	-3	-27	24
Nose, sinuses, etc.	5	6	28	-7	35	3	3	22	-4	26
Larynx	24	33	38	1	37	4	6	35	7	28
Trachea, bronchus and lung	292	352	20	-18	39	190	318	67	39	28
Pleura	18	25	39	3	35	3	4	40	22	18
Mediastinum, thymus and heart	1	2	36	-2	38	1	1	-2	-29	27
Bone	3	4	18	4	13	6	6	9	-5	14
Melanoma of skin	109	133	21	-6	28	119	122	3	-17	21
Other skin	168	271	62	28	34	145	234	61	46	15
Connective tissue	14	18	29	-3	33	10	11	15	-3	18
Breast	3	4	28	3	26	567	854	50	29	21
Uterine cervix	.	.	.	.	.	61	59	-4	-13	9
Uterine corpus	.	.	.	.	.	116	145	25	-1	25
Placenta	.	.	.	.	.	0	0	8	20	-12
Uterus unspecified	.	.	.	.	.	4	4	-5	-21	16
Ovary, etc.	.	.	.	.	.	98	107	9	-12	21
Other female genital organs	.	.	.	.	.	23	28	22	1	21
Prostate	658	919	40	0	40	.	.	.	.	.
Testis	44	55	24	18	6	.	.	.	.	.
Other male genital organs	8	10	30	3	27	.	.	.	.	.
Kidney excluding renal pelvis	62	101	62	28	35	40	49	23	3	21
Renal pelvis and ureter	14	19	36	1	35	6	7	17	1	16
Bladder and other urinary organs	169	218	29	-4	33	59	73	22	2	20
Eye	6	7	22	-1	23	8	9	19	-1	19
Brain, nervous system	71	86	20	-3	24	98	116	19	-2	21
Thyroid gland	8	9	22	-5	27	24	26	7	-9	16
Other endocrine organs	1	1	-4	-7	3	2	2	12	-7	19
Other and unspecified sites	63	85	34	3	32	76	90	19	2	16
Hodgkin lymphoma	11	12	8	-6	14	8	8	-4	-15	11
Non-Hodgkin lymphoma	78	120	54	23	31	63	78	23	1	22
Multiple myeloma	35	48	36	-2	38	29	36	24	1	23
Leukemia, acute	28	33	18	-8	26	22	26	16	1	15
Leukemia, non-acute	42	56	34	1	32	25	29	16	-6	22
All sites	2494	3364	35	0	35	2315	3076	33	12	21

¹ Modified ICD-7 (ICD-10 conversion table; Table S4 on page S7).² Average annual number of new cases 2000–2004.

Table S11: WESTERN NORWAY HEALTH REGION. Observed (2000–2004) and predicted (2010) incidence, percent changes from last observed period (ΔT), hereof changes due to risk (ΔR) or population (ΔP), by gender and cancer site.

Cancer sites ¹	Men					Women				
	incidence		changes (%)			incidence		changes (%)		
	2004 ²	2010	ΔT	ΔR	ΔP	2004 ²	2010	ΔT	ΔR	ΔP
Lip	7	10	33	12	20	2	2	14	9	5
Tongue	10	11	13	0	13	5	5	7	2	6
Floor of mouth	4	5	30	14	17	3	3	22	8	14
Mouth, other	7	9	24	8	16	6	7	10	0	10
Salivary glands	4	4	8	-3	11	3	3	8	5	3
Mesopharynx	8	9	7	-5	12	2	3	9	1	8
Nasopharynx	2	3	18	0	18	1	1	-12	-27	15
Hypopharynx	3	4	27	12	14	0	0	2	-12	14
Oesophagus	22	25	14	0	14	9	9	-3	-13	10
Stomach	75	66	-11	-21	10	54	45	-16	-22	6
Small intestine	9	9	1	-13	14	9	8	-7	-16	9
Colon	215	251	17	6	11	266	300	13	7	6
Rectum	135	154	14	1	13	104	118	13	6	7
Liver	14	14	4	-4	7	9	9	4	-2	6
Gallbladder	13	14	9	-1	11	16	18	10	2	8
Pancreas	55	63	14	3	12	60	64	6	0	6
Other digestive organs	4	3	-4	-12	8	5	4	-16	-21	5
Nose, sinuses, etc.	5	6	7	-4	12	3	3	9	3	6
Larynx	17	19	12	0	13	2	2	16	-1	17
Trachea, bronchus and lung	264	295	12	-1	12	139	185	33	24	9
Pleura	9	10	12	-1	13	0	0	21	29	-9
Mediastinum, thymus and heart	2	2	18	3	15	1	1	-11	-4	-7
Bone	4	5	9	5	4	4	4	2	-3	5
Melanoma of skin	95	107	12	1	11	115	126	9	2	8
Other skin	123	147	20	10	10	99	108	9	2	6
Connective tissue	13	15	14	4	10	12	13	8	2	6
Breast	3	3	9	2	7	488	597	22	12	10
Uterine cervix	.	.	.	.	.	50	48	-3	-8	4
Uterine corpus	.	.	.	.	.	121	132	9	-1	10
Placenta	.	.	.	.	.	2	2	14	18	-4
Uterus unspecified	.	.	.	.	.	4	4	-9	-16	7
Ovary, etc.	.	.	.	.	.	97	100	4	-5	9
Other female genital organs	.	.	.	.	.	19	22	11	2	9
Prostate	683	773	13	0	13	.	.	.	.	.
Testis	52	60	14	14	0	.	.	.	.	.
Other male genital organs	6	6	9	1	7	.	.	.	.	.
Kidney excluding renal pelvis	62	77	24	12	12	37	40	8	2	5
Renal pelvis and ureter	10	10	9	-2	11	9	10	2	0	2
Bladder and other urinary organs	164	181	10	0	10	60	66	10	4	6
Eye	6	6	6	0	6	6	7	5	-1	6
Brain, nervous system	79	84	6	-2	8	91	98	7	-1	8
Thyroid gland	12	13	7	1	5	29	30	5	-1	6
Other endocrine organs	2	2	-11	-15	5	2	2	-1	-9	8
Other and unspecified sites	52	58	13	1	11	71	77	8	2	6
Hodgkin lymphoma	13	13	0	-6	6	10	9	-10	-12	2
Non-Hodgkin lymphoma	69	80	16	5	10	64	70	9	2	7
Multiple myeloma	28	32	12	-3	14	27	29	7	3	4
Leukemia, acute	24	24	-1	-6	5	18	19	5	2	4
Leukemia, non-acute	31	35	11	0	11	22	23	1	-6	7
All sites	2417	2717	12	1	11	2159	2425	12	5	8

¹ Modified ICD-7 (ICD-10 conversion table; Table S4 on page S7).² Average annual number of new cases 2000–2004.

Table S12: WESTERN NORWAY HEALTH REGION. Observed (2000–2004) and predicted (2015) incidence, percent changes from last observed period (ΔT), hereof changes due to risk (ΔR) or population (ΔP), by gender and cancer site.

Cancer sites ¹	Men					Women				
	incidence		changes (%)			incidence		changes (%)		
	2004 ²	2015	ΔT	ΔR	ΔP	2004 ²	2015	ΔT	ΔR	ΔP
Lip	7	11	47	11	36	2	2	21	5	16
Tongue	10	13	23	1	22	5	5	14	3	11
Floor of mouth	4	6	43	16	27	3	3	32	9	23
Mouth, other	7	10	37	8	29	6	7	16	-2	19
Salivary glands	4	5	20	0	20	3	3	15	7	8
Mesopharynx	8	9	16	-5	21	2	3	17	5	12
Nasopharynx	2	3	29	-3	32	1	1	-5	-31	26
Hypopharynx	3	4	41	17	24	0	0	10	-4	14
Oesophagus	22	28	28	-2	29	9	10	3	-13	16
Stomach	75	67	-11	-31	20	54	44	-18	-30	12
Small intestine	9	10	12	-13	25	9	9	1	-17	18
Colon	215	279	30	6	23	266	324	22	9	13
Rectum	135	171	27	2	25	104	130	24	10	15
Liver	14	15	14	-5	18	9	10	12	1	11
Gallbladder	13	15	21	-2	23	16	19	16	1	15
Pancreas	55	71	29	5	24	60	68	13	0	13
Other digestive organs	4	4	5	-8	13	5	4	-8	-21	13
Nose, sinuses, etc.	5	6	19	-7	26	3	3	15	5	10
Larynx	17	21	26	-2	27	2	3	26	2	24
Trachea, bronchus and lung	264	319	21	-5	26	139	214	54	34	20
Pleura	9	11	25	-1	25	0	1	31	37	-6
Mediastinum, thymus and heart	2	2	29	5	24	1	1	-6	1	-7
Bone	4	5	12	6	7	4	4	4	-2	6
Melanoma of skin	95	113	19	-1	20	115	131	14	0	13
Other skin	123	166	35	15	21	99	115	16	5	11
Connective tissue	13	16	22	6	16	12	14	13	0	13
Breast	3	3	18	-1	18	488	674	38	21	17
Uterine cervix	.	.	.	.	.	50	48	-4	-11	8
Uterine corpus	.	.	.	.	.	121	142	18	0	18
Placenta	.	.	.	.	.	2	2	17	19	-3
Uterus unspecified	.	.	.	.	.	4	4	-6	-18	12
Ovary, etc.	.	.	.	.	.	97	104	7	-9	16
Other female genital organs	.	.	.	.	.	19	23	17	2	15
Prostate	683	870	27	0	27	.	.	.	.	.
Testis	52	64	22	20	2	.	.	.	.	.
Other male genital organs	6	7	20	1	20	.	.	.	.	.
Kidney excluding renal pelvis	62	89	44	21	22	37	43	16	3	13
Renal pelvis and ureter	10	12	22	-6	28	9	10	10	-1	11
Bladder and other urinary organs	164	198	20	-3	23	60	71	17	5	12
Eye	6	7	15	0	14	6	7	12	2	10
Brain, nervous system	79	89	13	-2	15	91	104	13	-2	15
Thyroid gland	12	13	14	2	12	29	31	10	-2	11
Other endocrine organs	2	2	-6	-15	9	2	2	4	-9	13
Other and unspecified sites	52	64	24	1	23	71	80	13	2	11
Hodgkin lymphoma	13	14	5	-8	13	10	9	-7	-10	3
Non-Hodgkin lymphoma	69	90	29	9	20	64	75	17	2	15
Multiple myeloma	28	35	24	-4	28	27	31	15	4	11
Leukemia, acute	24	26	6	-5	12	18	20	10	3	7
Leukemia, non-acute	31	38	23	-1	23	22	24	7	-7	14
All sites	2417	3001	24	1	23	2159	2633	22	7	15

¹ Modified ICD-7 (ICD-10 conversion table; Table S4 on page S7).² Average annual number of new cases 2000–2004.

Table S13: WESTERN NORWAY HEALTH REGION. Observed (2000–2004) and predicted (2020) incidence, percent changes from last observed period (ΔT), hereof changes due to risk (ΔR) or population (ΔP), by gender and cancer site.

Cancer sites ¹	Men					Women				
	incidence		changes (%)			incidence		changes (%)		
	2004 ²	2020	ΔT	ΔR	ΔP	2004 ²	2020	ΔT	ΔR	ΔP
Lip	7	12	62	18	44	2	3	31	4	27
Tongue	10	14	33	0	33	5	6	22	2	20
Floor of mouth	4	6	54	18	36	3	4	43	7	36
Mouth, other	7	11	50	9	41	6	8	25	-2	27
Salivary glands	4	5	32	-1	33	3	3	22	6	16
Mesopharynx	8	10	24	-8	32	2	3	25	11	14
Nasopharynx	2	3	38	2	37	1	1	1	-39	40
Hypopharynx	3	4	55	19	36	0	0	18	-3	21
Oesophagus	22	31	43	-2	44	9	11	12	-9	21
Stomach	75	71	-5	-41	36	54	46	-14	-35	20
Small intestine	9	11	24	-14	38	9	10	11	-21	31
Colon	215	310	44	5	39	266	352	32	10	23
Rectum	135	191	42	3	39	104	144	38	14	24
Liver	14	17	28	-7	35	9	11	21	2	19
Gallbladder	13	17	36	-3	39	16	21	27	2	24
Pancreas	55	81	47	8	39	60	73	22	-1	23
Other digestive organs	4	4	16	-4	20	5	5	1	-27	28
Nose, sinuses, etc.	5	7	31	-11	42	3	3	25	6	19
Larynx	17	24	40	-3	43	2	3	37	2	35
Trachea, bronchus and lung	264	343	30	-13	42	139	237	71	39	32
Pleura	9	13	41	3	39	0	1	47	32	14
Mediastinum, thymus and heart	2	3	41	8	33	1	1	2	-1	3
Bone	4	5	16	6	10	4	4	7	0	8
Melanoma of skin	95	117	23	-7	31	115	135	17	-3	20
Other skin	123	190	55	18	37	99	126	27	7	20
Connective tissue	13	18	32	5	27	12	15	19	-1	20
Breast	3	4	31	2	28	488	748	53	30	23
Uterine cervix	.	.	.	.	.	50	49	-2	-15	13
Uterine corpus	.	.	.	.	.	121	154	28	0	28
Placenta	.	.	.	.	.	2	2	22	20	2
Uterus unspecified	.	.	.	.	.	4	4	0	-23	23
Ovary, etc.	.	.	.	.	.	97	108	12	-13	25
Other female genital organs	.	.	.	.	.	19	24	26	4	21
Prostate	683	982	44	0	44	.	.	.	.	.
Testis	52	67	27	23	4	.	.	.	.	.
Other male genital organs	6	8	34	-2	36	.	.	.	.	.
Kidney excluding renal pelvis	62	103	65	30	35	37	47	27	3	24
Renal pelvis and ureter	10	13	39	-7	46	9	11	21	-6	27
Bladder and other urinary organs	164	220	34	-7	40	60	76	25	3	22
Eye	6	8	25	-2	27	6	7	21	4	17
Brain, nervous system	79	96	21	-2	23	91	110	21	-1	22
Thyroid gland	12	14	22	2	20	29	33	15	-2	17
Other endocrine organs	2	2	-1	-14	13	2	2	9	-6	15
Other and unspecified sites	52	72	39	1	38	71	87	22	2	20
Hodgkin lymphoma	13	14	8	-10	18	10	10	-3	-10	7
Non-Hodgkin lymphoma	69	100	44	13	31	64	82	27	1	27
Multiple myeloma	28	39	39	-2	41	27	35	26	3	23
Leukemia, acute	24	28	15	-6	21	18	21	17	3	14
Leukemia, non-acute	31	43	37	-2	39	22	26	16	-6	22
All sites	2417	3330	38	0	38	2159	2861	33	9	23

¹ Modified ICD-7 (ICD-10 conversion table; Table S4 on page S7).² Average annual number of new cases 2000–2004.

Table S14: CENTRAL NORWAY HEALTH REGION. Observed (2000–2004) and predicted (2010) incidence, percent changes from last observed period (ΔT), hereof changes due to risk (ΔR) or population (ΔP), by gender and cancer site.

Cancer sites ¹	Men					Women				
	incidence		changes (%)			incidence		changes (%)		
	2004 ²	2010	ΔT	ΔR	ΔP	2004 ²	2010	ΔT	ΔR	ΔP
Lip	8	11	31	24	7	3	3	11	4	7
Tongue	4	4	10	0	10	4	5	5	1	4
Floor of mouth	4	5	28	20	8	2	2	20	8	12
Mouth, other	3	4	23	15	7	4	5	6	4	2
Salivary glands	3	3	8	-4	12	1	1	4	4	1
Mesopharynx	6	6	5	-14	18	2	2	9	8	1
Nasopharynx	2	3	15	3	13	0	0	-17	-6	-11
Hypopharynx	3	4	25	9	16	1	1	1	-1	2
Oesophagus	13	15	11	-3	14	5	5	-4	-7	2
Stomach	60	53	-13	-21	8	32	26	-17	-20	3
Small intestine	10	10	-1	-13	13	10	9	-9	-10	1
Colon	165	188	14	6	8	187	207	11	6	5
Rectum	92	103	12	1	10	66	73	11	5	6
Liver	10	10	0	-8	8	7	7	1	-2	3
Gallbladder	8	9	7	4	3	9	10	8	6	2
Pancreas	46	49	5	-4	9	49	52	4	0	5
Other digestive organs	2	2	-5	-19	14	10	8	-20	-25	5
Nose, sinuses, etc.	3	3	4	-5	10	2	2	4	-2	7
Larynx	15	18	15	5	10	3	3	14	5	9
Trachea, bronchus and lung	182	199	9	1	8	106	138	30	23	7
Pleura	6	7	7	0	7	1	1	14	6	8
Mediastinum, thymus and heart	0	0	20	13	7	1	1	-16	-12	-4
Bone	4	4	7	3	4	2	2	2	-2	4
Melanoma of skin	65	76	18	9	10	73	79	7	3	4
Other skin	67	84	25	18	7	52	64	23	19	4
Connective tissue	11	12	9	6	3	11	12	5	3	3
Breast	3	3	8	2	5	360	441	22	14	8
Uterine cervix	.	.	.	.	.	29	24	-17	-19	2
Uterine corpus	.	.	.	.	.	79	84	7	-1	8
Placenta	.	.	.	.	.	0	0	NA	NA	NA
Uterus unspecified	.	.	.	.	.	1	1	-12	-15	3
Ovary, etc.	.	.	.	.	.	57	58	1	-5	6
Other female genital organs	.	.	.	.	.	13	14	10	7	2
Prostate	454	501	10	-1	11	.	.	.	.	.
Testis	44	50	12	14	-2	.	.	.	.	.
Other male genital organs	5	5	5	2	4	.	.	.	.	.
Kidney excluding renal pelvis	52	63	22	10	11	30	31	5	2	3
Renal pelvis and ureter	10	11	6	1	6	7	7	-1	-4	3
Bladder and other urinary organs	132	143	8	-1	9	43	46	7	4	4
Eye	3	3	4	-5	9	5	5	3	-3	6
Brain, nervous system	51	54	5	-2	7	67	70	5	-1	5
Thyroid gland	8	9	6	-7	12	22	21	-4	-8	4
Other endocrine organs	2	2	-13	-13	0	1	1	0	-13	13
Other and unspecified sites	40	44	12	3	8	49	52	5	0	6
Hodgkin lymphoma	9	9	-4	-6	2	7	6	-13	-13	0
Non-Hodgkin lymphoma	59	71	19	12	7	53	55	5	0	6
Multiple myeloma	28	31	10	3	8	22	23	4	0	4
Leukemia, acute	17	16	-2	-7	5	11	12	3	0	3
Leukemia, non-acute	27	29	9	0	9	17	17	1	-3	4
All sites	1739	1924	11	2	9	1516	1685	11	5	6

¹ Modified ICD-7 (ICD-10 conversion table; Table S4 on page S7).² Average annual number of new cases 2000–2004.

Table S15: CENTRAL NORWAY HEALTH REGION. Observed (2000–2004) and predicted (2015) incidence, percent changes from last observed period (ΔT), hereof changes due to risk (ΔR) or population (ΔP), by gender and cancer site.

Cancer sites ¹	Men					Women				
	incidence		changes (%)			incidence		changes (%)		
	2004 ²	2015	ΔT	ΔR	ΔP	2004 ²	2015	ΔT	ΔR	ΔP
Lip	8	12	43	24	18	3	3	16	3	13
Tongue	4	5	19	1	18	4	5	10	2	8
Floor of mouth	4	5	39	22	17	2	2	27	11	16
Mouth, other	3	4	34	13	22	4	5	11	5	6
Salivary glands	3	4	18	-4	22	1	2	9	10	0
Mesopharynx	6	6	12	-16	27	2	2	14	5	10
Nasopharynx	2	3	24	1	23	0	0	-11	-12	1
Hypopharynx	3	4	37	9	28	1	1	7	6	2
Oesophagus	13	16	23	-5	27	5	5	1	-6	7
Stomach	60	52	-14	-32	18	32	25	-21	-28	7
Small intestine	10	10	9	-16	25	10	9	-3	-12	9
Colon	165	206	25	7	18	187	220	18	8	10
Rectum	92	113	22	1	21	66	79	20	9	11
Liver	10	11	9	-10	18	7	7	7	0	8
Gallbladder	8	10	17	5	11	9	11	12	7	5
Pancreas	46	53	14	-3	17	49	54	9	-1	10
Other digestive organs	2	2	3	-24	27	10	9	-13	-28	15
Nose, sinuses, etc.	3	3	14	-4	18	2	2	9	-6	15
Larynx	15	19	26	8	18	3	3	23	2	20
Trachea, bronchus and lung	182	216	18	-1	20	106	157	48	32	17
Pleura	6	7	18	1	17	1	1	22	8	14
Mediastinum, thymus and heart	0	1	29	24	5	1	1	-13	-9	-4
Bone	4	4	10	2	8	2	2	3	0	3
Melanoma of skin	65	82	27	11	17	73	81	10	2	8
Other skin	67	95	41	27	15	52	70	34	27	8
Connective tissue	11	12	16	5	11	11	12	9	5	3
Breast	3	3	14	0	15	360	494	37	24	13
Uterine cervix	.	.	.	.	.	29	22	-23	-27	4
Uterine corpus	.	.	.	.	.	79	90	14	0	14
Placenta	.	.	.	.	.	0	0	NA	NA	NA
Uterus unspecified	.	.	.	.	.	1	1	-11	-19	8
Ovary, etc.	.	.	.	.	.	57	59	3	-8	11
Other female genital organs	.	.	.	.	.	13	15	14	7	7
Prostate	454	557	23	-1	23	.	.	.	.	.
Testis	44	52	16	19	-2	.	.	.	.	.
Other male genital organs	5	6	16	0	15	.	.	.	.	.
Kidney excluding renal pelvis	52	72	39	17	22	30	33	11	3	7
Renal pelvis and ureter	10	12	17	1	16	7	7	5	-4	9
Bladder and other urinary organs	132	153	16	-3	19	43	48	13	4	9
Eye	3	4	11	-6	17	5	6	8	-2	10
Brain, nervous system	51	57	11	-2	13	67	73	9	-1	11
Thyroid gland	8	9	12	-7	19	22	22	-1	-8	7
Other endocrine organs	2	2	-10	-10	0	1	1	3	-11	14
Other and unspecified sites	40	48	21	4	17	49	54	9	-1	10
Hodgkin lymphoma	9	9	0	-8	8	7	6	-12	-13	1
Non-Hodgkin lymphoma	59	80	34	18	16	53	59	11	0	11
Multiple myeloma	28	34	21	3	18	22	24	10	1	9
Leukemia, acute	17	17	4	-12	16	11	12	6	-2	8
Leukemia, non-acute	27	32	18	0	18	17	18	6	-2	7
All sites	1739	2101	21	2	19	1516	1810	19	9	11

¹ Modified ICD-7 (ICD-10 conversion table; Table S4 on page S7).² Average annual number of new cases 2000–2004.

Table S16: CENTRAL NORWAY HEALTH REGION. Observed (2000–2004) and predicted (2020) incidence, percent changes from last observed period (ΔT), hereof changes due to risk (ΔR) or population (ΔP), by gender and cancer site.

Cancer sites ¹	Men					Women				
	incidence		changes (%)			incidence		changes (%)		
	2004 ²	2020	ΔT	ΔR	ΔP	2004 ²	2020	ΔT	ΔR	ΔP
Lip	8	13	56	23	33	3	3	24	1	23
Tongue	4	5	26	6	20	4	5	16	5	11
Floor of mouth	4	6	47	19	28	2	2	35	17	18
Mouth, other	3	4	45	12	33	4	5	18	3	15
Salivary glands	3	4	28	0	27	1	2	14	12	2
Mesopharynx	6	7	18	-15	32	2	2	21	5	15
Nasopharynx	2	3	33	3	29	0	0	-7	-34	27
Hypopharynx	3	5	49	9	40	1	1	14	9	5
Oesophagus	13	18	36	-3	38	5	6	8	-12	20
Stomach	60	55	-9	-41	32	32	26	-18	-34	16
Small intestine	10	11	19	-15	34	10	10	4	-17	21
Colon	165	226	37	7	31	187	236	26	8	18
Rectum	92	125	35	1	34	66	87	31	13	18
Liver	10	12	21	-10	31	7	8	15	1	14
Gallbladder	8	11	29	3	26	9	11	21	7	14
Pancreas	46	59	27	-3	30	49	57	16	-2	18
Other digestive organs	2	2	12	-28	40	10	9	-5	-31	26
Nose, sinuses, etc.	3	4	24	-5	30	2	2	17	-9	26
Larynx	15	21	38	9	29	3	3	31	2	29
Trachea, bronchus and lung	182	231	27	-7	34	106	172	63	37	26
Pleura	6	8	33	0	33	1	1	36	10	26
Mediastinum, thymus and heart	0	1	40	41	-1	1	1	-6	-20	14
Bone	4	4	12	-1	13	2	3	5	5	1
Melanoma of skin	65	86	32	8	24	73	82	13	0	13
Other skin	67	107	59	31	28	52	75	45	31	14
Connective tissue	11	13	24	1	23	11	12	13	6	7
Breast	3	4	25	-1	27	360	543	51	33	18
Uterine cervix	.	.	.	.	.	29	22	-25	-32	8
Uterine corpus	.	.	.	.	.	79	96	21	1	20
Placenta	.	.	.	.	.	0	0	NA	NA	NA
Uterus unspecified	.	.	.	.	.	1	1	-7	-23	16
Ovary, etc.	.	.	.	.	.	57	61	6	-11	16
Other female genital organs	.	.	.	.	.	13	15	21	5	15
Prostate	454	621	37	0	37	.	.	.	.	.
Testis	44	53	20	21	-1	.	.	.	.	.
Other male genital organs	5	6	27	-4	31	.	.	.	.	.
Kidney excluding renal pelvis	52	81	58	26	31	30	36	19	2	17
Renal pelvis and ureter	10	13	33	-1	34	7	8	14	-3	17
Bladder and other urinary organs	132	168	27	-5	32	43	51	19	1	17
Eye	3	4	20	-4	25	5	6	15	0	16
Brain, nervous system	51	60	17	-3	20	67	77	15	-1	16
Thyroid gland	8	10	18	-7	25	22	23	2	-9	11
Other endocrine organs	2	2	-7	-8	1	1	1	7	-16	23
Other and unspecified sites	40	53	34	5	29	49	57	16	0	17
Hodgkin lymphoma	9	9	3	-11	14	7	6	-9	-14	5
Non-Hodgkin lymphoma	59	89	50	22	28	53	63	19	1	18
Multiple myeloma	28	38	34	4	30	22	27	20	4	16
Leukemia, acute	17	19	12	-14	26	11	12	12	-4	16
Leukemia, non-acute	27	35	30	-1	31	17	19	13	-1	14
All sites	1739	2307	33	1	31	1516	1946	28	11	17

¹ Modified ICD-7 (ICD-10 conversion table; Table S4 on page S7).² Average annual number of new cases 2000–2004.

Table S17: NORTHERN NORWAY HEALTH REGION. Observed (2000–2004) and predicted (2010) incidence, percent changes from last observed period (ΔT), hereof changes due to risk (ΔR) or population (ΔP), by gender and cancer site.

Cancer sites ¹	Men					Women				
	incidence		changes (%)			incidence		changes (%)		
	2004 ²	2010	ΔT	ΔR	ΔP	2004 ²	2010	ΔT	ΔR	ΔP
Lip	4	5	33	23	10	2	2	14	7	8
Tongue	6	7	8	1	8	4	4	5	-1	6
Floor of mouth	3	3	29	24	6	1	2	21	15	6
Mouth, other	2	2	23	20	3	4	4	9	6	3
Salivary glands	2	2	5	-1	6	2	2	7	1	5
Mesopharynx	6	6	4	-5	8	2	3	9	2	6
Nasopharynx	1	1	14	7	7	1	1	-13	-10	-4
Hypopharynx	3	4	24	12	12	1	1	0	-2	2
Oesophagus	14	15	11	2	10	7	7	-3	-9	6
Stomach	49	43	-12	-21	9	31	26	-16	-21	5
Small intestine	3	3	-2	-9	7	3	3	-9	-19	10
Colon	105	121	15	6	9	112	125	11	7	4
Rectum	57	64	12	2	9	42	46	11	6	5
Liver	10	10	2	-8	10	6	6	2	-3	5
Gallbladder	6	6	8	4	5	6	7	10	6	4
Pancreas	31	33	6	-4	10	35	36	4	3	1
Other digestive organs	1	1	-5	-15	10	5	4	-19	-22	3
Nose, sinuses, etc.	3	3	4	-3	8	1	1	5	9	-4
Larynx	13	15	14	2	12	2	3	15	14	1
Trachea, bronchus and lung	157	165	6	-4	10	89	115	30	24	6
Pleura	4	4	10	1	9	1	1	13	9	4
Mediastinum, thymus and heart	2	2	16	8	8	1	1	-14	-12	-1
Bone	2	2	8	7	1	2	2	2	-3	4
Melanoma of skin	25	26	6	-3	10	28	31	11	8	3
Other skin	34	43	26	17	9	27	35	30	23	7
Connective tissue	8	8	10	4	6	4	5	4	-2	6
Breast	1	1	4	-7	12	253	320	27	19	7
Uterine cervix	.	.	.	.	.	38	38	-1	-2	1
Uterine corpus	.	.	.	.	.	62	66	7	-1	7
Placenta	.	.	.	.	.	0	0	NA	NA	NA
Uterus unspecified	.	.	.	.	.	0	0	-14	-27	13
Ovary, etc.	.	.	.	.	.	49	49	1	-4	6
Other female genital organs	.	.	.	.	.	11	12	12	7	5
Prostate	293	326	11	0	11	.	.	.	.	.
Testis	22	24	12	13	-2	.	.	.	.	.
Other male genital organs	4	4	6	-4	10	.	.	.	.	.
Kidney excluding renal pelvis	36	43	21	11	10	26	28	6	-1	8
Renal pelvis and ureter	7	8	8	-2	10	4	4	-1	-10	9
Bladder and other urinary organs	95	102	8	-1	9	33	36	9	3	6
Eye	5	5	2	-4	6	3	3	4	6	-2
Brain, nervous system	35	37	4	0	5	52	54	4	0	4
Thyroid gland	8	8	4	-1	5	19	18	-4	-7	3
Other endocrine organs	2	2	-14	-24	10	2	2	-2	-4	2
Other and unspecified sites	34	38	12	4	8	39	41	6	1	5
Hodgkin lymphoma	6	5	-4	-12	8	6	5	-12	-14	2
Non-Hodgkin lymphoma	37	44	20	10	10	38	40	5	0	5
Multiple myeloma	18	19	10	1	9	18	18	4	0	4
Leukemia, acute	9	9	-1	-4	2	11	11	3	1	2
Leukemia, non-acute	17	17	4	-5	9	13	13	0	-5	5
All sites	1177	1291	10	0	9	1093	1229	12	7	5

¹ Modified ICD-7 (ICD-10 conversion table; Table S4 on page S7).² Average annual number of new cases 2000–2004.

Table S18: NORTHERN NORWAY HEALTH REGION. Observed (2000–2004) and predicted (2015) incidence, percent changes from last observed period (ΔT), hereof changes due to risk (ΔR) or population (ΔP), by gender and cancer site.

Cancer sites ¹	Men					Women				
	incidence		changes (%)			incidence		changes (%)		
	2004 ²	2015	ΔT	ΔR	ΔP	2004 ²	2015	ΔT	ΔR	ΔP
Lip	4	6	45	23	21	2	2	19	13	6
Tongue	6	7	16	0	16	4	4	9	-1	11
Floor of mouth	3	4	38	28	10	1	2	28	14	14
Mouth, other	2	3	33	23	11	4	4	13	7	6
Salivary glands	2	2	15	4	11	2	2	11	-3	14
Mesopharynx	6	6	9	-2	11	2	3	13	0	13
Nasopharynx	1	1	22	4	18	1	1	-8	-9	0
Hypopharynx	3	5	35	18	17	1	1	6	4	2
Oesophagus	14	17	23	1	22	7	7	2	-10	12
Stomach	49	43	-13	-32	19	31	25	-19	-31	12
Small intestine	3	3	7	-12	18	3	3	-3	-19	16
Colon	105	132	26	5	20	112	133	19	8	10
Rectum	57	70	22	3	19	42	50	20	9	11
Liver	10	11	10	-9	19	6	6	8	-5	13
Gallbladder	6	7	18	7	12	6	7	14	9	5
Pancreas	31	35	15	-7	21	35	38	10	3	6
Other digestive organs	1	1	2	-11	14	5	4	-14	-24	10
Nose, sinuses, etc.	3	3	14	-5	19	1	2	9	8	2
Larynx	13	16	25	2	22	2	3	22	17	5
Trachea, bronchus and lung	157	175	11	-9	20	89	131	47	32	15
Pleura	4	5	21	4	16	1	1	21	7	15
Mediastinum, thymus and heart	2	2	24	13	11	1	1	-10	-12	2
Bone	2	2	9	13	-4	2	2	2	0	2
Melanoma of skin	25	27	9	-7	16	28	32	16	13	4
Other skin	34	49	44	25	18	27	39	46	35	11
Connective tissue	8	9	17	6	10	4	5	7	-2	10
Breast	1	1	11	-10	21	253	360	43	32	11
Uterine cervix	.	.	.	.	.	38	38	-1	-2	1
Uterine corpus	.	.	.	.	.	62	70	13	0	13
Placenta	.	.	.	.	.	0	0	NA	NA	NA
Uterus unspecified	.	.	.	.	.	0	0	-12	-42	30
Ovary, etc.	.	.	.	.	.	49	50	3	-8	11
Other female genital organs	.	.	.	.	.	11	12	17	7	10
Prostate	293	362	23	0	23	.	.	.	.	.
Testis	22	25	16	17	-1	.	.	.	.	.
Other male genital organs	4	5	16	-6	22	.	.	.	.	.
Kidney excluding renal pelvis	36	49	37	19	18	26	29	12	-2	14
Renal pelvis and ureter	7	8	19	-5	23	4	4	5	-10	15
Bladder and other urinary organs	95	110	16	-3	19	33	38	14	2	12
Eye	5	5	9	-4	13	3	3	9	9	0
Brain, nervous system	35	38	9	0	9	52	56	8	0	9
Thyroid gland	8	9	9	-2	11	19	19	-2	-8	6
Other endocrine organs	2	2	-11	-25	14	2	2	1	-6	7
Other and unspecified sites	34	42	22	3	19	39	43	11	2	9
Hodgkin lymphoma	6	6	-1	-12	11	6	5	-10	-18	7
Non-Hodgkin lymphoma	37	50	34	17	17	38	42	11	-1	11
Multiple myeloma	18	21	20	1	19	18	19	10	0	10
Leukemia, acute	9	10	4	-3	7	11	11	6	0	6
Leukemia, non-acute	17	19	12	-7	19	13	14	5	-6	11
All sites	1177	1402	19	0	19	1093	1323	21	11	10

¹ Modified ICD-7 (ICD-10 conversion table; Table S4 on page S7).² Average annual number of new cases 2000–2004.

Table S19: NORTHERN NORWAY HEALTH REGION. Observed (2000–2004) and predicted (2020) incidence, percent changes from last observed period (ΔT), hereof changes due to risk (ΔR) or population (ΔP), by gender and cancer site.

Cancer sites ¹	Men					Women				
	incidence		changes (%)			incidence		changes (%)		
	2004 ²	2020	ΔT	ΔR	ΔP	2004 ²	2020	ΔT	ΔR	ΔP
Lip	4	6	57	24	33	2	2	28	21	7
Tongue	6	8	22	-3	25	4	5	15	-1	16
Floor of mouth	3	4	46	28	18	1	2	36	19	17
Mouth, other	2	3	43	19	24	4	4	20	5	15
Salivary glands	2	2	23	4	19	2	2	16	-3	19
Mesopharynx	6	7	13	2	11	2	3	19	0	19
Nasopharynx	1	1	28	-8	36	1	1	-5	-12	7
Hypopharynx	3	5	45	18	26	1	1	11	0	11
Oesophagus	14	19	35	2	33	7	8	9	-9	18
Stomach	49	45	-9	-42	33	31	26	-17	-37	20
Small intestine	3	3	16	-13	29	3	3	4	-15	19
Colon	105	145	38	3	34	112	142	27	8	19
Rectum	57	77	34	3	31	42	55	31	14	18
Liver	10	12	22	-10	32	6	7	16	-7	23
Gallbladder	6	8	31	4	27	6	7	23	13	10
Pancreas	31	39	26	-8	35	35	41	18	0	17
Other digestive organs	1	2	10	-14	24	5	5	-7	-25	18
Nose, sinuses, etc.	3	4	22	-6	28	1	2	17	0	17
Larynx	13	17	35	5	30	2	3	30	14	16
Trachea, bronchus and lung	157	183	17	-17	34	89	142	60	37	24
Pleura	4	5	34	3	31	1	1	33	-5	38
Mediastinum, thymus and heart	2	3	33	9	24	1	1	-4	-13	8
Bone	2	2	10	14	-4	2	2	3	1	3
Melanoma of skin	25	27	10	-11	21	28	33	20	13	7
Other skin	34	55	62	32	30	27	43	60	44	16
Connective tissue	8	9	24	8	16	4	5	11	-1	12
Breast	1	1	21	-9	30	253	396	57	42	15
Uterine cervix	.	.	.	.	.	38	39	2	0	2
Uterine corpus	.	.	.	.	.	62	74	20	1	19
Placenta	.	.	.	.	.	0	0	NA	NA	NA
Uterus unspecified	.	.	.	.	.	0	0	-8	-37	29
Ovary, etc.	.	.	.	.	.	49	51	5	-12	17
Other female genital organs	.	.	.	.	.	11	13	24	7	17
Prostate	293	400	36	-1	37	.	.	.	.	.
Testis	22	26	19	19	-1	.	.	.	.	.
Other male genital organs	4	5	27	-4	31	.	.	.	.	.
Kidney excluding renal pelvis	36	55	55	27	27	26	31	20	-2	22
Renal pelvis and ureter	7	9	32	-7	39	4	5	14	-6	21
Bladder and other urinary organs	95	120	27	-7	34	33	40	20	-1	21
Eye	5	6	17	-6	23	3	3	15	6	9
Brain, nervous system	35	40	15	0	15	52	58	13	0	13
Thyroid gland	8	9	14	-3	17	19	19	1	-7	8
Other endocrine organs	2	2	-9	-25	16	2	2	4	-9	13
Other and unspecified sites	34	46	35	1	34	39	46	18	2	17
Hodgkin lymphoma	6	6	0	-10	10	6	5	-8	-21	12
Non-Hodgkin lymphoma	37	55	48	23	25	38	45	18	-1	19
Multiple myeloma	18	23	32	0	32	18	21	19	0	19
Leukemia, acute	9	10	11	-2	14	11	12	11	-1	12
Leukemia, non-acute	17	21	23	-9	32	13	15	12	-7	19
All sites	1177	1525	30	-2	31	1093	1421	30	13	17

¹ Modified ICD-7 (ICD-10 conversion table; Table S4 on page S7).² Average annual number of new cases 2000–2004.

Table S20: NORWAY – ALL HEALTH REGIONS. Observed (2000–2004) and predicted (2010) incidence, percent changes from last observed period (ΔT), hereof changes due to risk (ΔR) or population (ΔP), by gender and cancer site.

Cancer sites ¹	Men					Women				
	incidence		changes (%)			incidence		changes (%)		
	2004 ²	2010	ΔT	ΔR	ΔP	2004 ²	2010	ΔT	ΔR	ΔP
Lip	41	53	31	20	11	15	17	13	7	6
Tongue	50	55	10	-2	13	27	29	6	-1	7
Floor of mouth	25	33	29	18	12	14	17	21	13	8
Mouth, other	29	36	23	11	12	28	31	8	0	8
Salivary glands	20	22	7	-2	9	19	21	7	0	7
Mesopharynx	48	52	8	-5	14	15	16	10	2	8
Nasopharynx	11	13	16	4	12	4	4	-13	-21	7
Hypopharynx	22	28	25	13	12	7	7	0	-8	8
Oesophagus	126	141	12	1	12	54	53	-2	-8	6
Stomach	352	307	-13	-21	9	230	188	-18	-22	4
Small intestine	51	51	0	-13	12	50	46	-8	-14	6
Colon	1059	1216	15	6	9	1207	1347	12	7	5
Rectum	598	662	11	0	10	482	538	12	6	6
Liver	77	81	4	-4	8	44	46	4	-1	4
Gallbladder	60	64	7	-3	9	75	81	8	3	5
Pancreas	291	313	7	-3	10	329	345	5	1	4
Other digestive organs	17	16	-4	-14	10	40	33	-19	-24	5
Nose, sinuses, etc.	24	25	5	-4	10	16	17	7	4	3
Larynx	107	120	13	2	11	18	20	15	9	6
Trachea, bronchus and lung	1347	1427	6	-4	10	834	1077	29	22	7
Pleura	61	68	10	2	9	8	9	15	12	3
Mediastinum, thymus and heart	9	11	16	6	10	8	7	-14	-16	3
Bone	23	25	10	1	9	19	19	3	-5	8
Melanoma of skin	474	515	9	-1	10	538	576	7	1	6
Other skin	602	742	23	14	9	505	618	22	18	4
Connective tissue	75	84	13	5	8	63	66	6	0	6
Breast	15	17	8	-1	9	2664	3275	23	14	9
Uterine cervix	.	.	.	.	.	291	267	-8	-13	5
Uterine corpus	.	.	.	.	.	607	653	8	0	8
Placenta	.	.	.	.	.	2	3	12	18	-6
Uterus unspecified	.	.	.	.	.	14	12	-11	-15	4
Ovary, etc.	.	.	.	.	.	480	491	2	-5	7
Other female genital organs	.	.	.	.	.	100	110	10	5	5
Prostate	3172	3535	11	0	11	.	.	.	.	.
Testis	254	288	13	13	1	.	.	.	.	.
Other male genital organs	38	40	6	-5	11	.	.	.	.	.
Kidney excluding renal pelvis	324	396	22	12	10	196	209	7	2	5
Renal pelvis and ureter	66	73	10	3	7	45	45	0	-4	4
Bladder and other urinary organs	851	916	8	-1	8	307	333	8	4	5
Eye	31	33	4	-4	7	31	32	4	-1	5
Brain, nervous system	367	390	6	-2	8	472	499	6	-1	6
Thyroid gland	51	54	6	-2	8	141	142	1	-4	5
Other endocrine organs	10	9	-13	-18	5	10	10	0	-8	8
Other and unspecified sites	294	326	11	2	9	371	393	6	2	4
Hodgkin lymphoma	64	65	2	-6	7	48	43	-10	-14	3
Non-Hodgkin lymphoma	380	454	19	10	10	341	364	7	1	6
Multiple myeloma	162	179	10	1	10	150	156	4	0	4
Leukemia, acute	122	125	2	-4	6	102	106	4	1	3
Leukemia, non-acute	184	200	9	-1	10	135	136	1	-4	5
All sites	11986	13255	11	1	10	11158	12508	12	6	6

¹ Modified ICD-7 (ICD-10 conversion table; Table S4 on page S7).² Average annual number of new cases 2000–2004.

Table S21: NORWAY – ALL HEALTH REGIONS. Observed (2000–2004) and predicted (2015) incidence, percent changes from last observed period (ΔT), hereof changes due to risk (ΔR) or population (ΔP), by gender and cancer site.

Cancer sites ¹	Men					Women				
	incidence		changes (%)			incidence		changes (%)		
	2004 ²	2015	ΔT	ΔR	ΔP	2004 ²	2015	ΔT	ΔR	ΔP
Lip	41	59	43	20	23	15	17	19	7	11
Tongue	50	59	20	-3	23	27	30	11	-1	12
Floor of mouth	25	36	41	18	23	14	18	30	15	15
Mouth, other	29	40	35	12	24	28	32	14	0	14
Salivary glands	20	24	18	-2	21	19	22	12	0	12
Mesopharynx	48	55	16	-6	22	15	17	16	2	14
Nasopharynx	11	14	26	3	23	4	4	-8	-20	12
Hypopharynx	22	31	38	15	24	7	8	7	-8	15
Oesophagus	126	157	25	1	24	54	56	4	-8	12
Stomach	352	305	-13	-32	19	230	180	-22	-31	10
Small intestine	51	56	10	-15	25	50	49	-1	-16	15
Colon	1059	1338	26	6	20	1207	1441	19	9	11
Rectum	598	726	21	0	21	482	588	22	10	12
Liver	77	88	14	-4	18	44	49	11	-1	11
Gallbladder	60	70	17	-2	19	75	85	13	4	9
Pancreas	291	343	18	-3	20	329	362	10	0	10
Other digestive organs	17	18	5	-15	19	40	35	-12	-26	14
Nose, sinuses, etc.	24	28	16	-5	21	16	18	12	3	9
Larynx	107	133	25	1	24	18	22	24	9	14
Trachea, bronchus and lung	1347	1520	13	-9	22	834	1228	47	30	17
Pleura	61	75	22	2	19	8	10	25	14	10
Mediastinum, thymus and heart	9	12	26	8	18	8	7	-9	-17	8
Bone	23	26	14	0	13	19	19	4	-5	9
Melanoma of skin	474	537	13	-5	18	538	594	10	-1	12
Other skin	602	837	39	22	17	505	680	35	27	8
Connective tissue	75	90	20	5	15	63	69	10	-1	11
Breast	15	18	15	-3	18	2664	3687	38	23	16
Uterine cervix	.	.	.	.	.	291	259	-11	-19	8
Uterine corpus	.	.	.	.	.	607	701	15	0	16
Placenta	.	.	.	.	.	2	3	15	20	-6
Uterus unspecified	.	.	.	.	.	14	13	-9	-16	8
Ovary, etc.	.	.	.	.	.	480	505	5	-9	14
Other female genital organs	.	.	.	.	.	100	115	15	5	10
Prostate	3172	3946	24	0	24	.	.	.	.	.
Testis	254	304	20	17	3	.	.	.	.	.
Other male genital organs	38	44	17	-5	23	.	.	.	.	.
Kidney excluding renal pelvis	324	455	41	20	20	196	223	14	2	11
Renal pelvis and ureter	66	81	22	3	20	45	48	7	-5	12
Bladder and other urinary organs	851	990	16	-3	19	307	352	14	4	11
Eye	31	35	12	-4	16	31	34	10	0	10
Brain, nervous system	367	414	13	-2	15	472	527	12	-1	13
Thyroid gland	51	58	13	-3	15	141	148	5	-5	10
Other endocrine organs	10	9	-9	-18	9	10	10	4	-8	12
Other and unspecified sites	294	354	21	2	19	371	410	10	2	9
Hodgkin lymphoma	64	68	7	-7	13	48	44	-8	-14	6
Non-Hodgkin lymphoma	380	512	35	15	19	341	386	13	1	13
Multiple myeloma	162	198	22	1	21	150	167	11	0	11
Leukemia, acute	122	134	9	-5	14	102	110	8	1	7
Leukemia, non-acute	184	219	19	-1	20	135	144	7	-4	10
All sites	11986	14514	21	1	20	11158	13526	21	9	13

¹ Modified ICD-7 (ICD-10 conversion table; Table S4 on page S7).² Average annual number of new cases 2000–2004.

Table S22: NORWAY – ALL HEALTH REGIONS. Observed (2000–2004) and predicted (2020) incidence, percent changes from last observed period (ΔT), hereof changes due to risk (ΔR) or population (ΔP), by gender and cancer site.

Cancer sites ¹	Men					Women				
	incidence		changes (%)			incidence		changes (%)		
	2004 ²	2020	ΔT	ΔR	ΔP	2004 ²	2020	ΔT	ΔR	ΔP
Lip	41	64	58	23	35	15	19	28	8	20
Tongue	50	64	28	-3	32	27	32	18	-2	20
Floor of mouth	25	38	51	18	33	14	19	39	16	23
Mouth, other	29	43	48	12	36	28	34	22	0	22
Salivary glands	20	26	29	-4	33	19	23	19	1	18
Mesopharynx	48	59	23	-7	31	15	18	24	2	22
Nasopharynx	11	15	35	2	33	4	4	-3	-25	23
Hypopharynx	22	34	51	14	36	7	8	13	-11	24
Oesophagus	126	174	38	1	37	54	60	12	-8	20
Stomach	352	323	-8	-42	34	230	185	-19	-38	18
Small intestine	51	62	21	-15	36	50	54	7	-17	25
Colon	1059	1478	40	5	34	1207	1557	29	9	20
Rectum	598	803	34	0	34	482	650	35	14	21
Liver	77	98	27	-4	31	44	53	20	-2	21
Gallbladder	60	78	31	-1	32	75	92	23	4	18
Pancreas	291	384	32	-2	34	329	391	19	0	19
Other digestive organs	17	19	14	-17	32	40	39	-3	-29	25
Nose, sinuses, etc.	24	31	27	-6	33	16	20	22	1	21
Larynx	107	147	37	1	36	18	24	33	9	24
Trachea, bronchus and lung	1347	1618	20	-17	37	834	1353	62	34	28
Pleura	61	84	37	2	35	8	11	39	14	24
Mediastinum, thymus and heart	9	13	37	7	30	8	8	-2	-19	17
Bone	23	26	17	0	17	19	20	8	-4	12
Melanoma of skin	474	551	16	-12	28	538	606	13	-5	18
Other skin	602	946	57	26	31	505	745	48	32	16
Connective tissue	75	97	30	4	26	63	72	15	-1	16
Breast	15	20	27	-2	30	2664	4075	53	31	22
Uterine cervix	.	.	.	.	.	291	259	-11	-23	12
Uterine corpus	.	.	.	.	.	607	754	24	0	25
Placenta	.	.	.	.	.	2	3	20	21	-1
Uterus unspecified	.	.	.	.	.	14	13	-4	-19	15
Ovary, etc.	.	.	.	.	.	480	522	9	-13	22
Other female genital organs	.	.	.	.	.	100	123	23	6	17
Prostate	3172	4421	39	1	38	.	.	.	.	.
Testis	254	316	24	19	6	.	.	.	.	.
Other male genital organs	38	49	30	-6	36	.	.	.	.	.
Kidney excluding renal pelvis	324	522	61	29	32	196	241	23	2	21
Renal pelvis and ureter	66	92	39	2	37	45	53	17	-5	22
Bladder and other urinary organs	851	1091	28	-6	34	307	374	22	2	20
Eye	31	38	22	-5	27	31	37	18	1	18
Brain, nervous system	367	443	20	-3	23	472	557	18	-1	20
Thyroid gland	51	61	20	-3	23	141	155	9	-6	15
Other endocrine organs	10	10	-5	-18	13	10	11	9	-8	17
Other and unspecified sites	294	396	35	2	33	371	440	18	2	17
Hodgkin lymphoma	64	70	10	-7	17	48	46	-4	-15	11
Non-Hodgkin lymphoma	380	572	50	20	30	341	418	22	0	22
Multiple myeloma	162	220	36	1	35	150	183	22	0	22
Leukemia, acute	122	144	18	-5	24	102	117	14	0	14
Leukemia, non-acute	184	243	32	-1	33	135	155	15	-4	19
All sites	11986	15983	33	0	34	11158	14634	31	11	21

¹ Modified ICD-7 (ICD-10 conversion table; Table S4 on page S7).² Average annual number of new cases 2000–2004.

Table S23a: Lip, men.

Annual observed and predicted number of new cases by period, age and region.

		2000–2004	2010	2015	2020
Eastern	0–54	1	2	2	2
	55–74	4	7	8	9
	≥ 75	5	4	4	5
	Total	10	13	14	16
Southern	0–54	2	2	2	2
	55–74	5	8	9	10
	≥ 75	4	5	5	6
	Total	11	15	16	18
Western	0–54	1	1	1	1
	55–74	4	5	6	6
	≥ 75	3	3	4	4
	Total	7	10	11	12
Central	0–54	1	1	1	1
	55–74	4	6	7	7
	≥ 75	3	4	4	4
	Total	8	11	12	13
Northern	0–54	1	1	1	1
	55–74	2	3	3	4
	≥ 75	2	2	2	2
	Total	4	5	6	6
Norway	0–54	5	7	7	7
	55–74	19	28	33	36
	≥ 75	17	19	19	22
	Total	41	53	59	64


Table S23b: Lip, women.

Annual observed and predicted number of new cases by period, age and region.

		2000–2004	2010	2015	2020
Eastern	0–54	1	1	1	1
	55–74	2	2	2	2
	≥ 75	2	2	2	2
	Total	4	5	5	6
Southern	0–54	1	1	1	1
	55–74	1	2	2	2
	≥ 75	2	2	2	2
	Total	4	4	5	5
Western	0–54	0	0	0	0
	55–74	1	1	1	1
	≥ 75	1	1	1	1
	Total	2	2	2	3
Central	0–54	0	1	1	1
	55–74	1	1	1	1
	≥ 75	1	1	1	1
	Total	3	3	3	3
Northern	0–54	0	0	0	0
	55–74	0	1	1	1
	≥ 75	1	1	1	1
	Total	2	2	2	2
Norway	0–54	2	3	3	3
	55–74	5	6	7	8
	≥ 75	7	7	7	8
	Total	15	17	17	19

Figure S1a: Lip, men.

Observed and predicted incidence by period and health region. Age-adjusted rates.

**Figure S1b: Lip, women.**

Observed and predicted incidence by period and health region. Age-adjusted rates.





Table S24a: Tongue, men.

Annual observed and predicted number of new cases by period, age and region.

		2000–2004	2010	2015	2020
Eastern	0–54	6	7	7	7
	55–74	13	14	16	17
	≥ 75	2	3	3	3
	Total	21	23	25	27
Southern	0–54	2	2	2	2
	55–74	5	5	6	6
	≥ 75	1	1	1	2
	Total	8	9	10	10
Western	0–54	2	3	3	3
	55–74	6	6	7	8
	≥ 75	2	2	2	2
	Total	10	11	13	14
Central	0–54	2	1	1	1
	55–74	2	3	3	3
	≥ 75	0	1	1	1
	Total	4	4	5	5
Northern	0–54	2	2	2	2
	55–74	4	4	4	5
	≥ 75	1	1	1	1
	Total	6	7	7	8
Norway	0–54	13	15	15	16
	55–74	29	32	36	39
	≥ 75	7	8	8	9
	Total	50	55	59	64

Figure S2a: Tongue, men.

Observed and predicted incidence by period and health region. Age-adjusted rates.

**Table S24b: Tongue, women.**

Annual observed and predicted number of new cases by period, age and region.

		2000–2004	2010	2015	2020
Eastern	0–54	1	2	2	2
	55–74	5	5	6	6
	≥ 75	4	3	3	4
	Total	10	11	12	12
Southern	0–54	0	1	1	1
	55–74	2	2	2	2
	≥ 75	1	1	1	1
	Total	4	4	4	4
Western	0–54	1	1	1	1
	55–74	2	2	3	3
	≥ 75	2	2	2	2
	Total	5	5	5	6
Central	0–54	1	1	1	1
	55–74	2	2	2	3
	≥ 75	2	2	2	2
	Total	4	5	5	5
Northern	0–54	1	1	1	1
	55–74	2	2	2	2
	≥ 75	1	1	1	1
	Total	4	4	4	5
Norway	0–54	5	6	6	6
	55–74	12	13	15	16
	≥ 75	10	9	9	10
	Total	27	29	30	32

Figure S2b: Tongue, women.

Observed and predicted incidence by period and health region. Age-adjusted rates.




Table S25a: Floor of mouth, men.

Annual observed and predicted number of new cases by period, age and region.

		2000–2004	2010	2015	2020
Eastern	0–54	2	3	3	3
	55–74	5	7	8	8
	≥ 75	1	2	2	2
	Total	9	11	12	13
Southern	0–54	1	2	2	2
	55–74	4	5	5	6
	≥ 75	0	1	1	1
	Total	6	8	9	9
Western	0–54	1	1	1	1
	55–74	2	3	4	4
	≥ 75	1	1	1	1
	Total	4	5	6	6
Central	0–54	1	1	1	1
	55–74	2	3	3	4
	≥ 75	1	1	1	1
	Total	4	5	5	6
Northern	0–54	1	1	1	1
	55–74	1	2	2	2
	≥ 75	1	0	1	1
	Total	3	3	4	4
Norway	0–54	7	8	8	8
	55–74	15	20	22	24
	≥ 75	4	5	5	6
	Total	25	33	36	38


Table S25b: Floor of mouth, women.

Annual observed and predicted number of new cases by period, age and region.

		2000–2004	2010	2015	2020
Eastern	0–54	0	1	1	1
	55–74	3	4	5	5
	≥ 75	3	2	2	2
	Total	6	7	8	8
Southern	0–54	0	0	0	0
	55–74	1	2	2	2
	≥ 75	0	1	1	1
	Total	2	3	3	3
Western	0–54	0	0	0	0
	55–74	2	2	2	2
	≥ 75	1	1	1	1
	Total	3	3	3	4
Central	0–54	0	0	0	0
	55–74	1	1	1	1
	≥ 75	1	1	1	1
	Total	2	2	2	2
Northern	0–54	0	0	0	0
	55–74	1	1	1	1
	≥ 75	1	1	1	1
	Total	1	2	2	2
Norway	0–54	1	2	2	2
	55–74	7	9	11	12
	≥ 75	6	5	5	6
	Total	14	17	18	19

Figure S3a: Floor of mouth, men.

Observed and predicted incidence by period and health region. Age-adjusted rates.

**Figure S3b: Floor of mouth, women.**

Observed and predicted incidence by period and health region. Age-adjusted rates.





Table S26a: Other parts of mouth, men.

Annual observed and predicted number of new cases by period, age and region.

		2000–2004	2010	2015	2020
Eastern	0–54	2	3	3	3
	55–74	6	9	10	11
	≥ 75	4	3	3	4
	Total	12	15	17	18
Southern	0–54	1	1	1	1
	55–74	2	4	4	5
	≥ 75	1	1	1	2
	Total	5	6	7	7
Western	0–54	1	2	2	2
	55–74	4	5	6	6
	≥ 75	2	2	2	2
	Total	7	9	10	11
Central	0–54	1	1	1	1
	55–74	2	2	2	3
	≥ 75	1	1	1	1
	Total	3	4	4	4
Northern	0–54	1	0	0	0
	55–74	1	1	2	2
	≥ 75	1	1	1	1
	Total	2	2	3	3
Norway	0–54	6	7	7	7
	55–74	16	21	24	26
	≥ 75	8	8	8	9
	Total	29	36	40	43

Figure S4a: Other parts of mouth, men.

Observed and predicted incidence by period and health region. Age-adjusted rates.

**Table S26b: Other parts of mouth, women.**

Annual observed and predicted number of new cases by period, age and region.

		2000–2004	2010	2015	2020
Eastern	0–54	1	2	2	2
	55–74	4	4	4	5
	≥ 75	3	4	4	4
	Total	9	10	10	11
Southern	0–54	1	1	1	1
	55–74	3	2	3	3
	≥ 75	2	2	2	3
	Total	5	6	6	7
Western	0–54	1	1	1	1
	55–74	2	3	3	3
	≥ 75	3	3	3	3
	Total	6	7	7	8
Central	0–54	0	1	1	1
	55–74	1	2	2	2
	≥ 75	3	2	2	2
	Total	4	5	5	5
Northern	0–54	1	1	1	1
	55–74	1	2	2	2
	≥ 75	2	2	2	2
	Total	4	4	4	4
Norway	0–54	4	5	5	5
	55–74	12	13	14	16
	≥ 75	13	13	13	14
	Total	28	31	32	34

Figure S4b: Other parts of mouth, women.

Observed and predicted incidence by period and health region. Age-adjusted rates.




Table S27a: Salivary glands, men.

Annual observed and predicted number of new cases by period, age and region.

		2000–2004	2010	2015	2020
Eastern	0–54	2	2	2	2
	55–74	3	4	5	6
	≥ 75	2	2	2	2
	Total	8	9	9	10
Southern	0–54	1	1	1	1
	55–74	2	2	3	3
	≥ 75	1	1	1	1
	Total	4	4	4	5
Western	0–54	1	1	1	1
	55–74	2	2	2	3
	≥ 75	1	1	1	1
	Total	4	4	5	5
Central	0–54	1	1	1	1
	55–74	2	2	2	2
	≥ 75	0	1	1	1
	Total	3	3	4	4
Northern	0–54	1	0	0	0
	55–74	1	1	1	1
	≥ 75	0	0	0	1
	Total	2	2	2	2
Norway	0–54	6	5	5	6
	55–74	10	11	13	15
	≥ 75	5	5	5	6
	Total	20	22	24	26


Table S27b: Salivary glands, women.

Annual observed and predicted number of new cases by period, age and region.

		2000–2004	2010	2015	2020
Eastern	0–54	2	2	2	2
	55–74	3	3	4	4
	≥ 75	2	3	3	3
	Total	8	8	9	9
Southern	0–54	2	2	2	2
	55–74	2	3	3	3
	≥ 75	1	2	2	2
	Total	6	6	6	7
Western	0–54	1	1	1	1
	55–74	1	1	1	2
	≥ 75	1	1	1	1
	Total	3	3	3	3
Central	0–54	0	0	0	0
	55–74	0	1	1	1
	≥ 75	1	0	0	0
	Total	1	1	2	2
Northern	0–54	0	1	1	1
	55–74	1	1	1	1
	≥ 75	1	1	1	1
	Total	2	2	2	2
Norway	0–54	6	6	6	6
	55–74	7	9	10	10
	≥ 75	7	7	7	7
	Total	19	21	22	23

Figure S5a: Salivary glands, men.

Observed and predicted incidence by period and health region. Age-adjusted rates.

**Figure S5b: Salivary glands, women.**

Observed and predicted incidence by period and health region. Age-adjusted rates.





Table S28a: Mesopharynx, men.

Annual observed and predicted number of new cases by period, age and region.

		2000–2004	2010	2015	2020
Eastern	0–54	5	6	6	6
	55–74	11	12	13	14
	≥ 75	2	2	2	2
	Total	18	20	21	23
Southern	0–54	3	3	3	4
	55–74	7	7	8	8
	≥ 75	1	1	1	1
	Total	11	11	12	13
Western	0–54	2	3	3	3
	55–74	5	5	6	6
	≥ 75	1	1	1	1
	Total	8	9	9	10
Central	0–54	1	2	2	2
	55–74	3	4	4	4
	≥ 75	1	1	1	1
	Total	6	6	6	7
Northern	0–54	3	2	2	2
	55–74	3	4	4	4
	≥ 75	0	1	1	1
	Total	6	6	6	7
Norway	0–54	14	15	16	16
	55–74	29	31	34	37
	≥ 75	6	5	5	6
	Total	48	52	55	59

Figure S6a: Mesopharynx, men.

Observed and predicted incidence by period and health region. Age-adjusted rates.

**Table S28b: Mesopharynx, women.**

Annual observed and predicted number of new cases by period, age and region.

		2000–2004	2010	2015	2020
Eastern	0–54	1	2	2	2
	55–74	3	4	4	4
	≥ 75	2	1	1	1
	Total	6	7	7	8
Southern	0–54	0	1	1	1
	55–74	1	1	1	2
	≥ 75	0	0	0	0
	Total	2	2	3	3
Western	0–54	1	1	1	1
	55–74	0	1	2	2
	≥ 75	1	0	0	1
	Total	2	3	3	3
Central	0–54	0	0	0	0
	55–74	1	1	1	1
	≥ 75	0	0	0	0
	Total	2	2	2	2
Northern	0–54	1	1	1	1
	55–74	1	1	2	2
	≥ 75	0	0	0	1
	Total	2	3	3	3
Norway	0–54	4	5	5	5
	55–74	7	9	9	10
	≥ 75	4	3	3	3
	Total	15	16	17	18

Figure S6b: Mesopharynx, women.

Observed and predicted incidence by period and health region. Age-adjusted rates.




Table S29a: Nasopharynx, men.

Annual observed and predicted number of new cases by period, age and region.

		2000–2004	2010	2015	2020
Eastern	0–54	1	1	1	1
	55–74	1	2	2	2
	≥ 75	1	1	1	1
	Total	3	3	4	4
Southern	0–54	0	1	1	1
	55–74	1	1	2	2
	≥ 75	1	0	0	1
	Total	2	3	3	3
Western	0–54	1	1	1	1
	55–74	1	2	2	2
	≥ 75	0	0	0	1
	Total	2	3	3	3
Central	0–54	1	1	1	1
	55–74	1	2	2	2
	≥ 75	0	0	0	1
	Total	2	3	3	3
Northern	0–54	0	0	0	0
	55–74	1	1	1	1
	≥ 75	0	0	0	0
	Total	1	1	1	1
Norway	0–54	3	4	4	4
	55–74	6	7	8	8
	≥ 75	2	2	2	3
	Total	11	13	14	15


Table S29b: Nasopharynx, women.

Annual observed and predicted number of new cases by period, age and region.

		2000–2004	2010	2015	2020
Eastern	0–54	1	0	0	0
	55–74	0	1	1	1
	≥ 75	1	0	0	0
	Total	2	1	1	2
Southern	0–54	0	0	0	0
	55–74	1	0	1	1
	≥ 75	0	0	0	0
	Total	1	1	1	1
Western	0–54	0	0	0	0
	55–74	0	0	0	0
	≥ 75	0	0	0	0
	Total	1	1	1	1
Central	0–54	0	0	0	0
	55–74	0	0	0	0
	≥ 75	0	0	0	0
	Total	0	0	0	0
Northern	0–54	1	0	0	0
	55–74	0	0	0	0
	≥ 75	0	0	0	0
	Total	1	1	1	1
Norway	0–54	1	1	1	1
	55–74	2	2	2	2
	≥ 75	1	1	1	1
	Total	4	4	4	4

Figure S7a: Nasopharynx, men.

Observed and predicted incidence by period and health region. Age-adjusted rates.

**Figure S7b: Nasopharynx, women.**

Observed and predicted incidence by period and health region. Age-adjusted rates.




Table S30a: Hypopharynx, men.

Annual observed and predicted number of new cases by period, age and region.

		2000–2004	2010	2015	2020
Eastern	0–54	1	2	2	2
	55–74	5	8	9	10
	≥ 75	2	2	2	2
	Total	9	11	12	14
Southern	0–54	0	1	1	1
	55–74	3	3	4	4
	≥ 75	1	1	1	1
	Total	4	5	6	6
Western	0–54	1	0	1	1
	55–74	2	2	3	3
	≥ 75	0	1	1	1
	Total	3	4	4	4
Central	0–54	0	1	1	1
	55–74	2	3	3	3
	≥ 75	1	1	1	1
	Total	3	4	4	5
Northern	0–54	0	1	1	1
	55–74	2	3	3	3
	≥ 75	1	1	1	1
	Total	3	4	5	5
Norway	0–54	3	4	4	4
	55–74	15	19	22	24
	≥ 75	5	5	5	6
	Total	22	28	31	34


Table S30b: Hypopharynx, women.

Annual observed and predicted number of new cases by period, age and region.

		2000–2004	2010	2015	2020
Eastern	0–54	1	0	0	0
	55–74	1	2	2	2
	≥ 75	1	1	1	1
	Total	3	3	3	3
Southern	0–54	0	0	0	0
	55–74	1	1	1	1
	≥ 75	0	0	0	1
	Total	2	2	2	2
Western	0–54	0	0	0	0
	55–74	0	0	0	0
	≥ 75	0	0	0	0
	Total	0	0	0	0
Central	0–54	0	0	0	0
	55–74	0	1	1	1
	≥ 75	0	0	0	0
	Total	1	1	1	1
Northern	0–54	0	0	0	0
	55–74	0	1	1	1
	≥ 75	1	0	0	0
	Total	1	1	1	1
Norway	0–54	1	1	1	1
	55–74	3	4	4	5
	≥ 75	2	2	2	2
	Total	7	7	8	8

Figure S8a: Hypopharynx, men.

Observed and predicted incidence by period and health region. Age-adjusted rates.

**Figure S8b: Hypopharynx, women.**

Observed and predicted incidence by period and health region. Age-adjusted rates.




Table S31a: Oesophagus, men.

Annual observed and predicted number of new cases by period, age and region.

		2000–2004	2010	2015	2020
Eastern	0–54	5	7	7	8
	55–74	26	31	37	40
	≥ 75	18	17	17	20
	Total	49	55	61	68
Southern	0–54	5	4	4	4
	55–74	13	18	21	23
	≥ 75	10	10	10	11
	Total	28	31	34	38
Western	0–54	3	3	3	3
	55–74	13	14	17	19
	≥ 75	6	8	8	9
	Total	22	25	28	31
Central	0–54	1	2	2	2
	55–74	7	8	10	11
	≥ 75	5	5	5	5
	Total	13	15	16	18
Northern	0–54	2	2	2	2
	55–74	7	9	11	11
	≥ 75	4	4	5	5
	Total	14	15	17	19
Norway	0–54	16	17	18	18
	55–74	66	80	95	104
	≥ 75	44	44	45	51
	Total	126	141	157	174


Table S31b: Oesophagus, women.

Annual observed and predicted number of new cases by period, age and region.

		2000–2004	2010	2015	2020
Eastern	0–54	1	2	2	2
	55–74	9	8	9	10
	≥ 75	10	11	10	11
	Total	21	21	22	24
Southern	0–54	2	1	1	1
	55–74	4	5	5	6
	≥ 75	6	5	5	5
	Total	11	11	12	13
Western	0–54	1	1	1	1
	55–74	3	4	4	5
	≥ 75	5	4	4	5
	Total	9	9	10	11
Central	0–54	1	1	1	1
	55–74	2	2	2	3
	≥ 75	3	2	2	2
	Total	5	5	5	6
Northern	0–54	1	1	1	1
	55–74	2	3	3	4
	≥ 75	4	3	3	3
	Total	7	7	7	8
Norway	0–54	5	5	6	6
	55–74	21	22	25	27
	≥ 75	28	26	25	27
	Total	54	53	56	60

Figure S9a: Oesophagus, men.

Observed and predicted incidence by period and health region. Age-adjusted rates.

**Figure S9b: Oesophagus, women.**

Observed and predicted incidence by period and health region. Age-adjusted rates.




Table S32a: Stomach, men.

Annual observed and predicted number of new cases by period, age and region.

		2000–2004	2010	2015	2020
Eastern	0–54	7	7	8	7
	55–74	50	46	49	51
	≥ 75	52	43	39	43
	Total	110	96	96	101
Southern	0–54	5	4	3	3
	55–74	25	23	25	26
	≥ 75	27	22	20	22
	Total	57	49	48	51
Western	0–54	7	5	5	5
	55–74	30	31	33	35
	≥ 75	38	30	29	31
	Total	75	66	67	71
Central	0–54	4	4	4	3
	55–74	29	25	26	28
	≥ 75	28	24	22	24
	Total	60	53	52	55
Northern	0–54	4	3	3	3
	55–74	25	22	22	23
	≥ 75	21	18	18	19
	Total	49	43	43	45
Norway	0–54	27	23	23	22
	55–74	159	147	155	162
	≥ 75	165	137	128	139
	Total	352	307	305	323


Table S32b: Stomach, women.

Annual observed and predicted number of new cases by period, age and region.

		2000–2004	2010	2015	2020
Eastern	0–54	9	7	6	6
	55–74	25	20	20	21
	≥ 75	39	31	26	26
	Total	73	57	53	53
Southern	0–54	4	3	3	3
	55–74	15	13	13	14
	≥ 75	21	17	16	16
	Total	40	33	32	33
Western	0–54	7	5	5	4
	55–74	17	16	17	19
	≥ 75	31	25	23	23
	Total	54	45	44	46
Central	0–54	3	3	2	2
	55–74	10	9	10	11
	≥ 75	19	14	13	13
	Total	32	26	25	26
Northern	0–54	2	2	2	2
	55–74	13	10	10	11
	≥ 75	16	14	13	13
	Total	31	26	25	26
Norway	0–54	24	20	19	18
	55–74	80	67	70	76
	≥ 75	126	101	90	91
	Total	230	188	180	185

Figure S10a: Stomach, men.

Observed and predicted incidence by period and health region. Age-adjusted rates.

**Figure S10b: Stomach, women.**

Observed and predicted incidence by period and health region. Age-adjusted rates.




Table S33a: Small intestine, men.

Annual observed and predicted number of new cases by period, age and region.

		2000–2004	2010	2015	2020
Eastern	0–54	3	4	4	4
	55–74	10	11	13	14
	≥ 75	7	5	5	6
	Total	20	20	22	24
Southern	0–54	1	2	2	2
	55–74	6	6	7	7
	≥ 75	3	3	3	3
	Total	10	10	11	12
Western	0–54	2	2	2	2
	55–74	5	5	6	7
	≥ 75	2	3	3	3
	Total	9	9	10	11
Central	0–54	2	2	2	2
	55–74	5	5	6	7
	≥ 75	3	3	3	3
	Total	10	10	10	11
Northern	0–54	1	0	0	0
	55–74	2	2	2	2
	≥ 75	0	1	1	1
	Total	3	3	3	3
Norway	0–54	9	9	9	9
	55–74	27	28	33	36
	≥ 75	15	14	14	17
	Total	51	51	56	62


Table S33b: Small intestine, women.

Annual observed and predicted number of new cases by period, age and region.

		2000–2004	2010	2015	2020
Eastern	0–54	2	3	3	3
	55–74	9	9	10	11
	≥ 75	7	5	5	5
	Total	18	16	18	19
Southern	0–54	2	1	1	1
	55–74	6	5	6	7
	≥ 75	3	3	3	3
	Total	10	10	10	11
Western	0–54	1	1	1	1
	55–74	4	4	5	5
	≥ 75	3	3	3	3
	Total	9	8	9	10
Central	0–54	1	1	1	1
	55–74	5	5	5	6
	≥ 75	3	3	3	3
	Total	10	9	9	10
Northern	0–54	1	0	0	0
	55–74	2	2	2	2
	≥ 75	1	1	1	1
	Total	3	3	3	3
Norway	0–54	7	7	7	7
	55–74	26	25	28	31
	≥ 75	17	14	14	15
	Total	50	46	49	54

Figure S11a: Small intestine, men.

Observed and predicted incidence by period and health region. Age-adjusted rates.

**Figure S11b: Small intestine, women.**

Observed and predicted incidence by period and health region. Age-adjusted rates.





Table S34a: Colon, men.

Annual observed and predicted number of new cases by period, age and region.

		2000–2004	2010	2015	2020
Eastern	0–54	37	34	35	33
	55–74	176	204	236	254
	≥ 75	155	183	192	223
	Total	368	421	462	510
Southern	0–54	18	17	18	17
	55–74	92	114	132	144
	≥ 75	95	104	109	126
	Total	205	235	259	287
Western	0–54	19	19	20	19
	55–74	98	119	139	152
	≥ 75	98	112	120	140
	Total	215	251	279	310
Central	0–54	15	14	13	13
	55–74	74	89	104	112
	≥ 75	76	86	88	102
	Total	165	188	206	226
Northern	0–54	9	9	9	8
	55–74	51	60	69	72
	≥ 75	45	51	55	64
	Total	105	121	132	145
Norway	0–54	98	94	94	89
	55–74	492	586	679	734
	≥ 75	468	536	565	655
	Total	1059	1216	1338	1478

Figure S12a: Colon, men.

Observed and predicted incidence by period and health region. Age-adjusted rates.

**Table S34b: Colon, women.**

Annual observed and predicted number of new cases by period, age and region.

		2000–2004	2010	2015	2020
Eastern	0–54	34	39	42	45
	55–74	162	184	208	224
	≥ 75	211	229	234	254
	Total	408	452	483	522
Southern	0–54	22	22	22	24
	55–74	96	109	122	132
	≥ 75	117	132	137	150
	Total	235	263	282	305
Western	0–54	24	26	27	29
	55–74	93	117	134	147
	≥ 75	149	157	162	176
	Total	266	300	324	352
Central	0–54	15	17	17	18
	55–74	73	83	93	100
	≥ 75	99	108	109	118
	Total	187	207	220	236
Northern	0–54	10	10	10	11
	55–74	45	51	57	60
	≥ 75	57	63	66	71
	Total	112	125	133	142
Norway	0–54	106	114	119	125
	55–74	469	544	614	663
	≥ 75	632	689	708	769
	Total	1207	1347	1441	1557

Figure S12b: Colon, women.

Observed and predicted incidence by period and health region. Age-adjusted rates.





Table S35a: Rectum, men.

Annual observed and predicted number of new cases by period, age and region.

		2000–2004	2010	2015	2020
Eastern	0–54	28	27	28	29
	55–74	94	110	127	141
	≥ 75	75	74	73	79
	Total	197	211	228	249
Southern	0–54	13	13	13	13
	55–74	54	71	83	93
	≥ 75	50	46	48	55
	Total	117	130	144	161
Western	0–54	15	17	16	16
	55–74	68	83	97	109
	≥ 75	52	54	58	66
	Total	135	154	171	191
Central	0–54	7	10	10	10
	55–74	49	56	65	72
	≥ 75	37	38	38	44
	Total	92	103	113	125
Northern	0–54	8	7	6	6
	55–74	29	36	41	44
	≥ 75	20	22	23	27
	Total	57	64	70	77
Norway	0–54	71	74	74	75
	55–74	293	355	413	458
	≥ 75	234	234	239	270
	Total	598	662	726	803

Figure S13a: Rectum, men.

Observed and predicted incidence by period and health region. Age-adjusted rates.

**Table S35b: Rectum, women.**

Annual observed and predicted number of new cases by period, age and region.

		2000–2004	2010	2015	2020
Eastern	0–54	23	29	32	34
	55–74	74	89	104	118
	≥ 75	81	79	79	86
	Total	177	197	215	238
Southern	0–54	13	14	16	16
	55–74	42	48	56	63
	≥ 75	38	41	42	46
	Total	93	104	114	126
Western	0–54	13	17	19	20
	55–74	41	52	62	71
	≥ 75	50	49	50	54
	Total	104	118	130	144
Central	0–54	8	10	11	11
	55–74	28	33	38	43
	≥ 75	30	30	30	33
	Total	66	73	79	87
Northern	0–54	8	7	7	7
	55–74	17	21	24	27
	≥ 75	17	18	19	21
	Total	42	46	50	55
Norway	0–54	64	77	84	88
	55–74	202	243	284	322
	≥ 75	217	218	220	240
	Total	482	538	588	650

Figure S13b: Rectum, women.

Observed and predicted incidence by period and health region. Age-adjusted rates.




Table S36a: Liver, men.

Annual observed and predicted number of new cases by period, age and region.

		2000–2004	2010	2015	2020
Eastern	0–54	4	5	5	5
	55–74	13	15	18	20
	≥ 75	14	13	13	15
	Total	31	33	36	40
Southern	0–54	3	2	2	2
	55–74	5	7	8	9
	≥ 75	6	5	5	6
	Total	13	14	15	17
Western	0–54	1	2	2	2
	55–74	6	7	8	9
	≥ 75	6	5	5	6
	Total	14	14	15	17
Central	0–54	1	1	1	1
	55–74	4	5	6	6
	≥ 75	4	4	4	4
	Total	10	10	11	12
Northern	0–54	1	1	1	1
	55–74	5	5	6	6
	≥ 75	4	3	4	4
	Total	10	10	11	12
Norway	0–54	11	12	12	12
	55–74	33	38	45	50
	≥ 75	33	30	31	36
	Total	77	81	88	98


Table S36b: Liver, women.

Annual observed and predicted number of new cases by period, age and region.

		2000–2004	2010	2015	2020
Eastern	0–54	2	2	2	2
	55–74	7	8	9	10
	≥ 75	8	8	8	8
	Total	17	18	19	21
Southern	0–54	1	1	1	1
	55–74	3	3	3	3
	≥ 75	2	3	3	3
	Total	6	6	7	7
Western	0–54	2	1	1	1
	55–74	2	4	4	5
	≥ 75	5	4	4	5
	Total	9	9	10	11
Central	0–54	0	1	1	1
	55–74	2	3	3	4
	≥ 75	5	3	3	3
	Total	7	7	7	8
Northern	0–54	1	1	1	1
	55–74	3	2	3	3
	≥ 75	2	3	3	3
	Total	6	6	6	7
Norway	0–54	6	6	6	6
	55–74	17	19	22	25
	≥ 75	21	21	21	22
	Total	44	46	49	53

Figure S14a: Liver, men.

Observed and predicted incidence by period and health region. Age-adjusted rates.

**Figure S14b: Liver, women.**

Observed and predicted incidence by period and health region. Age-adjusted rates.




Table S37a: Gallbladder, men.

Annual observed and predicted number of new cases by period, age and region.

		2000–2004	2010	2015	2020
Eastern	0–54	2	2	2	2
	55–74	8	8	10	11
	≥ 75	7	7	7	8
	Total	17	17	19	21
Southern	0–54	3	2	2	2
	55–74	7	8	9	11
	≥ 75	6	7	7	8
	Total	16	17	19	21
Western	0–54	2	2	2	2
	55–74	5	6	8	9
	≥ 75	5	6	6	7
	Total	13	14	15	17
Central	0–54	1	1	1	1
	55–74	3	4	5	5
	≥ 75	4	4	4	4
	Total	8	9	10	11
Northern	0–54	1	1	1	1
	55–74	2	3	4	4
	≥ 75	3	3	3	3
	Total	6	6	7	8
Norway	0–54	9	7	7	7
	55–74	26	30	35	40
	≥ 75	25	27	27	31
	Total	60	64	70	78


Table S37b: Gallbladder, women.

Annual observed and predicted number of new cases by period, age and region.

		2000–2004	2010	2015	2020
Eastern	0–54	3	3	3	3
	55–74	12	13	14	16
	≥ 75	15	16	16	17
	Total	30	31	33	36
Southern	0–54	1	1	1	1
	55–74	5	6	7	7
	≥ 75	8	8	8	8
	Total	13	15	15	17
Western	0–54	1	2	2	2
	55–74	6	7	8	9
	≥ 75	9	9	9	10
	Total	16	18	19	21
Central	0–54	0	1	1	1
	55–74	3	4	4	5
	≥ 75	6	5	5	6
	Total	9	10	11	11
Northern	0–54	1	1	1	1
	55–74	1	3	3	3
	≥ 75	4	3	3	4
	Total	6	7	7	7
Norway	0–54	7	7	8	8
	55–74	26	32	36	40
	≥ 75	42	42	41	44
	Total	75	81	85	92

Figure S15a: Gallbladder, men.

Observed and predicted incidence by period and health region. Age-adjusted rates.

**Figure S15b: Gallbladder, women.**

Observed and predicted incidence by period and health region. Age-adjusted rates.




Table S38a: Pancreas, men.

Annual observed and predicted number of new cases by period, age and region.

		2000–2004	2010	2015	2020
Eastern	0–54	12	11	11	11
	55–74	47	58	68	76
	≥ 75	44	40	39	44
	Total	102	108	118	131
Southern	0–54	6	5	5	6
	55–74	26	33	39	43
	≥ 75	25	22	22	25
	Total	57	61	66	74
Western	0–54	6	6	6	6
	55–74	27	34	41	47
	≥ 75	23	23	24	28
	Total	55	63	71	81
Central	0–54	6	4	4	4
	55–74	20	25	30	34
	≥ 75	20	19	18	21
	Total	46	49	53	59
Northern	0–54	3	3	3	3
	55–74	16	18	21	23
	≥ 75	11	11	12	13
	Total	31	33	35	39
Norway	0–54	32	30	30	30
	55–74	136	168	198	223
	≥ 75	123	115	115	132
	Total	291	313	343	384


Table S38b: Pancreas, women.

Annual observed and predicted number of new cases by period, age and region.

		2000–2004	2010	2015	2020
Eastern	0–54	10	10	10	10
	55–74	44	51	58	64
	≥ 75	68	67	65	69
	Total	122	127	133	144
Southern	0–54	4	5	5	5
	55–74	23	27	31	34
	≥ 75	36	35	34	37
	Total	63	66	70	75
Western	0–54	5	5	5	5
	55–74	21	25	29	32
	≥ 75	35	35	34	36
	Total	60	64	68	73
Central	0–54	4	4	4	4
	55–74	18	20	23	25
	≥ 75	28	28	27	28
	Total	49	52	54	57
Northern	0–54	2	2	3	3
	55–74	14	15	17	18
	≥ 75	19	19	19	20
	Total	35	36	38	41
Norway	0–54	24	25	26	26
	55–74	119	137	158	174
	≥ 75	186	183	179	191
	Total	329	345	362	391

Figure S16a: Pancreas, men.

Observed and predicted incidence by period and health region. Age-adjusted rates.

**Figure S16b: Pancreas, women.**

Observed and predicted incidence by period and health region. Age-adjusted rates.





Table S39a: Other digestive organs, men.

Annual observed and predicted number of new cases by period, age and region.

		2000–2004	2010	2015	2020
Eastern	0–54	2	2	2	2
	55–74	2	3	3	4
	≥ 75	2	2	2	2
	Total	6	6	6	7
Southern	0–54	1	1	1	1
	55–74	2	2	2	2
	≥ 75	1	1	1	1
	Total	4	4	4	4
Western	0–54	2	1	1	1
	55–74	1	2	2	2
	≥ 75	1	1	1	1
	Total	4	3	4	4
Central	0–54	0	1	1	1
	55–74	1	1	1	1
	≥ 75	1	1	1	1
	Total	2	2	2	2
Northern	0–54	0	0	0	0
	55–74	1	1	1	1
	≥ 75	0	0	0	0
	Total	1	1	1	2
Norway	0–54	4	4	4	4
	55–74	7	8	9	10
	≥ 75	6	4	4	5
	Total	17	16	18	19

Figure S17a: Other digestive organs, men.

Observed and predicted incidence by period and health region. Age-adjusted rates.

**Table S39b: Other digestive organs, women.**

Annual observed and predicted number of new cases by period, age and region.

		2000–2004	2010	2015	2020
Eastern	0–54	3	3	3	3
	55–74	6	6	7	7
	≥ 75	5	3	3	3
	Total	14	11	12	13
Southern	0–54	1	1	1	1
	55–74	3	3	3	4
	≥ 75	2	1	1	1
	Total	7	5	6	6
Western	0–54	1	1	1	1
	55–74	3	2	2	3
	≥ 75	1	1	1	1
	Total	5	4	4	5
Central	0–54	2	2	2	2
	55–74	5	4	5	5
	≥ 75	2	2	2	2
	Total	10	8	9	9
Northern	0–54	2	1	1	1
	55–74	2	2	2	3
	≥ 75	1	1	1	1
	Total	5	4	4	5
Norway	0–54	9	7	7	8
	55–74	20	17	20	22
	≥ 75	12	8	8	9
	Total	40	33	35	39

Figure S17b: Other digestive organs, women.

Observed and predicted incidence by period and health region. Age-adjusted rates.





Table S40a: Nose, sinuses, etc, men.

Annual observed and predicted number of new cases by period, age and region.

		2000–2004	2010	2015	2020
Eastern	0–54	2	2	2	2
	55–74	4	5	5	6
	≥ 75	2	2	2	2
	Total	8	9	9	10
Southern	0–54	2	1	1	1
	55–74	3	3	3	3
	≥ 75	0	1	1	1
	Total	5	5	5	6
Western	0–54	1	1	1	1
	55–74	3	3	4	4
	≥ 75	1	1	1	2
	Total	5	6	6	7
Central	0–54	1	1	1	1
	55–74	1	2	2	2
	≥ 75	1	1	1	1
	Total	3	3	3	4
Northern	0–54	0	1	1	1
	55–74	1	2	2	2
	≥ 75	1	1	1	1
	Total	3	3	3	4
Norway	0–54	6	6	6	6
	55–74	13	14	16	18
	≥ 75	6	6	6	7
	Total	24	25	28	31

Figure S18a: Nose, sinuses, etc, men.

Observed and predicted incidence by period and health region. Age-adjusted rates.

**Table S40b: Nose, sinuses, etc, women.**

Annual observed and predicted number of new cases by period, age and region.

		2000–2004	2010	2015	2020
Eastern	0–54	2	2	2	2
	55–74	2	3	3	4
	≥ 75	4	3	3	4
	Total	8	9	9	10
Southern	0–54	1	1	1	1
	55–74	1	1	1	1
	≥ 75	1	1	1	1
	Total	3	3	3	3
Western	0–54	1	1	1	1
	55–74	1	1	1	1
	≥ 75	1	1	1	1
	Total	3	3	3	3
Central	0–54	0	0	0	0
	55–74	1	1	1	1
	≥ 75	1	1	1	1
	Total	2	2	2	2
Northern	0–54	0	0	0	0
	55–74	1	1	1	1
	≥ 75	1	1	1	1
	Total	1	1	2	2
Norway	0–54	4	4	4	5
	55–74	5	6	7	8
	≥ 75	7	7	7	7
	Total	16	17	18	20

Figure S18b: Nose, sinuses, etc, women.

Observed and predicted incidence by period and health region. Age-adjusted rates.





Table S41a: Larynx, men.

Annual observed and predicted number of new cases by period, age and region.

		2000–2004	2010	2015	2020
Eastern	0–54	5	6	6	7
	55–74	22	25	30	32
	≥ 75	11	10	10	12
	Total	37	42	46	51
Southern	0–54	4	4	4	4
	55–74	14	17	19	21
	≥ 75	6	7	7	8
	Total	24	27	30	33
Western	0–54	2	3	3	3
	55–74	10	11	13	15
	≥ 75	5	5	5	6
	Total	17	19	21	24
Central	0–54	2	2	2	2
	55–74	8	11	13	14
	≥ 75	5	4	4	5
	Total	15	18	19	21
Northern	0–54	3	2	2	2
	55–74	7	9	10	11
	≥ 75	3	3	4	4
	Total	13	15	16	17
Norway	0–54	16	17	18	18
	55–74	61	74	86	93
	≥ 75	30	30	30	35
	Total	107	120	133	147

Figure S19a: Larynx, men.

Observed and predicted incidence by period and health region. Age-adjusted rates.

**Table S41b: Larynx, women.**

Annual observed and predicted number of new cases by period, age and region.

		2000–2004	2010	2015	2020
Eastern	0–54	1	1	1	1
	55–74	3	4	5	5
	≥ 75	2	2	2	2
	Total	6	7	8	9
Southern	0–54	0	1	1	1
	55–74	2	3	3	4
	≥ 75	2	1	1	1
	Total	4	5	5	6
Western	0–54	1	0	0	0
	55–74	1	1	2	2
	≥ 75	0	1	1	1
	Total	2	2	3	3
Central	0–54	0	0	0	0
	55–74	2	2	2	2
	≥ 75	1	1	1	1
	Total	3	3	3	3
Northern	0–54	0	0	0	0
	55–74	1	2	2	2
	≥ 75	1	1	1	1
	Total	2	3	3	3
Norway	0–54	3	3	3	3
	55–74	9	12	14	15
	≥ 75	6	5	5	6
	Total	18	20	22	24

Figure S19b: Larynx, women.

Observed and predicted incidence by period and health region. Age-adjusted rates.





Table S42a: Trachea, bronchus, lung, men.

Annual observed and predicted number of new cases by period, age and region.

		2000–2004	2010	2015	2020
Eastern	0–54	40	33	30	30
	55–74	248	274	305	316
	≥ 75	164	152	146	163
	Total	452	459	482	508
Southern	0–54	28	26	25	26
	55–74	160	180	202	213
	≥ 75	104	102	102	113
	Total	292	308	329	352
Western	0–54	23	25	26	27
	55–74	147	170	190	199
	≥ 75	95	100	103	116
	Total	264	295	319	343
Central	0–54	17	16	17	17
	55–74	97	114	130	136
	≥ 75	68	69	69	79
	Total	182	199	216	231
Northern	0–54	15	13	13	13
	55–74	85	98	108	110
	≥ 75	56	54	54	60
	Total	157	165	175	183
Norway	0–54	123	113	111	112
	55–74	736	837	935	974
	≥ 75	488	477	473	531
	Total	1347	1427	1520	1618

Figure S20a: Trachea, bronchus, lung, men.

Observed and predicted incidence by period and health region. Age-adjusted rates.

**Table S42b: Trachea, bronchus, lung, women.**

Annual observed and predicted number of new cases by period, age and region.

		2000–2004	2010	2015	2020
Eastern	0–54	36	41	46	50
	55–74	179	227	263	280
	≥ 75	95	120	131	154
	Total	311	388	439	484
Southern	0–54	29	28	29	31
	55–74	102	146	172	183
	≥ 75	60	77	87	104
	Total	190	250	288	318
Western	0–54	19	21	23	25
	55–74	79	106	125	134
	≥ 75	41	58	66	78
	Total	139	185	214	237
Central	0–54	15	15	16	17
	55–74	61	79	93	98
	≥ 75	29	43	48	57
	Total	106	138	157	172
Northern	0–54	12	12	13	14
	55–74	52	67	77	81
	≥ 75	24	35	40	48
	Total	89	115	131	142
Norway	0–54	112	117	127	137
	55–74	473	625	730	776
	≥ 75	250	334	371	441
	Total	834	1077	1228	1353

Figure S20b: Trachea, bronchus, lung, women.

Observed and predicted incidence by period and health region. Age-adjusted rates.





Table S43a: Pleura, men.

Annual observed and predicted number of new cases by period, age and region.

		2000–2004	2010	2015	2020
Eastern	0–54	2	2	2	2
	55–74	11	14	17	18
	≥ 75	11	10	10	12
	Total	24	26	29	33
Southern	0–54	1	1	1	1
	55–74	10	11	13	14
	≥ 75	7	7	8	9
	Total	18	20	22	25
Western	0–54	1	1	1	1
	55–74	5	6	7	8
	≥ 75	3	3	4	4
	Total	9	10	11	13
Central	0–54	0	0	0	0
	55–74	3	4	5	5
	≥ 75	4	2	2	3
	Total	6	7	7	8
Northern	0–54	0	0	0	0
	55–74	2	3	3	3
	≥ 75	1	1	1	2
	Total	4	4	5	5
Norway	0–54	4	5	5	5
	55–74	31	39	45	49
	≥ 75	26	25	25	30
	Total	61	68	75	84

Figure S21a: Pleura, men.

Observed and predicted incidence by period and health region. Age-adjusted rates.

**Table S43b: Pleura, women.**

Annual observed and predicted number of new cases by period, age and region.

		2000–2004	2010	2015	2020
Eastern	0–54	0	0	0	0
	55–74	1	2	2	2
	≥ 75	2	2	2	2
	Total	3	4	4	4
Southern	0–54	0	0	0	0
	55–74	1	1	2	2
	≥ 75	1	1	1	1
	Total	3	3	3	4
Western	0–54	0	0	0	0
	55–74	0	0	0	0
	≥ 75	0	0	0	0
	Total	0	0	1	1
Central	0–54	0	0	0	0
	55–74	0	0	0	0
	≥ 75	0	0	0	0
	Total	1	1	1	1
Northern	0–54	0	0	0	0
	55–74	1	1	1	1
	≥ 75	0	0	0	1
	Total	1	1	1	1
Norway	0–54	1	1	1	1
	55–74	3	4	5	5
	≥ 75	4	4	4	4
	Total	8	9	10	11

Figure S21b: Pleura, women.

Observed and predicted incidence by period and health region. Age-adjusted rates.




Table S44a: Mediastium, thymus, heart, men.

Annual observed and predicted number of new cases by period, age and region.

		2000–2004	2010	2015	2020
Eastern	0–54	1	1	1	1
	55–74	1	2	3	3
	≥ 75	1	1	1	1
	Total	4	4	5	5
Southern	0–54	0	0	0	0
	55–74	1	1	1	1
	≥ 75	0	0	0	0
	Total	1	2	2	2
Western	0–54	1	1	1	1
	55–74	1	1	1	1
	≥ 75	0	0	0	1
	Total	2	2	2	3
Central	0–54	0	0	0	0
	55–74	0	0	0	0
	≥ 75	0	0	0	0
	Total	0	0	1	1
Northern	0–54	0	1	1	1
	55–74	1	1	1	2
	≥ 75	1	0	0	1
	Total	2	2	2	3
Norway	0–54	3	3	3	3
	55–74	4	6	7	7
	≥ 75	3	2	2	3
	Total	9	11	12	13


Table S44b: Mediastium, thymus, heart, women.

Annual observed and predicted number of new cases by period, age and region.

		2000–2004	2010	2015	2020
Eastern	0–54	1	1	1	1
	55–74	1	1	1	1
	≥ 75	1	1	1	1
	Total	4	3	3	4
Southern	0–54	0	0	0	0
	55–74	1	0	1	1
	≥ 75	0	0	0	1
	Total	1	1	1	1
Western	0–54	0	0	0	0
	55–74	0	0	0	1
	≥ 75	1	0	0	0
	Total	1	1	1	1
Central	0–54	0	0	0	0
	55–74	0	0	0	0
	≥ 75	1	0	0	0
	Total	1	1	1	1
Northern	0–54	0	0	0	0
	55–74	0	0	0	0
	≥ 75	0	0	0	0
	Total	1	1	1	1
Norway	0–54	1	1	1	1
	55–74	3	3	3	3
	≥ 75	4	3	3	3
	Total	8	7	7	8

Figure S22a: Mediastium, thymus, heart, men.

Observed and predicted incidence by period and health region. Age-adjusted rates.

**Figure S22b: Mediastium, thymus, heart, women.**

Observed and predicted incidence by period and health region. Age-adjusted rates.




Table S45a: Bone, men.

Annual observed and predicted number of new cases by period, age and region.

		2000–2004	2010	2015	2020
Eastern	0–54	6	7	7	7
	55–74	2	3	3	3
	≥ 75	1	1	1	1
	Total	10	11	11	12
Southern	0–54	2	2	2	2
	55–74	1	1	1	1
	≥ 75	0	0	0	0
	Total	3	3	3	4
Western	0–54	4	3	3	3
	55–74	1	1	1	1
	≥ 75	0	0	0	0
	Total	4	5	5	5
Central	0–54	2	3	3	2
	55–74	1	1	1	1
	≥ 75	1	0	0	0
	Total	4	4	4	4
Northern	0–54	1	1	1	1
	55–74	0	1	1	1
	≥ 75	0	0	0	0
	Total	2	2	2	2
Norway	0–54	15	17	17	17
	55–74	4	6	7	8
	≥ 75	3	2	2	2
	Total	23	25	26	26


Table S45b: Bone, women.

Annual observed and predicted number of new cases by period, age and region.

		2000–2004	2010	2015	2020
Eastern	0–54	2	3	3	3
	55–74	1	1	1	1
	≥ 75	1	1	1	1
	Total	4	5	5	5
Southern	0–54	3	3	3	3
	55–74	2	1	2	2
	≥ 75	1	1	1	1
	Total	6	6	6	6
Western	0–54	3	3	3	3
	55–74	1	1	1	1
	≥ 75	0	1	1	1
	Total	4	4	4	4
Central	0–54	2	1	1	1
	55–74	0	1	1	1
	≥ 75	0	0	0	0
	Total	2	2	2	3
Northern	0–54	1	1	1	1
	55–74	0	1	1	1
	≥ 75	0	0	0	0
	Total	2	2	2	2
Norway	0–54	12	12	12	11
	55–74	4	5	5	5
	≥ 75	3	3	3	3
	Total	19	19	19	20

Figure S23a: Bone, men.

Observed and predicted incidence by period and health region. Age-adjusted rates.

**Figure S23b: Bone, women.**

Observed and predicted incidence by period and health region. Age-adjusted rates.





Table S46a: Melanoma of skin, men.

Annual observed and predicted number of new cases by period, age and region.

		2000–2004	2010	2015	2020
Eastern	0–54	55	50	45	40
	55–74	81	87	92	90
	≥ 75	44	48	50	58
	Total	181	184	187	188
Southern	0–54	35	32	30	27
	55–74	50	59	64	65
	≥ 75	25	31	34	41
	Total	109	121	128	133
Western	0–54	29	29	27	25
	55–74	41	50	55	55
	≥ 75	24	28	31	37
	Total	95	107	113	117
Central	0–54	22	18	18	18
	55–74	29	40	44	42
	≥ 75	13	18	20	25
	Total	65	76	82	86
Northern	0–54	9	7	7	7
	55–74	12	13	13	12
	≥ 75	4	6	7	8
	Total	25	26	27	27
Norway	0–54	151	136	128	118
	55–74	213	248	268	265
	≥ 75	110	130	141	168
	Total	474	515	537	551

Figure S24a: Melanoma of skin, men.

Observed and predicted incidence by period and health region. Age-adjusted rates.

**Table S46b: Melanoma of skin, women.**

Annual observed and predicted number of new cases by period, age and region.

		2000–2004	2010	2015	2020
Eastern	0–54	78	81	78	74
	55–74	70	83	90	94
	≥ 75	56	56	58	65
	Total	204	219	227	233
Southern	0–54	45	43	42	40
	55–74	47	48	50	48
	≥ 75	27	31	32	35
	Total	119	122	123	122
Western	0–54	46	46	44	42
	55–74	42	47	52	54
	≥ 75	28	32	35	39
	Total	115	126	131	135
Central	0–54	33	28	26	24
	55–74	25	30	33	34
	≥ 75	15	20	22	25
	Total	73	79	81	82
Northern	0–54	13	12	12	12
	55–74	9	11	12	12
	≥ 75	5	7	8	9
	Total	28	31	32	33
Norway	0–54	216	211	202	191
	55–74	192	219	237	243
	≥ 75	130	146	154	173
	Total	538	576	594	606

Figure S24b: Melanoma of skin, women.

Observed and predicted incidence by period and health region. Age-adjusted rates.




Table S47a: Other skin, men.

Annual observed and predicted number of new cases by period, age and region.

		2000–2004	2010	2015	2020
Eastern	0–54	11	14	16	18
	55–74	69	94	112	125
	≥ 75	129	148	160	180
	Total	210	257	288	322
Southern	0–54	9	11	13	14
	55–74	69	81	95	107
	≥ 75	90	118	132	151
	Total	168	210	239	271
Western	0–54	5	7	7	7
	55–74	44	56	67	78
	≥ 75	73	85	92	105
	Total	123	147	166	190
Central	0–54	3	4	5	5
	55–74	21	30	36	41
	≥ 75	43	50	54	61
	Total	67	84	95	107
Northern	0–54	4	2	3	3
	55–74	13	17	20	22
	≥ 75	18	24	27	31
	Total	34	43	49	55
Norway	0–54	33	39	43	46
	55–74	216	278	331	372
	≥ 75	353	425	464	528
	Total	602	742	837	946


Table S47b: Other skin, women.

Annual observed and predicted number of new cases by period, age and region.

		2000–2004	2010	2015	2020
Eastern	0–54	8	15	17	19
	55–74	52	64	75	82
	≥ 75	122	145	153	166
	Total	182	224	245	267
Southern	0–54	9	12	14	16
	55–74	33	53	65	73
	≥ 75	103	122	132	145
	Total	145	188	211	234
Western	0–54	7	7	7	7
	55–74	27	34	40	46
	≥ 75	65	67	68	73
	Total	99	108	115	126
Central	0–54	4	4	4	5
	55–74	14	18	21	23
	≥ 75	34	42	45	48
	Total	52	64	70	75
Northern	0–54	3	2	3	3
	55–74	9	10	12	13
	≥ 75	15	22	24	27
	Total	27	35	39	43
Norway	0–54	31	41	46	49
	55–74	136	179	213	237
	≥ 75	338	398	421	459
	Total	505	618	680	745

Figure S25a: Other skin, men.

Observed and predicted incidence by period and health region. Age-adjusted rates.

**Figure S25b: Other skin, women.**

Observed and predicted incidence by period and health region. Age-adjusted rates.




Table S48a: Connective tissue, men.

Annual observed and predicted number of new cases by period, age and region.

		2000–2004	2010	2015	2020
Eastern	0–54	10	12	12	12
	55–74	11	13	15	17
	≥ 75	8	8	8	9
	Total	29	33	36	38
Southern	0–54	5	6	6	6
	55–74	6	6	7	8
	≥ 75	3	4	4	5
	Total	14	16	17	18
Western	0–54	4	6	6	6
	55–74	5	6	7	7
	≥ 75	4	4	4	4
	Total	13	15	16	18
Central	0–54	3	4	4	4
	55–74	4	5	5	6
	≥ 75	4	3	3	3
	Total	11	12	12	13
Northern	0–54	3	3	3	3
	55–74	2	3	4	4
	≥ 75	2	2	2	2
	Total	8	8	9	9
Norway	0–54	25	30	31	30
	55–74	28	33	38	42
	≥ 75	21	21	21	24
	Total	75	84	90	97


Table S48b: Connective tissue, women.

Annual observed and predicted number of new cases by period, age and region.

		2000–2004	2010	2015	2020
Eastern	0–54	8	9	10	10
	55–74	9	9	10	11
	≥ 75	9	8	8	9
	Total	25	27	28	29
Southern	0–54	2	3	3	3
	55–74	3	3	4	4
	≥ 75	4	3	3	4
	Total	10	10	11	11
Western	0–54	4	5	5	5
	55–74	5	4	5	5
	≥ 75	3	4	4	5
	Total	12	13	14	15
Central	0–54	4	4	4	4
	55–74	2	4	4	5
	≥ 75	4	4	4	4
	Total	11	12	12	12
Northern	0–54	1	2	1	1
	55–74	2	2	2	2
	≥ 75	1	2	2	2
	Total	4	5	5	5
Norway	0–54	20	23	23	23
	55–74	21	22	25	27
	≥ 75	21	22	21	23
	Total	63	66	69	72

Figure S26a: Connective tissue, men.

Observed and predicted incidence by period and health region. Age-adjusted rates.

**Figure S26b: Connective tissue, women.**

Observed and predicted incidence by period and health region. Age-adjusted rates.




Table S49a: Breast, men.

Annual observed and predicted number of new cases by period, age and region.

		2000–2004	2010	2015	2020
Eastern	0–54	1	1	1	1
	55–74	2	3	3	3
	≥ 75	2	2	2	3
	Total	5	6	6	7
Southern	0–54	1	0	0	0
	55–74	1	2	2	2
	≥ 75	1	1	1	2
	Total	3	3	4	4
Western	0–54	1	0	0	0
	55–74	1	1	2	2
	≥ 75	1	1	1	1
	Total	3	3	3	4
Central	0–54	0	0	0	0
	55–74	2	1	2	2
	≥ 75	1	1	1	1
	Total	3	3	3	4
Northern	0–54	0	0	0	0
	55–74	1	1	1	1
	≥ 75	0	0	0	1
	Total	1	1	1	1
Norway	0–54	3	2	2	2
	55–74	7	8	9	10
	≥ 75	6	7	7	8
	Total	15	17	18	20


Table S49b: Breast, women.

Annual observed and predicted number of new cases by period, age and region.

		2000–2004	2010	2015	2020
Eastern	0–54	336	346	353	354
	55–74	450	653	775	847
	≥ 75	209	229	257	334
	Total	995	1228	1385	1534
Southern	0–54	177	182	180	178
	55–74	261	376	445	484
	≥ 75	130	132	148	191
	Total	567	689	774	854
Western	0–54	171	169	168	166
	55–74	196	310	374	414
	≥ 75	121	118	132	168
	Total	488	597	674	748
Central	0–54	111	115	114	112
	55–74	165	237	283	306
	≥ 75	85	88	97	125
	Total	360	441	494	543
Northern	0–54	85	83	79	77
	55–74	113	174	208	223
	≥ 75	54	63	73	97
	Total	253	320	360	396
Norway	0–54	880	894	894	887
	55–74	1184	1751	2086	2273
	≥ 75	600	630	707	915
	Total	2664	3275	3687	4075

Figure S27a: Breast, men.

Observed and predicted incidence by period and health region. Age-adjusted rates.

**Figure S27b: Breast, women.**

Observed and predicted incidence by period and health region. Age-adjusted rates.




Table S50a: Uterine cervix

Annual observed and predicted number of new cases by period, age and region.

		2000–2004	2010	2015	2020
Eastern	0–54	67	62	57	55
	55–74	30	27	28	29
	≥ 75	16	10	8	8
	Total	113	98	93	91
Southern	0–54	39	36	34	34
	55–74	14	17	19	20
	≥ 75	8	6	6	5
	Total	61	59	59	59
Western	0–54	32	30	29	29
	55–74	12	13	14	15
	≥ 75	6	5	4	4
	Total	50	48	48	49
Central	0–54	17	15	14	13
	55–74	6	6	6	6
	≥ 75	5	3	2	2
	Total	29	24	22	22
Northern	0–54	26	26	26	26
	55–74	7	9	10	11
	≥ 75	5	3	2	1
	Total	38	38	38	39
Alle	0–54	181	169	161	157
	55–74	70	71	77	81
	≥ 75	40	27	22	21
	Total	291	267	259	259

Figure S28a: Uterine cervix

Annual observed and predicted number of new cases by period, age and region.




Table S51a: Uterine corpus

Annual observed and predicted number of new cases by period, age and region.

		2000–2004	2010	2015	2020
Eastern	0–54	39	42	45	47
	55–74	124	140	157	170
	≥ 75	66	63	63	69
	Total	229	246	264	285
Southern	0–54	19	21	21	22
	55–74	63	72	81	88
	≥ 75	35	33	33	36
	Total	116	126	135	145
Western	0–54	23	23	23	24
	55–74	61	74	84	92
	≥ 75	37	35	35	38
	Total	121	132	142	154
Central	0–54	12	14	14	14
	55–74	42	48	54	58
	≥ 75	25	23	22	24
	Total	79	84	90	96
Northern	0–54	14	11	11	11
	55–74	31	38	42	44
	≥ 75	16	17	17	19
	Total	62	66	70	74
	0–54	107	110	114	118
	55–74	320	372	418	451
	≥ 75	179	171	170	186
	Total	607	653	701	754

Figure S29a: Uterine corpus

Annual observed and predicted number of new cases by period, age and region.




Table S52a: Placenta

Annual observed and predicted number of new cases by period, age and region.

		2000–2004	2010	2015	2020
Eastern	0–54	0	0	0	0
	55–74	0	0	0	0
	≥ 75	0	0	0	0
	Total	0	0	0	0
Southern	0–54	0	0	0	0
	55–74	0	0	0	0
	≥ 75	0	0	0	0
	Total	0	0	0	0
Western	0–54	2	2	2	2
	55–74	0	0	0	0
	≥ 75	0	0	0	0
	Total	2	2	2	2
Central	0–54	0	0	0	0
	55–74	0	0	0	0
	≥ 75	0	0	0	0
	Total	0	0	0	0
Northern	0–54	0	0	0	0
	55–74	0	0	0	0
	≥ 75	0	0	0	0
	Total	0	0	0	0
0–54		2	2	3	3
55–74		0	0	0	0
≥ 75		0	0	0	0
Total		2	3	3	3

Figure S30a: Placenta

Annual observed and predicted number of new cases by period, age and region.




Table S53a: Uterus unspecified

Annual observed and predicted number of new cases by period, age and region.

		2000–2004	2010	2015	2020
Eastern	0–54	1	1	1	1
	55–74	1	1	1	1
	≥ 75	3	2	2	2
	Total	4	4	4	4
Southern	0–54	0	1	1	1
	55–74	1	1	1	1
	≥ 75	2	2	2	2
	Total	4	4	4	4
Western	0–54	1	1	1	1
	55–74	1	1	1	1
	≥ 75	2	2	2	2
	Total	4	4	4	4
Central	0–54	0	0	0	0
	55–74	0	0	0	0
	≥ 75	1	1	1	1
	Total	1	1	1	1
Northern	0–54	0	0	0	0
	55–74	0	0	0	0
	≥ 75	0	0	0	0
	Total	0	0	0	0
0–54		2	2	2	2
55–74		4	3	3	4
≥ 75		8	7	7	7
Total		14	12	13	13

Figure S31a: Uterus unspecified

Annual observed and predicted number of new cases by period, age and region.




Table S54a: Ovary, etc

Annual observed and predicted number of new cases by period, age and region.

		2000–2004	2010	2015	2020
Eastern	0–54	44	46	44	43
	55–74	84	89	96	100
	≥ 75	52	48	48	53
	Total	180	183	189	195
Southern	0–54	27	24	23	21
	55–74	41	49	54	56
	≥ 75	30	27	27	30
	Total	98	100	103	107
Western	0–54	30	26	24	23
	55–74	42	47	52	55
	≥ 75	24	27	27	30
	Total	97	100	104	108
Central	0–54	18	14	13	12
	55–74	23	27	30	31
	≥ 75	17	16	16	17
	Total	57	58	59	61
Northern	0–54	11	12	11	10
	55–74	22	24	26	26
	≥ 75	16	14	13	15
	Total	49	49	50	51
		130	123	115	109
		212	236	258	269
		139	132	131	144
		480	491	505	522

Figure S32a: Ovary, etc

Annual observed and predicted number of new cases by period, age and region.




Table S55a: Other female genitals

Annual observed and predicted number of new cases by period, age and region.

		2000–2004	2010	2015	2020
Eastern	0–54	6	7	8	8
	55–74	8	12	14	15
	≥ 75	20	18	18	19
	Total	35	38	40	42
Southern	0–54	3	5	5	5
	55–74	7	8	9	10
	≥ 75	12	12	12	13
	Total	23	25	26	28
Western	0–54	4	4	4	4
	55–74	5	7	8	9
	≥ 75	10	11	11	11
	Total	19	22	23	24
Central	0–54	2	2	2	2
	55–74	4	4	5	6
	≥ 75	7	7	7	7
	Total	13	14	15	15
Northern	0–54	2	2	2	2
	55–74	4	4	4	5
	≥ 75	5	6	6	6
	Total	11	12	12	13
	0–54	17	21	21	21
	55–74	29	35	40	45
	≥ 75	54	54	54	57
	Total	100	110	115	123

Figure S33a: Other female genitals

Annual observed and predicted number of new cases by period, age and region.




Table S56a: Prostate

Annual observed and predicted number of new cases by period, age and region.

		2000–2004	2010	2015	2020
Eastern	0–54	40	39	41	44
	55–74	610	728	857	944
	≥ 75	434	437	442	511
	Total	1084	1204	1340	1499
Southern	0–54	22	22	23	24
	55–74	368	444	524	582
	≥ 75	268	265	271	313
	Total	658	731	818	919
Western	0–54	24	25	26	27
	55–74	378	462	546	611
	≥ 75	282	286	298	344
	Total	683	773	870	982
Central	0–54	17	13	13	14
	55–74	249	298	354	389
	≥ 75	188	190	189	219
	Total	454	501	557	621
Northern	0–54	7	9	9	9
	55–74	166	204	234	253
	≥ 75	119	114	119	138
	Total	293	326	362	400
Norway	0–54	110	107	111	118
	55–74	1771	2136	2515	2778
	≥ 75	1291	1291	1320	1525
	Total	3172	3535	3946	4421

Figure S34a: Prostate

Annual observed and predicted number of new cases by period, age and region.




Table S57a: Testis

Annual observed and predicted number of new cases by period, age and region.

		2000–2004	2010	2015	2020
Eastern	0–54	85	97	101	103
	55–74	5	7	9	11
	≥ 75	1	1	1	1
	Total	91	104	111	116
Southern	0–54	40	46	47	48
	55–74	3	4	5	6
	≥ 75	1	1	1	1
	Total	44	50	53	55
Western	0–54	50	56	59	62
	55–74	2	3	4	4
	≥ 75	1	1	0	0
	Total	52	60	64	67
Central	0–54	41	45	46	47
	55–74	3	4	5	6
	≥ 75	1	1	1	1
	Total	44	50	52	53
Northern	0–54	20	22	23	23
	55–74	1	2	2	3
	≥ 75	0	0	0	0
	Total	22	24	25	26
Norway	0–54	237	265	276	284
	55–74	14	20	25	29
	≥ 75	3	3	3	3
	Total	254	288	304	316

Figure S35a: Testis

Annual observed and predicted number of new cases by period, age and region.




Table S58a: Other male genitals

Annual observed and predicted number of new cases by period, age and region.

		2000–2004	2010	2015	2020
Eastern	0–54	1	3	3	3
	55–74	10	8	10	11
	≥ 75	4	5	5	6
	Total	15	16	18	20
Southern	0–54	1	1	1	1
	55–74	3	4	5	6
	≥ 75	4	3	3	3
	Total	8	8	9	10
Western	0–54	1	1	1	1
	55–74	3	3	4	4
	≥ 75	2	2	2	3
	Total	6	6	7	8
Central	0–54	0	1	1	1
	55–74	3	3	3	4
	≥ 75	2	2	2	2
	Total	5	5	6	6
Northern	0–54	1	1	1	1
	55–74	2	2	3	3
	≥ 75	1	1	1	2
	Total	4	4	5	5
Norway	0–54	5	6	6	6
	55–74	20	21	25	27
	≥ 75	13	13	14	15
	Total	38	40	44	49

Figure S36a: Other male genitals

Annual observed and predicted number of new cases by period, age and region.




Table S59a: Kidney, excl. renal pelvis, men.

Annual observed and predicted number of new cases by period, age and region.

		2000–2004	2010	2015	2020
Eastern	0–54	27	32	39	43
	55–74	51	72	86	101
	≥ 75	34	33	33	38
	Total	112	137	158	182
Southern	0–54	14	17	20	22
	55–74	34	42	50	58
	≥ 75	14	18	18	22
	Total	62	76	88	101
Western	0–54	12	17	21	23
	55–74	28	40	48	57
	≥ 75	22	20	20	23
	Total	62	77	89	103
Central	0–54	11	13	16	17
	55–74	28	34	40	46
	≥ 75	13	16	15	18
	Total	52	63	72	81
Northern	0–54	7	9	11	12
	55–74	20	24	28	31
	≥ 75	9	10	10	12
	Total	36	43	49	55
Norway	0–54	72	88	107	116
	55–74	161	212	252	293
	≥ 75	92	96	97	113
	Total	324	396	455	522


Table S59b: Kidney, excl. renal pelvis, women.

Annual observed and predicted number of new cases by period, age and region.

		2000–2004	2010	2015	2020
Eastern	0–54	9	12	15	18
	55–74	28	30	33	35
	≥ 75	27	26	25	26
	Total	63	68	72	79
Southern	0–54	6	7	9	10
	55–74	16	19	21	22
	≥ 75	17	16	16	17
	Total	40	42	45	49
Western	0–54	6	7	9	10
	55–74	14	17	19	21
	≥ 75	17	16	15	16
	Total	37	40	43	47
Central	0–54	4	5	6	7
	55–74	11	14	15	16
	≥ 75	15	13	12	12
	Total	30	31	33	36
Northern	0–54	2	4	5	6
	55–74	14	13	14	14
	≥ 75	10	11	10	11
	Total	26	28	29	31
Norway	0–54	27	36	44	51
	55–74	83	92	101	109
	≥ 75	86	81	78	82
	Total	196	209	223	241

Figure S37a: Kidney, excl. renal pelvis, men.

Observed and predicted incidence by period and health region. Age-adjusted rates.

**Figure S37b: Kidney, excl. renal pelvis, women.**

Observed and predicted incidence by period and health region. Age-adjusted rates.





Table S60a: Renal pelvis and ureter, men.

Annual observed and predicted number of new cases by period, age and region.

		2000–2004	2010	2015	2020
Eastern	0–54	2	2	3	3
	55–74	13	17	20	22
	≥ 75	11	10	10	12
	Total	26	29	33	37
Southern	0–54	1	1	1	1
	55–74	6	8	10	11
	≥ 75	7	5	5	6
	Total	14	15	16	19
Western	0–54	1	1	1	1
	55–74	5	6	7	8
	≥ 75	3	4	4	4
	Total	10	10	12	13
Central	0–54	1	1	1	1
	55–74	4	6	7	8
	≥ 75	5	4	4	4
	Total	10	11	12	13
Northern	0–54	0	1	1	1
	55–74	4	4	5	6
	≥ 75	2	2	3	3
	Total	7	8	8	9
Norway	0–54	5	6	6	6
	55–74	34	41	49	55
	≥ 75	27	25	26	30
	Total	66	73	81	92

Figure S38a: Renal pelvis and ureter, men.

Observed and predicted incidence by period and health region. Age-adjusted rates.

**Table S60b: Renal pelvis and ureter, women.**

Annual observed and predicted number of new cases by period, age and region.

		2000–2004	2010	2015	2020
Eastern	0–54	1	1	1	1
	55–74	8	8	10	11
	≥ 75	8	8	8	9
	Total	18	18	19	21
Southern	0–54	0	0	0	0
	55–74	2	3	4	4
	≥ 75	4	3	3	3
	Total	6	6	7	7
Western	0–54	0	1	1	1
	55–74	4	4	5	6
	≥ 75	5	5	5	5
	Total	9	10	10	11
Central	0–54	0	0	0	0
	55–74	3	3	4	4
	≥ 75	3	3	3	3
	Total	7	7	7	8
Northern	0–54	0	0	0	0
	55–74	3	2	2	2
	≥ 75	1	2	2	2
	Total	4	4	4	5
Norway	0–54	2	3	3	3
	55–74	20	21	24	27
	≥ 75	22	21	21	23
	Total	45	45	48	53

Figure S38b: Renal pelvis and ureter, women.

Observed and predicted incidence by period and health region. Age-adjusted rates.




Table S61a: Bladder, men.

Annual observed and predicted number of new cases by period, age and region.

		2000–2004	2010	2015	2020
Eastern	0–54	25	25	24	24
	55–74	131	150	173	191
	≥ 75	134	134	134	149
	Total	291	309	332	365
Southern	0–54	14	14	13	13
	55–74	73	88	103	115
	≥ 75	82	80	81	89
	Total	169	182	197	218
Western	0–54	13	14	14	14
	55–74	77	87	101	114
	≥ 75	75	80	83	92
	Total	164	181	198	220
Central	0–54	13	11	10	10
	55–74	62	68	80	88
	≥ 75	57	64	64	71
	Total	132	143	153	168
Northern	0–54	7	8	7	7
	55–74	47	52	59	64
	≥ 75	40	43	44	50
	Total	95	102	110	120
Norway	0–54	72	71	68	68
	55–74	390	445	516	572
	≥ 75	388	400	405	452
	Total	851	916	990	1091


Table S61b: Bladder, women.

Annual observed and predicted number of new cases by period, age and region.

		2000–2004	2010	2015	2020
Eastern	0–54	9	8	9	9
	55–74	45	51	57	60
	≥ 75	58	61	61	66
	Total	111	120	126	134
Southern	0–54	4	4	4	4
	55–74	23	27	31	32
	≥ 75	32	33	33	36
	Total	59	64	68	73
Western	0–54	4	4	5	5
	55–74	22	27	31	33
	≥ 75	35	35	35	38
	Total	60	66	71	76
Central	0–54	3	3	3	3
	55–74	16	19	21	22
	≥ 75	24	25	24	26
	Total	43	46	48	51
Northern	0–54	2	2	2	2
	55–74	14	16	17	18
	≥ 75	17	18	19	20
	Total	33	36	38	40
Norway	0–54	22	22	23	23
	55–74	119	139	156	165
	≥ 75	166	172	172	186
	Total	307	333	352	374

Figure S39a: Bladder, men.

Observed and predicted incidence by period and health region. Age-adjusted rates.

**Figure S39b: Bladder, women.**

Observed and predicted incidence by period and health region. Age-adjusted rates.




Table S62a: Eye, men.

Annual observed and predicted number of new cases by period, age and region.

		2000–2004	2010	2015	2020
Eastern	0–54	2	4	4	4
	55–74	6	6	7	7
	≥ 75	3	3	3	3
	Total	11	12	13	14
Southern	0–54	1	2	2	2
	55–74	2	3	4	4
	≥ 75	2	1	1	2
	Total	6	6	7	7
Western	0–54	2	2	2	2
	55–74	2	3	3	4
	≥ 75	2	1	1	2
	Total	6	6	7	8
Central	0–54	1	1	1	1
	55–74	2	2	2	2
	≥ 75	1	1	1	1
	Total	3	3	4	4
Northern	0–54	2	1	1	1
	55–74	2	2	3	3
	≥ 75	1	1	1	1
	Total	5	5	5	6
Norway	0–54	8	9	9	10
	55–74	14	16	18	20
	≥ 75	9	7	7	9
	Total	31	33	35	38


Table S62b: Eye, women.

Annual observed and predicted number of new cases by period, age and region.

		2000–2004	2010	2015	2020
Eastern	0–54	2	2	3	3
	55–74	4	4	5	5
	≥ 75	3	3	3	3
	Total	9	10	10	11
Southern	0–54	2	2	2	2
	55–74	3	4	4	5
	≥ 75	3	2	2	3
	Total	8	8	9	9
Western	0–54	2	2	2	2
	55–74	1	3	3	4
	≥ 75	3	2	2	2
	Total	6	7	7	7
Central	0–54	1	1	1	1
	55–74	2	2	3	3
	≥ 75	2	2	2	2
	Total	5	5	6	6
Northern	0–54	1	1	1	1
	55–74	1	1	1	1
	≥ 75	1	1	1	1
	Total	3	3	3	3
Norway	0–54	7	8	8	8
	55–74	12	14	16	18
	≥ 75	12	10	10	11
	Total	31	32	34	37

Figure S40a: Eye, men.

Observed and predicted incidence by period and health region. Age-adjusted rates.

**Figure S40b: Eye, women.**

Observed and predicted incidence by period and health region. Age-adjusted rates.





Table S63a: Brain, CNS, men.

Annual observed and predicted number of new cases by period, age and region.

		2000–2004	2010	2015	2020
Eastern	0–54	64	64	65	66
	55–74	48	56	63	70
	≥ 75	20	21	21	25
	Total	131	141	150	161
Southern	0–54	30	32	32	32
	55–74	26	32	36	39
	≥ 75	15	12	12	14
	Total	71	75	80	86
Western	0–54	39	38	38	38
	55–74	27	33	38	42
	≥ 75	13	13	13	16
	Total	79	84	89	96
Central	0–54	23	23	22	22
	55–74	20	22	25	27
	≥ 75	8	9	9	10
	Total	51	54	57	60
Northern	0–54	18	15	15	15
	55–74	12	16	17	18
	≥ 75	5	6	6	7
	Total	35	37	38	40
Norway	0–54	174	172	173	174
	55–74	133	159	180	196
	≥ 75	61	60	62	72
	Total	367	390	414	443

Figure S41a: Brain, CNS, men.

Observed and predicted incidence by period and health region. Age-adjusted rates.

**Table S63b: Brain, CNS, women.**

Annual observed and predicted number of new cases by period, age and region.

		2000–2004	2010	2015	2020
Eastern	0–54	61	66	67	69
	55–74	65	75	84	91
	≥ 75	38	34	34	37
	Total	165	175	185	196
Southern	0–54	37	36	37	37
	55–74	41	46	52	56
	≥ 75	19	21	21	23
	Total	98	103	109	116
Western	0–54	38	37	37	38
	55–74	34	41	47	51
	≥ 75	20	20	20	21
	Total	91	98	104	110
Central	0–54	24	25	24	24
	55–74	26	30	34	37
	≥ 75	16	15	14	16
	Total	67	70	73	77
Northern	0–54	20	19	19	18
	55–74	19	24	26	28
	≥ 75	12	11	11	12
	Total	52	54	56	58
Norway	0–54	181	182	184	186
	55–74	186	216	243	262
	≥ 75	105	101	100	109
	Total	472	499	527	557

Figure S41b: Brain, CNS, women.

Observed and predicted incidence by period and health region. Age-adjusted rates.




Table S64a: Thyroid gland, men.

Annual observed and predicted number of new cases by period, age and region.

		2000–2004	2010	2015	2020
Eastern	0–54	7	7	7	7
	55–74	6	7	8	8
	≥ 75	2	2	2	3
	Total	15	16	17	19
Southern	0–54	3	3	4	4
	55–74	3	4	4	5
	≥ 75	1	1	1	1
	Total	8	8	9	9
Western	0–54	6	6	6	6
	55–74	4	5	6	7
	≥ 75	2	2	2	2
	Total	12	13	13	14
Central	0–54	3	4	4	4
	55–74	5	4	4	5
	≥ 75	0	1	1	2
	Total	8	9	9	10
Northern	0–54	3	3	3	3
	55–74	3	4	4	4
	≥ 75	2	1	1	1
	Total	8	8	9	9
Norway	0–54	24	23	23	24
	55–74	20	23	26	29
	≥ 75	7	8	8	9
	Total	51	54	58	61


Table S64b: Thyroid gland, women.

Annual observed and predicted number of new cases by period, age and region.

		2000–2004	2010	2015	2020
Eastern	0–54	27	27	28	28
	55–74	13	15	16	18
	≥ 75	8	7	7	8
	Total	47	49	51	54
Southern	0–54	14	12	12	13
	55–74	8	7	8	9
	≥ 75	2	4	4	4
	Total	24	24	25	26
Western	0–54	16	17	17	17
	55–74	8	9	10	11
	≥ 75	4	5	5	5
	Total	29	30	31	33
Central	0–54	12	11	11	11
	55–74	6	7	7	8
	≥ 75	4	4	4	4
	Total	22	21	22	23
Northern	0–54	10	10	10	9
	55–74	5	6	6	7
	≥ 75	4	3	3	3
	Total	19	18	19	19
Norway	0–54	79	77	78	79
	55–74	39	43	48	52
	≥ 75	23	22	22	24
	Total	141	142	148	155

Figure S42a: Thyroid gland, men.

Observed and predicted incidence by period and health region. Age-adjusted rates.

**Figure S42b: Thyroid gland, women.**

Observed and predicted incidence by period and health region. Age-adjusted rates.




Table S65a: Other endocrine organs, men.

Annual observed and predicted number of new cases by period, age and region.

		2000–2004	2010	2015	2020
Eastern	0–54	2	2	2	2
	55–74	1	1	1	1
	≥ 75	0	0	0	0
	Total	3	3	3	3
Southern	0–54	1	0	0	0
	55–74	0	0	0	0
	≥ 75	0	0	0	0
	Total	1	1	1	1
Western	0–54	1	1	1	1
	55–74	1	1	1	1
	≥ 75	0	0	0	0
	Total	2	2	2	2
Central	0–54	1	1	1	1
	55–74	0	1	1	1
	≥ 75	0	0	0	0
	Total	2	2	2	2
Northern	0–54	1	1	1	1
	55–74	1	1	1	1
	≥ 75	0	0	0	0
	Total	2	2	2	2
Norway	0–54	5	5	5	5
	55–74	3	3	3	4
	≥ 75	2	1	1	1
	Total	10	9	9	10


Table S65b: Other endocrine organs, women.

Annual observed and predicted number of new cases by period, age and region.

		2000–2004	2010	2015	2020
Eastern	0–54	1	1	1	1
	55–74	1	1	1	1
	≥ 75	1	0	0	0
	Total	3	3	3	3
Southern	0–54	1	1	1	1
	55–74	1	1	1	1
	≥ 75	0	0	0	0
	Total	2	2	2	2
Western	0–54	2	1	1	1
	55–74	1	1	1	1
	≥ 75	0	0	0	0
	Total	2	2	2	2
Central	0–54	0	0	0	0
	55–74	0	0	0	0
	≥ 75	0	0	0	0
	Total	1	1	1	1
Northern	0–54	1	1	1	1
	55–74	1	1	1	1
	≥ 75	0	0	0	0
	Total	2	2	2	2
Norway	0–54	5	5	5	5
	55–74	3	4	4	4
	≥ 75	2	1	1	2
	Total	10	10	10	11

Figure S43a: Other endocrine organs, men.

Observed and predicted incidence by period and health region. Age-adjusted rates.

**Figure S43b: Other endocrine organs, women.**

Observed and predicted incidence by period and health region. Age-adjusted rates.





Table S66a: Other and unspec. sites, men.

Annual observed and predicted number of new cases by period, age and region.

		2000–2004	2010	2015	2020
Eastern	0–54	8	9	10	10
	55–74	46	52	61	68
	≥ 75	50	54	55	62
	Total	105	115	125	139
Southern	0–54	4	6	6	6
	55–74	25	31	37	42
	≥ 75	34	33	33	38
	Total	63	70	76	85
Western	0–54	3	5	5	5
	55–74	21	26	30	34
	≥ 75	27	28	29	33
	Total	52	58	64	72
Central	0–54	4	3	3	3
	55–74	16	20	23	26
	≥ 75	20	21	21	24
	Total	40	44	48	53
Northern	0–54	3	3	3	3
	55–74	14	18	21	23
	≥ 75	18	17	18	20
	Total	34	38	42	46
Norway	0–54	22	26	27	27
	55–74	122	147	171	192
	≥ 75	149	153	156	176
	Total	294	326	354	396

Figure S44a: Other and unspec. sites, men.

Observed and predicted incidence by period and health region. Age-adjusted rates.

**Table S66b: Other and unspec. sites, women.**

Annual observed and predicted number of new cases by period, age and region.

		2000–2004	2010	2015	2020
Eastern	0–54	9	11	11	11
	55–74	42	45	52	58
	≥ 75	86	88	86	91
	Total	136	143	149	160
Southern	0–54	4	6	6	6
	55–74	21	25	29	32
	≥ 75	51	49	49	51
	Total	76	80	83	90
Western	0–54	4	6	6	6
	55–74	20	23	27	30
	≥ 75	48	48	48	51
	Total	71	77	80	87
Central	0–54	4	3	3	4
	55–74	14	16	18	20
	≥ 75	32	33	32	33
	Total	49	52	54	57
Northern	0–54	3	3	3	3
	55–74	10	13	15	16
	≥ 75	26	25	25	27
	Total	39	41	43	46
Norway	0–54	23	28	29	29
	55–74	107	122	141	157
	≥ 75	241	244	240	253
	Total	371	393	410	440

Figure S44b: Other and unspec. sites, women.

Observed and predicted incidence by period and health region. Age-adjusted rates.




Table S67a: Hodgkin lymphoma, men.

Annual observed and predicted number of new cases by period, age and region.

		2000–2004	2010	2015	2020
Eastern	0–54	18	19	19	19
	55–74	5	7	8	8
	≥ 75	1	1	1	1
	Total	24	26	28	29
Southern	0–54	8	8	8	8
	55–74	3	3	3	3
	≥ 75	0	0	1	1
	Total	11	11	12	12
Western	0–54	9	10	10	10
	55–74	3	3	3	4
	≥ 75	1	1	1	1
	Total	13	13	14	14
Central	0–54	7	6	6	6
	55–74	2	2	3	3
	≥ 75	1	0	0	0
	Total	9	9	9	9
Northern	0–54	4	4	4	4
	55–74	1	1	1	2
	≥ 75	0	0	0	0
	Total	6	5	6	6
Norway	0–54	47	46	47	47
	55–74	14	16	18	19
	≥ 75	3	3	3	3
	Total	64	65	68	70


Table S67b: Hodgkin lymphoma, women.

Annual observed and predicted number of new cases by period, age and region.

		2000–2004	2010	2015	2020
Eastern	0–54	13	11	12	12
	55–74	2	2	3	3
	≥ 75	3	2	2	2
	Total	18	16	17	17
Southern	0–54	5	5	5	5
	55–74	2	1	1	1
	≥ 75	1	1	1	1
	Total	8	7	7	8
Western	0–54	8	6	7	7
	55–74	0	1	1	2
	≥ 75	2	1	1	1
	Total	10	9	9	10
Central	0–54	3	4	4	4
	55–74	1	1	1	1
	≥ 75	2	1	1	1
	Total	7	6	6	6
Northern	0–54	3	4	4	4
	55–74	1	1	1	1
	≥ 75	1	1	1	1
	Total	6	5	5	5
Norway	0–54	32	30	31	31
	55–74	7	7	7	8
	≥ 75	9	6	6	7
	Total	48	43	44	46

Figure S45a: Hodgkin lymphoma, men.

Observed and predicted incidence by period and health region. Age-adjusted rates.

**Figure S45b: Hodgkin lymphoma, women.**

Observed and predicted incidence by period and health region. Age-adjusted rates.




Table S68a: Non-Hodgkin lymphoma, men.

Annual observed and predicted number of new cases by period, age and region.

		2000–2004	2010	2015	2020
Eastern	0–54	39	38	37	36
	55–74	62	84	101	111
	≥ 75	36	42	48	62
	Total	137	164	186	208
Southern	0–54	20	20	20	19
	55–74	38	49	59	65
	≥ 75	20	24	28	36
	Total	78	94	107	120
Western	0–54	22	19	18	16
	55–74	28	40	48	53
	≥ 75	19	21	24	31
	Total	69	80	90	100
Central	0–54	13	15	14	13
	55–74	26	36	44	48
	≥ 75	20	20	22	28
	Total	59	71	80	89
Northern	0–54	10	10	9	9
	55–74	19	24	28	30
	≥ 75	8	11	13	17
	Total	37	44	50	55
Norway	0–54	104	101	98	93
	55–74	173	234	279	306
	≥ 75	103	119	134	173
	Total	380	454	512	572


Table S68b: Non-Hodgkin lymphoma, women.

Annual observed and predicted number of new cases by period, age and region.

		2000–2004	2010	2015	2020
Eastern	0–54	22	24	25	26
	55–74	54	63	71	78
	≥ 75	47	43	42	46
	Total	123	130	139	150
Southern	0–54	10	12	12	12
	55–74	27	33	37	41
	≥ 75	26	22	22	24
	Total	63	67	72	78
Western	0–54	12	14	14	15
	55–74	30	33	38	42
	≥ 75	22	24	24	26
	Total	64	70	75	82
Central	0–54	9	10	10	10
	55–74	22	27	30	33
	≥ 75	21	19	19	20
	Total	53	55	59	63
Northern	0–54	8	8	8	8
	55–74	19	19	21	23
	≥ 75	11	14	14	15
	Total	38	40	42	45
Norway	0–54	62	67	68	70
	55–74	151	174	198	217
	≥ 75	127	122	120	131
	Total	341	364	386	418

Figure S46a: Non-Hodgkin lymphoma, men.

Observed and predicted incidence by period and health region. Age-adjusted rates.

**Figure S46b: Non-Hodgkin lymphoma, women.**

Observed and predicted incidence by period and health region. Age-adjusted rates.




Table S69a: Multiple myeloma, men.

Annual observed and predicted number of new cases by period, age and region.

		2000–2004	2010	2015	2020
Eastern	0–54	8	8	8	8
	55–74	25	31	36	40
	≥ 75	20	20	20	23
	Total	53	58	65	72
Southern	0–54	2	5	5	5
	55–74	18	21	24	27
	≥ 75	15	14	14	16
	Total	35	39	43	48
Western	0–54	3	4	4	4
	55–74	15	16	19	22
	≥ 75	10	11	12	13
	Total	28	32	35	39
Central	0–54	5	4	4	4
	55–74	13	16	19	21
	≥ 75	11	11	11	13
	Total	28	31	34	38
Northern	0–54	2	2	2	2
	55–74	9	10	12	13
	≥ 75	7	6	7	8
	Total	18	19	21	23
Norway	0–54	20	23	23	23
	55–74	80	94	111	123
	≥ 75	62	63	64	73
	Total	162	179	198	220


Table S69b: Multiple myeloma, women.

Annual observed and predicted number of new cases by period, age and region.

		2000–2004	2010	2015	2020
Eastern	0–54	6	5	6	6
	55–74	23	24	28	32
	≥ 75	25	26	25	28
	Total	54	56	59	65
Southern	0–54	2	3	3	3
	55–74	12	14	16	18
	≥ 75	15	14	14	15
	Total	29	30	32	36
Western	0–54	3	3	3	3
	55–74	9	13	15	17
	≥ 75	15	14	14	15
	Total	27	29	31	35
Central	0–54	2	2	2	2
	55–74	8	10	12	13
	≥ 75	13	11	11	11
	Total	22	23	24	27
Northern	0–54	2	2	2	2
	55–74	7	8	9	10
	≥ 75	8	8	8	9
	Total	18	18	19	21
Norway	0–54	15	14	15	15
	55–74	59	69	80	89
	≥ 75	75	73	72	78
	Total	150	156	167	183

Figure S47a: Multiple myeloma, men.

Observed and predicted incidence by period and health region. Age-adjusted rates.

**Figure S47b: Multiple myeloma, women.**

Observed and predicted incidence by period and health region. Age-adjusted rates.




Table S70a: Leukaemia, acute, men.

Annual observed and predicted number of new cases by period, age and region.

		2000–2004	2010	2015	2020
Eastern	0–54	16	18	18	19
	55–74	15	17	20	23
	≥ 75	13	11	12	13
	Total	44	47	50	55
Southern	0–54	10	11	11	11
	55–74	11	10	12	13
	≥ 75	7	7	8	9
	Total	28	29	31	33
Western	0–54	12	11	11	11
	55–74	6	8	9	11
	≥ 75	6	5	6	7
	Total	24	24	26	28
Central	0–54	7	7	6	6
	55–74	6	6	7	7
	≥ 75	3	4	4	5
	Total	17	16	17	19
Northern	0–54	5	4	4	4
	55–74	2	3	4	4
	≥ 75	2	2	2	2
	Total	9	9	10	10
Norway	0–54	50	50	50	51
	55–74	41	44	52	58
	≥ 75	31	30	31	35
	Total	122	125	134	144


Table S70b: Leukaemia, acute, women.

Annual observed and predicted number of new cases by period, age and region.

		2000–2004	2010	2015	2020
Eastern	0–54	16	16	16	16
	55–74	10	13	15	16
	≥ 75	14	12	12	13
	Total	40	41	43	46
Southern	0–54	8	9	9	9
	55–74	7	8	9	9
	≥ 75	7	6	6	7
	Total	22	23	24	26
Western	0–54	8	8	8	8
	55–74	5	6	7	7
	≥ 75	5	5	5	6
	Total	18	19	20	21
Central	0–54	4	5	5	5
	55–74	3	4	4	5
	≥ 75	4	3	3	3
	Total	11	12	12	12
Northern	0–54	4	4	4	4
	55–74	3	4	4	4
	≥ 75	3	3	3	3
	Total	11	11	11	12
Norway	0–54	41	42	43	43
	55–74	28	33	38	42
	≥ 75	33	30	30	32
	Total	102	106	110	117

Figure S48a: Leukaemia, acute, men.

Observed and predicted incidence by period and health region. Age-adjusted rates.

**Figure S48b: Leukaemia, acute, women.**

Observed and predicted incidence by period and health region. Age-adjusted rates.




Table S71a: Leukaemia, non-acute, men.

Annual observed and predicted number of new cases by period, age and region.

		2000–2004	2010	2015	2020
Eastern	0–54	11	11	11	11
	55–74	29	35	41	45
	≥ 75	27	27	28	31
	Total	67	73	79	88
Southern	0–54	8	6	6	7
	55–74	18	22	26	29
	≥ 75	16	17	18	20
	Total	42	46	50	56
Western	0–54	5	5	5	5
	55–74	13	16	19	22
	≥ 75	13	13	14	16
	Total	31	35	38	43
Central	0–54	3	4	4	4
	55–74	12	14	16	18
	≥ 75	12	11	11	13
	Total	27	29	32	35
Northern	0–54	3	3	3	2
	55–74	8	9	10	11
	≥ 75	6	6	7	8
	Total	17	17	19	21
Norway	0–54	30	29	29	30
	55–74	80	96	113	125
	≥ 75	74	75	77	88
	Total	184	200	219	243


Table S71b: Leukaemia, non-acute, women.

Annual observed and predicted number of new cases by period, age and region.

		2000–2004	2010	2015	2020
Eastern	0–54	10	8	8	8
	55–74	20	23	27	30
	≥ 75	27	27	27	29
	Total	57	59	62	67
Southern	0–54	4	3	3	3
	55–74	11	10	11	13
	≥ 75	10	12	12	13
	Total	25	25	26	29
Western	0–54	3	3	3	3
	55–74	7	8	10	11
	≥ 75	12	11	11	12
	Total	22	23	24	26
Central	0–54	2	2	2	2
	55–74	6	7	8	8
	≥ 75	9	8	8	9
	Total	17	17	18	19
Northern	0–54	2	2	2	2
	55–74	5	5	6	6
	≥ 75	7	6	6	7
	Total	13	13	14	15
Norway	0–54	19	18	18	19
	55–74	49	53	61	68
	≥ 75	66	65	64	69
	Total	135	136	144	155

Figure S49a: Leukaemia, non-acute, men.

Observed and predicted incidence by period and health region. Age-adjusted rates.

**Figure S49b: Leukaemia, non-acute, women.**

Observed and predicted incidence by period and health region. Age-adjusted rates.





Table S72a: All sites, men.

Annual observed and predicted number of new cases by period, age and region.

		2000–2004	2010	2015	2020
Eastern	0–54	609	627	642	648
	55–74	1990	2344	2714	2963
	≥ 75	1560	1588	1612	1846
	Total	4159	4559	4968	5457
Southern	0–54	332	340	346	350
	55–74	1205	1441	1676	1843
	≥ 75	957	985	1020	1171
	Total	2494	2765	3042	3364
Western	0–54	341	358	367	370
	55–74	1151	1391	1620	1793
	≥ 75	925	967	1015	1167
	Total	2417	2717	3001	3330
Central	0–54	247	246	248	249
	55–74	825	984	1152	1249
	≥ 75	667	694	702	809
	Total	1739	1924	2101	2307
Northern	0–54	167	159	159	158
	55–74	589	698	789	843
	≥ 75	418	434	454	524
	Total	1177	1291	1402	1525
Norway	0–54	1696	1729	1761	1774
	55–74	5759	6858	7951	8691
	≥ 75	4531	4668	4802	5518
	Total	11986	13255	14514	15983

Figure S50a: All sites, men.

Observed and predicted incidence by period and health region. Age-adjusted rates.


**Table S72b: All sites, women.**

Annual observed and predicted number of new cases by period, age and region.

		2000–2004	2010	2015	2020
Eastern	0–54	912	959	983	995
	55–74	1699	2082	2389	2591
	≥ 75	1464	1511	1550	1744
	Total	4075	4553	4921	5330
Southern	0–54	508	517	519	522
	55–74	964	1209	1392	1506
	≥ 75	842	890	928	1048
	Total	2315	2616	2838	3076
Western	0–54	509	510	513	515
	55–74	825	1073	1250	1374
	≥ 75	825	842	869	972
	Total	2159	2425	2633	2861
Central	0–54	325	327	324	322
	55–74	617	768	888	954
	≥ 75	574	591	599	670
	Total	1516	1685	1810	1946
Northern	0–54	259	252	248	248
	55–74	459	571	650	692
	≥ 75	375	406	425	481
	Total	1093	1229	1323	1421
Norway	0–54	2513	2565	2586	2602
	55–74	4564	5703	6569	7117
	≥ 75	4081	4240	4370	4915
	Total	11158	12508	13526	14634

Figure S50b: All sites, women.

Observed and predicted incidence by period and health region. Age-adjusted rates.



Cancer Registry of Norway

Institute of Population-based Cancer Research

Postal address:
N-0310 OSLO

Office address:
Fr. Nansens vei 19, Oslo

Telephone: +47 22 45 13 00
Telefax: +47 22 45 13 70

E-mail: kreftregisteret@kreftregisteret.no
Internet: www.kreftregisteret.no

